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Abstract
The main subjects of my thesis can be divided into three related areas.
Firstly, determination of the mechanisms of tumoriogenesis associated with a 
recently identified, recessively inherited syndrome, MK//-associated polyposis 
(MAP). MAP results from defective base excision repair (BER) caused by bi- 
allelic germline mutations in the human Mut-Y homologue (MUTYH, MYH) 
and leads to the development of colorectal adenomas and cancer. My work 
includes: further characterisation of the MAP phenotype; completion of 
screening for mutations in other BER enzymes (OGGI and MTH1) in 
individuals with multiple colorectal adenomas; determination of the genetic 
pathway(s) involved in MAP tumorigenesis through studying loss of 
heterozygosity (LOH) and chromosomal abnormalities with array comparitive 
genomic hybridisation. A mouse model of MAP was developed as part of this 
thesis in order to study the development of intestinal adenomas from their 
earliest stages, and to evaluate the impact of environmental modification and 
chemopreventative therapies.
Secondly, I determined to identify novel predisposition genes for the multiple 
adenoma phenotype. Up to fifty percent of individuals with multiple (5-100) 
colorectal adenomas (MCRAs) have no germline mutation in known 
predisposition genes (.APC and MYH), but probably have a genetic origin. In 
these cases I determined to identify novel predisposition genes for the MCRA 
phenotype utilising various techniques. These included somatic screening of 
the adenomas for mutational signatures, expression array analysis of 
lymphoblastoid cell lines from these individuals and candidate gene 
approaches.
Finally, I investigated the clonal origins of colorectal adenomas through 
studying adenomas from familial adenomatous polyposis (FAP), attenuated 
FAP (AFAP) and sporadic cases. In this thesis I developed a novel technique 
which utilises somatic APC  mutations as clonal markers. This approach found 
100% of FAP adenomas to be polyclonal and 100% of AFAP adenomas to be 
clonal in their origin.
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mb mega base pairs
MCR mutation cluster region
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Min multiple intestinal neoplasia
MLH1 human homologue of E.coli MutL
MLPA multiplex ligation-dependent probe amplification
MMR mismatch repair
Moml modifier of Min 1
MSH2 human homologue of E. coli MutS
MSI microsatellite instability
5
MTH1 human homologue of E. coli MutT
MTHF methyl tetrahydrofolate
MYH human homologue of E. coli MutY
NAT2 N-acetyltransferase 2
nm nanometer
NSAID nonsteroidal anti-inflammatory drug
nt nucleotides
OGGI human homologue of E. coli MutM
8-oxo-G 8-oxo-7,8-dihydroxy guanosine
PCR polymerase chain reaction
PJS Peutz-Jeghers syndrome
PMS2 postmeiotic segregation increased 2
POLE2 DNA polymerase epsilon subunit 2
PPAR peroxisome proliferators-activated receptor
PTEN phosphatase and tensin homologue deleted on chromosome 10
PTT protein truncation test
RNA ribonucleic acid
ROS reactive oxidative species
rpm rotations per minute
R-SMAD receptor-regulated SMAD
SMAD human homologue of Drosophila small mothers against
decapentaplegic 
SSCP single strand conformation polymorphism
TCF T cell factor
TDG thymine-DNA glycosylase
6
TGF-p transforming growth factor-p
UC ulcerative colitis
UDG uracil-DNA glycosylase
Wifi Wnt inhibitory factor 1
All genes have been italicised throughout the text, whereas proteins are shown 
in plain text.
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Introduction
1.1 Colorectal Cancer
1.1.1 Incidence and Aetiology
Colorectal cancer (CRC) is diagnosed in 35,000 people per year 
(approximately 100 people per day) in the United Kingdom. CRC is a 
common form of malignancy in developed countries but is much less common 
in developing countries. Worldwide, one million cases are diagnosed per 
annum. In the UK it is the second most common cause of cancer-related death 
with a mortality of 17,000 people per year. CRC accounts for 13% of all 
cancers in the UK and is the second most commonly diagnosed cancer in 
women following breast cancer and the third most common cancer in men 
following prostate and lung cancer (Cancer Research UK statistics, 
http://info.cancerresearchuk.org/cancerstats/).
Eighty three percent of CRC occurs in people who are 60 years of age or older 
[(Office for National Statistics. Cancer statistics registrations: Registrations 
for cancer diagnosed in 2002, England vol. Series MB1 no 33. London; 
National Statistics, 2005), (Welsh Cancer Intelligence and Surveillance unit. 
2005. www.wcisu.wales.nhs.uk) (ISD Online. Cancer incidence and mortality 
data. 2005 www.isdscotland.org ) (Northern Ireland Cancer Registry. Cancer 
statistics. 2005. www.qub.ac.uk/nicr ), (Cancer Research UK. Information 
Resource Centre, 2006 info.cancerresearchuk.org)]. The male:female ratio is 
1.2:1.0, the lifetime risk for men is 1:18 and women 1:20.
Ninety percent of CRC cases are adenocarcinomas, the vast majority of which 
arise from adenomas. Adenomas are benign, relatively common lesions 
occurring in approximately one third of the European and American 
populations (Midgley & Kerr, 1999). It is thought that up to 10% of adenomas 
progress to invasive cancer (Scholefield, 2000). Adenomas which are most 
likely to progress to adenocarcinoma are o f larger size with villous histology 
and exhibit severe dysplasia (Terry et al., 2002).
In general terms, there is no association between socio-economic deprivation 
and CRC risk in the UK. Within the UK there is no associated geographical 
distribution of CRC cases as seen with lung and stomach cancer (Quinn 
MWH, 2005).
Interestingly, epidemiological studies have demonstrated a rapid increase in 
CRC risk in migrants moving from low to high risk countries (Boyle & 
Langman, 2000). The risk for second generation migrants is double that of the 
first, most likely due to the “Westernisation of the diet” (Flood et al., 2000). 
When considering these studies, other factors need to be taken into 
consideration such as differences in CRC reporting between countries, 
availability and provision of local heath care and variation in life expectancy 
between developed and developing countries.
1.1.2 CRC Risk Factors
Over the last thirty years significant progress has been made in determining 
risk factors not only for CRC but for cancer in general in terms of inherited 
predisposition, lifestyle and attitudes towards health. Poor diet, obesity, lack 
of physical exercise and alcohol and tobacco use are known to contribute to 
many cancers (Doll, 2003). It has been predicted that two thirds of CRC could 
be prevented by changes to diet and lifestyle (Doll & Peto, 1981).
I will discuss the following in relation to CRC.
Diet
The incidence of CRC is higher in populations with a “westernised diet”, who 
also have higher incidence of obesity and sedentary life style.
An observation by Burkitt in 1969 (Burkitt, 1969) suggested a link between 
dietary fibre intake and CRC, in that CRC appeared to have a similar 
geographical distribution to diverticular disease -  which is associated with low 
dietary fibre intake. Since then it has been determined that it is the insoluble as 
opposed to the soluble dietary fibres which promote bacterial fermentation in 
the large bowel and increased stool bulk -  and hence protection against CRC. 
Cummings et al (Cummings & Englyst, 1987; Englyst et al., 1987) 
demonstrated a role of starched resistant to digestion in the small bowel which 
then promotes fermentation in the large bowel (in a similar way to fibre) with
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production of fatty acids. Of these fatty acids it is thought butyrate confers the 
most protection as it has been shown to reduce the liability of epithelial cells 
to malignant change.
Specific studies in to the amount of red meat, fibre, fat, vitamin and 
micronutrients have determined that a diet high in fibre, fish, dairy fat, fruit 
and vegetables and low in red and processed meat is the healthiest diet in 
terms of CRC prevention. The European Prospective Investigation Into Cancer 
and Nutrition (EPIC) study demonstrated a significantly increased CRC risk of 
55% in those with lOOg/day increased intake of red and processed meat (Norat 
et al., 2005). This study also demonstrated the protective effect of a high fibre 
diet -  particularly if the fibre is sourced from fresh fruit and vegetables. At the 
present time in the UK, 75% of the population are failing to eat the 
recommended five portions of fruit and vegetables per day (National Statistics 
Health Survey for England 2004 and 2005).
Obesity
It is predicted that up to 11% of CRC in developed countries is associated with 
being overweight or obese. CRC risk increases by 15% in overweight and 
33% in obese individuals (Bergstrom et al., 2001). This relationship is most 
obvious in men and pre-menopausal women (Murphy et al., 2000). A 
worrying statistic is that of the increasing incidence of obesity in both men and 
women in the UK, between 1995 and 2004 the percentage of obese men rose 
from 15% to 24% and women from 18% to 24% (2005) (National Statistics 
Health Survey for England 2004, 2005).
Physical exercise
Few studies have specifically addressed CRC in relation to exercise. In studies 
looking at risk factors in the broader context, men with higher levels of 
activity throughout their lives are at lower risk of colon cancer but this risk 
reduction has not been statistically associated with rectal cancer (Wei et al., 
2004); (Slattery et al., 2003); (Viano H, 2002).
Alcohol and tobacco
A meta-analysis of eight cohort studies has demonstrated an increased CRC 
risk of 16% in people who drink 30-45g alcohol/day and 41% in those
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drinking >45g alcohol/day (Cho et al., 2004). Alcohol is likely to have a 
stronger effect in those with poor dietary folate in take.
Inflammatory disease o f the large bowel
Inflammatory syndromes affecting the large bowel namely Crohn’s disease 
and Ulcerative colitis (UC) predispose to CRC. In UC the lifetime CRC risk is 
40% (Gillen et al., 1994) (Levin, 1992) (Sugita et al., 1991). There is also 
some evidence to suggest that there is a genetic element in CRC development 
in UC as there is a higher sibling relative risk of CRC when compared to the 
general population (Satsangi et al., 1998). A potential linkage locus on 
chromosome 12 has been identified for UC (Parkes et al., 2001). UC-related 
CRCs have several distinct features when compared to sporadic CRC, namely 
there is a predominance of left sided, multiple, mucinous cancers which often 
arise from flat adenomas rather than polypoid adenomas (Colliver et al., 2006) 
(Crawford et al., 2005).
The incidence of precursor areas of dysplasia is as common in the right side of 
the colon as the left - which suggests there are other factors present in the 
transition from dysplasia to neoplasia. A “field effect” has been suggested by 
Rutter (Rutter et al., 2004). More recently a mechanism has been suggested by 
Castellone et al (Castellone et al., 2005) whereby increased levels of 
inflammatory cyclooxygenases inhibit the degradation of P-catenin through 
the binding o f prostaglandin E2 to its receptor. This activates a G-protein 
coupled receptor (Gas) which in turn binds axin. Axin complexed with APC 
and GSK3/3 phosphorylate p-catenin leading to accumulation and nuclear 
entry whereby target genes are transcribed resulting in an increased rate of 
cellular proliferation.
Pharmaceutical agents affecting CRC risk 
Non-steroidal anti-inflammatory drugs (NSAIDs)
There is strong evidence to support a protective effect of non-steroidal anti­
inflammatory drugs (NSAID) use in adenoma development and progression to 
CRC. This effect was first observed in large population based studies where 
NSAIDs were ingested for other medical indications and followed up as a
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result of astute clinical observation (reviewed in(DuBois et al., 1996)). Aspirin 
has been in longest use with a recent study including 10 years of follow up 
data demonstrating a reduced risk of 40-50% (Chan et al., 2005). Two 
randomised controlled trials have also supported the finding that aspirin use 
reduces adenoma formation (Baron et al., 2003) (Sandler et al., 2003).
The protective mechanism of NSAIDs is through the inhibition o f COX-2, 
which in turn slows adenoma development and growth (Ricchi et al., 2003). 
COX-2 is an inducible enzyme which regulates prostaglandin synthesis. 
Prostaglandins promote many varied biological effects including 
immunological induction of inflammatory processes, vascular endothelial 
integrity, reproductive regulation, nerve growth production and development, 
bone metabolism and activation of nuclear hormone receptors (via it’s 
metabolites) (Dubois et al., 1998). COX-2 is over-expressed in 50% of 
adenomas and 85% of CRCs. In the same samples, COX-1 expression 
remained unchanged between normal mucosa and CRC (Eberhart et al., 1994). 
COX-2 has been demonstrated to promote tumour-associated angiogenesis, 
although the mechanism of this remains unclear (Dormond et al., 2001).
Other members of the NSAID family, sulindac (both COX-1 and 2 inhibitor) 
and celecoxib (a selective COX-2 inhibitor), have been used in the prevention 
and treatment of individuals with familial adenomatous polyposis (FAP) 
(Nugent et al., 1993) (Phillips et al., 2002) (Giardiello, 1994) (Debinski et al., 
1995).
The Colorectal Adenoma/carcinoma Prevention Programme (CAPP (formerly 
Concerted Action Polyp Prevention)) studies set out to prospectively address 
the preventative impact of NSAIDs and diet in patients with FAP (CAPP 1 
study) and more recently HNPCC (CAPP 2 study). The CAPP studies are 
international, multi-centre randomised controlled trials. CAPP 1 investigated 
the effects of aspirin (600mg/d) and/or resistant starch (30g/d) in 206 FAP 
carriers. One year follow up found that although there was not a significant 
decrease in polyp number, the mean largest polyp size was reduced in the 
aspirin only group. Intestinal crypt length was also affected in that those 
individuals treated with starch had significantly shorter crypts, and those on 
aspirin had longer crypts and 37% increased crypt cell proliferation rate. It 
was suggested that both interventions have a protective effect but with
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differing mechanisms (Bum et al., 1998) (Mathers et al., 2003). CAPP 2 is 
investigating the impact of aspirin and resistant starch (at the same dose as 
CAPP 1) in 1000 individuals with HNPCC. Recruitment was completed in 
March 2007 and results awaited.
The impact of NSAIDs on adenoma and CRC development have been 
confirmed in animal models. The ApcMtn+/ mouse, the ApcA?16 mouse (both 
models of FAP), azoxymethane (AOM) treated rat and the nude mouse 
xenograft assay have all demonstrated that either non-selective inhibition of 
COX-1 and -2 or COX-2 inhibition alone suppress adenoma multiplicity and 
CRC cell growth. Polyp multiplicity was reduced in the FAP mouse models 
using celecoxib and rofecoxib respectively (Jacoby et al., 2000) (Oshima et 
al., 2001). Celecoxib use led to decreased tumour incidence, multiplicity and 
growth in AOM treated rats (Reddy et al., 2000); (Kawamori et al., 1998). In 
the nude mouse celecoxib caused reduced colon carcinoma cell growth and 
also demonstrated the absence of toxicity to normal gut mucosa whilst using 
COX-2 selective inhibitors (Williams et al., 2000). This evidence is further 
supported by crossing ApcMin mice with COX-2 knockout mice and mice 
lacking the prostaglandin E2 receptor (Oshima & Taketo, 2002). These 
animals develop fewer adenomas therefore demonstrating the significance of 
both COX-2 and prostaglandin E2 and inflammatory processes per se in the 
development o f adenomas.
Statins
Statin (HMG-CoA reductase inhibitor) use has been shown to reduce CRC risk 
by 47% when taken over a five year period in a large case-control study 
(Poynter et al., 2005). Statins are used to treat hypercholesterolaemia, 
ishaemic heart disease and inflammatory bowel disease. This study included 
1953 CRC cases and 2015 controls, the observed association remained 
significant when other factors such as concurrent aspirin use, physical activity, 
hypercholesterolaemia, family history of CRC and ethnic group were taken in 
to consideration. However, a recent population-based study with 1809 CRC 
cases and controls (Coogan et al., 2007) found no evidence of a decreased 
incidence of CRC when statins were used for longer than 3 months -  with no
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consistent trend across dose taken or duration of use. A significant reduction 
in the incidence of Stage IV disease was observed (OR 0.49, 95% Cl 0.26- 
0.91) in the individuals taking statins. As it has been shown that statins have 
anticancer activity in various cancer cell lines (including CRC cell lines) these 
observations warrant further study.
Hormonal manipulation -  HRT and OCP
Women who have ever used Hormone replacement therapy (HRT) have a 20% 
reduction in CRC risk and current users have a 30% risk reduction. A large 
meta-analysis found the risk of all bowel cancers to be reduced by 50% within 
5-10 years o f use (Grodstein et al., 1999). However, these results were 
muddied as further case-control studies demonstrated further reduced risk in 
women taking oestrogen only and trans-dermal HRT preparations (Csizmadi 
et al., 2004). These results are not entirely reproducible in randomised 
controlled trials with a 44% reduced risk of CRC seen in women taking 
combined oestrogen and progestogen preparations (Chlebowski et al., 2004), 
but another further study found no reduced risk in women taking oestrogen 
only HRT (Anderson et al., 2004).
In pre-menopausal women, oral contraceptive (OCP) use has been found to 
result in a reduced risk of CRC of up to 18% in a meta-analysis undertaken in 
2001 (Fernandez et al., 2001). A more recent case-control study in 2005 found 
a non-significant CRC risk reduction of 11% for women who had ever used 
OCP’s and a significant reduction in rectal cancer of 50% in women who had 
taken OCP’s in the preceding 14 months (Nichols et al., 2005).
Inherited risk factors
Up to 6% of CRC is caused by known inherited genetic syndromes, although 
it is likely there is a hereditary component in up to 35% (Lichtenstein et al., 
2000). Inherited genetic factors affect not only a predisposition to CRC but 
also concurrent illness, handling of pharmaceutical agents and overall 
outcome. The genetic make-up of any individual tumour affects the grade, 
response and overall outcome for any individual with CRC. The known 
inherited CRC predisposition syndromes will be dealt with in detail in a later 
section of this chapter.
25
1.1.3 Natural History, Staging, Treatment and Current CRC 
Outcome
1.1.3.1 The Natural history of CRC
The natural history of a cancer can be described as the histological progression 
from normal tissue through tumour initiation to distant metastases. In CRC 
this progression is well characterised and has been called the adenoma -  
carcinoma sequence whereby adenomas form from normal colonic mucosa 
and then progress to carcinoma.
Specific mutations have since been identified and associated with different 
steps in the adenoma -  carcinoma sequence, the “stepwise model of colorectal 
carcinogenesis” was suggested by Fearon and Volgestein in 1988 (Vogelstein 
et al., 1988) see Figure 1-1. This is explained in detail in section 1.1.3.3
Figure 1-1 The stepwise model of CRC (Vogelstein et al., 1988)
The study of CRC from its earliest stages is facilitated by access to tissue for 
study -  through colonoscopy and surgery. This can further the understanding 
of sequential development of CRC from normal gut mucosa through 
adenomatous polyp formation to invasive carcinoma with metastatic spread.
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The colorectum has nine anatomical regions, the caecum, appendix, ascending 
colon, transverse colon, descending colon, sigmoid colon and rectum see 
Figure 1-2.
Figure 1-2 Anatomy of the colon, sites of CRC by incidence England 
1997-2000 (CRUK Statistics)
The normal colonic mucosa comprises invaginated crypts lined with a single 
layer of absorptive cells. These are interspersed with mucin-secreting goblet 
cells, neuroepithelial and paneth cells. The mucosa rests on a basement 
membrane (muscularis mucosa), lamina propria and muscularis propria. Cell 
division is thought to occur in the lower third of the crypt, termed the 
“proliferative compartment”. It is here that stem cells reside. As cells migrate 
up the crypts the mature and develop differentiating and finally undergoing 
programmed cell death -  apoptosis. At this point the cells are sloughed off in 
to the gut lumen.
Cell turnover in crypts takes approximately 3-6 days (Cotran R, 1999).
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1.1.3.2 Clonal origins of colorectal tumours
Current theories o f clonality in colonic tumorigenesis
The Unitarian theory of the origin of the four epithelial cell types suggests that 
differentiated cell lineages found within the intestinal epithelium arise from a 
single stem population (Cheng & Leblond, 1974). Stem cells, due to their 
longevity and capacity for self-renewal, are considered by some to be the 
original targets for the mutation(s) required to initiate a neoplasm (Bach et al., 
2000) (Wong & Wright, 1999). The subsequent question is whether such a cell 
acts alone or in co-operation with other mutated stem cells. Proponents of an 
interaction theory suggest that tumours are not initially clonal and that any 
later apparent clonality is the consequence of outgrowth of a dominant clone 
(Alexander, 1985) (Rubin, 1985).
Clonality studies of neoplasms are therefore of great relevance to our 
understanding o f tumourigenesis. To date the study of clonality in human 
tissue has relied on utilising natural mutations or polymorphisms which can be 
used as “markers” of clonality.
The clonality o f colonic adenomas and tumours is a source of some debate. 
Early X-chromosome inactivation studies examining the status of tumours 
from female patients mosaic for various X-linked genes were conflicting. 
Beutler reported a polyclonal colorectal carcinoma (Beutler et al., 1967) and 
Hsu described polyclonal adenomas (Hsu et al., 1983) based on gel 
electrophoresis analysis o f X-inactivation mosaicism of G6PD isoenzymes. 
Fearon et al used DNA rather than protein polymorphisms and examined X- 
inactivation patterns of the phosphoglycerate kinase (PGK) gene, using 
restriction fragment length polymorphisms. They found that adenomas and 
carcinomas taken from female patients with sporadic and familial 
adenomatous polyposis (FAP) associated lesions, had a consistently 
monoclonal pattern of X-chromosome inactivation (Fearon et al., 1987). It 
should be noted however that patch size was overlooked in these studies, and 
it is possible that tumours were covertly polyclonal but appeared monotypic as 
they arose within a large X linked patch. Following this, Novelli et al 
(Novelli et al., 2003) studied Sardinian females heterozygous for the glucose-
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6-phosphatase (G6PD) Mediterranean mutation (563 C—»T) and heat 
deactivated the defective gene followed by enzyme histochemistry to 
demonstrate glucose-6-phosphate activity. Crypts were arranged in hexagonal 
arrays in large patches, with irregular patch borders, containing up to 450 
individual crypts with only 8% of crypts situated on patch borders. For a 
polyclonal tumour to appear heterotypic for an X-inactivated gene it has to 
occur on a patch border and thus the large patch size in the colon means that 
X-inactivation studies are heavily biased toward showing colorectal tumour 
monoclonality.
Direct observation, rather than the indirect methods previously utilised led to 
some confounding results. Novelli and colleagues (Novelli et al., 1996) 
studied a highly unusual individual who had a diagnosis of FAP and was also 
a sex chromosome mixoploid chimera (presumably as a consequence of a 
dicentric Y chromosome). Thus his tissues were a mosaic with the majority -  
some 80% of cells, being XY and the remaining 20%, XO. The detection of 
the Y chromosome in the excised colonic tissues provided an excellent binary 
marker for lineage analysis. Of the 263 adenomas analysed, 246 were wholly 
XY, 4 were entirely XO, while 13 were o f mixed XO/XY genotype. When 
considering only the tumours containing the XO lineage, 13/(13 + 4), or 76% 
of all adenomas appeared to be polyclonal. A very similar result was produced 
in a study using mice heterozygous for the multiple intestinal neoplasia (Min) 
allele o f the adenomatous polyposis coli {Ape) gene and chimaeric for the 
lineage reporter gene ROSA 26 expressing lacZ. 22 of 251 adenomas were 
heterotypic for the blue (ROSA 26) and white (non-ROSA 26) lineages. 
Applying the same ratio as Novelli et al, gave an adenoma polyclonal fraction 
of 79% (Merritt et al., 1997).
Three hypotheses have been proposed to explain tumour polyclonality.
1. Adenoma “pseudo” mosaicism caused by focal loss of the lineage 
marker in otherwise clonal dysplastic tissue.
2. Random / regional collision between independently arising neoplasms 
as a consequence of high tumour multiplicity in FAP patients (Novelli et al., 
1996) and chimeric Min mice (Merritt et al., 1997).
To test this hypothesis Thliveris et al reduced tumour multiplicity in the 
chimaeric mouse model described above by introducing homozygosity for the
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tumour resistance allele of Mom 1. Overall tumour multiplicity was reduced 8- 
fold but the percentage of mixed tumours ranged from 8-63%, with a mean of  
22% (Thliveris et al., 2005). This is higher than would be expected if  
heterotypic tumours are indeed formed through random collision.
3. Active interaction between adjacent crypts. Possible mechanisms 
include microheterogeneity of tumour susceptibility where local stroma 
promotes somatic mutation in adjacent crypts - the so-called landscaper effect 
or stem cell interaction between neighbouring intiated crypts.
To date no firm conclusion has been drawn as to which of these theories holds 
true.
Niche succession
Several theories have been put forward to suggest how a single mutated stem 
cell in normal intestinal crypt can then proliferate to dominate the whole crypt 
(a monocryptal clone) -  this has been termed “niche succession”. Possible 
mechanisms resulting in niche succession include genetic drift, selective 
advantage or “hitchhiking”. Genetic drift can occur through an imbalance in 
symmetric and asymmetric division (or death) of stem cells, therefore altering 
the balance of the number of clones within a normal intestinal crypt. Selective 
advantage or “natural selection” is only possible in a population demonstrating 
three characterstics i) variation within the population ii) variation which is 
heritable and iii) variation which affects the progeny. Therefore when 
considering mutagenesis in the intestinal crypt, genetic instability results in the 
production of many heritable genetic variants which are then selected for the 
growth advantage they confer to the cell. It is equally possible that the 
heritable variants confer a selective disadvantage in that they may trigger 
apoptosis and cell death. A malignant cell population therefore fulfils the 
criteria for natural selection -  resulting in the selection of cells harbouring 
mutations which confer a growth advantage (Nowell, 1976). Maley et al 
suggested that certain mutations found within malignant cells are 
evolutionarily “neutral” in that they confer no selective advantage or 
disadvantage to the cell. When such mutations are present in cells which also 
contain a selectively advantageous allele these “neutral” mutations hitch-hike 
alongside the strongly selected advantageous allele (Maley et al., 2004).
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Crypt fission and clonal expansion
Following niche succession and formation of a monocryptal clone the next 
step in the development o f a microadenoma is the expansion of this clone in to 
the surrounding tissue.
Studies in human and mouse tissue have demonstrated clusters of 
phenotypically similar crypts found together in patches in the intestinal 
mucosa (Taylor et al., 2003) (Greaves et al., 2006) (Park et al., 1995). It has 
been suggested that a process of “crypt fission” whereby crypts bifurcate and 
divide through longitudinal division is responsible for this. Crypt fission is 
certainly the mechanism by which intestinal crypts multiply in the post-natal 
period (Maskens & Dujardin-Loits, 1981) and also during regeneration of gut 
mucosa following radiation (Caimie & Millen, 1975). It has been calculated 
that the crypt fission cycle (the time taken for a single crypt grow and then 
produce two daughter crypts by crypt fission) is 108 days in the mouse 
jejunum and anything from 9-18 years in the human (Bjerknes, 1986; 
Totafumo et al., 1987). In pathological conditions such as inflammatory bowel 
disease, FAP, sporadic and hyperplastic adenomas, the rate of crypt fission 
increases (Cheng et al., 1986) (Bjerknes et al., 1997) (Wasan et al., 1998; 
Wong et al., 2002).
The mutator phenotype hypothesis is based on the observation that malignant 
cells accrue genomic alterations (mutations) at a higher rate than normal 
somatic cells. It is estimated that a malignant cell has up to 1012 genomic 
alterations (Tomlinson et al., 2002). This hypothesis suggests that early 
mutations which allow the maintenance of genetic stability result in an 
increased mutation rate in that cell and overall may be one of the main 
mechanisms driving tumorigenesis (Loeb, 2001). A increased mutation rate 
per se may not be sufficient to initate tumourigenesis - in that individuals with 
HNPCC with MMR defects develop the same number of bowel tumours as the 
general population. In HNPCC however a higher number of these tumours 
become malignant. Additionally, a raised mutation rate may in fact be 
detrimental if it results in the activation of apoptotic mechanisms. Therefore it 
may be that the mutator phenotype simply enables the progression to cancer to 
occur at an increased rate (Tomlinson & Bodmer, 1999).
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There remains much to be determined as to the mechanisms underlying the 
expansion of a few dysplastic crypts (microadenoma) to an adenoma and 
potentially a carcinoma and whether adenomas are truly monoclonal or 
polyclonal in their origin.
1.1.3.3 The stepwise model of colorectal carcinogenesis
The adenoma-carcinoma sequence describes a series of (epi)genetic and 
pathological changes which occur in stepwise progression from normal bowel 
mucosa through to carcinoma (Vogelstein et al., 1988). It is thought that the 
progression from adenoma to carcinoma takes anything from 10 to 40 years 
(Ilyas et al., 1999).
In sporadic CRC (accounting for ~ 90% of cases), the adenoma-carcinoma 
sequence is usually initiated by bi-allelic mutation of the adenomatous 
polyposis coli (APC) tumour suppressor gene. It is therefore described as a 
gatekeeper gene in this context as it appears APC mutation must occur before 
subsequent genetic changes (Levy et al., 1994). The bi-allelic loss of APC 
follows Knudsons two-hit hypothesis for tumour suppressor genes (Knudson, 
1971). In normal circumstances, tumour suppressor genes inhibit cellular 
turnover and growth, and therefore growth inhibition is lost when both alleles 
of the tumour suppressor gene are either mutated or lost through chromosomal 
changes. Oncogenes, in contrast, exert their effect through stimulation of 
cellular proliferation and growth. Proto-oncogenes are the non-mutated (wild 
type) version of oncogenes. Mutations in proto-oncogenes lead to 
inappropriate or excessive expression of their protein resulting in accelerated 
cellular proliferation. This occurs when only one allele is mutated.
Up to 80% of sporadic adenomas and CRC’s harbour somatic APC mutations 
(Cottrell et al., 1992) (Powell et al., 1992) (Nakamura et al., 1992). APC 
mutations have also been found in microadenoma pre-cursor lesions (Smith et 
al., 1994) (Otori et al., 1998).
It therefore follows that bi-allelic APC mutations are the initiating step in 
adenoma development and subsequent genetic and epigenetic changes are 
required for adenoma growth and progression.
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1.1.3.4 The Wnt signalling pathway
Bi-allelic inhibition of APC leads to Wnt signalling dysregulation. Wnt 
signalling is responsible for driving epithelial proliferation in the bowel 
epithelium.
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Figure 1-3 Schematic overview of the Wnt signalling pathway
One of the key elements of the Wnt signalling pathway is /3-catenin which is 
found both cytoplasmically and in the cell nucleus where it triggers target 
gene transcription and cellular proliferation. /3-catenin levels and activity are 
therefore tightly controlled. Wnt signalling is initiated by extracellular binding 
of the Wnt ligand to a co-receptor comprised of the transmembrane receptor 
frizzled and a low density lipoprotein receptor related proten (LRP). This 
triggers translocation of axin, a scaffold protein, from the cytoplasm to the 
membrane, where it binds to the intracellular tail of the LRP co-receptor. This 
results in destabilisation of the /3-catenin degradation complex. (Pinson et al., 
2000) (Mao et al., 2001). f3-catenin degradation is further inhibited via the 
inhibition of GSK3-P through hyperphosphorylation of dishevelled (Dsh) 
(Yanagawa et al., 1995). This leads to nuclear and cytoplasmic accumulation
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of fFcatenin resulting in up-regulation of many genes, through stimulation of 
transcription factors (T cell factor/lymphoid enhancer factor), resulting in over 
production of the proto-oncogenes cyclin D1 and c-myc. (Parker et al., 2002) 
(Thompson et al., 2002). Therefore, when the Wnt pathway is dysregulated 
high levels of cytoplasmic and nuclear fi-catenin are found, leading to over­
transcription of target genes and uncontrolled cellular proliferation.
Following Wnt dysregulation, mutations in the oncogenes K-ras and BRAF 
appear to facilitate adenoma growth. Historically, K-ras is associated with 
classical adenoma growth whereas BRAF is associated with the serrated 
adenoma pathway (Jass et al., 2002). To date, it has not been reported that any 
adenomas harbour mutations in both of these oncogenes. Both K-ras and 
BRAF are members of the mitogen activated protein kinase (MAPK) pathway 
and mutations in these oncogenes are found in adenomas undergoing 
transition from early to intermediate stage. K-ras is found in approximately 
50% and BRAF in 10% of these adenomas (Bos et al., 1987) (Rajagopalan et 
al., 2002) (Yuen et al., 2002).
Adenoma progression from intermediate to late stage is associated with loss of 
chromosome 18q, this is observed in approximately 80% of adenomas >5mm 
size and 75% of CRC’s (Law et al., 1988) (Vogelstein et al., 1988) 
(Vogelstein et al., 1989). There are two tumour suppressor genes SMAD2 and 
SMAD4 (small mothers against decapentaplegic) which are thought to be 
associated with this loss. They both belong to the transforming growth factor- 
p/bone morphogenic pathway (TGF-p/BMP) signalling pathway. Point 
mutations have been reported in SMAD2 and SMAD4 in CRC’s (Eppert et al., 
1996) (Thiagalingam et al., 1996).
Transition from late adenoma to carcinoma is associated with loss of 
chromosome 17q -  where the tumour suppressor gene p53 resides (Fearon et 
al., 1987) (Vogelstein et al., 1988). Missense and truncating mutations in p53 
correlating with 17q loss of heterozygosity (LOH) have been reported (Baker 
et al., 1989) (Baker et al., 1990).
In addition to the adenoma-carcinoma sequence, two other genetic and 
epigenetic changes are observed in CRC resulting in genomic instability 
which is partly responsible for accumulation of mutations in tumour
34
suppressor genes and oncogenes. Chromosomal instability and microsatellite 
instability appear to occur early in tumorigenesis (Jacoby et al., 1995) (Nowak 
et al., 2002). Chromosomal instability, demonstrated by whole and partial 
chromosomal losses and gains is observed in tumours of FAP patients and 
although not completely understood, it is thought that mutations in APC  may 
be the underlying cause of chromosomal instability (Fodde et al., 2001). 
Karyotypic changes namely polyploidy have been observed in in-vitro studies 
of cells with mutant APC  suggesting that it has a role in chromosomal 
segregation. However, there is little evidence to support this finding in vivo 
(Fodde et al., 2001) (Kaplan et al., 2001).
Microsatellites are numerous mono, di, tri, or tetra nucleotide repeats in DNA 
sequences, both intronic and extronic. They occur throughout the genome. 
During DNA replication, mutations can occur in the microsatellite regions 
causing misalignment o f the daughter strands -  this is termed microsatellite 
instability. Therefore MSI is associated with underlying germline mutation in 
mismatch repair enzymes which are the cause o f HNPCC cancers (Aaltonen et 
al., 1993) (Aaltonen et al., 1994; Boland et al., 1998).
1.1.3.5 Characteristics of adenomatous polyps
Adenomatous polyps develop when the homeostatic balance between cell 
proliferation and apoptosis is disrupted in the bowel epithelium. Adenomatous 
polyps are discrete lesions comprising dysplastic or neoplastic tissue bounded 
by an intact basement membrane. On histological examination, dysplastic 
epithelium is characterised by cellular crowding, nuclear abnormalities 
(enlargement, elongation and hyperchromatism) and cellular abnormalities 
(loss of polarity and loss of stratification). As nuclear size increases, so the 
cytoplasmic volume decreases. The proliferative compartment of dysplastic 
crypts enlarges from its usual third, and in some cases extends to the crypt 
surface. It is thought that adenomas arise from unicryptal lesions which 
enlarge and multiply by crypt fission (Chang & Whitener, 1989) (Wasan et al., 
1998) {Wong, 1999 #647, forming microadenomas (clusters of up to 20 
abnormal crypts). As the microadenoma continues to grow in, there is further
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evidence that dysplastic epthelium may also contribute to growth in adjacent 
crypts through “top down” growth (Preston et al., 2003). The clonality of 
microadenoma/adenoma development and progression is addressed in the 
work described in chapter 9.
Adenomatous polyps can be morphologically classified into three distinct 
groups, tubular, tubulovillous and villous. Tubular adenomas have a villous 
component which makes up less than 25% of the whole adenoma. Villous 
components are areas of non-dyplastic fronds which are up to twice the height 
of normal crypts. Villous adenomas have a villous component of 75% or 
higher whereas tubulo-villous adenomas have a villous component somewhere 
between 25 and 75%. As adenoma size increases, so the grade of dysplasia 
generally worsens and the villous component enlarges (O’Brien et al., 1990). 
Large adenomas with severe dysplasia, but with an intact basement membrane 
are termed carcinoma in situ.
Tubular adenoma Tubulo-villous adenoma Villous adenoma 
Figure 1-4 Endoscopic view of tubular, tubulo-villous and villous adenomas
1.1.3.6 Characteristics of hamartomatous polyps
Hamartomatous polyps arise in two inherited syndromes, juvenile polyposis 
and Peutz-Jeghers syndrome. They do not normally exhibit any of the classical 
signs of dysplasia, but can contain areas of adenomatous dysplasia and 
invasive carcinoma. Hamartomatous polyps associated with Juvenile 
Polyposis are characterised by stromal, mucin-filled cysts which are lined by
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flattened epithelium. In Peutz-Jeghers syndrome, the polyps are characterised 
by normal epithelial mucosa and a tree-like branching smooth muscle core.
Figure 1-5 H&E stained tubuloadenoma \200 (A) and hamartomatous juvenile 
polyposis polyp x200 (B) characterised by mucinous cysts
1.1.3.7 CRC symptoms and presentation
Symptoms and presentation of CRC may vary considerably depending on the 
site and size of the primary tumour. Symptoms may in fact be absent in early 
disease or non-specific such as weight loss and anaemia secondary to occult 
blood loss. Tumours arising in the distal colon and rectum can present with 
rectal bleeding, a change in bowel habit and in late and extreme cases show 
symptoms of bowel obstruction and perforation (up to one fifth of patients 
present with bowel obstruction or peritonitis secondary to bowel perforation).
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1.1.3.8 Staging of CRC
CRC staging involves a combination of Dukes staging for CRC (introduced in 
1932) and the T (tumour size), N (nodal involvement), M (presence or absence 
of distant metastases) system. This combined system gives more precise 
clinico/pathological information than either used alone (see Figure 1-6 and 
Table 1-1 for TNM staging with the approximations of Dukes staging).
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Figure 1-6 Staging of CRC -  (National Cancer Institute, USA)
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TNM Modified Dukes’
S tage  0 Carcinoma in situ A
S tage  1 Tumour invades subm ucosa (T1)
Tumour invades m uscularis propria (T2)
No nodal involvement, no distant m etastases
A
S tage  II Tumour invades beyond m uscularis propria (T3) 
Tumour invades into other organs (T4)
No nodal involvement, no distant m etastases
B
S tage  III 1-3 regional lymph nodes involved - any T (N1) 
4 or more regional lymph nodes involved (N2) 
No distant m etastases , any T
C
S ta g e  IV Distant m e tas tases  
Any T stage, any N stag e
D
Table 1-1 TNM staging with approximate Modified Dukes staging for CRC
Ten percent o f patients at presentation are diagnosed as stage 0 or stage I. The 
remaining 90% of patients at diagnosis are equally distributed between stages 
II, III and IV. Up to 50% of patients are diagnosed with liver metastases either 
at the time of diagnosis or as a result of disease recurrence. A small proportion 
of these patients are candidates for surgical resection of the metastasis.
Dukes’ stage Freq. at diagnosis Approx. 5-year 
survival
A 11% 83%
B 35% 64%
C 26% 38%
D 29% 3%
Table 1-2 Frequency of CRC diagnoses by Dukes stage with 5 year survival 
(England and Wales 1996-1999)
At this time early diagnosis o f CRC is uncommon (unless an individual is 
screened due to an affected family member(s)). This may be for many reasons 
including the insidious onset, vague, non-specific symptoms and the fact that
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the average General Practitioner in the UK will see one case of CRC per year 
(Hobbs, 2000). A nation-wide screening programme is in progress involving 
the use o f faecal occult blood tests and colonoscopy in individuals aged 60-69 
years of age. It is expected that the whole of the UK will be actively involved 
in CRC screening by 2009.
1.1.3.9 Current treatment strategies
Current treatment incorporates surgery, +/- chemotherapy, +/- radiotherapy, 
+/- molecularly targeted treatments depending on the CRC stage at diagnosis. 
Surgery
Standard surgical treatment for CRC patients is open resection of the primary 
tumour with regional lymph node dissection. Eighty percent of CRC patients 
undergo surgery with curative intent (NICE. Improving outcomes in CRC, 
updated manual Sept 2003). However up to 50% of all patients with > Stage II 
disease recur by two years o f follow up. Variation in recurrence rate has been 
observed in different treatment centres with surgeons of varying experience 
(Dorrance et al., 2000). Therefore it is vital that CRC patients are cared for 
and treated in designated cancer centres with multidisciplinary team 
management.
Chemotherapy and Radiotherapy
The most commonly used chemotherapy regimes use 5-fluoruracil (5-FU, a 
nucleoside analogue), leucovorin and more recently oxaliplatin (a DNA 
chelator) and irinotecan (a topoisomerase inhibitor).
Neo-adjuvant therapy -  The role of neo-adjuvant therapy is to reduce the size 
of the primary tumour before surgical resection, it would also incorporate the 
“adjuvant” treatment up-front should this be required.
Adjuvant therapy -  Adjuvant therapy is used following surgery -  allowing 
sufficient time for healing. The aim is to treat “micro-metstases” systemically 
and is currently offered to patients with stage III disease where there is an 
improved overall survival benefit of 12% when compared to patients who 
undergo surgery alone (Laurie et al., 1989). The most commonly used
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adjuvant treatment is the De-Gremont regime which incorporates infusional 5- 
FU with leucovorin, There is some debate as to whether adjuvant 
chemotherapy should be offered to patients with stage II disease, particularly 
those with higher risk clinical features such as tumour adherence to adjacent 
tissue or higher risk molecular features such as aneuploidy or deletion of 
chromosome 18q (Lanza et al., 1998) (Jen et al., 1994). There are currently 
trials addressing the use of adjuvant therapy in stage lib disease. Currently 
stage II patients are candidates for clinical trials in which either surgery alone 
or 5-FU-leucovorin remain the standard treatment (Poplin et al., 2005). 
Post-operative radiotherapy is indicated in higher risk patients, T3 or 4 
primary tumour, tumour location in immobile sites, local perforation, 
obstruction and residual disease post resection.
Chemotherapy for advanced disease, recurrent disease and palliative therapy -  
Treatment options at this stage include the use of oxaliplatin, irinotecan (a 
topo-isomerase inhibitor) and capecitabine (an oral pre-metabolite of 5-FU) 
alongside surgical resection and radio-ablation of liver metastses, should they 
be amenable to that approach.
Molecularly targeted treatments
Since 2003 molecularly targeted treatments have been approved for use in 
CRC following the results o f two randomised controlled trials.
Bevacizumab -  a monoclonal antibody directed against vascular endothelial 
growth factor (VEGF) demonstrated improved progression free survival and 
overall survival in patients with advanced disease (Kabbinavar et al., 2003). 
Cetuximab -  a monoclonal antibody directed against epidermal growth factor 
receptor, was used either alone or in combination with irinotecan in patients 
with irinotecan resistant CRC. An improved response rate and progression free 
survival was seen in the cetuximab treated group, but no improvement in 
median survival was observed (Cunningham et al., 2004). Current studies are 
assessing the use of cetuximab in higher risk patients in the adjuvant setting.
41
1.1.3.10 CRC outcome in the UK
Individuals with stage I and II disease have an 83% and 64% 5 year overall 
survival rates respectively. When considering stage III patients, 50% are cured 
by surgery alone, 7% are cured by surgery and adjuvant chemotherapy and 
43% relapse in spite of surgery and adjuvant chemotherapy. See Table 1-2 for 
survival rates per stage. One of the most important prognostic factors is lymph 
node status (Berger et al., 2005). A study of predictive molecular factors with 
11 years post-operative follow up in stage III patients who received adjuvant 
chemotherapy found that those tumours with no chromosome 18q loss, 
microsatellite stable (MSS) tumours without chromosome 18q loss compared 
to MSS tumours with 18q loss, tumours with microsatellite instability (MSI) 
compared to MSS tumours and MSI tumours with TGF$ 1 mutation compared 
to MSI without the TGFpl mutation all had improved overall survival 
(Watanabe et al., 2001). MSI status itself can be used as a predictive factor for 
response to treatment with 5-FU, MSI high tumours have an increased overall 
survival but do not respond as well to 5-FU treatment (Ribic et al., 2003). 
Tumour markers measured in the serum -  carcinoembryonic antigen (CEA) 
and carbohydrate antigen 19.9 (CA 19.9) are also indicative o f poor prognosis 
or recurrence of disease (Reiter et al., 2000).
Therefore it is imperative that further understanding of the CRC risk factors, 
inherited genetic predisposition, molecular markers and natural history of the 
disease continue alongside improved primary prevention and screening 
programmes if we are to improve on the current incidence, survival and 
mortality statistics.
1.2 Hereditary Colorectal Cancer Syndromes
Germline mutations can be identified in approximately 2-6% of CRC cases, 
the majority of which occur in families showing Mendelian inheritance 
(Kinzler & Vogelstein, 1996). Until recently, the known inherited CRC
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syndromes were solely the result o f autosomal dominant, highly-penetrant 
high risk alleles which facilitated early recognition of the underlying genetic 
diagnosis (Cannon-Albright et al., 1988), (Houlston et al., 1992), (Esteller et 
al., 2001). These syndromes are well characterised and include Hereditary 
Non-Polyposis CRC (HNPCC) with germline mutations in MLHl, MSH2, 
PMS2 and MSH6 genes, Familial Adenomatous Polyposis (FAP) with 
mutations in the APC tumour suppressor gene. The most recently identified 
inherited CRC predispositon syndrome is A/y//-associated polyposis (MAP) 
which is caused by mutations in the base excision repair gene MYH. MAP was 
first described in 2002 (Al-Tassan et al., 2002) (Crabtree et al., 2003), and is 
inherited in an autosomal recessive manner. MAP will be described in more 
detail in a following section of this chapter. Other inherited polyposis 
syndromes include Peutz-Jeghers syndrome (LKB1 gene) and juvenile 
polyposis (SMAD4 and ALK3 genes). See Table 1-3 for overview of inherited 
CRC syndromes and mode o f discovery.
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Syndrome Gene Location Inheritance Function Method of discovery
FAP APC 5q AD Inhibition of wnt signalling
Linkage
analysis
HNPCC MLH1 3p AD DNA mismatch repair
Linkage
analysis
MSH2 2p AD DNA mismatch repair
Linkage
analysis
MSH6 2p AD DNA mismatch repair Candidate gene
PMS2 7p AD DNA mismatch repair Candidate gene
MAP MYH 1P AR
Base excision 
repair
Somatic
mutation
screening
Peutz-Jeghers LKB1 19p AD
Serine
threonine
kinase
CGH and 
linkage analysis
Juvenile
polyposis SMAD4 18q AD
TGF-beta
signalling
Candidate 
linkage analysis
ALK3 10q AD TGF-betasignalling
Linkage
analysis
Cowden’s PTEN 10q AD
Phosphatase, 
inhibition of 
AKT signalling
Somatic
screening,
Linkage
Table 1-3 Summary of inherited CRC syndromes, inheritance and 
method of discovery (AD -  autosomal dominant; AR -  autosomal 
recessive; BER -  base excision repair; CGH -  comparative genomic 
hybridisation)
At this time defects in the known predisposition genes account for up to 6% of 
all CRC. However, twin studies suggest that up to 35% of colorectal cancers 
have a genetic component (Lichtenstein et al., 2000), and the relative risk in 
siblings is 2-3 fold for adenomas and CRC (Cannon-Albright et al., 1988; 
Houlston et al., 1992). Some of these cases may be due to as yet undiscovered 
moderate or high penetrance genes, but the remainder are likely to involve 
changes in genes conferring a lower level of risk and also highly probable that 
they are harder to identify.
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Hereditary colorectal cancer predisposition syndromes can be divided into two 
main categories depending on the presence or absence of multiple benign 
precursor lesions.
1.2.1 Hereditary Non-Polyposis Colorectal Cancer (Lynch 
syndrome).
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal 
dominant disorder characterised by few colonic adenomas, early onset of 
predominantly right sided CRC, and specific extra-colonic tumours including 
cancer o f the ovary, endometrial, stomach, small bowel and uro-epithelial tract 
(although there is a lower risk of developing these tumours than CRC). A 
diagnosis of HNPCC is made if the affected individual and family members 
fulfill the Amsterdam criteria (Vasen et al., 1999), see table Table 1-4 for 
Amsterdam criteria. The disease accounts for approximately 1-6% of 
colorectal cancer cases when the Amsterdam and Bethesda criteria are used 
for diagnosis.
Table 1-4 Amsterdam criteria (Vasen et al., 1999)
Mutations in the DNA mismatch repair (MMR) genes MLH1 and MSH2 
account for 90% of cases and MSH6 and PMS2 for the remaining 10% of
45
cases (Miyaki et al., 1997). Up to 29% of MLH1 and 16% of MSH2 mutations 
are missense making it difficult to determine the potential pathogenicity 
(Thibodeau et al., 1998) (nonsense mutations often lead to either a stop codon 
or a frameshift). A database of germline mutations in HNPCC has been 
developed by the International Collaborative Group on Hereditary 
Nonpolyposis Colorectal Cancer and can be found at http://www.nfdht.nl. If 
left without screening there is an 80% lifetime chance of developing CRC 
when carrying a heterozygous mutation in one of these MMR genes. The 
average age at CRC diagnosis is 45 years.
When compared to sporadic cancers HNPCC cancers are more poorly 
differentiated and there is a higher incidence of synchronous cancers 
(occurring within six months of diagnosis) and metachronous cancers 
(occurring greater than six months from diagnosis). Histologically, an excess 
of mucoid and signet cells occur along with a Crohn’s like picture of 
inflammatory infiltrate.
Adenoma development in HNPCC has previously been reported to range from 
between 17 and 49%, the largest study to date of 695 patients with proven 
MMR mutations found 10.6% of HNPCC patients to have at least one 
adenoma at first colonoscopy (Liljegren et al., 2008). Interestingly, the same 
study found 5.3% of HNPCC patients to have at least one hyperplastic polyp. 
When present, adenomas progress more rapidly to carcinoma in HNPCC, in 2- 
3 years compared to 8-10 years in the general population (Lynch & de la 
Chapelle, 2003).
Microsatellite instability occurs due to the loss of function of MMR genes and 
immunohistochemistry can be performed on tumour tissue to demonstrate the 
absence or weak expression of the MMR protein (Thibodeau et al., 1998). 
Individuals with HNPCC (with either known germline MMR mutations or 
strong clinical evidence) are screened from the age of 20-25 onwards with 
annual colonoscopy. In women, screening for endometrial and ovarian cancer 
is undertaken with annual trans-vaginal ultrasonography which is performed 
from the age of 30 onwards. Serum Ca-125 levels are also measured as a sign 
of ovarian malignancy. However the sensitivity and specificity of both of 
these is limited in ovarian cancer diagnosis.
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There is a relatively high incidence of CRC (albeit non-fatal cases) in those 
patients who are screened (study of 15 year follow up of 3-year and annual 
screening) due to the accelerated pathogenesis of HNPCC and in light of this, 
subtotal colectomy and total abdominal hysterectomy with bilateral salpingo- 
oopherectomy are offered to selective high risk patients.
1.2.2 Familial Adenomatous Polyposis.
Familial Adenomatous Polyposis (FAP) is a highly penetrant autosomal 
dominant disorder accounting for -1% of CRC diagnoses. Its incidence is 
approximately 1:13,500 (Bisgaard et al., 1994). Affected individuals develop 
hundreds to thousands o f adenomatous polyps during the second and third 
decades o f life, one or more of which progress to cancer in nearly 100% of 
cases. The selective disadvantage associated with such a highly penetrant 
disease (with in certain cases an extreme phenotype) is overcome by the fact 
that there is a high incidence of de novo germline mutations which account for 
up to 25% of cases (Bisgaard et al., 1994) (Bulow, 1986). Diagnosis is made 
clinically in individuals with >100 adenomas (fewer in younger patients) 
(Vasen et al., 1993).
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Figure 1-7 Colectomy specimen and H&E stained adnenoma (x20) from an FAP 
patient
Each individual adenoma has a low likelihood of progressing to carcinoma but 
the sheer number results in a lifetime risk of 100% with most affected 
individuals developing CRC in their forties if left untreated.
Extracolonic features include desmoids, osteomas, congenital hypertrophy of 
the retinal epithelium (CHRPE), sebaceous cysts and abnormal dentition 
(Blair & Trempe, 1980) (Heiskanen & Jarvinen, 1996). Associated cancers 
include sarcomas, papillary cancer of the thyroid, hepatoblastomas, pancreatic 
cancer and medulloblastoma (Turcot’s syndrome type 1) (Hamilton et al., 
1995) (Van Meir, 1998).
1.2.2.1 The APC tumour suppressor gene.
The APC gene is located on chromosome 5q21. It consists of 15 translated 
exons with its most common isoform encoding a 2843 amino acid protein 
(Groden et al., 1993). Exon 9 may undergo alternative splicing which adds an 
additional 18 amino acids to the transcribed protein (Sulekova & Ballhausen,
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1995). APC  is expressed in a variety of tissues including epithelial and 
mesenchymal cells of both foetal and adult tissue (Midgley et al., 1997) and 
has a number of functional domains.
The 5’ amino-terminal domain contains a series of heptad repeats which are 
thought to be involved in APC homo-dimer formation (Groden et al., 1991) 
(Joslyn et al., 1993). Amino acids 453-767 share some homology with the 
central repeat region of the Drosophila segment polarity protein armadillo 
which through binding Asef controls cell adhesion and motility through the 
actin cytoskeleton (Kawasaki et al., 2000). The following two motifs -  an 
imperfect repeat of 15 amino acids occurring three times between codons 1020 
and 1169 and another imperfect repeat of 20 amino acids occurring seven 
times between residues 1262 and 2033 are involved in /3-catenin binding and 
degradation (Rubinfeld et al., 1993) (Su et al., 1993). /3-catenin is a central 
component o f the Wnt signalling pathway (see section 1.1.3.4). Each o f the 20 
amino acid repeats contains an SXXXS consensus site which acts as a 
substrate for GSK3/3 phosphorylation (Munemitsu et al., 1995) (Rubinfeld et 
al., 1996). Three SAMP repeats occur between the 20 amino acid repeats, 
these mediate the binding of axin (Kishida et al., 1998). Several signalling 
motifs exist which are thought to mediate nuclear import and export o f APC 
(Rosin-Arbesfeld et al., 2000). Interaction with microtubules occurs through a 
region located between codons 2200 and 2400 (Deka et al., 1998) and also at 
the carboxyl terminal (codons 2560 -  2843) where the microtubule associated 
protein EB1 binds (Su et al., 1995). A role in chromosomal segregation has 
been suggested by Fodde and Kaplan in that APC and EB1 co-localise at the 
ends of microtubules attached to kinetochores at mitosis (Fodde et al., 2001) 
(Kaplan et al., 2001).
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Figure 1-8 The APC gene with functional domains annotated
Due to the diversity of its function, APC  has been implicated in a variety of 
cellular processes including cell migration, cytoskeletal organisiation, cell 
cycle control and apotosis (Sieber et al., 2000). In terms of its role as a tumour 
suppressor gene in CRC, it appears that it is the impact it has on Wnt 
signalling through controlling levels of P-catenin that is most important. 
Mutant APC  is unable to down-regulate p-catenin, therefore resulting in clonal 
expansion o f mutant cells. This is supported by studies demonstrating that 
colorectal tumours without APC  mutations can harbour mutations in P-catenin 
which prevent the degradation of the protein and resulting in similar 
dysregulation of cell cycle control (Ilyas et al., 1997) (Sparks et al., 1998). 
There also appears to be an “optimal level” of Wnt signalling through which 
there is a relationship between the underlying germline mutation in APC and 
the somatic “second hit” mutation (Lamlum et al., 1999). The role that APC 
may play in chromosomal segregation suggests a mechanism by which it may 
cause chromosomal instability observed in FAP tumours.
APC harbours detectable germline mutations in approximately 85% of cases 
of FAP. The vast majority of these are insertions, deletions and nonsense 
mutations resulting in frameshifts and premature stop codons. Ten percent of 
FAP patients have a deletion of AAAAG at codon 1309. Initiation of tumour 
growth occurs following a second somatic event through either mutation, 
allelic loss or silencing leading to inactivation of the wild type APC allele. 
There is a distinct genotype-phenotype correlation in FAP. Mutations between
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codons 450 and 1580 are associated with classical polyposis with mutations 
between codons 1250 and 1464 causing particularly severe disease. In 
contrast, germline mutations in the extreme 5’ or 3’ ends of APC or in the 
alternatively spliced regions of exon 9 cause attenuated adenomatous 
polyposis (AAPC or AFAP) (Spirio et al., 1993). The genotype-phenotype 
correlation also applies to some of the extracolonic features - desmoids are 
associated with mutations between codons 1395 and 2000 (Wallis et al., 1999) 
and CHRPE with mutations between codons 457 and 1444 (Caspari et al., 
1995). In a recent study of 599 index cases of “attenuated polyposis” somatic 
mosaicism of the APC  gene was found to be responsible in up to one fifth of 
cases (Hes et al., 2007). At this time there are no other studies to support this 
finding.
There is also some evidence suggesting that other environmental and genetic 
factors play a role in disease severity, as some individuals with identical 
germline APC  mutations have differing polyp burden (Paul et al., 1993).
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Figure 1-9 Genotype/phenotype correlation associated with germline APC 
mutations
1.2.2.2 Somatic mutations at APC  -  the mutation cluster 
region
In the majority of FAP tumours the second allele of APC is disrupted through 
either a truncating mutation or through allelic loss. In patients with germline 
mutations at codon 1309 (5bp deletion) the second allele is lost (LOH) in up to 
85% of tumours studied (Crabtree et al., 2003). Through studying tumours of
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individuals with FAP alot has been learned to improve the understanding of  
tumorigenesis in sporadic cases. In both FAP and sporadic cases the majority 
of somatic mutations occur in the 5’ region o f the APC gene. There is a region 
between codons 1284 and 1580 where 80% of somatic mutations occur. This 
was termed the mutation cluster region by Miyoshi et al, there are three 
“hotspots” at codons 1309, 1450 and 1554 which account for 20% of all 
somatic mutations (Miyoshi et al., 1992).
1.2.2.3 Clinical management of FAP patients.
Following clinical and molecular diagnosis -  through genetic counselling and 
testing, strict surveillance is the key with annual colonoscopy and elective 
sub-total colectomy when adenoma burden deems it necessary. This is usually 
by the mid 20’s. Colonoscopic surveillance usually commences in the teenage 
years. Regular endoscopic surveillance of the upper GI tract with endoscopy is 
recommended as is screening for papillary carcinoma of the thyroid (Lynch & 
de la Chapelle, 2003).
Genetic testing in classical FAP patients is usually restricted to the 5’ half of 
the APC  gene in the first instance, if a mutation is not found the whole gene is 
then screened and MLPA analysis undertaken for whole exon deletions and 
duplications.
1.2.3 Hamartomatous Polyposis Syndromes.
The hamartomatous polyposis syndromes comprise familial juvenile 
polyposis, Peutz-Jehgers syndrome, Cowdens disease and Bannyan- 
Ruvalcaba-Riley syndrome.
Juvenile polyposis
Juvenile polyposis syndrome (JPS) is a rare autosomal dominant syndrome 
caused by germline mutations in SMAD4/DPC4 (Howe et al., 1998b), 
BMPR1A/ALK3 (bone morphogenic protein receptor lA/activin receptor-like 
kinase 3) (Howe et al., 2001) (Sayed et al., 2002). Both SMAD4 and BMPR1A
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are members of the TGFp/BMP signalling pathway which is a target in CRC 
carcinogenesis.
The phenotype is that of multiple colonic hamartomatous polyps and 
sometimes polyps in the small intestine and stomach (Hofting et al., 1993) 
(Veale et al., 1966). Associated clinical manifestations and can include mental 
retardation, macrocephaly, heart defects (aortic valve malformations) and 
polydactyly. Diagnosis is usually made before the age of 10 years due to rectal 
bleeding, diarrhoea and abdominal pain (Heiss et al., 1993). There is an 
associated CRC risk despite there being fewer benign colonic polyps 
(Giardiello et al., 2000). Clinical management of JPS depends on the severity 
of the polyp burden whereby prophylactic surgery is sometimes indicated 
(Heiss et al., 1993) (Scott-Conner et al., 1995), or colonoscopic surveillance 
(Howe et al., 1998a).
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Peutz-Jehgers Syndrome
Peutz-Jehgers syndrome is an autosomal dominant condition characterised by 
hamartomatous polyps of the small intestine and less commonly the colon. 
Other clinical features include peri-oral pigmentation, pigmentation if the 
fingers and sex cord tumours with annular tubules of the ovary (Giardiello et 
al., 1987). The syndrome is caused by germline mutations in serine threonine 
kinase LKB1/STK11 (Hemminki et al., 1998). The highest cancer risk is in the 
GI tract (both small intestine and colon), but tumours also occur in the breast, 
ovary, pancreas and endometrium (Boardman et al., 1998) (Giardiello et al., 
2000). Diagnosis is often made in adolescence due to gastrointestinal 
bleeding, abdominal pain or intestinal obstruction. The characteristic peri-oral 
and finger freckling aid clinical diagnosis. Germline mutation of LKB1 is 
found in 50% of PJS families and between 30-60% of sporadic cases resulting 
in truncation or loss o f the protein (Hemminki et al., 1998) (Jenne et al.,
1998).
LKB1 appears to play a role in apoptosis and foetal development. It is found in 
apoptotic intestinal cells (Karuman et al., 2001) and has also been found to 
regulate p53 dependent apoptosis and control of cellular proliferation (Yoo et 
al., 2002).
Cowdens syndrome and Bannyan-Riley-Ruvalcaba Syndrome
Cowdens syndrome is an autosomal dominant disorder characterised by 
multiple muco-cutaneous lesions including multiple trichilemmomas, acral 
keratoses and oral mucosal papillomatosis (Brownstein et al., 1979) (Starink et 
al., 1986). 40% of patients develop multiple hamartomatous polyps involving 
the whole of the GI tract (Hizawa et al., 1994) (Waite & Eng, 2002). 
Hamartomatous polyps demonstrate excessive smooth muscle in the core of 
the polyps which are also often inflamed or fibrotic (Oberhuber & Stolte, 
2000). In Cowdens syndrome there is an increased risk of developing thyroid, 
breast and genito-urinary cancers (Salem & Steck, 1983) (Starink et al., 1986). 
Bannayan-Riley-Ruvalcaba syndrome is characterised by macrocephaly, 
lipomatosis, haemangiomatosis and speckling of the penis. Patients may also 
develop hamartomatous polyps (Gorlin et al., 1992).
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The presence of hamartomatous polyps in both of theses syndromes suggests 
an increased risk of CRC but a firm association is yet to be made.
Germline mutations in PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) tumour suppressor gene cause both of these syndromes 
(Liaw et al., 1997) (Marsh et al., 1997). PTEN is a dual specificity 
phosphatase which has a number of pro-apoptotic functions including negative 
regulation of PI3K/AKT and MAPK signalling pathways (Waite & Eng, 
2002).
1.2.4 The Hereditary Mixed Polyposis Syndrome
Hereditary mixed polyposis syndrome (HMPS) is an autosomal dominant 
condition characterised by the development of multiple tumours within the 
colon. These include atypical juvenile polyps, hyperplastic polyps, serrated 
adenomas, classical adenomas and carcinoma (Whitelaw et al., 1997). The 
locus for HMPS (CRAC1) has been mapped to chromosome 15ql3-14 in 
Ashkenazi families and has been found to correlate with the Ashkenazi 
susceptibility locus CRAC1 (Jaeger et al., 2003). Some Asheknazi families 
with the HMPS/C&4C7 locus only develop multiple classical adenomas and 
CRC (Jaeger et al., 2003).
More recently, (single nucleotide polymorphism) SNP genotyping of a panel 
of SNPs associated with the CRAC1 locus in CRC cases and controls found 2 
SNPs associated with GREM1 and SCG5 (both found within the CRAC1 
locus) to be strongly associated with CRC risk (/>=4.44xl014)(Jaeger et al., 
2008).
1.2.5 Hyperplastic Polyposis Syndrome
Hyperplastic polyps (HPPs) are common bowel tumours usually found in 
individuals aged 60 and over. The great majority o f HPPs do not have 
malignant potential but there is increasing evidence to suggest that some may 
progress to CRC (Church et al., 1988) (Jass et al., 2002). This risk is highest
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when polyps exhibit dysplastic features as in cases of mixed 
HPP/adenomatous polyps and serrated adenomas. The age at presentation, 
size, number and anatomical location (ascending colon) all contribute to the 
CRC risk (Goldstein et al., 2003). The diagnostic criteria o f HPPS and the real 
CRC risk associated with it are still evolving, Burt and Jass defined HPPS as 
any individual with >5 HPP’s proximal to the sigmoid colon two of which 
>lcm  in diameter or any individual with >30 HPP’s anywhere in the colon 
(Burt, 2000). Rashid et al have devised a different classification for HPPS 
whereby any individual with >20 HPP’s anywhere in the colon may be 
diagnosed. Further classification based on size (>lcm) or “multiple” HPP’s 
(5-10) was also suggested (Rashid et al., 2000).
The proposed “serrated pathway” of colorectal neoplasia suggests HPP’s to be 
the initiating lesion prior to development in to mixed polyposis 
(hyperplastic/adenomatous polyps), serrated adenomas and finally CRC. 
BRAF mutations are found commonly in serrated adenomas (Jass et al., 2002) 
(Goldstein et al., 2003).
A recent study o f somatic mutations in 245 HPP’s found mutations in BRAF 
and KRAS2 in 75% o f polyps, the frequency of BRAF mutations was higher 
individuals with >10 polyps (Carvajal-Carmona et al., 2007). Patients would 
have either BRAF or KRAS2 mutations in any one polyp, none were found to 
have both. MSI was not observed and the epithelium of the polyps was found 
to be monoclonal (which is also the case for JPS).
There is mounting evidence to suggest a genetic predispostion to HPPS in 
young onset patients with multiple HPP’s but to date a locus or candidate gene 
is yet to be determined (Niv et al., 2003) (Jeevaratnam et al., 1996) (Lage et 
al., 2004).
1.2.6 MYH-associated Polyposis and CRC
The role of MYH as a polyposis and CRC predisposition gene was discovered 
in 2002 through somatic screening of adenomas found in an interesting family 
with multiple adenomas and CRC which harboured a germline APC mutation
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E1317Q of questionable pathogenicity (Sampson et al., 2003). MYH 
associated polyposis (MAP) has an autosomal recessive inheritance.
Al Tassan et al found that analysis of the somatic mutation spectrum of APC 
in tumour samples from a single family who had none of the known germline 
APC  or MMR mutations revealed 18 somatic inactivating mutations in APC, 
15 o f which were G:C -> T:A transversions - a significantly higher proportion 
than that found in sporadic or FAP tumours (Sampson et al., 2003). This 
mutational signature suggested faulty DNA repair of 7,8-dihydro-8-oxo- 
2 ’deoxyguanosine (8 -oxo-G), which led to screening for germline mutations 
in MYH and other BER enzymes, MTH1 (Mut-T Homologue) and OGGI. 
Mutations in MYH were identified in both maternal and paternal alleles in 
affected individuals. MYH associated polyposis (MAP) is the first human 
cancer predisposition disorder to be linked to BER.
MYH is a DNA glycosylase involved in the repair o f oxidative damage of 
DNA by base excision repair (BER). MYH maps to the short arm of 
chromosome 1, between p32.1-p34.3. It is 7.1 kb long, and contains 16 exons. 
It encodes a 535 amino acid protein with 41% identity to the shorter E coli 
protein (Slupska et al., 1996).
1.2.6.1 DNA base excision repair glycosylases and the
function of MYH
Genomic integrity is maintained through several DNA repair mechanisms 
which continuously identify and rectify damaged and mispaired bases. Base 
excision repair involves a family o f DNA glycosylases working alongside 
apyrimidine/apurine (AP) lyases, structure specific nuclease, repair 
polymerase, DNA ligase and PCNA tethering complexes. The overall 
mechanism is that of a simple cut and patch process removing DNA bases 
which have undergone oxidative damage. Damage specific excision is 
initiated by the recognition o f oxidatively damaged bases either in the mother 
or daughter strand of replicating DNA or in the nucleotide pool itself. Once 
the commitment to excision is made this is followed by protection of the 
abasic site -  in particular avoidance of deleterious double-stranded breaks in 
DNA, insertion of the correct base by a repair DNA polymerase and finally
57
sealing of the nicked DNA backbone by DNA ligase. As base damage is the 
most common form of cellular DNA damage, BER is one of the major 
mechanisms for dealing with the majority of DNA damage (Lindahl & Wood,
1999) (Wood, 1996).
Reactive oxygen species are generated through normal cellular oxygen 
metabolism and through external oxidative stress. They have been implicated 
in aging and carcinogenesis (Mamett, 2000).
The mutagenic effects o f 8 -oxo-G are opposed by the synergistic action of 
MYH, MTH1 and OGGI. MTH1 is a nucleotide phosphatase which catalyses 
the hydrolysis o f 8 -oxoGTP to 8 -oxo-GMP, preventing its incorporation 
opposite adenine during replication. OGGI detects and then removes 8 -oxo-G 
mispaired with adenine. MYH acts as “belt and braces” by detecting and 
removing adenine preventing it mis-pairing with thymine in subsequent 
rounds of replication. See Figure 1-10 for site of action of BER enzymes.
The frequency of oxidative damage to DNA is estimated at 104 
lesions/cell/day in humans (Lu et al., 2001). This is most commonly caused 
endogenously as a by-product o f cellular metabolism (Demple & Harrison, 
1994) (Izumi et al., 2003). External factors such as radiation and cigarette 
smoke also contribute to oxidative damage. 8-oxo-7,8- 
dihydro2’deoxyguanosine (8 -oxodG) is one of the most stable deleterious 
products o f oxidative DNA damage. It readily mispairs with adenine (A) 
residues leading to G:C > T:A transversion mutations in the daughter strand. 
Levels o f 8 -oxydG are high in breast, lung and kidney cancers (Malins & 
Haimanot, 1991) (Jaruga et al., 1994; Olinski et al., 1992) (Okamoto et al., 
1994). The incorporation o f 8 -oxoG into DNA is either through the direct 
oxidation o f guanine (G) residues in the template strand or via the 
incorporation of an 8 -oxodGTP from the nucleotide pool (Hayashi et al., 
2002). The resultant G:C > T:A transversions after the next round of DNA 
replication occur because polymerases incorporate adenine opposite 8 oxodG 
at a rate between 5 fold and 200 fold more frequently than they incorporate 
cytosine opposite the 8 -oxoG lesions. (Shibutani et al., 1991).
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When compared to other DNA repair mechanisms, such as nucleotide excision 
repair, BER is vertically well conserved from bacteria to humans in terms of 
the core components of BER machinery. This is very useful for studying the 
functional implications of BER enzyme mutations in vitro. In E.coli, three 
enzymes protect the cell against damage from ROS, their homologues MTH1, 
OGGI and MYH have similar functions in human cells. MTH1 hydrolyses the 
oxidised triphosphate 8 -oxo-dGTP to monophosphate 8 -oxo-dGMP, thus 
eliminating mutagenic substrates from the cell’s nucleotide pool (Nakabeppu, 
2001). OGGI provides a second level o f defence by detecting and removing 8 - 
oxodG from the DNA leaving an abasic site (Slupska et al., 1996). MYH, 
provides the third level of defence by scanning the daughter strand after 
replication, removing A mispaired with G or 8 -oxoG (Slupska et al., 1996) 
(Slupska et al., 1999) (Lu et al., 2001).
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Figure 1-10 Schematic overview of the sites of action of the BER repair 
genes MYH , OGGI and MTH1. Oxidised guanine is shown in red
MutY and it’s homologues have a catalytic core domain with an [4Fe-4S] iron 
sulphur cluster in the N terminus (Guan et al., 1998) and a C-terminal MutT 
like domain (Volk et al., 2000) (Fromme et al., 2004). It is the C-terminal 
domain that is thought to be responsible for recognition of 8 -oxoG, as when 
this domain is truncated discrimination between 8 -oxoG:A and G:A mispairs 
is lost (Gogos et al., 1996) (Noll et al., 1999). In 2004, the full-length structure 
of MutY interacting with DNA was determined (Fromme et al., 2004). This 
has enabled further understanding of how 8 -oxoG and adenine are recognised. 
The [4Fe-4S] catalytic core domain is very similar to that of Endonuclease III 
which excises oxidised pyrimidines (Kuo et al., 1992) (Guan et al., 1998). The 
C-terminal domain is very similar to MutT. Both the catalytic core domain and 
MutT domains encircle oxidatively damaged DNA making contact with the 
appropriate DNA strands. Adenine is then flipped out in to a deep pocket 
(similar to other Hairpin-helix-Hairpin DNA glycosylases) the 8 -oxoG 
remains in position and undergoes removal and repair by other members of the 
BER family.
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Eukaryotic BER enzymes have additional termini which elaborate the activites 
and function of these enzymes in more complex organisms. These include 
binding sites for enzymes from other DNA repair mechanisms for example 
MSH6 in mismatch repair and the MutSa molecule. This enables co­
ordination of DNA repair and also protects from potential deleterious DNA 
double-strand breaks during cellular replication.
The exact mechanism(s) through which tumorigenesis occurs in MYH are yet 
to be determined. Development of a faithful model o f MYH deficiency in the 
mouse has been perplexing. If MYH alone is knocked out there is no apparent 
phenotype, if  both MYH and OGGI are knocked out mice develop lymphoma, 
ovarian and thyroid tumours (Xie et al., 2004). More recently mouse fibroblast 
cell lines have been developed which are deficient for MYH and deficient for 
both MYH and OGGI. When these cell lines were exposed to low dosage 
oxidative stress a reduction o f S phase and increase of G2/M phase in Myh 
O g g lA cells was observed than in wild type cells. A similar level of cell death 
was observed in both cell lines. The oxidants also induced a greater number of 
multinucleated cells in Myh O ggl~/_ cells than in wild type, centrosome 
amplification and multi-polar spindle formation was also seen (Xie et al., 
2008).
It was concluded from this study that when under oxidative stress, MYH and 
OGGI are likely required for normal cell cycle progression and nuclear 
division, suggesting multiple roles of MYH and OGGI in the maintenance of 
genome stability and tumor prevention.
Despite MTH1 and OGGIs known roles in the base excision repair pathway, 
numerous studies o f patients with multiple adenoma phenotype or FAP and 
with no known APC  mutations failed to show any definite pathogenic changes 
in OGGI and MTH1. (Al-Tassan et al., 2002) (Jones et al., 2002) (Sieber et 
al., 2003).
1.2.6.2 Clinico-pathological features of MAP
Common pathogenic variants occur in MYH amongst different ethnic groups. 
Northern European populations have a predominance of Y165C and G382D 
mutations (Jones et al., 2002). Other pathogenic variants include Y90X in
61
patients of Pakistani origin and E466X which has been found solely in patients 
of Indian origin. An in frame deletion ntl395delGGA has been identified in 
patients of Mediterranean origin (Gismondi et al., 2004).
The phenotype of affected individuals is that of 10's to 1000's of adenomatous 
polyps and CRC. It is thought to account for approximately 1% of CRC 
(Farrington et al., 2005) (Webb et al., 2006) and to also account for up to 30% 
of patients with 15-100 adenomas (Sieber et al., 2003).
Affected individuals generally present in their fifth or sixth decade although 
there have been exceptional cases presenting in their late teens 
(Y165C/G382D) and thirties (E466X/E466X) -  unpublished data. A handful 
of extracolonic features have been found in the small number of patient 
cohorts described to date such as congenital hypertrophy o f the retinal pigment 
epithelium (CHRPE) -  (4 cases), duodenal polyps -  (3 cases), osteomas -(2  
cases), gastric cancer -  ( 1  case), desmoids -  ( 1  case) and dental cysts -  ( 1  
case) (Enholm et al., 2003; Gismondi et al., 2004; Sampson et al., 2003; 
Sieber et al., 2003). To date no definite genotype-phenotype correlation has 
been identified.
The prevalence of CRC associated with MAP at presentation varies between 
populations studied; one group has reported a prevalence nearing that of FAP 
of 78% (Gismondi et al., 2004), whereas others have reported a lower 
frequencies of 48% (Sampson et al., 2003) and 50% (Sieber et al., 2003). 
MAP cancers are predominantly left sided (71%). Metachronous or 
synchronous CRCs occur in a substantial number (27%) of bi-allelic mutation 
carriers (Lipton et al., 2003b). In homozygous individuals, the cancer 
penetrance is 100% at 60 years (Farrington et al., 2005), that is, similar to FAP 
(albeit at an older age).
1.2.6.3 Mutation spectrum associated with MAP
Molecular analysis of adenomas and cancers from MAP patients has 
demonstrated that APC  is targeted and a higher frequency of G:C>T:A 
transversions are seen at TGAA/AGAA motifs, creating nonsense mutaitons. 
Somatic screening for APC  mutations in adenomas and cancers did not find a
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“mutation cluster region” as observed in FAP. Mutations in K-ras have only 
been found at codon 12, all are G:C>T:A transversions. MAP cancers are near 
diploid (using flow cytometry) and microsatellite stable (Lipton et al., 2003b). 
A recent study examining micro-dissected MAP adenomas with comparitive 
genomic hybridisation has suggested that chromosomal instability is present in 
MAP adenomas (Cardoso et al., 2006).
1.2.6.4 Significance of the heterozygous state in MYH
To date there has been some debate as to the significance in terms of polyposis 
and CRC risk in heterozygote MYH carriers. Farrington et al (Farrington et al.,
2005) suggested an increased relative risk of 1.68 (95% Cl 1.07-2.95) in 
simple heterozygote patients with either Y165C or G382D mutations, 
arbitrarily over the age o f 55 in a large population based study of 2239 cases 
and 1845 controls. This compared all patients with CRC irrespective of the 
presence of adenomas with age and sex matched controls in Scotland. Webb 
et al (Webb et al., 2006) published a series of 2561 cases and 2695 controls 
finding no significant increase in CRC risk in mono-allelic carriers of the 
same common Caucasian mutations.
The first MYH mouse model described in this thesis (ApcMin+l~ / Myh+/') did 
not demonstrate an increased number of intestinal adenomas in the MYH 
heterozygote group when compared to wt controls (Sieber et al., 2004). 
Heterozygous status in the general population has been found to be 1% in a 
sample of 1845 individuals (Farrington et al., 2005). Common polymorphisms 
of as yet unknown pathological significance have also been identified. In 
Caucasian northern European populations Q324H is observed in 20%, V22M 
in 10% and S521F in 2% of the population, predominantly as heterozygote 
carriers. These polymorphisms may have implications if  they form compound 
heterozygotes with known pathogenic mutations or in the presence of external 
or environmental factors such as cigarette smoking or radiation.
In the clinic, testing for MYH mutations is available for individuals and at risk 
relatives in whom no known APC  mutation has been found or who appear to 
have recessively inherited multiple adenomas or CRC. For individuals who 
have homozygous deletions the follow up would be identical to those who
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have APC  mutations, that is annual colonoscopy. However, to date a firm 
follow up programme for heterozygous carriers is yet to be published.
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1.3 The Multiple Adenoma Phenotype
Individuals who develop multiple colorectal adenomas (MCRAs) are a 
genetically and clinically heterogeneous group who are at increased risk of 
CRC. The MCRA phenotype can usefully, but arbitrarily, be defined as the 
development o f 5-100 adenomas during an individual’s lifetime. Germline 
mutations in the APC  gene account for about 15% of cases with an MCRA 
phenotype, these patients have AFAP (Spirio et al., 1999). An additional 
-35% of such patients have bi-allelic germline mutations in the MYH gene and 
are classified as having MAP (Sieber et al., 2003) (Sampson et al., 2003). As 
mentioned previously, MYH deficiency leads to adenoma formation through 
somatic hypermutation o f the APC  and K-ras genes. The remaining MCRA 
patients have no known underlying genetic cause for their phenotype.
To date, the most widely used strategy for identifying candidate predisposition 
genes for polyposis syndromes and CRC has been through genetic linkage 
analysis. This approach has been particularly successful for the dominantly 
inherited syndromes FAP and HNPCC. Its ability to disclose moderate and 
low penetrance genes is more questionable. No susceptibility gene for a 
complex cancer has yet been identified using this approach.
The frequency of low penetrance genes may be much higher than the 
frequency o f high penetrance genes in the general population due to the low 
selective disadvantage associated with these changes. Identification of these 
novel predisposition genes is important, enabling clinical geneticists to 
identify individuals at risk and raises the possibility o f setting up reliable, cost 
effective population screening.
However, detection of low penetrance genes using linkage analysis requires 
prohibitively large numbers o f multi-generational families in order to yield 
results. For example, a dominant model with a gene frequency of 0.1 and risk 
ratio o f 6  would require 473 affected sib pairs, 205 three affected sibs, 145 
four affected sibs, 545 cousin pairs or 550 avuncular pairs to give a lod score 
of 3.3. (Houlston & Tomlinson, 2000). Therefore alternative approaches need 
to be utilised.
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It is likely that there may still be highly penetrant CRC predisposition genes as 
yet undiscovered, but the majority of remaining are genes most likely to be of 
moderate and low penetrance. The possibility of the remainder of the genetic 
influence of CRC being inherited as a polygenic trait or through the 
inheritance o f multiple low penetrance alleles at several genetic loci is 
becoming more accepted (reviewed in (Kemp et al., 2004)).
Rodent studies have led to the identification of modifier genes loci associated 
with murine FAP models. The identification of the (Modifier of Min 1) Moml 
and Mom2 alleles being one such example in mice (Dietrich et al., 1993). 
Moml maps to the phospholipase 2 (Plga2) gene in humans. However, to date 
no mutation or evidence to suggest this is a modifier gene in humans has been 
found. The search for modifier genes which affect the severity of Mendelian 
cancer syndromes is of importance as these genes may act as a low-penetrance 
pre-disposition genes in their own right.
In order to identify these remaining genes, different strategies need to be used 
in tandem for the highest chance of success. Linkage analysis should not be 
disregarded however, with the development of array technology traditional 
linkage analysis can be superseded with tagged single nucleotide 
polymorphism (SNP) arrays. This approach allows linkage to be undertaken 
with a higher resolution across the genome. Traditional linkage analysis 
utilises up to 400 microsatellite markers across the genome whereas the first 
SNP arrays (Affymetrix®) contained 10 000 SNPs (Risch, 2001). This 
approach led to the identification of an area of interest on chromosome 3q21- 
q24 when germline DNA from 69 families (with a family history of CRC but 
no mutations in the known predisposition genes) were analysed (Kemp et al.,
2006).
Array comparative genomic hybridisation (CGH) followed by linkage analysis 
identified the locus (19p) and then pre-disposition gene LKB1 for Peutz- 
Jegher’s syndrome in 1998 (Hemminki et al., 1998).
Mutation screening of potential candidate genes may help to identify future 
pre-disposition genes and sub-polymorphic variants. Selection of candidate 
genes for screening is guided by preliminary studies -  such as linkage analysis 
and more recently association studies and through knowledge of the 
underlying pathological mechanisms involved in polyposis and CRC.
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Therefore genes involved in the Wnt signalling pathway and DNA repair 
mechanisms are obvious first line candidates, with cell cycle checkpoint genes 
and modulators of apoptosis being of significance in any cancer pre­
disposition syndrome.
1.3.1.1 APC Missense variants and the Multiple Colorectal 
Adenoma Phenotype
The APC missense variant E1317Q
The germline missense variant APC  E1317Q was first reported in 1996 by 
White et al (White et al., 1996) as an incidental finding when screening for 
somatic, protein-truncating APC mutations in sporadic colorectal cancers. 
Further studies in a set of 164 individuals with multiple (3-100) colorectal 
adenomas screened for germline APC  mutations (Lamlum et al., 2000) found a 
small number o f these patients carried protein-truncating mutations in exon 9 
and the 3 ’ part o f exon 15 of APC, seven patients carried E1317Q, compared 
with only two o f 503 UK controls. These data suggested E1317Q to be a low- 
frequency (or sub-polymorphic) risk allele for colorectal adenomas (in this 
sample set, odds ratio=11.2, 95%CI=2.30-54.3, p<0.001). At this time it was 
not possible to provide a convincing mechanism for the effects of the 1317Q 
allele, since the amino acid change (glutamine>glutamic acid) is a relatively 
conserved one. It was hypothesised, however, that since the polymorphism lay 
within a critical region o f the APC  protein, between repeat sequences involved 
in P-catenin binding and degradation, subtly increased P-catenin levels and 
hence activated Wnt signalling were a plausible mechanism of increased 
tumour susceptibility.
Several subsequent studies have examined the possible association between 
the APC  1317Q allele and colorectal adenomas and/or carcinoma. Popat et al 
(Popat et al., 2000) found E1317Q in 2 o f 364 early-onset colorectal cancer 
patients and 2 o f 290 controls. Gismondi et al (Gismondi et al., 2002) found 
E l317Q in 2/182 patients with single or multiple colorectal adenomas and in 
2/135 controls (OR=1.29, 95% 0=0.09-18.0). Hahnloser et al (Hahnloser et 
al., 2003) found no excess o f E1317Q in colorectal adenoma patients (5/231)
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or cancer cases (9/377) compared with spouse controls (10/362), but did find 
an excess compared with individuals who had had a normal screening 
colonoscopy (1/317), thus providing an odds ratio of 1.164 for 1-3 adenomas, 
0.523 for 4-100 adenomas and 0.838 for cancer in the latter case (95% CIs
0.28-4.78, 0.10-2.68 and 0.31-2.26 respectively). These studies involve 
patients with different inclusion criteria and controls from differing sources. 
Overall, they suggest that APC  E1317Q has at most a small effect on the risk 
of colorectal tumours and it is possible that it is simply a non-functional rare 
polymorphism (Evertsson et al., 2001) (Popat et al., 2000).
How studying E1317Q led to the discovery o f MYH
Researchers were attempting to find some clues as to possible functional 
effects of the 1317Q allele. One strategy was to determine whether or not 
colorectal tumours from these patients had acquired an independent somatic 
APC mutation on the 1317Q allele and, if so, whether that mutation lay 5’ or 
3’ of codon 1317; if mutations were found which truncated the APC protein 
before codon 1317, for example, a functional effect of the Q allele would be 
much less likely. In colorectal adenomas from one family which carried 
1317Q, not only did the somatic mutations appear to target both the 1317E 
and 1317Q alleles equally, but also the mutation spectrum was grossly 
atypical for APC. Allelic loss and frameshift mutations -  the most common 
types o f change - were almost absent and nearly all point mutations were 
G:C>T:A transversions, typical of oxidative damage or defective base 
excision repair. The identification of pathogenic bi-allelic mutations in the 8 - 
oxo-guanine DNA glycosylase MYH followed soon afterwards (Al-Tassan et 
al., 2 0 0 2 ).
The APC germline missense variant 11307K
The I1307K APC  variant occurs in roughly 6-9% of Ashkenazi Jews (Redston 
et al., 1998) and is very rarely found in any other ethnic groups. This variant 
leads to the appearance of an Ag tract which is hypermutatble resulting in 
somatic slippage and frameshift mutations (Laken et al., 1997). Similarly to 
the E1317Q variant there are differing reports as to the relative risk of 
developing colorectal adenomas and CRC. Frayling et al (Frayling et al.,
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1998) and Gryfe et al (Gryfe et al., 1999) found an associated relative risk of 
1.5-2.0 when studying a solely Ashkenazim population, whereas Figer and 
Woodage (Figer et al., 2001) (Redston et al., 1998) found no increased risk in 
unselected Israelis and Ashkenazim. Interestingly only 50% of CRC tumours 
from I1307K carriers demonstrate slippage o f the Ag tract (Gryfe et al., 1998) 
(Laken et al., 1997) (Zauber et al., 2003). It appears that other oligonucleotide 
tracts within APC  are not hypermutable. As I1307K lies within a region of 
APC  associated with severe FAP phenotype it may simply have a direct 
functional effect as well as predisposing to hypermutability.
1.3.1.2 Non-APC related rare low risk alleles and their CRC
risk
The current situation as regards rare low-risk alleles and colorectal tumour risk 
is intriguing. Whilst CHEK2 alleles are convincingly associated with 
increased breast cancer risk, the evidence for an effect on colorectal cancer is 
mixed. Meijers-Heijboer et al (Meijers-Heijboer et al., 2002) found no 
association between CHEK2 and colorectal cancer: the llOOdelC allele was 
present in 3 index cases from 107 colorectal cancer families of otherwise 
unknown genetic origins, compared with 18/1620 controls of mixed origins 
(OR=2.34, 95%CI=0.95-5.79). llOOdelC was, however, over-represented in 
breast cancer families which also contained members with evidence of 
hereditary colon cancer, compared with breast cancer families without such 
evidence (OR=5.41, 95%CI=2.29-12.8). Meijers-Heijboer et al (Meijers- 
Heijboer et al., 2002) have interpreted these data as showing evidence for the 
hypothesised distinct hereditary breast-colon cancer phenotype, but they found 
no mirroring evidence to show that colorectal cancer families with evidence of 
hereditary breast cancer had an excess of the llOOdelC allele. Lipton et al 
(Lipton et al., 2003a) studied 149 patients with 3-100 colorectal adenomas and 
found no excess o f llOOdelC. Cybulski et al (Cybulski et al., 2004) typed 
1 lOOdelC in 300 Polish colorectal cancer cases and 4,000 controls, but found 
no significant excess in the former, although the missense CHEK2 I157T 
variant was over-represented in cases. Kilpivaara et al (Kilpivaara et al., 2003)
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evaluated the frequency of llOOdelC in 662 familial and sporadic colorectal 
cancer cases, including some putative hereditary breast-colon cancer kindreds, 
and found no increased frequency compared with population controls.
It is likely that definitive answers about alleles such as APC E1317Q and 
CHEK2 1 lOOdelC will only come from large international studies and/or from 
meta-analyses, which have the associated risks o f imperfect matching of cases 
and controls and population-specific effects on risk.
Other variants in candidate genes conferring increased CRC risk have also 
been described, these include cyclin D1 (CCND1) (Porter et al., 2002), E- 
cadherin (CDH-1) (Kim et al., 2000) and a member of the transforming 
growth factor p family (BMPR1A) (Lipton et al., 2003c). One study including 
analysis o f beta-catenin (CTNBB1), axin (AXIN1), MLH1 and MSH2 in 124 
MCRA patients and 483 controls found significant odds ratios in AXIN1 ( 6  
missense variants in total) and MSH2 (3 missense variants in total) (p=0.012 
and p=0.001 respectively) (Feamhead et al., 2004). In this case the AXIN1 
P312T missense variant substituted a polar threonine with a neutral proline in 
a region where axin binds with APC and GSK3/3
Two variants in Methylene tetrahydrofolate reductase (MTHF) (C677T and 
A1298C), rapid acetylator alleles in N-acetyl transferase 2 (NAT2) and VNTR 
rare alleles in Harvey rat sarcoma virus 1 (HRAS1) have also been reported as 
low risk alleles (Houlston & Tomlinson, 2001) (de Jong et al., 2002).
The careful use o f strategies such the analysis o f familial cases and the study 
of negative, rather than population, controls may enhance the power of 
studies, but the accumulation of overwhelming evidence on variants such as 
APC E l317Q, I1307K  and CHEK2 1 lOOdelC may take many years.
1.4 Common disease variants and CRC risk
It is becoming increasingly apparent that many o f the remaining polyposis and 
CRC pre-disposition genes may be common, less penetrant disease variants 
with small effects on risk.
70
Genome-wide approaches are currently being undertaken with the hope of 
identifying common, low-risk alleles but historically their discovery to date 
has relied on candidate gene analysis followed by determining allele 
frequencies in large case-control cohorts (Meijers-Heijboer et al., 2002). 
Association studies enable an unbiased approach for searching for disease 
associations without prior knowledge of function or presumptive involvement 
of any gene in disease causation. This has been made possible by utilising 
second generation SNP arrays (550 000 SNPs) allowing genome-wide case- 
control association studies to be performed. In principle it is possible to 
identify the real disease-associated variant by scanning nearby genes for 
variants that could plausibly have a real effect in the pathogenesis of the 
disease being studied.
This approach using 550K SNP arrays has recently led to the identification of 
a series of regions o f interest in CRC development on chromosomes 8q24, 
10pl4, llq23 and 18q21, (Tomlinson et al., 2007; Zanke et al., 2007), 
(Haiman et al., 2007) (Tomlinson et al., 2008) (Tenesa et al., 2008).
Second stage analysis (3 replication sample sets totalling 7,473 CRC cases and 
5,948 controls) o f the top 5% of polymorphic SNPs identified from Tomlinson 
et als first genome wide association study of 940 CRC cases and 965 controls 
(Tomlinson et al., 2007) identified 3 SNPs in SMAD7 to be significantly 
associated with development o f CRC (TVend= 1.Ox 1012)(Broderick et al., 2007).
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1.5 Aims of this Thesis
The main objectives of this thesis can be divided into three main areas -
1: Determination of the mechanisms of carcinogenesis associated with MYH- 
associated polyposis (MAP).
This includes -
i) further characterisation of the MAP phenotype
ii) search for any genotype/phenotype correlation in MAP
iii) completion o f germline screening for mutations in enzymes of the same 
family (OGGI and MTH1) in individuals with the multiple adenoma 
phenotype
iv) looking for evidence and mechanisms of genomic instability in the 
development o f MAP through comparative genomic hybridisation
v) development o f a mouse model of MAP
2: Identification of novel predisposition genes for the multiple adenoma 
phenotype was undertaken utilising various techniques, including somatic 
screening for mutational signatures, expression microarray analysis of 
lymphoblastoid cell lines from MCRA cases and subsequent candidate gene 
screening.
3: Investigation o f the clonal origins of colorectal adenomas and CRC
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2 Materials and Methods
Solutions and media which are shown in bold have their recipes given at the 
end of this chapter.
2.1 DNA Extraction
2.1.1 DNA extraction from blood
DNA extraction from fresh frozen blood taken via peripheral venesection was 
performed using either the ammonium acetate method described below or 
latterly with the automated Chemagen system.
The ammonium acetate method involves three key steps. Cell lysis by 
hypotonic shock, nuclei lysis (and further cell lysis) by detergent action and 
proteinase K digestion, and finally precipitation of DNA with ammonium 
acetate and ethanol.
Nine ml of fresh frozen, EDTA preserved venous blood were thawed and 
transferred in to a 50ml polypropylene tube (Coming). Cells were lysed by 
adding ice-cold distilled water (dl-bO) to a final volume of 50ml. This was 
mixed by inversion, and cells separated by centrifugation at 2300 rpm for 20 
minutes at 4°C in a swing out rotor centrifuge (CR412 Jouan). Following 
discarding of the supernatant, the cell pellet was washed in 25ml of 0.1% NP- 
40 at 4°C. Nuclei were lysed by the addition of 3ml of nuclei lysis buffer, 
200pl 10% SDS, and 600pl proteinase K solution. The sample was then 
vortexed until the pellet was completely resuspended and incubated for 2  
hours at 60°C. One ml o f saturated ammonium acetate was added to the tube 
which was then vortexed for 15 seconds. The sample was then incubated at 
room temperature for 10-20 minutes and centrifuged at 2300 rpm fro 20 
minutes at room temperature. The supernatant was then transferred to a clean 
50ml polypropylene tube and two volumes of ice-cold 100% ethanol (BDH) 
were added. The DNA was precipitated by gentle inversion of the tube several 
times and then spooled out using a plastic inoculating loop. The spooled DNA
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was dipped in to an Eppendorf tube containing 70% ethanol to remove excess 
salt, and transferred to a labelled screw-capped Eppendorf tube. Following air 
drying, the DNA was re-suspended and stored in 1ml dFhO. Quantification of 
the DNA extracted was performed with spectrophotometry at 260 and 280nm.
2.1.2 DNA extraction from cell lines
DNA extraction from lymphoblastoid or colorectal cell lines was performed 
using a high salt method. This method avoids the use of toxic phenol which is 
used conventionally to separate DNA from protein debris. The high salt 
method involves four key steps. Cell lysis by detergent action and proteinase 
K digestion, degradation o f ribonucleic acids (RNAs) as these can interfere 
with downstream applications, separation of DNA from protein debris using 
sodium chloride and chloroform, and precipitation of DNA with isopropanol. 
Approximately 5x l0 7 cells were transferred to a 50ml polypropylene tube 
(Coming) and then centrifuged for 10 minutes at 1500 rpm at room 
temperature (CR412 Jouan centrifuge). The supernatant was discarded and the 
remaining cell pellet washed twice in PBS before resuspending in 15ml SE 
buffer. RNA’s were degraded by adding 50pi of lOmg/ml RNAseA to the 
mixture followed by incubation for 1 hour at 37°C. Proteinase K (BDH) was 
added to a final concentration of 2 0 0 pg/ml and cells lysed by overnight 
incubation at 55°C. Separation o f DNA from protein debris was performed by 
the addition of 4.5ml o f 5M sodium chloride (final concentration 1.5M) and 
20ml of chloroform (BDH). The tube was mixed by rotation for 30 minutes 
and then centrifuged at 2000rpm for 10 minutes at room temperature. The 
DNA-containing aqueous layer was transferred to a new 50ml tube, and an 
equal volume o f isopropanol (BDH) was mixed together for 5 minutes to 
precipitate the DNA. Extracted DNA was spooled out using a plastic 
inoculation loop and washed in 70% ethanol for 1 hour to remove excess salt. 
Following air drying, the DNA was re-suspended and stored in 1ml dH2<3 . 
Quantification o f the DNA extracted was performed with spectrophotometry 
at 260 and 280nm.
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2.1.3 DNA extraction from fresh frozen tissue
DNA extraction from fresh frozen tissue was performed using the QIAamp 
DNA mini kit (Qiagen) according to the manufacturers instructions. This 
method allows the isolation of up to 40pg of DNA from 25mg of tissue.
Tissue was cut in to small pieces and digested with proteinase K overnight. 
Following digestion, RNaseA lOmg/ml was added to degrade RNAs, DNA 
was precipitated by adding ethanol which was then collected by binding on a 
spin column. Following a series of washes to remove protein debris, the DNA 
was eluted from the column with dH20 . Quantification o f the DNA extracted 
was performed with spectrophotometry at 260 and 280nm.
2.1.4 DNA extraction from formalin fixed paraffin embedded 
tissue
DNA extraction from formalin fixed paraffin embedded tissue involved two 
key steps -  manual dissection of dewaxed tissue from unstained slides 
followed by cell lysis and proteinase K digestion.
Formalin fixation o f tissue causes cross-linkage and breakage of DNA, 
therefore DNA extracted with this method is generally fragmented and of 
relatively poor quality. In light o f this, when using this DNA for PCR, primers 
should be designed to amplify small amplicons of approximately 1 - 2 0 0  base 
pairs. This method does however allow the investigation o f historical samples 
which may be up to 40 years old.
Depending on the size o f the sample tissue, between 5 and 8  10pm sections 
were cut from each paraffin block on to non-coated glass slides using a 
microtome (Reichert-Jung). The tissue was then dewaxed in xylene (BDH) for 
10 minutes, and washed twice in 100% ethanol (BDH) for 10 minutes. One 
section was stained with haematoxylin and eosin (Merck) according to 
manufacturers instructions, and inspected using an Eclipse 400 light 
microscope (Nikon). Haematoxylin, a dye obtained from the heartwood of the 
Haematoxylon campechianum tree stains cell nuclei purple whilst eosin, a 
halogenated derivative o f fluoroscein, stains cell cytoplasm red. Following
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identification of areas of interest, tissue was micro-dissected using sterile 
needles under microscope guidance. Extracted tissue was digested in a small 
volume (50- lOOptl) of proteinase K buffer [500pl lOx Mg2+ free PCR buffer 
(Promega), 50pl 20mg/ml proteinase K (BDH), 4.45ml d H2O]. The tissue and 
proteinase K buffer were transferred to a screw top Eppendorf tube and 
digested for 24-48 hours at 55°C. The proteinase K was then denatured and 
inactivated by heating to 95°C for 10 minutes. The sample was then 
centrifuged at 1300rpm for 15 minutes in a 5415C bench-top centrifuge 
(Eppendorf). The supernatant containing DNA was then removed with a 
pipette and transferred into a fresh Eppendorf tube. Spectrophotometry of 
DNA extracted via this method is often inaccurate due to fragmentation of the 
DNA.
2.1.5 DNA extraction from laser micro-dissected single 
crypts
DNA extraction from single large bowel epithelial crypts involves three key 
steps. Isolation of crypts, digestion with proteinase K solution and inactivation 
of proteinase K.
Up to six crypts were cut and isolated in to a 50pl capped tube (see Laser- 
microdissection method for details of slide preparation and micro-dissection). 
These were digested overnight in lOpl of proteinase K solution at 60°C in 
PicoPure DNA extraction proteinase K (PicoPure DNA Extraction kit 
(Kit:0103), Molecular Devices Corporation, CA94089-1136, USA) as per 
manufacturers directions. Each tube was sealed with Parafilm (Parafilm M 
sealing film, Pechiney Plastic Packaging, WI 54952, USA) to prevent sample 
evaporation. Proteinase K was then denatured and inactivated by heating to 
90°C for 10 minutes. Samples were then centrifuged at 13000 rpm for 10 
minutes in a 5415C bench-top centrifuge (Eppendorf) before use.
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2.1.6 DNA extraction from mouse tail and ear clips
DNA extraction from mouse tail and ear clips involves four key steps. 
Digestion of tissue in proteinase K solution, DNA extraction using the high 
salt method, precipitation and washing of DNA.
Mouse tail and ear snips were received in screw topped Eppendorf tubes on 
dry ice. To each tail snip tube 400^1 of tail lysis buffer and 5^1 of proteinase 
K (BDH) stock solution (20mg/ml) were added. This was followed by 
incubation for 3 hours minimum or overnight at 55°C. 160p,l of 5M NaCl was 
added and vortexed well, tubes were returned to 55 °C for a few minutes to 
allow any precipitate to dissolve. Samples were vortexed and centrifuged at 
13000 rpm for 1 0  minutes (5415C bench-top centrifuge (Eppendorf)) at room 
temperature. 500pl of the supernatant was pipetted into a new 1.5ml 
Eppendorf tube and DNA was precipitated by the addition of 300p,l of 
isopropanol (BDH). The samples were mixed gently by inversion to aid the 
precipitation of DNA and then centrifuged at 13000 rpm for 10 minutes 
(5415C bench-top centrifuge (Eppendorf)) at room temperature. The resulting 
supernatant was aspirated with a pipette and the sample washed with 300pl of 
70% ethanol. Samples were then vortexed and centrifuged at 13000 rpm for 
10 minutes (5415C bench-top centrifuge (Eppendorf)) at room temperature. 
The resulting supernatant was aspirated with a pipette and the extracted DNA 
resuspended in lOOpl dH2 0  (tail snip) or 30^1 dH2 0  (ear snip) as there is less 
starting material with ear snips. Quantification of the DNA extracted was 
performed with spectrophotometry at 260 and 280nm.
2.2 RNA Extraction
2.2.1 RNA extraction from cell lines
RNA extraction from lymphoblastoid cell lines was undertaken using the 
trizol (Invitrogen) / chloroform method. Trizol is a monophasic solution of 
phenol and guanidine isothiocyanate. During RNA extraction, trizol maintains
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RNA integrity whilst disrupting the cell membrane and dissolving cellular 
components. Centrifugation following the addition of chloroform separates the 
solution in to an aqueous phase (containing the extracted RNA) and an organic 
phase. The RNA is then recovered following precipitation with isopropyl 
alcohol.
Lymphoblastoid cells in culture were washed with phosphate buffered saline 
and pelleted prior to RNA extraction.
Fifty mis o f lymphoblastoid cells in culture medium were pelleted in a 50ml 
polypropylene tube (Coming) and centrifuged for 4 minutes at 300 g in a 
swing out rotor centrifuge (CR412 Jouan) at room temperature. These cells 
were re-suspended and washed and pelleted twice in 50 ml of phosphate 
buffered saline. 1.5 ml o f Trizol was added to the pelleted cells, mixed gently 
and left for 5 minutes at room temperature. 300pl of chloroform (BDH) was 
added, mixed gently and left to stand for 5 minutes at room temperature. 
Samples were then transferred and split between two screw top Eppendorf 
tubes and centrifuged (5415C bench-top centrifuge (Eppendorf)) at 12000 g at 
4°C for 15 minutes. The upper aqueous phase containing the RNA was 
removed via pipette and placed in a new screw top Eppendorf tube. 750pl of 
isopropyl alcohol (BDH) was added, gently mixed with a pipette and left to 
stand at room temperature for 5 minutes. Samples were then centrifuged 
(5415C bench-top centrifuge (Eppendorf)) at 12000 g at 4°C for 10 minutes. 
The pelleted RNA was then washed with 1 ml of 75% ethanol and 
centrifuged (5415C bench-top centrifuge (Eppendorf)) at 7500 g at 4°C for 5 
minutes. The resulting RNA was re-suspended in 200pl RNAse free dH2 0  and 
immediately placed on wet ice. Samples were further cleaned prior to use in 
expression array work on a Qiagen column (details o f kit). Quality and 
quantity of RNA extracted was assessed using the Agilent platform and by 
running lOpl of the final RNA product on a 1% agarose gel at 100V for 45 
minutes.
2.2.2 RNA extraction from tissue
RNA extraction from mammalian tissue was undertaken using the Sigma 
GenElute mammalian total RNA mini-prep kit (RTN-70) following
78
manufacturers instructions. A total of up to 150fig of total RNA can be 
extracted from up to 40mg (10 cells) of starting material.
2.3 Spectrophotometry
DNA quantity and quality was assessed with spectrophotometry at 260nm and 
280nm using the Nanodrop (supplier) spectrophotometer. An optical density 
(OD) of 1 at 260nm corresponds to approximately 50pg/ml double stranded 
DNA. Therefore DNA sample concentrations in ng/ml were calculated as 
“dilution factor x 50 x OD26o”- DNA quality was assessed by calculation of 
OD260/OD280 ratios with 1.8 being the ratio found in a pure sample of DNA. 
Contamination with protein decreases the ratio towards 1.4 and RNA 
contamination increases the ratio towards 2.0.
RNA samples (on wet ice) were assessed for quantity and quality using the 
Nanodrop spectrophotometer following the same principles as outlined above 
and also using the Agilent (supplier) system following manufacturers 
instructions.
2.4 Polymerase Chain Reaction
The polymerase chain reaction (PCR) is an in vitro technique used for 
selective amplification of a specific DNA sequence.
The DNA region of interest is amplified using two complementary 
oligonucleotide primers which hybridise to the selected region of the template 
DNA on opposing strands.
A typical PCR reaction consists o f 35 cycles, each made up of three steps: (i) 
denaturation of the DNA template through heating to 94°C, (ii) annealing of 
the primers to the separated template strands through heating to 55-60°C 
(varies between primer sets) and (iii) extension of the primers by DNA 
polymerase at 72°C. The reaction requires addition of the four 
deoxyribonucleoside triphosphates dATP, dTTP, dGTP, dCTP and 
thermostable DNA polymerase.
The first cycle produces two new strands of DNA template o f variable length, 
which can then be a target for the second cycle. The third cycle results in the
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production of double stranded DNA product which includes the target region. 
The following cycles produce an exponential doubling of the target sequence 
which becomes the predominant reaction product. PCR amplification can 
saturate with the desired target sequence gradually failing to accumulate. 
Factors affecting when this point occurs include utlisation of the reaction 
substrates -  dNTP’s or primers, the stability of DNA polymerases and finally 
competition for substrates by non-specific products or primer dimers.
Primers for use in PCR were designed using the Primer3 programme designed 
by the Whitehead institute of Biomedical Research fhttp://www- 
genome.wi.mit.edu/cgi-bin/primer/primer3 www.cgiT 
Typically a 25pl PCR reaction contains 30-50ng of template DNA, 0.4pmols 
of each primer, 1 x Mg2+ - free PCR buffer (Promega), l-2mM MgC^ 
(Promega). 0.2mM of each dNTP (Amersham) and 1 unit of PIC Taq 
polymerase (Cancer Research UK). PCR reactions were undertaken in 96 well 
plates (ABgene). DNA samples were aliquoted in to the plate and the PCR 
master mix then added after vortexing. The plate was sealed with Thermowell 
sealers (Coming) and immediately run on a Tetrad PCR machine (MJ 
Research). The PCR reaction programme typically consisted of initial 
denaturation at 94°C for 5 minutes followed by 35 cycles of 94°C for 1 
minute, 55 °C for 1 minute, 72 °C for 1 minute with a final extension at 72 °C 
for 10 minutes. Various parameters were altered such as Mg2+ concentration, 
annealing temperature, extension time and other additives were altered 
depending on which conditions suited the selected primer pairs and target 
DNA size. Primer sequence details and required PCR conditions are listed in 
Appendix 1.
Resultant PCR products were analysed by agarose gel electrophoresis with 
ethidium bromide staining.
2.4.1 Purification of PCR products
PCR products were cleaned up prior to sequencing using either of the two 
methods below.
80
2.4.1.1 Qiagen clean up
QIAquick PCR purification kit (Qiagen) can be used to purify single or double 
stranded PCR products ranging from lOObp to lOkb from primers, 
polymerases and salts. All solutions were supplied by Qiagen and 
manufacturer’s protocol followed.
Briefly, this method utilises a spin column with a membrane whereby the PCR 
product (DNA) is first bound to the membrane, undergoes two washes whilst 
bound to the membrane with buffer to remove impurities and finally eluted 
with either TE buffer or dP^O.
2.4.1.2 ExoSAP-IT®
ExoSAP-IT (USB Corporation, Cleveland, Ohio, USA, product no. 78201) is 
an alternative method for PCR product purification which utilises the action of 
recombinant exonuclease I and shrimp alkaline phosphatase (Pandalus 
borealis) in a buffered solution. Manufacturer’s instructions were followed. 
Briefly, 5 pi of PCR product was mixed with 2pl of ExoSAP-IT in a PCR plate 
(ABgene) and underwent the following programme on a tetrad PCR machine. 
Heating to 37 °C for 15 minutes followed by heating to 80 °C for 15 minutes, 
samples were then left at 8°C until used for sequencing reactions. Cleaned up 
PCR products were then diluted with dH20 depending on their strength as 
determined on a 2% agarose gel.
2.5 Agarose Gel Electrophoresis
Agarose gel electrophoresis is a tool which separates DNA molecules by their 
size. When in solution DNA molecules carry a negative charge and therefore 
migrate towards the anode of an electrical field. Agarose gel is a 3D matrix 
which enables DNA to migrate according to its size, larger molecules migrate 
at a slower rate than smaller ones. Ethidium bromide dye staining is used to 
visualise DNA. The ethidium bromide intercalates between DNA base pairs 
and fluoresces when exposed to UV light of 302nm.
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Agarose gel electrophoresis was performed using either 1 or 2% agarose 
depending on the size o f the DNA PCR products to be analysed. Either lOg 
(1%) or 20g (2%) of agarose powder (Invitrogen) was dissolved in lx  TBE 
buffer and boiled. The molten agarose was allowed to cool to 60°C at which it 
was then stored for use. Ethidium bromide was added at a final concentration 
of 0.25p,g/ml. Molten agarose was poured in to a gel casting tray (Bio-rad) 
with well combs in position and left to set. Following removal of the comb the 
gel was covered with lx  TBE buffer. For standard PCR products, lOpl of 
DNA was combined with 2pl of 5 x Orange G Loading Dye (Trevigen) and 
loaded in to a gel well. 10^1 of lkb ladder (Gibco BRL) -  prepared as per 
manufacturers instructions was added to the outermost well as a guide for the 
size of the DNA products under analysis. The gel was then connected to a DC 
power pack (Bio-rad PowerPac 300), and run at 120V for 20 -30 minutes. 
After removal from the tank the DNA was visualised under UV light at 
302nm in a White / 2UV box transilluminator (UV products). Photographs for 
record keeping were taken with a UV products recording camera.
2.6 Mutation Detection
2.6.1 Single-strand Conformation Polymorphism Analysis
Single strand conformation polymorphism (SSCP) analysis enables detection 
of mutations in DNA target regions amplified by PCR. This method allows the 
detection of nucleotide insertions, deletions, substitutions and inversions in 
DNA fragments ranging from 100-500 base pairs in size.
SSCP analysis has three main steps -  amplification of the DNA target region, 
denaturation of the double-stranded PCR product by heating with a denaturing 
chemical and finally separation of the resultant single strands by 
electrophoresis on a non-denaturing gel matrix. The conditions of the non­
denaturing gel allows single stranded DNA fragments to form unique 
secondary structures which are determined by their primary sequence and 
stabilised by hydrogen-bonding. As the complementary strands of DNA have 
different primary sequences they form different conformations in the non­
denaturing gel. The same single-stranded fragment may adopt more than one
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secondary structure. Subsequent mutation detection relies on the different 
conformations of DNA migrating at differing speeds through the 
electrophoresis gel than wild-type strands under analysis. The formation of 
secondary structures is affected by variables such as temperature and ionic 
strength, each sample is run at two temperatures as certain mutations will only 
be detected under certain running conditions.
SSCP analysis PCR amplification is undertaken using fluorescently labelled 
forward and reverse primers (FAM, HEX and less commonly TET). Resultant 
PCR products were diluted with dH20 and multiplexed for analysis depending 
on the product size and the fluorescent labelling of the PCR primers. 4pl 
aliquots were transferred in to a 96 well optical reaction plate (PE-Applied 
Biosystems), and 0.5pil o f 0.3M sodium hydroxide, 0.5pl TAMRA-350 size 
standard (PE-Applied Biosystems), and 1 Opil formamide (BDH) were added. 
Samples were then denatured at 95°C for 5 minutes, placed on ice and then run 
on the ABI3100 sequencer (PE-Applied Biosystems). The ABB 100 sequencer 
is a high throughput mutation analysis system which runs on a capillary based 
system rather than a less sensitive gel-based systems. All samples were run at 
18 °C and 24 °C on 36cm capillaries containing 5% native polymer (PE- 
Applied Biosystems), 10% glycerol (BDH) and lx  TBE running buffer 
containing 10% glycerol. GENESCAN and GENOTYPER software (PE- 
Applied Biosystems) were used for sample analysis. Mutant strands were 
identified, reamplified and sequenced in both forward and reverse orientation 
(see section 2.1.8 for sequencing analysis method).
2.6.2 Denaturing High Performance Liquid Chromatography 
using the WAVE platform.
Denaturing High Performance Liquid Chromatography (DHPLC) is a 
mutation detection tool dependent on temperature sensitive separation of DNA 
containing mismatched base pairs from a pool of PCR amplified DNA 
fragments. Mutation detection with DHPLC is reliant on formation and 
subsequent separation on double-stranded DNA fragments which contain
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mismatched base pairs termed heteroduplex DNA. Heteroduplex DNA is 
generated by denaturing and re-annealing both reference “wild type” DNA 
and “mutant” sample DNA. These heteroduplex fragments form as a result of 
complementary pairing between single stranded mutated DNA and single 
stranded wild type DNA. These strands do not form hydrogen bonds at the 
mutation site due to mis-pairing therefore giving the “mutant” heteroduplex 
different melting properties to the “wild type” homoduplexes. The WAVE 
system separtes heteroduplexes from homoduplexes over pre-selected 
temperature gradients calculated from the sequence of the DNA fragment 
amplified by PCR. At a critical temperature (partially denaturing conditions), 
the mismatched bases in the heteroduplexes begin to separate, while the 
matched bases in the homoduplex remain intact. Heteroduplexes elute from 
the HPLC column earlier than homoduplexes. The “mutant” samples -  either 
containing a polymorphism or pathological mutation are detected on the 
chromatogram by additional “peaks”, “shoulders” or by having a different 
conformation when compared to the “wild type” chromatogram.
DHPLC was performed on the 3500HT WAVE nucleic acid fragment analysis 
system (Transgenomic, Crewe, UK). Mutation detection is possible for larger 
amplicons of target DNA than with SSCP analysis (250 to 500+ base pairs). 
Unlabelled primer sets were designed accordingly using Primer3 software as 
described previously. To enhance formation of heteroduplexes prior to 
DHPLC, the PCR products were heated to 94°C and then re-annealed by 
cooling gradually to a temperature of 50 °C at a rate of 1 °C per minute. 
DHPLC was then performed at temperatures calculated by Wavemaker 
(version 4.0) software (Transgenomic) with a 12% acetonitrile gradient over 
2.5 minutes. Samples demonstrating abnormalities on the chromatogram were 
sequenced directly as described later in this chapter.
2.6.3 Lightscanner Analysis
Lightscanner analysis subjects PCR-amplified products to a high-precision 
denaturation process in the presence of a double-strand DNA binding dye 
(LCGreen® Plus) on the Idaho Technology LightScanner® Instrument 
(Herrmann, Durtschi et al. 2006). High-resolution melting analysis of the PCR
84
products amplified in the presence of LCGreen Plus can identify both 
Mutation detection analysis using the LightScanner® is most successful when 
analysing products of 120-220bp with a low GC content, but has been shown 
to have near 100% sensitivity and specificity when used on products of up to 
400 bp in length (Liew, Seipp et al. 2007).
Nucleic acid melting is tracked by monitoring the fluorescence o f the mixture 
across a defined temperature range, generating melting profiles that can be 
used to identify the presence o f sequence variation within the amplicon. PCR 
reactions were performed in duplicate and with positive and negative sequence 
controls. The reaction is optimised by testing these sequence controls with 
varying concentrations o f Q® (Qiagen), MgCL and different annealing 
temperatures (as described in PCR methods), lpl of the LCGreen dye is added 
to the reaction mix. The total reaction volume of 12.5|il is overlaid with 
mineral oil which is a necessary step for analysis by the LightScanner. Melting 
curves are produced which differentiate sequence variants. The advantage of 
this technique over SSCP is that it is cheaper and has a higher throughput as 
up to 144 samples (288 PCR products) may be analysed per hour. Another 
benefit is that following analysis on the LightScanner the PCR products may 
be processed directly for sequencing.
2.6.4 Loss of Heterozygosity Analysis
Loss of heterozygosity (LOH) analysis is one method by which chromosomal 
instability can be assessed in tumour samples. Tumour suppressor genes have 
a negative effect on cell growth and division. If one tumour suppressor gene 
allele is left intact this is generally enough to control cell growth and division. 
Tumour growth occurs when both alleles are disrupted either by mutation or 
epigenetic change. The first genetic change on one allele is usually a small 
inactivating mutation within the tumour suppressor gene itself. The second 
genetic change may be a small genetic change, an epigenetic change or allelic 
loss due to partial or whole chromosomal abnormalities. It is thought that 
possible mechanisms leading to loss o f heterozygosity include non-disjunction 
of homologues during mitosis, mitotic recombination or de-novo interstitial 
mutations.
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For LOH analysis to be undertaken, matched germline (peripheral venous 
blood) DNA and tumour tissue DNA were genotyped at a set of microsatellite 
markers lying close to the tumour suppressor gene under investigation. 
Microsatellite markers are short mono-, di-, tri- or tetra-nucleotides which are 
frequently polymorphic in the general population. PCR was performed for 
each of the microsatellite markers using a fluorescently labelled forward 
primer (FAM, HEX or less commonly TET) and unlabelled reverse primer. 
The resulting PCR products were run on a semi-automated ABI Prism 377XL 
DNA sequncer (PE-Applied Biosystems) together with the GENESCAN-350 
TAMRA size marker (PE-Applied Biosystems). Results analysis for LOH was 
performed using the GENESCAN and GENOTYPER software (PE-Applied 
Biosystems). Heterozygous samples could be analysed for LOH. The area 
under each allele peak was calculated and the ratio of the peak areas 
calculated. The LOH value was determined by dividing the allelic ration of 
normal tissue by the allelic ration o f the tumour tissue. LOH values smaller or 
equal to 0.5, or larger or equal to 2.0 were scored as having allelic loss on the 
assumption that the tumour contained more than 50% neoplastic starting 
material as confirmed by histological analysis.
2.6.5 MLPA analysis for whole exon deletion or duplication
Multiplex ligation-dependent probe amplification (MLPA) analysis was 
undertaken using an MLPA kit designed specifically to screen for whole exon 
deletions or duplications in the APC  gene (MRC-Holland, Amsterdam, The 
Netherlands. Probe kit P043 APC). Manufacturer’s instructions were 
followed. This kit contains a probe mix for each of the 15 coding regions of 
APC. Three probes were also included for the promoter region of the APC 
gene according to Esteller et al (Esteller, Sparks et al. 2000) and Lambertz et 
al (Lambertz and Ballhausen 1993). As exon 15 has a coding region o f more 
than 8kb, 5 probes are used for this exon. As a control, 13 probes for other 
human genes located on different chromosomes are included for each 
experiment. Details of the probe ligation sites for APC  used in this kit can be 
found at http://www.mrc-holland.com
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Briefly, MLPA is used to detect deletions and duplications in one or more 
exons of the gene of interest. Deletions o f probe recognition sequences are 
apparent by a 35-50% reduction in the relative peak area of the amplification 
product of that probe. Mutations and polymorphisms occurring close to the 
probe ligation site may result in a reduced relative peak area and therefore any 
apparent exon deletion is always confirmed with further investigation.
MLPA analysis consists o f four main steps.
1. DNA denaturation and hybridisation of the SALSA-probes 
Between 20-500ng o f starting template DNA is required and diluted with TE 
buffer to 5 p i This is heated for 5 minutes at 98°C in a tetrad PCR thermal 
cycler, then cooled to 25oC. 1.5pl o f the SALSA-probe mix is added along 
with 1.5p,l MLPA buffer. Samples were incubated at 95°C for 1 minute and 
then 60°C for 16 hours.
2. Ligation reaction
Samples were reduced from 60°C to 54°C and 32pl of Ligase-65 mix was 
added to each sample and mixed with a pipette. Samples were then incubated 
at 54°C for 15 minutes and then 98°C for 5 minutes.
3. PCR reaction
4pl of lOxSALSA PCR buffer was added to 26pl of dPLO and lOjxl of the 
MLPA ligation reaction. The samples were placed in a thermal cycler at 60°C 
and then 10pl of polymerase was added to each sample and the PCR reaction 
started. PCR cycling conditions were as follows -  35 cycles of 30 seconds at 
95°C, 30 seconds at 60°C, 30 seconds at 72°C followed by a final incubation at 
72°C for 20 minutes.
Samples were then run on the ABI-3100 genescan (PE-Applied Biosystems) 
and data analysed with Genotyper® v.2.5 software. The area under each peak 
for each probe was calculated and compared with that of the control samples. 
The size and peak areas are imported in to an Excel (Microsoft office) file for 
further analysis. Non-specific amplification products, primer dimer peaks, and 
the peaks produced by the MLPA control mix can be removed at this stage. 
When only the peak areas of the expected MLPA products remain, all peak 
areas are normalised by dividing each peak area by the combined peak area of 
all peaks in that lane. These normalised peak areas are then compared to the
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average results obtained on all samples. A deletion of one copy of a probe 
target sequence will usually result in a reduction of the relative peak size of 
35-50%. A gain in copy number for two or three copies / diploid genome 
usually results in an increase in peak area o f 35-50%.
2.7 Fluorescence cycle-sequencing of PCR products
Fluorescence cycle sequencing is an automated method of DNA sequencing 
which uses double stranded DNA as a template. The original technique 
developed by Sanger in 1977 (Sanger, Nicklen et al. 1977) is based on the 
dideoxy procedure. This procedure depends on the ability of DNA polymerase 
to synthesise complementary copies of single stranded target DNA. Therefore 
DNA synthesis is undertaken in the presence of one specific primer for the 
target sequence, the four dNTP’s and a low concentration of their dideoxy 
analogues each of which is labelled with a different fluorophore. The standard 
sequencing reaction involves 34 cycles o f heat denaturation, primer annealing 
and extension. As dideoxy nucleotides lack the 3 ’-hydroxyl group necessary 
for extension, chain termination occurs whenever one of these nucleotides is 
incorporated. As they are present at low concentration, chain termination 
occurs at each nucleotide along the target DNA sequence. The resultant 
strands therefore have a common 5’ end defined by the primers but vary in 
length depending on their base specific 3 ’ ends. The different resultant strands 
are then separated by PAGE. As the chain terminating events have a 
specifically attached fluorophore identifier (one for each base) the sequence 
can be read as the strands pass a fluorescence detector.
PCR products selected for DNA sequencing were first purified -  removing 
unincorporated primers and nucleotides using the QIAquick PCR purification 
kit (Qiagen) according to manufacturer’s instructions. Proteins and 
oligonucleotides smaller than lOObp’s were removed by washing through a 
silica-gel membrane under different salt conditions. The resultant purified 
PCR products were then sequenced in the forward and reverse orientation 
using the same primer as for the original PCR reaction. Each 20pl reaction 
contained 8|xl of Big Dye Terminator Ready Reaction mix (PE-Applied 
Biosystems), 2pl primer (2pM; forward or reverse), 2pl of purified product
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and 8jil of dH20 . Sequencing cycle conditions for the Tetrad PCR machine 
(MJ Research) consisted of an initial denaturation at 94°C for 4 minutes, 25 
cycles of 94 °C for 30 seconds, 50 °C for 10 seconds and 60 °C for 4 minutes 
with a final extension step at 60 °C for 7 minutes. The resultant sequencing 
products were finally purified from excess dye-labelled dideoxy nucleotides 
using the QIAquick PCR purification Kit with a final elution in 8pl of 
microSTOP loading buffer (PE-Applied Biosystems). Sequencing samples 
were then denatured at 94 °C for 4 minutes and run on a 5% polyacrylamide 
gel on a semi-automated ABI prism 377XL DNA sequencer (PE-Applied 
Biosystems). Sequence analysis was perfomed using the Semi-adaptive Base 
Calling option of the Sequencing Analysis Programme Version 2.1 (PE- 
Applied Biosystems). The NCBI BLAST database was then searched with the 
resultant sequence to ensure correct origin of the target DNA sequence 
(http://www.ncbi.nlm.nih.gov/blastL All sequences were also analysed by eye 
for mutations.
2.8 Cloning of PCR products
Cloning allows the amplification of a single DNA fragment such as a PCR 
product. The techniques involves ligation of the DNA fragment into an 
appropriate vector which, following transformation, can be propagated in a 
suitable bacterial host. Recombinant clones are selected based on vector- 
encoded genes, grown up to a high density, and the recombinant vector is then 
purified.
Cloning of PCR products was undertaken using the pGEM®-T Easy vector 
system (Promega). This system utilises a high copy number vector which 
carries a gene conferring resistance to the antibiotic ampicillin. The vector is 
provided ready for ligation, having been prepared by cutting with the 
restriction endonuclease EcoRW. The EcoKV restriction site is located with an 
open reading frame encoding the a-peptide of (3-galactosidase (lacZ'). When 
intact, this enzyme can convert the colourless substrate X-gal into a blue 
product upon induction with IPTG. This vector has a 3’ thymidine overhang 
which allows insertion of PCR products which have a 3’ overhang of
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adenines. PCR products are ligated to the vector then incubated with 
competent cells following heat shock at a temperature specific to the vector. 
Transformation is undertaken and the transformation culture then plated out 
on to LB/ampicillin/IPTG/X-Gal plates. The culture plates are incubated at 
37°C overnight (whilst shaken at 150 rpm). White colonies are then selected 
(containing successful PCR product inserts) for subsequent sequencing. All 
solutions were supplied by Promega unless otherwise stated.
1. Ligation:
PCR products were purified and cleaned up using the Qiagen QIAquick kit 
following manufacturers instructions.
Additional adenine bases were attached to the 3’ end of the PCR product by 
firstly denaturing at 95°C for 20 minutes, 25pi of the denatured product was 
then incubated with 7pi o f lOOpM dATP (AR stock check) and 5U of Taq 
polymerase (CRUK) at 70°C for 15 minutes.
Ligation to the pGEM®-T Easy vector was performed by incubating 2pl of 
PCR product (with poly-A tail), lp l pGEM®-T Easy vector, lp l T4 DNA 
ligase and 5 pi o f rapid ligation buffer at 4°C overnight.
2. Transformation:
LB/ampicillin/IPTG/X-Gal plates were set up by adding 400pl of ampicillin 
(lOOmg/ml), 2000pl of IPTG (lOOmM stock AR) and 640pl of X-gal to 400ml 
of LB agar (at 55°C). 15-20ml o f this solution was poured in to bacteriological 
plates under sterile conditions and left to set for 20 minutes. Plates could then 
be stored at 4°C prior to use. All o f the following steps for transformation 
were undertaken in sterile conditions.
Transformation of JM109 high efficiency competent cells was undertaken by 
adding 50pl of the thawed competent cells to 2pl of the ligation reaction in a
sterile 1.5ml tube (source) on ice, the solution was mixed by gentle flicking of
the tube and then left on ice for 20 minutes. A control tube was also prepared 
containing 0.1 ng o f uncut plasmid. The cells were heat shocked by placing in 
a water bath at exactly 42°C for 45-50 seconds. The tube was then 
immediately placed on ice for 2 minutes. 950pl of SOC at room temperature 
was added to the tubes and incubated at 37 °C for 1 Vi hours whilst being 
shaken at 150 rpm. lOOpl of each transformation culture was plated in
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duplicate on to the pre-prepared LB/ampicillin/IPTG/X-gal plates and 
incubated overnight at 37 °C. White cultures (indicative of successful ligation 
and transformation) were then picked for further analysis and sequencing.
2.9 Cell Culture
2.9.1 Sterile Lymphocyte Separations
Sterile lymphocyte separations were performed in order to establish permanent 
cell lines containing germ line DNA from patients and controls under 
investigation. Cell lines were established through immortilisation of 
lymphocytes with Epstein-Barr virus (CRUK cell services). All of the steps 
for lymphocyte separation and cell line production were undertaken in sterile 
conditions.
25ml of peripheral venous blood was collected via venesection into a Falcon 
tube containing 25ml o f sodium citrate medium. The 50ml of blood and 
sodium citrate medium were poured in to a 250ml flask, the tube was then 
rinsed with 4ml of RPMI medium (CRUK) at room temperature. Defibrination 
of the whole blood was performed by adding approximately 25 glass beads 
(BDH) and 600p.l of 1M CaCh (BDH) to the flask which was then placed on 
a gyratory shaker (source) at 250rpm for 15 minutes at room temperature. 
20ml of RPMI was then added to the flask and the sample split between two 
falcon tubes each containing 15ml o f lymphoprep (Robbins scientific). Each 
sample was layered carefully over the lymphoprep solution with a pipette. The 
tubes were then spun at 1800rpm for 20 minutes in a centrifuge with a swing 
out rotor (with the brake off) which allowed the defibrinated sample to be 
passed thorough the lymphoprep solution forming a gradient with different 
cellular components being present in each layer. The interface containing the 
lymphocytes was aspirated off using a pipette, transferred to a new 50ml 
falcon tube and centrifuged at 2300rom for 10 minutes. The lymphocyte cell 
pellets were re-suspended in 2ml o f freeze mix (90% foetal calf serum / 
10% DMSO), divided equally between 2 cryotubes (Coming) and placed 
immediately at -80°C overnight. The samples were then placed in liquid 
nitrogen until ready for transformation.
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2.9.2 Feeding Cell Lines
Once the lymphocytes had been successfully transformed and a growing 
culture established they would require regular feeding or spinning down for 
DNA or RNA extraction (as described previously). Lymphoblastoid cells lines 
were cultured in RPMI/10%FCS (CRUK) medium which is used for cells in 
suspension. Colon cancer cell lines (eg HCT116) were cultured in 
E4/10%FCS meduim (CRUK) which is used for adherent cells.
Cells in culture were examined daily under a microscope to determine 
viability and density. If cells were being deliberately left to be cultured they 
would be “split” when they became confluent, 50% of the cultured medium 
was removed under sterile conditions and replaced with fresh culture medium. 
Culture flasks (Falcon) were incubated at 37°C in 10% CO2. Cells were then 
either left for further culture or spun down for their required protocol.
2.9.3 Freezing down and re-suspending cells to replace 
stocks
To ensure a permanent cell line resource an aliquot of the growing cells in 
culture were frozen down and stored in liquid nitrogen. 50ml of the growing 
culture was removed in to a falcon tube under sterile conditions and spun at 
2000rpm for 5 minutes. The supernatant was removed and the tube in verted 
to dry. The pellet was re-suspended in 2ml freeze mix (90% foetal calf 
serum / 10% DMSO) and aliquoted in to 2 cryotubes (Coming) for long term 
storage. Tubes were stored at -80°C overnight and then in liquid nitrogen.
2.10 Comparative Genomic Hybridisation
Comparative genomic hybridisation (CGH) enables the screening of the whole 
genome for chromosomal losses and gains in a single experiment. This 
technique has been used widely to study tumour karyotypes . (Kallioniemi, 
Kallioniemi et al. 1992). Conventional CGH (resolution 5-10 Mb) has been
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super-ceded by microarray CGH (aCGH) with a higher resolution of screening 
across the genome. I used 1Mb resolution arrays designed by Nigel Carters 
group at the Wellcome Trust Sanger Centre (Cambridge, UK). These arrays 
consist o f 3125 human Bacterial Artificial Chromosome (BAC) clones, 
amplified by degenerate oligonucleotide primer PCR (DOP-PCR) and printed 
in duplicate on to glass slides. In addition 6 BAC clones from Drosophila 
melanogaster were also printed on to the array as a control for background 
hybridisation.
The BAC clones were selected from the Golden Path at a spacing of 
approximately 1 Mb across the whole genome, excluding the short arms of the 
acrocentric chromosomes. Clones FISH-mapped to a single location or 
localised to known oncogenes and tumour suppressors were preferred, but the 
selection was arbirtrary in the majority of cases (Fiegler, Carr et al. 2003).
1. Array preparation
Array printing was performed by Cordelia Langford at the Wellcome Trust 
Sanger Centre (Cambridge, UK). Aminolinked PCR products were diluted 
into lx  printing buffer (250mM sodium phosphate pH 9.0, lx l0 ‘6 % N- 
laurylsarcosine) and filtered through 0.22pm filter plates (Millipore), before 
re-arraying in to 384-well plates. The DNA products were printed on to 
Codelink™ activated slides (GE Healthcare) using a Microgrid II array spotter 
(Biorobotics). Printed slides were transferred to a humid chamber at room 
temperature for 72 hours to drive the covalent attachment of the DNA to the 
slides. Slides were then immersed in 1% w/v ammonium hydroxide for 5 
minutes, 0.1% sodium dodecyl sulphate for 5 minutes and then rinsed in 
water. The bound DNA was denatured by immersing the slides in water at 
95°C for 2 minutes before being rinsed in ice-cold water and finally the slides 
were dried by centrifugation.
2. DNA labelling and purification
450ng of normal (“reference”) and tumour (“test”) DNA were labelled with 
Cy3-dCTP and Cy5-dCTP (Amersham) respectively, using the Bioprime array 
CGH labelling kit (Invitrogen), according to the manufacturers instructions. 
Briefly, DNA was diluted to a volume of 2 lpl nuclease-free water and 
combined with 20pl random octamer primers in 2.5x buffer (125mM Tris-HCl
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(pH 6.8), 12.5mM MgCh, 25mM Ji-mercaptoethanol, 750pg/ml random 
octamers). The sample was incubated at 100°C for 10 minutes and 
immediately cooled on ice. 5p.l o f dNTP mix (1.2mM dATP, dGTP and 
dCTP), 3pil o f Cy3- or Cy5-dCTP (lpM ) and lpl of Exo-Klenow fragment 
(40U/pl) were mixed with the cooled sample. The samples were incubated 
overnight at 37°C. Reactions were then stopped by the addition of 5pl of 0.5M 
EDTA.
Labelled DNA was then purified using Microspin G-50 columns (Amersham) 
according to the manufacturer’s protocol. DNA samples were run on a 2% 
TBE-agarose gel at 120V for 20 minutes to confirm DNA labelling. 
Successfully labelled samples would produce a low-molecular weight smear 
(~50-200bp) when viewed under UV light.
3. DNA precipitation and hybridisation
Slides were prepared for hybridisation by first forming a seal around the 
arrayed area o f the slide by applying 2 layers of adhesive PCR film (AB-gene, 
AB-0558), cut to size with reference to a “dummy” printed slide.
Labelled test and reference DNA samples were combined and precipitated 
with 135pg Cotl DNA (Roche) in 0.1 volumes 3M sodium acetate (pH 5.2) 
and 2.5 volumes o f ice-cold ethanol at -80°C for 30 minutes. Concurrently, 
lOpg of Herring sperm DNA was precipitated with 135pg Cotl DNA. 
Precipitated DNA was then pelleted by centrifugation at 16,000g for 15 
minutes. The resultant pellet was washed with 80% ice-cold ethanol and re­
pelleted at 16,000g for 5 minutes. The supernatant was removed and the pellet 
dried.
The labelled pellet was then re-suspended in 80pl hybridisation buffer (50% 
deionised formamide, 10% dextran sulphate, 0.1% Tween-20, 2xSSC, lOmM 
Tris (pH 7.4)) and 8pl yeast tRNA (lOOpg/^l, Invitrogen). The herring sperm 
pellet was then re-suspended in 180pl hybridisation buffer. Both samples were 
heated at 80°C and frequently mixed by vortex until the pellets were re­
suspended. The labelled DNA sample was then placed at 37°C for 1 hour to 
allow the labelled samples to compete with the Cotl DNA, blocking repetitive 
sequences. The re-suspended herring sperm DNA mixture was carefully 
pipetted on to the prepared slide to pre-hybridise for 1 hour at 37°C in a humid
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chamber formed of a slide box containing 3 mm paper (Whatman) soaked in 
40% formamide/2xSSC. Following competition, the labelled DNA sample 
was applied to the pre-hybridised array via pipette. The humidity chamber was 
sealed with electrical tape to form a firm seal. The array was then incubated at 
37°C on a rocking platform for 48 hours.
4. Microarray CGH slide washing protocol
All steps were performed in the dark to preserve the fluorochromes (Cy3 and 
Cy5).
Arrays were removed from the humidity chamber and placed in wash buffer 1 
(2x SSC/0.1% Tween-20) in a coplin jar at room temperature. The seal was 
then removed with forceps after approximately 30 seconds. The arrays were 
then washed in this solution on a rocking platform for 5 minutes. Arrays were 
then washed again in buffer 1 at 65 °C for 5 minutes. Arrays were then washed 
in buffer 2 (0.2 x SSC) at room temperature for 5 minutes -  3 washes in buffer 
2 were performed with fresh buffer for each wash (1 wash for 2 minutes, 2 
washes for 20 minutes). Arrays were then transferred to wash buffer 3 
(lxPBS, 0.1% Tween-20), for 5 minutes, then wash buffer 4 (lxPBS) for 5 
minutes, and a final brief wash in dH20. The arrays were then dried by 
centrifugation at 500g for 3 minutes in slide boxes lined with bleach-free 
tissue paper. Slides were then stored in the dark at room temperature until 
scanning.
5. Microarray CGH slide scanning and data analysis
A Scanarray confocal scanner and software (Perkin Elmer) was used to scan 
the arrays. Every array was pre-scanned and settings adjusted to ensure even 
signal detection from both Cy3 and Cy5 fluorochromes. Detailed scanning 
was then performed at 10pm resolution and TIFF image files produced for 
each array for further analysis.
Microarray based experiments produce very large quantities of data for 
analysis which requires handling in a constant and robust manner in order to 
be able to compare experimental results between research groups. There are 
two important factors which need addressing. One is appropriate 
normalisation o f the data -  whereby raw ratios are transformed to a defined 
baseline allowing for experimental artefacts such as uneven hybridisation. The 
second is accurate selection of significant regions of change for further study.
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Fielger et al addressed these issues by braking down microarray data analysis 
into five steps (Fiegler, Carr et al. 2003).
i) Overlaying of image files and data-point quantification -  individual output 
files for each fluorescent dye channel are overlaid and the intensity of each 
individual spot calculated.
ii) Data rejection -  individual spots are accepted of rejected on the basis of 
spot quality and the level o f “background” hybridisation. Data is then 
normalised to the number of copies of test genome per copy of reference 
genome. In the arrays used, this rejection was determined by the presence of 6 
Drosophila melanogaster clones which are known not to hybridise to human 
DNA. These were therefore controls for non-specific hybridisation.
iii) Normalisation -  Accepted data values are then normalised across the array 
to give a ratio of the number of test genomes per copy of the reference 
genome.
iv) Duplicate rejection -  variability of data for duplicated BAC clones is 
compared and if  excessively variable the data is rejected.
v) Identification o f significant changes -  calculated log2 ratios are used to 
identify regions o f altered copy number in the test DNA sample with respect 
to the test sample.
Spot software (Jain, Tokuyasu et al. 2002) was used for overlaying Cy3 and 
Cy5 array images. This software calculates intensity values for each spot on 
the array using a local histogram method. Normalisation was performed using 
a Microsoft Excel spreadsheet written by Heike Fiegler in Nigel Carter’s 
group (Fiegler, Carr et al. 2003). Duplicate clone spots were then compared to 
determine that both were giving an identical hybridisation ratio. This was 
determined by taking the median of the normalised ratios between the test and 
reference signals -  and assessing for any deviation between these and the 
originals. If a duplicate had greater than 10% variance when compared to the 
calculated median it was rejected, if  not the median was then used to calculate 
the final log2 ratio for this clone.
Finally, the identification of areas of significant change was undertaken using 
a file from UCSF Spot (Jain, Tokuyasu et al. 2002) using the statistical 
package R (Team 2006). In theory, the log2 output for each (duplicated) clone 
on the array should be representative of the number of copies of the test
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genome per copy of the reference genome. Therefore a diploid tumour losing 
one copy of a particular chromosome would result in a ratio of 0.5 -  one copy 
of test genome per two copies of reference genome. In practice it can be 
difficult to meet these theoretical thresholds due to experimental artefacts such 
as contaminating normal DNA in the test (tumour) samples which would 
dilute the observed change.
The determination of copy number changes was performed using the program 
DNAcopy(http://www.bioconductor.org/repository/releasel.5/package/html/D 
NAcopy.html), supplemented by a formal paired t-test comparing 
tumour:normal and normalinormal hybridisations to determine regions of 
significant copy number change using a threshold of p<0.001. Only autosomes 
were analysed.
2.11 Expression-Microarray Analysis
RNA from lymphoblastoid cell lines was extracted using the trizol method (as 
described previously) and cleaned up with the Qiagen RNeasy kit following 
manufacturers instructions. Quality and quantity of extracted RNA was 
assessed using the Agilent 2100 bioanalyzer.
Purified total RNA (5pg) was labelled and hybridised on to Affymetrix®
U133 Plus 2.0 GeneChip oligonucleotide arrays (Affymetrix, Santa Clara,
CA). The following is a summary of the hybridisation protocol.
Full details can be found at -
https://www.affvmetrix.com/support/downloads/manuals/expression_s2_manu
al.pdf.
U133 Plus 2.0 Expression Micro-array protocol.
All reagents used were supplied by Affymetrix unless otherwise specified.
In summary, first and second round cDNA was made from the extracted 
purified RNA. cRNA was then made from the cDNA. This was purified and
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quantified then 20pg subsequently fragmented prior to hybridisation on to the 
oligonucleotide arrays.
1. First Strand cDNA synthesis
Poly-A control stock was diluted with poly-A control buffer 1:20, then 1:50, 
and finally 1:10 in preparation. 2pl o f the diluted poly-A control was then 
added to 2pl o f T7-01igo(dT) Primer, 50 pM, and 8pl sample RNA to a total 
volume of 12pl. This was incubated at 70°C for 10 mins, then cooled at 4°C 
for a further 2 mins. A first strand master mix was prepared consisting of 4pl 
5x 1st strand reaction mix, 2pl 0.1M DTT and lpl lOmM dNTP (total 7pl 
volume). These were mixed together to make up a 19pl volume which was 
then incubated immediately at 42°C x 2 min. lp l Superscript II was then 
added and the mix of 20pl incubated for 1 hour at 42°C, then cooled for at 
least 2 minutes at 4°C.
2. Second Strand cDNA synthesis
A master mix o f 130pl was prepared with: 91 pi RNase-free water, 30pl 5x 
2nd strand reaction mix, 3pi dNTP lOmM, lpl E coli DNA ligase, 4pl E coli 
DNA polymerase I, 1 pi RNase H. This was added to the 20pl from the first 
strand synthesis and incubated for 2 hours at 16°C. 2pl of T4 DNA 
polymerase was then added and incubated at 16°C for 5 mins. The reaction 
was stopped by the addition of lOpl EDTA 0.5M.
3. Cleanup o f cDNA
600pl of the cDNA binding buffer was added to the double-stranded cDNA 
preparation and mixed by vortexing. 500pl of this mixture was pipetted into a 
cDNA cleanup column sitting in a collection tube then centrifuged for 1 min at 
>8000g. The eluate was discarded and the spin column re-loaded with the 
remaining mixture, repeating the spin as above. The collection tube was 
changed and 750pl o f cDNA wash buffer was applied and the spin repeated as 
above. The eluate was discarded and spun once more at maximum speed. The 
collection tube was changed and 14pl o f cDNA elution buffer was applied via 
pipette, it was then spun for 1 minute at maximum speed.
4. cRNA synthesis
12pl o f the eluate was mixed with lOpl RNase-free water, 4pl lOx IVT 
labelling buffer, 12pl IVT labelling NTP mix and 4pl IVT labelling enzyme to 
make a final volume of 40pl which was then incubated at 37°C for 16 hours.
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5. Cleanup and quantification of cRNA
60pl RNase-free water was added to the IVT reaction and mixed by vortexing. 
350pl IVT cRNA binding buffer was added to this and vortexed again. Finally 
250pl ethanol (96-100%) was added and mixed with a pipette. This mix was 
applied to the cRNA cleanup column placed in a collection tube. The column 
was then centrifuged for 15 seconds at > 8000g. The column membrane was 
washed with 500pl IVT cRNA wash buffer, then spun for 15 seconds at > 
8000g. 500pl 80% ethanol was then added to the column and spun for 15 
seconds at > 8000g. The eluate was discarded and the column spun for a 
further 5 min at maximum speed, then transferred to a new tube, l lp l  of 
RNase-free water was applied to the spin column membrane and centrifuged 
for 1 min at maximum speed to elute the cRNA. This step was then repeated 
with a further lOpl RNase-free to maximise the quantity of eluted cRNA. The 
eluate in was diluted 1:50 with dt^O to determine the final concentration and 
then analysed on the ND-3100 Nanodrop.
6. Fragmentation o f cRNA
20pg of cRNA (1 to 2 lp l depending on concentration) was added to 8pl 
fragmentation buffer (Affymetrix cleanup kit) and made up to 40pl with 
RNase free water. This was incubated at 94°C for 35 min, then placed on ice. 
The fragmentation product was then run on a 2% agarose gel at 120V for 30 
mins for confirmation o f fragmentation.
7. Hybridisation
The following mix was made: 36pl fragmented cRNA, 5pi 3nM control 
oligonucleotide B2, 15 pi 20x eukaryotic hybridisation controls (the 20x 
eukaryotic hybridisation controls were heated to 65°C for 5 min before 
aliquoting.), 3 pi herring sperm DNA, 3pi BSA (50mg/ml), 150pl 2x 
hybridisation buffer, 30pl DMSO and H2O to a total volume of 300pl. This 
was then heated to 99°C for 5 mins in a heat block. Meanwhile the array was 
wet by filling it with lx  hybridisation buffer, and incubated at 45°C in the 
hybridisation oven for 10 min. The hybridisation cocktail was transferred from 
the 99°C block to a 45 °C block and then spun for 5 mins at maximum speed to 
remove insoluble material. The buffer solution in the array was then 
exchanged for the hybridisation cocktail and placed back in the hybridisation 
oven for 16 hours at 45°C.
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8. Washing and Staining
SAPE stain solution was made by mixing 600jil 2x stain buffer, 48pl 50mg/ml 
BSA, 12pl lmg/ml SAPE and 540pl ddH20 making a final volume of 1200pl. 
Antibody solution was made by mixing 300pl 2x stain buffer, 24pl 50mg/ml 
BSA, 6pl lOmg/ml Goat IgG stock (Sigma-Aldrich), 3.6jj.1 0.5mg/ml 
biotinylated antibody and 266.4pl dfhO. The arrays are washed and stained 
using the automated Affymetrix wash station using the protocol 
EukGE_w52v5.450.
9. Scanning
This was performed using the Affymetrix GeneChip 3000 scanner. 
Affymetrix GCOS software (vl.4) was used to obtain DAT image files which 
were then converted to CEL files containing information about the expression 
levels of the individual probes.
Unsupervised analysis o f microarray data aims to detect groups of samples or 
outliers without knowledge o f the clinical features of each sample. 
Hierarchical clustering is an unsupervised method for organizing expression 
data into groups with similar signatures, which is represented by a cluster 
dendrogram. A ‘volcano plot’ arranges genes along dimensions of biological 
and statistical significance. The first axis indicates biological impact of the 
change; the second indicates the statistical evidence, or reliability of the 
change.
My data was analysed using the R statistical package (Team 2006) by the 
Bioinformatics department at CRUK. The standard test statistic used for 
comparing the two groups was the t-statistic: 
t = (xi,l -x i,2 )  / si,
where xi,l is the mean value of gene i in group 1, xi,2 is the mean in group 2, 
and si is the (non-pooled) within-groups standard error (SE) for gene i. 
Usually the majority o f genes are not consistently changed between groups. 
For the unchanged genes, the values of their t-statistic would follow the t- 
distribution indexed by nl+n2 -  2 degrees o f freedom, in repeated trials, 
provided there are no outliers in the samples. As a matter of practice, in almost 
all cases, the values o f the t-statistics for all o f the unchanged genes in a single 
experiment also follow a t-distribution. If the researcher expects only a small 
number of genes are greatly changed, then a convenient way of assessing the
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most likely true positives is to plot the t-scores obtained, against the t- 
distribution. Usually the t-scores of the unchanged genes follow the t- 
distribution; if the unchanged genes are the overwhelming majority, then this 
plot will be a straight line at 45°. The t-scores for the few really significant 
genes are more extreme, and stand out from the straight line, where they can 
be easily seen.
Cluster dendrograms were produced to demonstrate hierarchical clustering 
between the sample analysed. Dendrograms graphically present information 
regarding each individual sample analysed which are then grouped together at 
various levels o f similarity. At the bottom of the dendrogram each observation 
is considered as having its own cluster and identity. Vertical lines extend up 
for each observation, and at various similarity values these lines are connected 
to the lines from other observations with a horizontal line. The observations 
continue to combine until, at the top of the dendrogram, all observations are 
grouped together. The height of the vertical lines and the range of the 
similarity axis give visual clues about the strength of the clustering. Long 
vertical lines indicate more distinct separation between the groups. Long 
vertical lines at the top o f the dendrogram indicate that the groups represented 
by those lines are well separated from one another. Shorter lines indicate 
groups that are not as distinct.
The ‘volcano plot’ arranges genes along dimensions of biological and 
statistical significance. The first (horizontal) dimension is the fold change 
between the two groups (on a log scale, so that up and down regulation appear 
symmetric), and the second (vertical) axis represents the p-value for a t-test of 
differences between samples (most conveniently on a negative log scale -  so 
smaller p-values appear higher up). The first axis indicates biological impact 
of the change; the second indicates the statistical evidence, or reliability of the 
change.
The data presented in this thesis will include both dendrograms and volcano 
plots.
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2.12 Laser Capture Microdissection
Laser capture microdissection (LCM) is a technique used for isolation of 
highly pure cell populations from a heterogeneous tissue section, cytological 
preparation or a live cell culture via direct visualisation of the cells. There are 
two main classes of laser microdissection, infra-red capture systems and 
ultraviolet (UV) cutting systems. A UV cutting system on the P.A.L.M. laser 
capture dissection microscope (P.A.L.M Microlaser Technologies, GmbH, 
http://www.zeiss.com) (Micke, Ostman et al. 2005). This system allows both 
UV laser cutting and catapulting of the cut tissue into a collecting cap using a 
UV laser pulse.
The principle components of LCM are -
1. visualisation of the cells of interest via microscopy
2. transfer o f laser energy with photo volatisation of cells surrounding a 
selected area
3. Removal of cells of interest from the heterogeneous tissue section 
(with UV laser pulse)
Using LCM, both frozen and fixed tissues can be dissected and recovered cells 
can be used for DNA, RNA and protein analysis.
Sections were cut from paraffin embedded archival tissue. Six 6pm section 
were taken from paraffin embedded tissue on to PALM slides (PALM Laser 
technologies, GmbH, 82347, Germany). The slides have a polymer membrane 
and were pre-treated with UV light (302 nm) for 30 minutes. Two 
haematoxylin and eosin (H&E) slides were taken for reference for each 
sample -  one at the beginning and one at the end. Individual crypts from 
adenomas at their earliest stages were then cut in to caps (PALM Laser 
technologies, GmbH, 82347, Germany. Ref 1440-0250) for extraction of 
DNA. In order to obtain suitable amount of DNA for performing mutation 
detection, six sequential sections of the same crypt were cut in to each 
individual cap. These samples were digested overnight in proteinase K and 
buffer (PicoPure DNA Extraction kit (Kit:0103), Molecular Devices 
Corporation, CA94089-1136, USA). See method for extraction of DNA from 
LCM dissected crypts for further details.
102
2.13 Immunohistochemistry
Immunohistochemistry was performed staining for p-catenin and PMS2.
1. Slide preparation
4 pm sections from paraffin embedded archival tissue were placed on to glass 
slides. Slides were then dewaxed in xylene (BDH) for 5 minutes then 100% 
ethanol (BDH) for 3 minutes, 90% ethanol for 3 minutes and 70% ethanol 
for 3 minutes.
Endogenous peroxidase was blocked by incubating the slides in 3% hydrogen 
peroxide (H2O2, BDH)/phosphate buffered saline (PBS) for 30 minutes.
2. Exposing antigen and applying primary antibody
Citrate buffer was heated to boiling in a pressure cooker and slides were 
placed in the pressure cooker on full pressure for four minutes. Slides were 
then allowed to cool in the citrate buffer and rinsed in phosphate buffered 
saline (PBS) (pH 7.45).
The slides were incubated in normal rabbit serum (NGS-1:25, DAKO Ltd.) 
for 10 minutes to block non-specific binding. 75pl of primary antibody (|3- 
catenin, 1:100 dilution, Transduction Labs, (20pl antibody in 1980pl PBS )) 
and PMS2 (purified mouse anti-PMS2 monoclonal antibody, BD Pharmingen, 
1:40 concentration, (40\mu 1 in 1000ml PBS)) were added to the slides and 
incubated for 45 minutes. Positive and negative control slides were included in 
every run
3. Application o f secondary antibody and counterstaining
Slides were rinsed in PBS for 5 minutes and then incubated with secondary 
antibody (biotinylated rabbit anti-mouse Ig, DAKO Ltd.) for 35 minutes. The 
slides were incubated for 30 minutes at room temperature, washed in PBS and 
then incubated with streptavidin-peroxidase conjugate (1:500, P397, DAKO 
Ltd.) for 35 minutes at room temperature. The peroxidase activity was 
demonstrated by activated 3,3’-diaminobenzidinetetrahydrochloride solution 
(DAB) (Sigma D5637) and 0.1% H2O2 . Finally slides were dehydrated 
through a series o f ethanol washes of 70%, 90% and 100%, then xylene before 
being mounted using Pertex mountant (CellPath).
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2.14 Mouse husbandry
Animals were bred at Cancer Research United Kingdom Laboratories (South 
Mimms, UK). Experiments were conducted in full accordance with the United 
Kingdom Animal Procedures Act 1986. All animals were sacrificed under 
schedule 1 regulations. Any sick animal was reviewed by the resident Vet at 
Clare Hall laboratories and either treated for its condition or sacrificed and 
post mortem examination undertaken.
The C57BL/6J-/f/?cA//«+/' mice were originally a gift from A. R. Moser 
(McArdle Laboratory, University of Wisconsin, Madison, WI). The 
129/C51BL/6JMyh+/~ mice were a gift from J. Miller (Molecular Biology 
Institute, University of California, Los Angeles, USA). AKR wild type mice 
used for backcrossing were obtained from CRUK stocks in the animal unit at 
Clare Hall laboratories (CRUK).
2.15 Ethical Approval
All samples and clinico-pathological data were obtained with informed 
consent and local ethical review board approval in accordance with the tenets 
of the Declaration o f Helsinki. All patients were recruited to the CORGI 
(COloRectal Gene Identification) study, MREC 99/2/14.
2.16 Solutions I Media
Ammonium acetate (saturated)
148g NH4Ac (BDH), 50ml dH20
Ampicillin, lOOg/ml
lg  ampicillin (Sigma), 10ml dH20 , stored at -20°C
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CaCl21M
14.7g CaCl2 (BDH) in 100ml CIH2O, mixed thoroughly and filtered (0.22pm 
filter)
Citrate buffer stock pH6.0
210.14g citric acid (BDH) in 1000ml dH20, adjusted to pH6.0 using NaOH 
pellets (BDH)
Citrate buffer solution
20mls citrate stock (pH6.0), 1980mls dH20
DAB
5mg DAB (Sigma D5637), 10ml PBS, 20pl H2O2 
Ethanol
70% - 700ml absolute ethanol (BDH) and 300ml CIH2O 
75% - 750ml absolute ethanol (BDH) and 250ml (IH2O 
90% - 900ml absolute ethanol (BDH) and 100ml (IH2O 
95% - 950ml absolute ethanlol (BDH) and 50ml CIH2O 
100% - absolute ethanol (BDH)
Ethylene-diamine-tetra-acetate (EDTA) 0.5M for 11
Na-EDTA 184.1 g, pH 8.0, autoclave
Ethidium bromide (lOmg/ml)
O.lg Ethidium bromide (Pierce) dissolved in 10ml dH20. Store in dark
Formamide wash solution (2xSSC, §0% formamide)
50ml 20xSSC, 250ml formamide (BDH), made up to 500ml with dH20
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Freeze Mix (90% FCS/10%DMSO)
9ml foetal calf serum (GibcoBRL) mixed with 1ml dimethyl-sulphoxide 
(BDH)
Growth medium E4/FCS
180ml E4 cell culture medium (CRUK), 20ml foetal calf serum (GibcoBRL) 
Growth medium RPMI/FCS
180ml RPMI cell culture medium (CRUK), 20ml foetal calf serum 
(GibcoBRL)
Hybridisation buffer (2xSSC, §0% formamide, 10% dextran sulphate)
lml 20xSSC, 5ml formamide (BDH), lg  dextran sulphate (BDH), made up to 
10ml with dH2 0
H202 0.1%
600ml methanol, 1.8ml H 202 (30%)
H202 3%
600ml methanol, 54ml H2O2 (30%)
IPTG (0.1M)
1.2g IPTG (Promega), 50ml dH20, filter-sterilised (0.22pm filter), stored at 
-20°C
Luria broth (LB)
lOg sodium chloride, 5g bacto yeast extract, lOg bacto-trytone, 900ml dH20, 
pH 7.0, autoclaved
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LB agar plates
LB medium prepared as above, 15g bacto-agar added prior to autoclaving 
NP-40 0.1%
200pl nonidet P40 (BDH), 200ml dH20  
Nuclei lysis buffer (50ml)
lOmM Tris (500pl 1M), 400mM NaCl (4ml 5M), 2mM EDTA (200pl 0.5M 
(BDH)), 45.3ml dH20
Phosphate buffered saline (lx ), for 11
NaCl 8g (137mM), KC1 0.25g (2.7mM), Na2HP04 1.43g (lOmM P 04), 
KH2P 04 (0.25g), pH 7.4, autoclave
PBS/5% Tween-20
9.5ml PBS, 500pl Tween-20 (Sigma)
PBS/0.5% Tween-20
9ml PBS, 500pl Tween-20 (Sigma), 500pl BSA (NEB)
Proteinase K buffer (store 4°C)
2mg proteinase K (Merck) in lml dH20
RNAseA, lOmg/ml
lOOmg RNAseA (Advanced biotechnologies), 10ml dH20 , stored at -20°C 
SE buffer
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75mM NaCl (7.5ml 5M), 25mM EDTA pH 8.0 (2.5ml 0.5M), 1% SDS (50ml 
10%) made up to 500ml with dH20, filtered 0.22pm filter.
Sodium acetate (3M)
61.52g sodium acetate (BDH), 200ml dH20, pH 6.0 made up to 250ml with 
dH2 0 , autoclaved
Sodium chloride (5M)
73.lg  NaCl (BDH), made up to 250ml with dH20, autoclaved 
Sodium chloride (0.9%) pH 1.5
4.5g NaCl, 400ml dH20 adjusted to pH 1.5 with HC1 (BDH), made up to 
500ml with dH20
Sodium dodecyl sulphate (SDS)
10% w/v volume SDS (BDH) in sterile dH20
Sodium hydroxide 0.3M
1.2g NaOH pellets (BDH), 100ml dH20
SSC buffer (20x) for 11
NaCl 175.32g (3M), Na-citrate 88.23g (0.3M), pH 7.0, autoclave 
Tail lysis buffer
50mM Tris/HCl pH8.0, lOOmM EDTA, lOOmM NaCl, 1%SDS, store at room 
temperature
TBE buffer (lOx) for 11
108
Tris base 108g (0.89M), boric acid 55g (0.89M), Na-EDTA 9.3g (0.02M), pH 
8.3, autoclave
TE buffer (lx ) for 11
10 ml 1M Tris (pH 8.0), 2ml 0.5M EDTA (pH 8.0), filter (0.2pm) and UV 
sterilise for 15 minutes
Tris 1M for 11
Tris base 121.14g, pH as required using HC1 (BDH), autoclave 
Tris-HCl 0.5M pH 6.8
78.8g TRIZMA HC1 (Sigma), 400ml dH20, adjusted to pH8.0 with HC1 
(BDH), made up to 500ml with dH2<3
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3 Clinical MYH related studies - Determination of 
clinico-pathological features and potential 
genotype-phenotype correlations in MYH
3.1 Introduction
In this Chapter I set out to review and refine MAP in terms of its clinical and 
pathological features in order to improve the understanding o f MAP 
pathogenesis, selection o f individuals for genetic screening and subsequent 
clinical management.
The development of the understanding o f genotype-phenotype correlation in 
FAP and AFAP has improved clinical and molecular diagnosis, appropriate 
surveillance and intervention. For example, in patients with severe phenotype 
of 1000’s o f adenomas are more likely to have germline mutations between 
codons 1250 and 1464 of APC. The presence of extracolonic features also 
guides molecular screening in FAP, with CHRPE being associated with 
mutations between codons 457 and 1444 and desmoids having an association 
with mutations between codons 1395 and 2000. In AFAP, patients harbour 
germline mutations in the 5’, 3 ’ regions o f APC  or the alternatively spliced 
region of exon 9.
See Table 3-1 for an overview of the phenotypes and extracolonic features of 
FAP, HNPCC and MAP.
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Upper Gl 
polype
Colonic
polyp
burden
Skin/mesodermal
manifestations
Extracolonic
cancers
Average
age
CRC
Heterozygote
allele
frequency
FAP Both
gastric and
duodenal
polyps
Typically
100’s - 
1000’s
Sebaceous cysts,
osteomas,
CHRPE,
desmoids, dental 
abnormalities
Duodenal
cancer
hepatoblastoma
40 1:10 000
HNPCC none 10’s Cafe-au-lait 
macules in 
homozygotes
Endometrium, 
stomach, 
brain,ovary, 
urothelium
50 1:1000
MYH Both
gastric and
duodenal
polyps
10’s - 
>1000
As yet
undetermined
As yet
undetermined
50 1:100
Table 3-1 Comparison of phenotype and extracolonic features o f FAP, HNPCC and
MAP
Historically, microadenomas (a collection of less than 20 dysplastic crypts 
measuring <lmm) have been associated with adenoma formation in FAP. 
During colonoscopy, microadenomas can be identified using dye spray with 
indigo-carmine staining of the colonic epithelium.
Figure 3-1 Dye spray colonoscopy demonstrating a microadenoma highlighted by 
the use of indigo-carmine dye spray.
To date, there has been no hard evidence to suggest that microadenomas (see 
Figure 3-1) are present in MAP. If present it would suggest that two “hits” at 
APC would be required for adenoma formation to be initiated in MAP. It 
therefore follows that the presence or absence of microadenomas in MAP
1 1 1
would also aid clinical diagnosis at colonoscopy and guide molecular 
diagnosis.
The identification of potential genotype-phenotype correlations in MAP 
whether it be for colonic or extra-colonic manifestations would be instructive 
in the further understanding o f the pathogenesis of MAP and potentially lead 
to clues as the why the GI tract appears to be targeted in MYH deficiency. 
Furthermore, improved knowledge of any genotype-phenotype correlation and 
associated ethnic correlation would further improve cost-effective genetic 
mutation analysis and clinical protocols for management and surveillance of  
MAP patients.
3.2 Methods
A restrospective study of MAP patients (both homozygous and heterozygous) 
from St Marks Hospital was undertaken to determine whether any genotype- 
phenotype correlations exist in MAP. Colonoscopy and histopathology reports 
were examined and clinical examination of patients was undertaken looking 
for specific extracolonic features. This cohort includes the largest collection 
reported to date of individuals with the E466X mutation found in the asian 
population. The colonoscopy reports o f 41 asymptomatic heterozygote carriers 
were also examined.
All individuals included in this study were recruited through St Mark’s 
Hospital Polyposis Registry or Family Cancer Clinic, London, UK. Every 
individual had confirmed pathogenic germline mutations in MYH. The clinical 
notes and pathological reports o f 41 patients were reviewed and 19 patients 
were examined specifically for any extra-colonic features including skin 
lesions, tooth abnormalities, and soft tissue lesions. Thirty-four patients had 
bi-allelic germline mutations and four had one germline mutation, so called 
“affected-carriers”. These individuals had all exons of MYH screened for a 
second mutation and three had MLPA performed; in all cases these results 
were negative. See table 1-2 for a summary o f bi-allelic germline mutations in 
the study group.
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In addition H&E slides from colectomy samples of 6 patients were examined 
for evidence of microadenomas.
3.3 Results
Eighty-nine patients were identified with confirmed pathogenic germline 
mutations in MYH. Fifty-one were simple heterozygotes undergoing review 
and surveillance. Twenty-four patients were homozygous carriers of MYH 
mutations, and 10 were compound MYH heterozygotes. Of the homozygous 
MYH carriers, a curiosity was that 6 were also heterozygote carriers for the 
APC  missense variant E1317Q. Four patients had a mono-allelic identified 
germline mutation (1 Y165C, 1 G382D and 2 E466X) and also had 2-593 
(median 70) colorectal adenomas and/or colorectal cancer -  so-called 
“affected carriers”. The “affected carriers” presented at 44-67 (median 50) 
years, 3 were female and 1 was male. These individuals presumably have a 
second occult MYH mutation as yet unidentified, despite screening of all 
exons of MYH, and use of MLPA.
Two of these patients developed CRC (1 Dukes A and 1 Dukes B) at 44 and 
67 years of age. One o f these, (an apparent G382D heterozygote) had a 
mixture of adenomatous and hyperplastic polyps, concentrated on the right 
side of the colon. These patients were excluded for the purposes of further 
analysis, as their genotype information is likely to be incomplete.
Garmiina mutation No. pationta
E466X/E466X 18
Y165C/G382D 7
Y165C/Y165C 4
G382D/G382D 2
Y165C/1452 dal C 2
G382D/1103 dot C 1
Table 3-2 Summary of bi-allelic germline MYH mutations of the 34 individuals 
studied
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Of the relatives, 7 were affected by CRC, 8 had colorectal adenomas and 1 
had pancreatic cancer and colorectal adenomas. All patients with E466X 
mutation were of Indian origin, while all Y165C and G382D homozygotes 
were Caucasians.
3.3.1 Colonic Disease
Colonic adenoma burden at presentation in E466X homozygotes ranged from 
20 to 6250 (median 120). Two were counted at colonoscopy for surveillance 
and 16 at colectomy the most common procedure being ileo-rectal 
anastomosis (see Figure 3-2).
Figure 3-2 Colon o f MYH E466X homozygous patient (48 years of age)
In Caucasian Y165C and G382D homozygotes adenoma burden ranged from 
25 to 265 (median 70). In compound heterozygotes adenoma burden ranged 
from 18 to 300 (median 70). Of the Caucasian mutations, 3 were counted at 
colonoscopy and 13 at colectomy. There was wide variation in adenoma size 
ranging between 1 and 360mm. There was no statistically significant 
difference in adenoma size between the asian and Caucasian patient groups 
(p=0.25 for E466X versus all Caucasian mutations, t-test). The majority of 
adenomas were of tubular or tubulovillous type, although 2 patients also had 
hyperplastic polyps (1 individual had 1 HPP 4mm and 1 individual had 2 HPPs 
3 and 5mm). Of the patients that underwent colonoscopic surveillance, 
microadenomas were present in both groups (using indigo-carmine dye spray
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colonoscopy only). The microadenomas identified by indigo-carmine spray 
were not confirmed histologically as colectomy specimens were not available. 
No statistically significant difference in polyp burden or CRC incidence or age 
at presentation was observed on comparison by genotype (p=0.25 for adenoma 
burden E466X versus Caucasian and p=0.31 for age at diagnosis E466X vs 
Caucasian, t-test). However, the stage at which CRC presented was 
statistically significant with a higher number of individuals with bi-allelic 
E466X mutations presenting with Dukes C and D (36% vs 10% for Dukes C 
and 18% vs 0% for Dukes D). A summary is shown in Table 3-3.
E466X homoaygotes 
(n«18)
Y165C/G382D horn and 
compound hate (n*16) Mann Whitney U test
AgecRagnosis 
rang* (median) 30-74 (45) 25-71 (55) p*0.03
Adenoma number 
range (median) 20-6250 (120) 18-300 (70) p=0.08
Microadenomas
(dyeapray) 3/6 7/12
CRC incidence 61% 62%
Dukes A 18% 30% p=0.10
Dukes B 28% 60% p=0.001
Dukas C 36% 10% p-0.001
Dukas D 18% 0% p«0.03
Table 3-3 Comparison of bi-allelic E466X and Caucasian phenotypes
3.3.2 Upper Gastro-intestinal disease
Seventeen patients underwent upper gastrointestinal endoscopy, all were 
offered endoscopy but a number of individuals declined. Table 3-4 shows a 
summary o f upper gastrointestinal disease by genotype.
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E466X/E466X horn Y1 <5063820 hom/comp hets
no. patients undergoing 
upper 61 endoscopy 14 11
length of follow up (years) 3.72 (SD 1.48) 4.70 (SD 0.94)
Fundal polyps 3/14 2/11
median (range) 4 (2-8) all cystic 4 (2-6) all cystic
Duodenal polyps 3/14 3/11
median (range) 6 (1-20) 5 (2-10)
size (mm) 1-30 mm 3-10 mm
Table 3—4 Upper gastro-intestinal disease by germline MYH mutation
Duodenal polyps were found in 5 o f 19 (26%) homozygote patients (3 E466X 
and 2 Y165C), and 3 o f 10 (30%) compound heterozygotes (all 
Y165C/G382D). Duodenal polyps were generally a few mm in size, but some 
large polyps were found in E466X homozygotes, up to 3cm. In addition, cystic 
fundal polyps were found in 5 homozygotes (4 E466X -  3 o f which also had 
duodenal polyps and 1 G382D) and one compound heterozygote
(Y165C/G382D -  also had duodenal polyps). There were no gastric or 
duodenal cancers in this patient cohort.
3.3.3 Extra-intestinal Manifestations
Eleven E466X homozygotes and eleven Y165C/G382D homozygotes and 
compound heterozygotes were retrospectively examined by a clinical nurse 
specialist (J. Wright, St Marks Hospital) for specific skin, bone, dentitian and 
soft tissue manifestations. On clinical examination, cafe-au-lait spots were 
found in five of 11 patients with homozygous E466X mutations (46%) and 
one Y165C homozygous mutation carrier. These varied in diameter from 1 -  
5cm and were found on the arms, abdomen, neck and trunk. Four individuals 
had one or two cafd-au-lait spots with one individual having three. There were 
no cafe-au-lait spots in compound heterozygotes. Two E466X homozygotes 
had sebaceous cysts and two E466X homozygotes and 2 Y165C/G382D 
compound heterozygotes had abnormal dentition (supernumerary teeth). 
Extracolonic cancers included sarcoma and melanoma in two E466X
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homozygotes. No extracolonic cancer was diagnosed at an age younger or 
higher frequency than that expected in the general population (see Table 3-5).
E466X/E466X
Y165C/G382D 
horn and 
compound hets
No. patients 
examined 11 8
Caf6-au-lait spots 5 1
Sebaceous cysts 1 1
Abnormal teeth 1 3
Extracolonic CRC 1 sarcoma 1 melanoma
(age diagnosis) (74 years) (66 years)
Table 3-5 Comparison of extracolonic features and extracolonic cancers between 
E466X and Y165C/G382D germline MYH mutation carriers
3.3.4 Heterozygote carriers under follow up
There were 51 family members of this cohort who were asymptomatic 
unaffected heterozygotes under follow up. Forty one E466X heterozygotes 
underwent colonoscopy (as part o f screening at St Marks Colorectal Unit), 1 
individual had 1 hyperplastic polyp (1mm) at 20 years o f age and one had 2 
hyperplastic polyps (both 1mm) at 21 years of age. One individual was 
diagnosed with ulcerative colitis (asymptomatic) as a consequence of the 
investigation. Eight Y165C heterozygotes were offered colonoscopy, 1 
declined, 4 are due when reaching 25 years of age and 3 underwent 
colonoscopy, all o f which were normal. Two G382D heterozygotes underwent 
colonoscopy, one o f which was normal and the other found evidence of 
ischaemic colitis. All individuals had one colonoscopy only with no further 
colonoscopic follow up planned.
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3.3.5 Microadenoma detection
Microadenomas were present in 3 o f 16 sections from colectomy samples 
examined (by myself and confirmed by a Gastro-intestinal Histopathologist 
M.Novelli, Dept. Histopathology, University College Hospital) from 6 
patients included in this study (1 G382D homozygote and 2 Y165C/G382D 
compound hets). The number of samples available for study was limited by 
the low number of individuals undergoing colectomy. In cases where 
microadenomas were present, they occurred at 0.01 microadenomas per mm2 
of colonic mucosa examined. See Figure 3-3.
200 pm
Figure 3-3 Microadenoma in MYH  E466X homozygote, 2 dysplastic crypts 
(arrowed)
Microadenomas were detected at colonoscopy using dye spray in ten 
individuals (3 E466X homozygotes, 3 Y165C or G382D homozygotes and 4 
Y165C/G382D compound heterozygotes). None of these were confirmed 
histologically as tissue was not taken for sampling.
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3.4 Discussion
3.4.1 Is there genotype-phenotype correlation in MAP?
As MAP is a relatively recently identified syndrome accounting for 
approximately 1% of all CRC, it is difficult to draw firm conclusions from 
studies involving small numbers o f individuals. Published cohorts to date 
include data ranging from 4 to 25 individuals including the Y165C, G382D, 
1395delGAA and rarer missense variants G175E, P391L (Sieber, Lipton et al. 
2003) (Sampson, Dolwani et al. 2003) (Gismondi, Meta et al. 2004) (Enholm, 
Hienonen et al. 2003) (Balaguer, Castellvi-Bel et al. 2007) (Croitoru, Cleary et 
al. 2007) (Kanter-Smoler, Bjork et al. 2006) (Russell, Zhang et al. 2006). This 
is the first cohort including patients with the Indian E466X mutation.
On comparison o f the E466X individuals with the Caucasian Y165C and 
G382D individuals, no significant genotype-phenotype correlation was 
observed in terms of adenoma number (apart from one exceptional E466X 
homozygote who had 6250 adenomas), age of onset, incidence o f CRC or 
presence o f extra-colonic manifestations. There was a significant difference in 
the stage o f CRC at presentation in that a higher number o f E466X 
homozygotes presented with Dukes C and D CRC. This finding may be due to 
increased pathogenicity o f the E466X mutation if BER is more severely 
impaired with this mutation rather than Y165C or G382D. To date there have 
been no functional in-vitro studies o f the E466X mutation to study the ability 
of repair of 8-oxoG lesions with this germline mutation. Studies of this nature 
would shed some light as to whether individuals with this mutation may 
progress more quickly as a result o f a higher degree of impaired BER. In-vitro 
studies of site directed mutageneis in E.coli for the Y165C and G382D 
equivalent mutations (Y82C and G253D) have found and 80 times reduction 
in the ability to repair 8-oxoG in Y165C and 6 times reduction in G382D 
(Chmiel, Livingston et al. 2003).
These findings may also be related to cultural differences between the Asian 
and Caucasian population, three of the E466X homozygous patients presented 
in overt bowel obstruction secondary to their underlying CRC requiring 
emergency laparotomy, in comparison none o f the Caucasian patients did,
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indicating that the Asian patients may present at a later stage than Caucasian 
patients.
This finding is o f importance when considering screening and surgical 
intervention in these individuals, and certainly justifies bi-annual colonoscopy. 
Previously, the MAP phenotype has been described and understood as an 
“attenuated” polyposis described a phenotype developing between 10-100 
adenomas. In this study it was found that this is not the case as eight E466X 
patients developed >100 and <1000 adenomas and one E466X patient had 
several thousand (6250) adenomas. In the Caucasian group, four patients had 
>100 and <1000 and none had >1000. A Portuguese case study has recently 
reported two siblings with homozygous 1103delC MYH mutations one with 
four synchronous adenocarcinomas (and ~30 coloreactal adenomas) and one 
with severe Spiegelmans III duodenal adenomas. Their heterozygote parents 
had 5 and 2 colorectal adenomas respectively (De Ferro, Lage et al. 2007). 
These findings are relevant when considering which polyposis patients to 
screen for MYH when making a molecular diagnosis.
This study supports previous findings that upper gastrointestinal disease is less 
severe than that found in FAP - but is still present in a significant number of 
patients to necessitate the need for upper GI surveillance endoscopically. 
Thirty percent of compound heterozygote patients and 26% of homozygote 
patients developed duodenal adenomas. Bougen et al reported gastric and 
duodenal adenomas in 1 o f 11 MYH homozygotes in a recently reported study 
(Bouguen, Manfredi et al. 2007). No upper gastrointestinal malignancies were 
found in this patient cohort although they have been reported in MAP 
(Sampson, Dolwani et al. 2003; Croitoru, Cleary et al. 2007).
When considering extra-colonic manifestations there was an increased (but not 
significantly) incidence o f cafe-au-lait spots, sebaceous cysts and dental 
abnormalities in E466X patients. Sebaceous adenomas have been reported in 
one Italian patient (1395deIGAA) and one Indian (Gujarati) individual 
(E466X) with MAP (Gismondi, Meta et al. 2004; Ajith Kumar, Gold et al. 
2007). Cafe-au-lait spots have also been reported in Turcot’s syndrome 
(associated with homozygous mutations in PMS2 and MLHl) (Bandipalliam 
2005).
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Bametson and colleagues screened 225 endometrial cancer patients for 
germline MYH mutations. One individual was found to be a compound 
heterozygote with Y165C and G382D mutations, along with endometrial 
cancer she was found to have a sebaceous carcinoma (a feature of Muir-Torre 
syndrome). Five heterozygote carriers were also identified (3 G382D and 2 
Y165C) which is 2.2% of the cohort. This finding is not surprising as the 
heterozygote carrier rate in the general population is ~ 2% (Bametson, Devlin 
et al. 2007).
The extra-intestinal cancers evident in 2 patients in this cohort occurred at an 
age similar to that found in the general population. It therefore appears that 
homozygote MYH mutation carriers appear to develop extracolonic features 
associated with other hereditary colorectal cancer syndromes including FAP, 
HNPCC, and syndromes related to defective DNA repair, Turcot’s and Muir- 
Torre.
It is still not understood why the GI tract is targeted by defective BER 
associated with germline MYH mutations. Theoretically, other tissues with 
high epithelial turnover or with high exposure to oxidative damage might also 
be targeted -  such as the skin or the lung in smokers. To date no firm 
associations have been made, although there have been two reports benign 
lesions (sebaceous adenomas). The most common form of damage to the skin 
is through UV damage which is repaired by nucleotide excision repair (NER). 
In one study in individuals with lung cancer, no germline mutations in MYH 
(Al-Tassan, Eisen et al. 2004). A Myh/Oggl double knockout mouse has been 
found to have higher levels o f 8-oxoG in the liver and the lung (Xie, Yang et 
al. 2004). However, to date no germline mutations in OGGI (or MTH1) have 
been found in individuals with lung cancer or multiple adenomas.
3.4.2 MYH and the APC missense variant E1317Q
It was through work on the APC  missense variant E1317Q that MYH was 
discovered. The association between APC  E1317Q and the MAP was re­
examined in this study. The original family through which MYH was 
discovered are also heterozygous carriers o f the APC  missense variant 
E1317Q (Al-Tassan, Chmiel et al. 2002). In this study 6 of the homozygote
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patients included in the study were also heterozygous carriers for E1317Q. In 
this group there was no evidence to suggest any significant effect this has on 
phenotype in terms o f either colonic adenoma burden or extra-colonic 
manifestations. There doesn’t appear to be any reason for this association 
except chance. It is possible that E1317Q might act as a phenotypic modifier 
of MAP (perhaps by preventing nonsense G:C>T:A mutations at codon 1317), 
but this was not borne out in the clinico-pathological findings of these 6 
patients.
When combining these findings with those o f collaborators in the UK, Italy, 
Australia, Finland and Portugal, of 96 individuals with homozygote germline 
MYH mutations, 9 were found who also harboured the APC missense variant 
E1317Q. Again, examination of the phenotype and extracolonic features found 
no obvious genotype phenotype correlation or evidence of a modifer effect.
3.4.3 The significance of the heterozygous state
In the 48 asymptomatic heterozygote family members which underwent 
screening, 3 hyperplastic polyps were found at a relatively young age (20 and 
21 years respectively). However, hyperplastic polyps have previously been 
found in individuals as young as 10 years o f age in a study of hyperplastic 
polyposis (Carvajal-Carmona, Howarth et al. 2007). One asymptomatic 
individual was diagnosed with ulcerative colitis as a result of this screening. 
There has been some interest in a potential link between MYH deficiency and 
inflammatory bowel disease as it is likely there would be increased levels of 
oxidative damage secondary to the underlying inflammatory process. In a 
small study (of 6 individuals) in our laboratory no MYH heterozygotes were 
identified in screening individuals with ulcerative colitits (unpublished data).
It may be prudent to screen heterozygote carriers “once o ff’, however there is 
little justification for aggressive colonoscopic screening of heterozygote 
family members at this time apart from in the research setting.
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3.4.4 Microadenomas occur in MAP
Historically, microadenomas have been thought to be pathognomonic of FAP. 
They are classified as a collection of dysplastic crypts (< 20 crypts less than 
1mm in diameter in total). Microadenomas were present in 3 of 16 sections 
examined (by a Gastointestinal Histopathologist M. Novelli) from six patients 
included in this study (see figure 1-3). The density of microadenomas was 
significantly less than those detected in FAP (0.01 per mm2 of mucosa 
examined in MAP and 0.22 per mm2 in FAP). Given that some FAP 
microadenomas harbour somatic mutations at APC  (see Chapter 9) it is likely 
that they are the earliest detectable lesion which has been ‘initiated’ by ‘two 
hits’ at APC  (germline plus somatic mutation for (A)FAP, or two somatic 
mutations for MAP).
3.4.5 Current management protocols for MAP -  how this 
study may help to improve screening criteria
Since its discovery in 2002, screening for the common MYH mutations is 
possible in NHS molecular diagnostic laboratories. MYH screening should be 
considered in patients with MCRAs -  not just those with an “attenuated” 
phenotype, and/or early-onset CRC (Wang, Baudhuin et al. 2004), although 
APC remains a much stronger candidate in families with vertical transmission 
of disease. Mutation testing should be tailored to the ethnic group, with 
mutations Y165C and G382D more common in Caucasians, Y90X in 
Pakistanis, E466X in Indians and ntl395delGGA in those of southern 
Mediterranean origin (Gismondi, Meta et al. 2004) (Enholm, Hienonen et al.
2003) (Jones, Emmerson et al. 2002) (Halford, Rowan et al. 2003). MLPA is 
now available for MYH, and it would therefore be appropriate to perform this 
in “affected heterozygous” patients in whom only one germline mutation has 
been found. Abnormal methylation in the germline o f MLH1 is responsible for 
one genotype causing for HNPCC (Suter, Martin et al. 2004). To date 
germline methylation studies have not been undertaken in MYH. This might 
account for the “affected heterozygotes” identified in this study.
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When screening a new index case, the initial germline MYH screening should 
be directed towards the common mutations depending on the ethnicity of the 
individual. If only one mutation is found the whole gene should then be 
screened prior to MLPA analysis. Due to the recessive inheritance in MAP, 
screening of the index case’s spouse for common mutations (ethnicity 
specific) should be undertaken to define the risk conferred and guide 
appropriate further testing and surveillance of their offspring.
The follow up of heterozygotes at this time varies from centre to centre. 
Current recommendations include a one-off colonoscopy at 50 years in some 
centres (Oxford) and screening starting at 35 years (St Marks Colorectal Unit) 
with repeat colonoscopy five yearly thereafter, in others. In certain situations, 
colonoscopies have been undertaken at the individual heterozygote’s request, 
usually following a diagnosis o f MAP-associated CRC in other young family 
members. The results o f my study do not support routine regular colonoscopy 
in heterozygote carriers.
In the white, northern European population, the incidence o f UC is 43.6/100 
000 and in the Asian population it is 5.6/100 000 (Baumgart and Carding 
2007). Therefore the coincidental finding of ulcerative colitis in one individual 
and a hyperplastic polyp in another individual was not significantly higher 
than would be expected in the general population.
At this time, and due to the recessive nature of the disease and hence limited 
family history, the majority of novel or founder bi-allelic MYH mutation 
carriers are not detected at an early enough age to prevent colectomy.
In light of the finding that the E466X patients in this study presented with a 
higher Dukes stage o f CRC, further studies incorporating larger patient 
numbers are required to determine whether it is necessary to screen these 
individuals more regularly than individuals with the Caucasian mutations is 
necessary.
As the numbers of individuals diagnosed with MAP is increasing, it is vital 
that collaborative studies continue to develop to facilitate the understanding of 
the pathogenesis of MAP, in order to identify novel pathogenic and ethnic 
mutations and subsequently to continue to improve genetic counselling, 
clinical management and outcome in the future.
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4 Clinical MYH related studies — Determination of 
presence and potential underlying mechanisms 
of genomic instability in MAP
4.1 Introduction
4.1.1 Chromosomal instability (CIN) and colorectal cancer
The mechanism(s) underlying genomic instability in the pathogenesis of MAP 
are yet to be fully determined. Genomic instability can be defined as an 
increased intrinsic mutation rate and hypermutation either through 
chromosomal instability (CIN) or microsatellite instability (MSI) (Lengauer, 
Kinzler et al. 1998). Historically, CIN has been associated with FAP through 
mutations in the tumour suppressor gene APC  and MSI associated with defects 
in the MMR “housekeeping” genes.
The effects o f defective BER in MAP are observed by the presence of 
G:C>T:A transversions found somatically at APC  and K-ras suggesting an 
underlying “mutator phenotype” (Lipton, Halford et al. 2003) (van 
Puijenbroek, Nielsen et al. 2008). However, the genome wide implications of 
defective BER in MAP and whether it leads to chromosomal instability are not 
fully understood.
The stage at which CIN occurs during tumorigenesis and indeed how to define 
CIN in the first instance is a subject of ongoing debate. Some suggest that CIN 
initiates colorectal tumorigenesis (Nowak, Komarova et al. 2002) whilst others 
believe that it occurs early in adenoma growth (Alberici, de Pater et al. 2007). 
Further groups suggest it occurs after the adenoma-carcinoma transition 
(Hermsen, Postma et al. 2002; Sieber, Heinimann et al. 2002).
APC  mutations occur in about 75% of human CRCs, roughly 70% of these 
cases also demonstrate CIN. There is, therefore a case that APC deficiency 
may be one cause o f CIN. Further evidence supporting this has been 
demonstrated in mouse ES cells homozygous for the Apcx6nj mutation. The
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v4/?c-mutant ES cells demonstrated CIN with multiple numerical and structural 
chromosomal abnormalities (Fodde, Kuipers et al. 2001).
4.1.2 Methods of measuring CIN
CIN can be measured using flow cytometry, fluorescent in-situ hybridisation 
(FISH), conventional CGH (resolution 5 -10Mb), array CGH (resolution 1Mb), 
SNP-LOH and conventional LOH utilising microsatellite markers.
Variation in the definition o f CIN may in part be due to the different 
experimental techniques used to detect it. Flow cytometry and FISH identify 
changes at gross whole or part-chromosome level whereas aCGH and LOH 
analysis provides information at the molecular level.
Array CGH identifies chromosomal or sub-chromosomal copy number 
changes (gains and deletions) in relation to total genome dosage. Therefore 
this method can detect aneuploidy but will not detect polyploidy (as this can 
be copy number neutral). However in previous studies CIN+ cancers 
demonstrate a higher number o f aCGH changes than CIN- cancers as 
aneuploidy and polyploidy often co-exist.
Array CGH analysis is prone to intra and inter-experimental variation. It is 
sensitive at detecting small regions o f chromosomal losses and gains but is 
less reliable at detecting polyploidy and aneuploidy. For example, regions of 
normal copy number in a diploid nucleus (2:2) and tetraploid nucleus (4:4) 
have a ratio of 1 and a log2 ratio o f 0. In true aneuploidy the situation is harder 
to interpret, if a tetraploid tumour has a single copy loss (3:4 ratio) the log2 
ratio becomes -0.41 (Table 4—1).
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Diploid Tetraploid Ratio log] ratio
0:2 0:4 0 -oo
- 1:4 0.25 -2
1:2 2:4 0.5 -1
- 3:4 0.75 -0.41
2:2 4:4 1 0
- 5:4 1.25 0.32
3:2 6:4 1.5 0.58
- 7:4 1.75 0.81
4:2 8:4 2 1
10:2 20:4 5 2.32
20:2 40:4 10 3.32
Table 4-1 aCGH fluorescence ratios with corresponding log2 ratios for 
diploid and tetraploid tumours
In aCGH analysis thresholds are set in order identify true “signal” (copy 
number change) from “noise” (region where log2 deviation from zero is due to 
experimental variation). The threshold used in this study was a log2 ratio of £ - 
0.5 or 2:0.5 based on work by Fiegler et al (Fiegler, Carr et al. 2003). This 
threshold would not however detect tetraploid tumours with nuclear ratios of  
3:4 or 5:4, particularly if  normal tissue is included in the study sample (Table
4-1).
Each individual clone (replicated on the aCGH slide) generates its own log2 
ratio. Therefore variation in hybridisation can be observed and relative log2 
values of surrounding clones can be incorporated in to the analysis (see 
methods chapter for further details). In the past some groups have used 
“moving thresholds” whereby the value of surrounding clones are taken into 
account for each region o f loss and gain (Clark, Edwards et al. 2003) (Clark, 
Edwards et al. 2002) (Pollack, Sorlie et al. 2002).
LOH analysis utilising microsatellite markers in principle measures the dosage 
of the maternal allele against the paternal allele at the site o f the microsatellite 
polymorphism, relative to normal. Three situations may occur in which LOH 
may be detected without a change in copy number (Gaasenbeek, Howarth et 
al. 2006)-
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i) deletion of one chromosomal homologue and regain of the other homologue 
through duplication, resulting in whole chromosome LOH
ii) LOH extending from a telomere involving whole or part of a chromosome 
arm -  “mitotic recombination”
iii) LOH in an interstitial region as a result o f mitotic recombination also 
termed “mitotic gene conversion”
When using flow cytometry, sporadic and familial colorectal adenomas 
(including MAP adenomas) are usually near-diploid, especially when small 
and of low grade (Sieber, Heinimann et al. 2002) (Lipton, Halford et al. 2003). 
These findings have been criticised on the grounds that this method is not 
sufficiently sensitive to detect more subtle manifestations of CIN, such as 
occasional aneusomy (Cardoso, Molenaar et al. 2006). Conventional CGH and 
more recently aCGH alongside digital SNP PCR (dS-PCR) and aCGH have 
also been used to demonstrate aneusomies in CRAs (Rowan, Halford et al. 
2005; Cardoso, Molenaar et al. 2006).(Alberici, de Pater et al. 2007) (Shih, 
Zhou et al. 2001).
Conventionally, cancers demonstrating CIN are held to be aneuploid/polyploid 
with large-scale gains and deletions (Douglas, Fiegler et al. 2004; Rajagopalan 
and Lengauer 2004). The majority of cancers contain cells with abnormal 
numbers of chromosomes (commonly between 60-90) which commonly have 
structural abnormalities very rarely seen in normal cells. These include 
inversions, translocations, duplications and deletions (Rajagopalan and 
Lengauer 2004).
In reality the term CIN can also be used to describe small scale changes with 
gains and deletions o f a few Mb, as well as larger scale changes with 
translocations and gross ploidy changes. The underlying mechanisms leading 
to these changes differ in that cell cycle check point abnormalities result in 
gross ploidy changes and translocations where-as smaller scale changes may 
be due to defective housekeeping genes (such as MMR genes. It is therefore 
likely that different types o f CIN exist with differing underlying pathogenesis 
(Douglas, Fiegler et al. 2004; Jones, Douglas et al. 2005) (Gaasenbeek, 
Howarth et al. 2006). CIN could therefore be described as both an initiating 
element and a consequence of tumorigenesis, some believe that it is an 
essential event for tumorigenesis to occur (Lengauer, Kinzler et al. 1998).
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One theory is that CIN is caused by a two-step process whereby an initial 
development o f a polyploid, (yet euploid) karyotype occurs followed by 
smaller scale chromosomal gains and losses (Shackney, Smith et al. 1989). 
Wang et al suggested that specific mutations or gene silencing may cause CIN 
either directly or indirectly (Wang, Cummins et al. 2004). In this situation a 
large number o f underlying defects may be responsible such as dysfunction of 
microtubules, centromere or centrosomes, chromosome breakage and telomere 
erosion.
Specific genes have been identified in vitro as causing CIN in CRC. The 
tumour suppressor gene APC  (Fodde, Kuipers et al. 2001), G l/S checkpoint 
regulators CDC4/FBXW7 (Rajagopalan, Jallepalli et al. 2004), mitotic 
checkpoint regulators BUB1/BUBR1 (Cahill, Lengauer et al. 1998) and 
centrosome dysfunction through mutations in aurora kinases (Zhou, Kuang et 
al. 1998). APC  is the only gene in which somatic mutations are consistently 
found in all CRC karyotypes in vivo (Rowan, Halford et al. 2005).
CIN is likely to confer a survival advantage in cancerous cells through 
acceleration o f LOH o f tumour suppressor genes and amplification of 
oncogenes through chromosomal duplication (Rajagopalan and Lengauer
2004). CRCs and adenomas can be classified on the presence of MSI or CIN 
(Jass, Whitehall et al. 2002). Very rarely are CRCs found to be MSI and CIN+ 
when using older methods for measuring CIN.
Cancer cells which demonstrate MSI have an intrinsic mutation rate at the 
nucleotide level 2-3 times higher than observed in normal cells (Boyer, Umar 
et al. 1995). Using flow cytometry and FISH analysis MSI+ CRCs have been 
found to be diploid or near-diploid (Lengauer, Kinzler et al. 1997). More 
recently CIN has been observed in MSI cell lines using SNP-LOH and array 
CGH (Gaasenbeek, Howarth et al. 2006), the underlying MSI mutator 
phenotype may in these cases be responsible for the small scale changes 
observed in this study.
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4.1.3 Current understanding of CIN in sporadic colorectal 
adenomas and CRC’s using aCGH
A number of studies have been undertaken using aCGH to study adenomas, 
CRCs and CRC cell lines (see Table 4-2  for an overview). Loss of 
chromosome 4q and 18q has been reported by several groups using 
conventional and aCGH (Douglas, Fiegler et al. 2004) (Jones, Douglas et al. 
2005) (Gaasenbeek, Howarth et al. 2006).
When analysed according to the type of genomic instability exhibited - 
“conventional” CIN (determined by flow cytometry / FISH analysis) or MSI, a 
greater number of copy number changes were observed in CIN CRC’s and cell 
lines than MSI+ tumours. A higher incidence of amplification of chromosome 
20 was also observed (Douglas, Fiegler et al. 2004). The pattern of copy 
number changes observed was very similar between cell lines and primary 
cancers.
Jones et al studied a set o f 23 MSI-/CIN- CRC’s finding little evidence of 
genomic instability. When compared to subsets of MSI+/CIN- and MSI-/CIN+ 
CRCs the MSI-/CIN- cancers had significantly fewer chromosomal losses and 
gains than both the MSI+/CIN- and MSI-/CIN+ tumours (Jones, Douglas et al.
2005). A degree of heterogeneity was observed in the MSI-/CIN- CRC’s in 
that two subgroups were identified, those with <6 chromosomal scale changes 
and those with >10 chromosomal changes resembling the changes observed in 
MSI-/CIN+ CRC’s. No specific changes by clone were identified in the MSI- 
/CIN- group. However low frequencies o f 5q loss, 9p and 19p gain and high 
frequency of 20p gain were seen (Jones, Douglas et al. 2005).
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Sample type No. samples Chromosomallosses
Chromosomal
gains Methods Ref.
CRC both MSJ+ 
and CIN+ 37 18q,4q34-q35 8q, 13, 20 aCGH
Douglas et 
al
CRC call lines 
both MSI-*- and 
CIN+
48 18q, 4q34-q35, 
6
8q, 13,20 
12p, 15 aCGH
Douglas et 
al
CRC MSI-/CIN- 23 5q (infrequent) 9p, 19p (lowfreq) 
20p (high freq)
aCGH Jones et al
CRC MSI-/CIN+ 
cell lines 34
18q, 17p (LOH 
or deletion) 
FreqLOH 
genom e wide
Freq LOH genome 
wide
aCGH/SNP- 
LOH
G aasenbeek 
eta1
CRC MSI+/CIN- 
cell lines 11 none none
aCGH/SNP- 
LOH
Gaasenbeek
eta!
Table 4-2 Overview of aCGH studies in CRC
One of the first studies to incorporate SNP-LOH alongside aCGH in analysis 
in CRC cell lines found that on examination of 11 MSI-*- and 34 MSI- CRC 
cell lines the array based CGH changes found were not identified by SNP- 
LOH analysis (as they did not demonstrate reduction-to-homozygosity) 
(Gaasenbeek, Howarth et al. 2006). Regions of SNP-LOH were also observed 
without aCGH changes -  the majority of cell lines demonstrating whole 
chromosome LOH of 2 chromosomes, 1-2 terminal regions o f LOH (mitotic 
recombination sites) and 1 interstitial region of LOH. The MSI+ cell lines 
rarely demonstrated chromosomal gains and deletions or whole chromosome 
LOH. However, the near-diploid karyotype o f this group concealed mitotic 
recombination frequencies similar to the MSI- group. From this study the 
relationships between LOH, CIN and copy number change are far from clear 
and that it is possible to have LOH without copy number change.
Until recently, examination o f MAP adenomas and cancers has found these 
tumours to be near diploid (using flow cytometry) and microsatellite stable 
(Lipton, Halford et al. 2003). The mutational signature o f defective BER is 
detected in the somatic mutation spectra o f APC  and K-ras (Lipton, Halford et 
al. 2003). It is thought that through hyper-mutation o f APC  that MAP 
tumourigenesis is driven. K-ras mutations are known to occur in adenomas 
from MAP patients -  targeting the mutational hotspot at codon 12 (Lipton,
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Halford et al. 2003). In keeping with defective BER all mutations reported to 
date are G:C>T:A tranversions.
Somatic mutations in BRAF have not been observed in these tumours.
Cardoso et al (Cardoso, Molenaar et al. 2006) at the same time as this study 
was undertaken used array-comparative genomic hybridisation (aCGH) to 
analyse approximately 0.6mm2 dissected tissue from adenomas of 5 MAP and 
8 FAP patients. Tumour samples were microdissected and subsequently 
amplified with whole genomic amplification prior to hybridisation. Small 
copy number changes were observed in both MAP (80%) and FAP (60%) 
frequently with losses at chromosomes lp, 17, 19 and 22 with gains on 
chromosomes 7 and 13. It was concluded from this study that CIN is observed 
in both of these syndromes. However, some caution should be used when 
interpreting these results as the process of whole genome amplification is 
likely to introduce artefactual losses and gains.
4.1.4 Aims of this chapter
The primary objectives o f this study were to identify underlying mechanisms 
of genomic instability in MAP using a variety of experimental approaches to 
address the following areas -
1: As CIN does not occur in MMR deficient cancers should it occur in BER 
deficient tumours?
2: To confirm the findings o f CIN in MAP tumours described by Cardoso et al 
(undertaken at the same time as my work) without using whole-genome 
amplification
3: If CIN is present -  what are the underlying mechanisms for this?
The results of this study are discussed alongside results obtained from aCGH 
analysis performed on FAP and sporadic CRAs undertaken by other 
laboratory members (A Jones and W Chambers).
133
4.2 Methods
Array CGH was performed on adenomas from 4 MAP patients with confirmed 
germline MYH mutations (1 Y165C homozygote and 3 E466X homozygotes). 
Fourteen adenomas and 1 carcinoma were analysed with aCGH, SNP LOH 
and microsatellite analysis from 4 MAP individuals
Adenomas were snap frozen and analysed against paired blood or 
morphologically normal tissue. The clinico-pathological features of these 
tumours are in Table 3. Histological review was undertaken to confirm at least 
65% dysplastic tissue was present in each tumour.
DNA extraction, aCGH analysis, LOH analysis (including SNP-LOH) was 
undertaken as described in the Methods 2.1.10 and 2.1.6.4. Chromosome maps 
and clone positions (Mb) were taken from the Sanger Centre and UCSC 
websites (http://www.sanger.ac.uk. http://genome.ucsc.eduV Where copy 
number changes were found, confirmation of the copy number changes was 
then undertaken using microsatellite-based LOH analysis on the same DNA 
extracted from the whole tumours that had been used for the aCGH analysis. 
For increased genome-wide resolution and the ability to detect copy-neutral 
LOH, SNP-LOH analysis was carried out on 3 MAP tumours where sufficient 
DNA was available for analysis.
For microsatellite LOH analysis, whole tumours were initially analysed. 
Subsequently, for analysis o f potential spatially distributed sub-clones within 
the tumour, frozen sections o f MAP adenomas were cut onto slides and 12 
samples of epithelium (each about the size of a white needle tip) were 
removed with the aid of the dissecting microscope. Whole tumours, each of 
the twelve dissected samples and paired normal tissue were genotyped at 17 
microsatellite markers (D1S201, D1S2729, D1S2749, D1S470, D9S1818, 
D9S1826, D9S1829, D9S1830, D17S786, D17S1832, D17S1353, D17S1844, 
D19S886, D19S878, D19S215, D19S565 and D19S591) with standard 
reaction conditions (see Appendix 1 for primer sequences and conditions).
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4.3 Results
4.3.1 Overview of aCGH analysis
Of the 14 MAP adenomas analysed, eleven (78%) had changes; four 
adenomas had 1 -3 changes, six had 6-7 changes and one had 17 changes 
(median 3 (range 0-17) and IQR 1-7). Sixty-seven changes were observed in 
total; 11 of these were of a whole chromosome. The MAP CRC analysed 
identified 2 whole chromosome deletions (chromosomes 1 and 10), and a 
whole chromosome gain of chromosome 7. Regions of loss were observed on 
chromosome 8p and 8q and regions of gain observed on regions 5p and 9p. 
(See Table 4-3 and Figures 4-1 to 4-6 for clinico-pathological features and 
examples of aCGH changes).
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Figure 4-1 Loss of lp (0-46 Mb) in MAP adenoma M12
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Figure 4-2 Gain of whole chromosome 7 in MAP adenoma Ml
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Figure 4-3 Gain of whole o f chromosome 13 in MAP adenoma M5
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Figure 4—4 Loss of 17p (0-20 Mb) and 17q (65-ter) in MAP adenoma M3
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Figure 4-5 Deletion of whole o f chromosome 19 in MAP adenoma M3
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Figure 4-6 Loss of whole chromosome 22 in MAP adenoma M3
The overall frequency of genetic changes detectable by aCGH, the proportion 
of gains versus deletions, and the proportion of whole-chromosome versus 
part-chromosome changes did not differ with adenoma size, morphology, or 
degree of dysplasia (p= 0.25, Kruskal-Wallis test).
Gains were less common than deletions with (medians of 1 (range 0-4) and 3 
(0-13) respectively). Whole-chromosome changes were less common than 
part-chromosome changes with (medians o f 0 (range 0-3) and 3 (0-15) 
respectively. MAP adenomas with larger numbers of whole-chromosome 
changes tended to have more part-chromosome changes (linear regression 
analysis, t=2.23, p=0.033), and tumours with higher numbers of gains tended 
also to have higher numbers of deletions (linear regression analysis, t=3.17, 
p=0.003). See Figures 4-7 to 4-9 for overview of chromosomal losses and 
gains for all MAP adenomas studied.
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mild dysplas 
d esc  colon
7,all, gain
19, all, del
20,all,gain
M2
E466X hom 
242
12mm TVA 
severe dyspl 
rectum
17,0-10,del 
19,all,del
M3 M4
E466X hom Y165C hom
242 265
14mm TVA 8mm TA
severe dysplasia mild dysplasia
rectum hep flexure
1,27-46,del 1,0-41,del
8,0-31,del 1,145-162,del
17,0-20,del 3,49-58,del
17,65-ter,del 4,0-8, del
18,all,del 4,14-ter,gain
19,all,del 6,33-37,del
22,all,del 7,78-127,gain 
9,121-ter,del 
12,111-ter,del 
13,56-96,gain 
14,88-ter,del 
17,18-50,del 
17,71-ter,del 
19,all,del 
20,29-ter,del 
21,13-31,gain 
22,all,del
No. aCGH c h a n g e s  3
c h a n g e s  in bold = log2T:N ratio  >0.5
17
Table 4-3 aCGH analysis of 15 MAP tumours
M5 M6 M7 M8 M9
Y165C hom E466X hom E466X hom E466X hom E466X hom
265 242 242 >100 >100
9mm TA 29mm TA 33mm TA 6.3mm TA 4.1mm TA
mild dysplasia mild dysplasia mild dysplasia m oderate dysplasia m oderate dysplasia
sigmoid colon a  sc  colon d esc  colon transverse colon ascending colon
13,all,gain 1,0-46,del 1,0-51,del 1,28-46,del
9.121-ter,del 17,0-12,del 3,19-36,gain
13,59-96,gain 19,0-18,del 9,121-ter,del
17,0-10,del 12,111-ter,del
17,35-46,del 19,all,del
19,0-17,del 21,0-29, gain
19,38-ter,del
1 7 3 0 6
G erm line m utation  
No. a d e n o m a s  
size  ad en o m a 
h isto log ica l g rade  
p osition  in colon
chro m o so m al lo s s e s  an d  g a in s
No. aCGH c h a n g e s  0
c h a n g e s  in bold = log2T:N ratio  >0.5
M10
E466X hom 
>100
6.8mm TA 
mild dysplasia 
transverse colon
M11
E466X hom 
>100
7.3mm TA 
moderate dysplasia 
sigmoid colon
Table 4-3 aCGH analysis of 15 MAP tumours
M12
E466X hom 
242
29mm TA 
mild dysplasia 
ascending colon
1.0-46,del 
9,121-ter,del 
13,59-96 .gain
17.0-10,del 
17,35-46,del
19.0-17,del 
19,38-ter,del
M13
E466X hom 
242
21mm TA 
mild dysplasia 
transverse colon
1.0-46,del
9,121-ter,del
13,59-96,gain
17.0-10,del
17,35-46,del
19.0-17,del
19,38-ter,del
M14
E466X hom 
242
30mm TA 
mild dysplasia 
descending colon
1.0-46,del
9,121-ter,del
13,59-96,gain
17.0-10,del
17,35-46.del
19.0-17,del
19,38-ter,del
M15
E466X hom 
>100
45mm adenocarcinom a 
adenocarcinom a 
descending colon
1,all,del
5.0-45,gain 
7,all .gain
8.0-42,del 
8,48-ter,del
9.0-30,gain 
10,ail,del
7 7 7 7
Chromosomes 1 and 7 MAP
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Figure 4-7 Summary of aCGH changes in all MAP adenomas for 
chromosomes 1 and 7
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Figure 4—8 Summary of aCGH changes in all MAP adenomas for 
chromosomes 8 and 9
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Figure 4—9 Summary of aCGH changes for chromosomes 13, 17, 19 and 22
4.3.2 Genomic locations of aCGH changes
Particularly frequent sites of change were deletion of chromosome lp (57% of 
adenomas), gain of chromosome 13 (43%), deletion of 17p (64%), deletion of 
chromosome 19 (71%), gain of chromosome 21 (14%) and deletion of 
chromosome 22 (14%). Comparing frequencies of change among whole 
chromosomes a tendency for deletion or gain of the smaller chromosomes was 
observed (linear regression analysis, t=2.25, p=0.032). This is with the 
exception of chromosome 1, which showed frequent deletion involving its 
short arm. A similar tendency was found for part-chromosome changes to be 
more frequent on smaller chromosomes (linear regression analysis, t=-3.11, 
p=0.006). In order to determine if the chromosome lp losses were artefactual 
or due to poor hybridisation, dye swap experiments were performed and the 1 p 
loss was still observed. Conventional LOH analysis was also performed on 
whole tumours using microsatellite markers from lp (D1S201, D1S2729, 
D1S2749 and D1S470) but no LOH was observed.
LOH was observed in one MAP adenoma (MAP 9) at marker D1S470 when 
microdissected.
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4.3.3 Magnitude of copy number changes and the possibility 
of genetic heterogeneity
Of the 67 changes observed in the 11 MAP adenomas (with changes present), 
only 7 changes in 3 adenomas demonstrated log2T:N ratios approaching ±0.5 
(corresponding to a theoretical gain or loss o f approximately 25% of DNA, 
allowing for the presence o f some normal cells). These changes are 
highlighted in bold in adenomas M l, M3 and M5 in Table 4-3. The remainder 
of adenomas demonstrated changes closer to ±0.1 -  0.2 (theoretically 
corresponding to a gain or loss of between 7 and 14% of DNA in each tumour 
sample). These low-magnitude changes were also found in the 3 MAP polyps 
which also harboured changes with log2T:N ratios close to ±0.5. A plausible 
explanation is that the copy number changes detected were present in tumour 
sub-clones.
4.3.4 Conventional LOH analysis
No LOH was found on chromosomes 1, 9, 17 and 19 when microsatellite- 
based LOH analysis, on the same DNA extracted from the whole tumours that 
had been used for the aCGH analysis. However, when LOH analysis was then 
undertaken on frozen sections using the same microsatellites in a single 
adenoma (M9) that had shown small-scale deletions by aCGH, LOH was 
observed in the region o f lp and 17q. Twelve different regions of tumour 
epithelium were micro-dissected, no chromosome 9 or 19 LOH was found, but 
LOH was observed in two o f 12 tumour regions using chromosome 1 markers 
(D1S470) and in a different two regions using chromosome 17 markers 
(D17S786 adjacent to p53). Neither o f these were the regions that showed 
LOH contiguous within the tumour. See Figure 4-10.
141
I t I I I I I I I I I I I I I I I I I I I I I I I I I I
15 150 155 160 165 170
03fsa  3 Blue
Figure 4-10 LOH at D1S470 in microdissected adenoma MAP 9 (upper 
tracing), normal tissue (lower tracing)
4.3.5 SNP-LOH analysis
In order to determine whether LOH was present in copy number neutral 
regions on aCGH analysis SNP-LOH was performed using the Infinium II 
assay.
Three MAP adenomas (M8, M10 and M i l )  were analysed for SNP-LOH 
analysis (this procedure was performed by A. Jones). None of these adenomas 
had changes on aCGH analysis. One MAP polyp (M10), a tubular adenoma 
with mild dysplasia measuring 6.8mm without any aCGH changes, showed 
copy number-neutral LOH involving the whole of chromosomes 7 and 12 
(Figure 4-11). Adenomas M8 and M13 displayed no evidence of copy neutral 
LOH or gross CIN on aCGH.
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Figure 4-11 SNP-LOH data for MAP adenoma M10. Chromosomes 7 (upper 
panel A and C) 12 (lower panel B and D). A and B = normal controls, with no 
LOH. Copy number neutral LOH present in C and D
4.3.6 Comparison of MAP aCGH changes with FAP and 
sporadic adenomas
Small-scale aCGH changes were observed in 66% (6/9) of FAP adenomas and 
71% (10/14) of sporadic adenomas studied (by A. Jones and W.Chambers). Of 
the FAP adenomas four had 1-3 changes, one had 7 and one had 9 changes. Of 
the sporadic adenomas six had 1-3 changes, two had 4 changes, one had 12 
changes and one had 13 changes. Only MAP tumours had any log2T:N 
changes of ^0.5 whereas all o f the FAP and sporadic changes were in the
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region of 2:0.1. A similar distribution of changes was observed throughout the 
genome in the MAP and sporadic adenomas that was not observed in the FAP 
group.
See Appendix 2 for details of changes in FAP and sporadic cases.
When considering the frequency o f genetic changes detected, proportion of 
gains versus losses and proportion of whole or part-chromosome gains and 
losses, no statistical difference was observed between the three groups (p>0.45 
in all cases, Kruskal-Wallis test). Again, no statistical significance was 
detected when considering adenoma size, morphology or degree of dysplasia 
(p>0.48 in all cases). Deletions were more common than gains and part- 
chromosome changes were more common than whole-chromosome changes 
across the three groups. Adenomas demonstrating a higher number o f whole- 
chromosome changes also harboured a greater number of part-chromosome 
changes (linear regression analysis t=2.23, p=0.033). Correspondingly, 
adenomas with a higher number of gains also had a higher number of deletions 
(linear regression analysis t=3.17, p=0.003).
Analysis o f the frequency distribution of aCGH changes found that the whole- 
chromosome changes fitted a Poisson distribution well with a mean o f 0.94 
(z=0.34, p=0.73). For part-chromosome changes the dataset failed to fit the 
Poisson distribution (z=4.02, p<0.001) even with the exclusion o f the two 
adenomas with the greatest number o f changes (Sporadic 8 and MAP 4). 
When excluding the six adenomas in the dataset which harboured >5 aCGH 
changes (removing non-random distribution bias) the remaining 28 adenomas 
fitted the Poisson distribution well (z=0.76, p=0.45).
4.4 Discussion
4.4.1 Evidence of CIN in MAP
When considering whether CIN is present in this sample set, subtle changes 
alongside large-scale chromosomal changes (observed in “true” CIN) need to 
be considered. These include the tendency for individual tumours to harbour 
specific changes relating to an underlying defect in cell division or DNA
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repair, a deviation from the number o f changes observed in Poisson or normal 
distribution and an excess o f changes that might be expected in “normal” 
tissue.
Using these criteria, this data suggest that CIN is present in MAP.
Small amplitude copy number changes both whole and part-chromosome were 
observed in both whole and part chromosomes in 78% of MAP adenomas 
suggesting that CIN occurs in MAP. With the exception of one MAP adenoma 
and one sporadic adenoma the number o f aCGH changes followed Poisson 
distributions for whole and part-chromosome changes. The two “outlying” 
adenomas (causing deviation from the Poisson distribution) had a large 
number of part-chromosome changes suggesting a high level o f double DNA 
strand breaks. The higher frequency of part-chromosome changes observed in 
these adenomas may have been a consequence o f them having progressed 
further along the adenoma-carcinoma sequence. However histologically they 
did not exhibit any exceptional morphology with the MAP adenoma 
displaying “mild dysplasia” and the sporadic adenoma “moderate dysplasia”. 
Only a small subset o f the MAP adenomas harboured aCGH changes with 
log2T:N ratios o f ^0.5, the ratio was nearer 0.1 for all the FAP and sporadic 
samples.
A similar distribution o f copy number changes throughout the genome was 
observed between the MAP and sporadic adenomas suggesting a similar 
underlying cause o f genomic instability, this distribution was not seen in the 
FAP adenomas analysed by aCGH.
Based on their size (0.6-3.5 cm), none o f the adenomas studied would be 
described as “early” lesions, previous studies o f similar sized adenomas would 
almost certainly find them to be diploid using flow cytometry (Sieber, 
Heinimann et al. 2002) (Sieber, Tomlinson et al. 2005).
It is possible that some o f the low-magnitude changes observed in this study 
were artefacts o f the aCGH technique (some studies have reported these in 
gene- and GC-rich regions such as chromosome 19) (N. Carter, personal 
communication). It has been previously speculated that aCGH data smoothing 
algorithms might not be effective at removing regional differences in 
hybridisation efficiency resulting in systematic over- or under-reporting of 
Cy3:Cy5 ratios. Loss o f chromosome lp is frequently reported and it has been
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suggested that this region is prone to erroneous reporting (N. Carter, personal 
communication). It is possible that some o f the changes in this region in this 
study are in fact artefactual.
Previous aCGH studies o f early CRC tumour samples have found frequent 
losses at chromosomes 4q and 18q (Hermsen, Postma et al. 2002; Douglas, 
Fiegler et al. 2004) (Jones, Douglas et al. 2005) (Gaasenbeek, Howarth et al.
2006). In this study loss at 4q was seen in one MAP adenoma and loss of the 
whole of chromosome 18 in another. In the FAP adenomas no changes were 
observed at 4q and 1 18q deletion and 1 whole chromosome 18 deletion were 
seen. The sporadic adenomas demonstrated no 4q changes and one 18q loss in 
a single adenoma. It is therefore likely that these changes occur later in the 
pathway of progression from adenoma to carcinoma.
Bartkova et al (Bartkova, Horejsi et al. 2005) have suggested that CIN occurs 
in CRA’s through an elevated rate o f chromosomal breakage at fragile sites as 
a consequence o f elevated DNA damage response. Chromosomes 
8p23.1/8p21.3, 9q32 and 1 lp l5.1 were cited as fragile sites in their study. 
None of the changes observed in the three adenoma groups studied were 
breakages at these fragile sites and therefore do not provide any evidence to 
support this hypothesis.
The sites o f chromosomal loss and gain throughout the genome in the MAP 
adenomas were similar to those observed by Cardoso et al (Cardoso, Molenaar 
et al. 2006), with the exception that this dataset found no gains of whole- 
chromosome 7. Cardoso et al studied 17 MAP tumours from 5 patients and 
found aCGH changes in 6 o f these. Multiple small regions (approx 0.6mm2) 
were microdissected and analysed with the aim of identifying aneusomic 
subclones within the tumour. Array CGH changes were found on 
chromosomes lp, 7, 13, 17p, 19 and 22. Array CGH changes were also seen in 
samples from “normal” colorectal mucosa. In this study copy number changes 
were scored for any smoothed data point lying outside the 15 and 85% 
quantile bands. This approach may lead to high sensitivity at the cost of 
specificity. In both this and Cardoso’s study a high incidence of changes in 
chromosome 19 were observed. It is known that chromosome 19 is gene rich 
and therefore prone to aberrant behaviour in both conventional and aCGH
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experiments. Therefore results for this chromosome should be interpreted with 
caution.
Overall, these results super-cede Cardoso et al (Cardoso, Molenaar et al. 
2006) as DNA used for this studies did not undergo whole-genome 
amplification prior to aCGH analysis. The process o f whole-genome 
amplification can introduce artefactual changes would could be interpreted as 
small-scale chromosomal losses and gains.
4.4.2 Conventional LOH analysis did not replicate aCGH 
changes
Microsatellite LOH analysis on chromosomes 1, 9, 17 and 19 of whole 
adenoma samples found no evidence o f LOH. This may in part be due the fact 
the majority of aCGH changes detected were small scale with very small 
quantitative changes in gene dosage (approx 7% for log2T:N ratio of ^ 0.1). 
Therefore it could be suggested that the non-artefactual changes observed are 
from sub-clones within the tumour rather than the bulk of the tumour tissue. 
The LOH analysis undertaken on microdissected samples support this theory.
4.4.3 SNP-LOH demonstrates copy number neutral LOH in 
MAP
Analysis o f 3 MAP adenomas with SNP-LOH found evidence o f copy number 
neutral LOH on chromosome 7 and 12 in one MAP adenoma (MAP 10) which 
harboured no changes on aCGH. This suggests the presence of CIN in the 
absence of aCGH changes.
The remaining MAP adenomas examined found no evidence of LOH or copy 
number neutral LOH.
This study would have been improved should there have been sufficient DNA 
to analyse all o f the adenomas by SNP-LOH therefore enabling comparison of 
SNP-LOH data from adenomas with whole or part-chromosome changes on 
aCGH.
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4.4.4 Evidence of LOH in sub-clones within MAP adenomas
LOH was found in micro-dissected clones from one MAP adenoma (M9) in 
2/12 dissected regions on chromosomes lp and 17q. In the same sample no 
LOH was detected on analysis o f the whole adenoma. These findings also 
support the finding of 6 small scale changes (5 part-chromosome and 1 whole- 
chromosome) observed on aCGH analysis of the same sample. The adenoma 
analysed was relatively small at 4.1 mm exhibiting moderate dysplasia.
This data suggest the possibility that sub-clones may develop from 
hypothetical tumour stem cells leading to faster progression to carcinoma.
4.5 Conclusions
CIN occurs with both small-scale part and whole-chromosomal losses and 
gains in 78% of MAP adenomas and whole chromosomal losses and gains in a 
minority o f MAP adenomas. Copy number neutral LOH was observed in one 
of three MAP adenomas analysed by SNP-LOH analysis.
No correlation was identified between the size or grade o f dysplasia o f the 
adenoma and the number o f chromosomal losses and gains observed with 
aCGH.
The majority of losses and gains were of a magnitude far below predicted 
levels for single copy number loss and gain; SNP-LOH and conventional LOH 
found the majority o f these subsequently to be either artefactual or occurring 
in sub-clones within the adenoma.
The finding of LOH in microdissected sub-clones may represent a faster 
progression towards carcinoma. It is very difficult to predict however whether 
these clones would have in fact progressed to carcinoma if left in situ.
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5 Development of a mouse model of MAP
5.1 Introduction
In humans, MAP is a rare disorder accounting for ~ 1% of CRC. Development 
of a mouse model reflecting human disease is desirable in order to study the 
pathogenesis of MAP from its earliest stages, to study MAP cases in numbers 
which are statistically high enough and also to consider experimentally 
controlled environmental factors such as oxidative stress and diet.
Once developed, a mouse model o f MAP could be used to determine the 
impact of therapeutic interventions such as the use of NSAIDs and anti­
oxidants both in the prophylactic setting and in the treatment of adenomas. A 
MAP mouse model would be useful for studying the impact of the M Yhf1' 
carrier state.
Knockout mice for the BER genes Mthl, Oggl and Myh have previously been 
generated (Hirano, Tominaga et al. 2003) (Klungland, Rosewell et al. 1999) 
(Minowa, Arai et al. 2000) (Sakumi, Tominaga et al. 2003). When knocked 
out, none o f these mouse lines developed intestinal adenomas. Mthl'1' 
deficient mice have a higher incidence of lung liver and stomach cancers 
compared to M thl+/+ mice (Tsuzuki, Egashira et al. 2001). M thlv' deficient 
mice when crossed with MMR deficient (Msh2+/') mice developed a higher 
frequency of G:C>T:A transversions on examination of the spleens of these 
animals(Egashira, Yamauchi et al. 2002). When Myh and Oggl are knocked 
out together, mice develop a higher frequency of lymphoma, lung and ovarian 
cancers (Russo, De Luca et al. 2004).
Two mouse models o f MAP were developed as part of this thesis. The first 
model was under development (by O.Sieber) as I joined the laboratory and I 
became involved as the animals were culled for analysis. The second mouse 
model was developed following initial pathological and mutational findings of 
the first model; this was solely my work.
The first mouse model o f MAP was determined on the basis that as Myh 
mice do not develop adenomas the majority o f MAP adenomas in humans 
harbour bi-allelic APC mutations (Jones, Emmerson et al. 2002) (Lipton,
Halford et al. 2003), by crossing Myh deficient mice with ApcMm+/~ mice, 
tumorigenesis would be driven at a higher rate without deviating far from the 
pathway of Myh'1' driven polyposis. ApcMm+/' mice harbour a germline 
mutation (truncating C>T) in codon 850 of Ape. These mice develop multiple 
adenomas in the small intestine, mammary tumours, desmoids and epidermoid 
cysts (Shoemaker, Gould et al. 1997). As homozygosity for the Min allele is 
embryonic lethal, ApcMin+/' mice were used in both models of MAP. Results of 
the first MAP mouse model have since been published (Sieber, Howarth et al. 
2004).
Initial results from the first MAP mouse model (described in detail in this 
chapter) indicated that despite G:C>T:A transversions being present in three 
adenomas of Myh deficient mice, the majority of “second hits” at Ape were 
through LOH (associated with ApcMm+/' mice bred on the C57BL6 
background). Shoemaker et al (Shoemaker, Moser et al. 1998) investigated the 
effect of murine genetic background on tumour multiplicity in ApcMin+/' mice 
demonstrating a reduction o f tumour frequency from 100% (68/68 animals) in 
C57BL6 Min+/'mice to 25% (43/170 animals) in AKR Min+/' mice at 85 and 
138 days respectively. Fewer adenomas developed due to a lower incidence of 
LOH as the “second hit” at Ape in AKR M in'' mice. Luongo et al have also 
demonstrated that the predominant somatic loss of Ape function in C57BL6 
ApcMm+/' (Myh+I+) mice is through LOH (Luongo, Moser et al. 1994).
Haigis et al whilst studying mechanisms of tumour regionality in the mouse 
demonstrated that when AKR Min+/' mice were crossed with Mlh knockout 
mice tumour multiplicity returned on the introduction of defective MMR. The 
AKR Min+/7Mlh+/+ mice developed a mean of 3.7 +/- 1.6 tumours, AKR 
Min+/7Mlh+/' mice developed 4.0 +/- 3.5 tumours and AKR Min+/7Mlh~'~ mice 
developed 34 +/- 6.4 tumours. The average lifespan was 149, 177 and 95 days 
respectively (Haigis, Hoff et al. 2004).
AKR mice are homozygous carriers of the resistant allele o f Modifier of Min 1 
(M omlR/R) locus found on chromosome 4, which is thought to confer 
resistance to tumour formation (colonic>small intestine) by acting as a 
modifer. The prime candidate gene for this modifer effect is the secretory 
phospholipase Pla2g2a, although a locus just distal to D4mit64 has also been 
identified as a complementary resistance loci for Moml resistance (Cormier,
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Bilger et al. 2000). When M o m l^  was introduced to C57BL6 mice (which 
are homozygous for the sensitive allele o f M omls/s), tumour multiplicity was 
reduced by 50% in Momls/R mice and by 75% in Momlm  mice (Gould, 
Dietrich et al. 1996). All mice were therefore genotyped for Moml in both 
MAP mouse models developed in this Chapter.
Therefore on developing the second MAP mouse model it was hypothesised 
that if Apc^^VM yh  ^ were bred on the AKR genetic background fewer of 
their adenomas would lose the second allele of Ape through LOH, 
consequently it would be expected that a higher proportion of adenomas 
would demonstrate G:C>T:A transversions somatically at Ape. By the 
introduction of defective BER to AKR ApcMm+/~ mice it would be predicted 
that tumour multiplicity would return in Apc^^^/Myh'^ mice bred on the 
AKR background.
5.1.1 Aims of this Chapter
The aim of this Chapter was to develop a faithful mouse model of MAP in 
order to study the development o f MAP from its earliest stages and in 
significant numbers.
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5.2 Methods
All animals were bred, housed and experiments carried out in accordance with 
the United Kingdom Animal Procedures Act 1986. Animals were housed at 
the Cancer Research United Kingdom Laboratories (South Mimms).
5.2.1 Mouse breeding
The original C57BL/6J-/fpcM"+/' mice were obtained from A.R Moser 
(McArdle Laboratory, University o f Wisconsin, USA). The SV129/C57BL/6J- 
Myh+/' mice were a gift from J. Miller (Molecular Biology Institute, University 
of California, Los Angeles, USA).
When breeding the first MAP mouse on the C57BL/6J background, male 
ApcMm+/~ mice were bred with female Myh+/ mice, from the Fi generation 
male ApcMm+/~ / Myh+/~ mice were inter-crossed with Apc+/+1Myh+/~ females.
The ApcM,n+/~ mutation was carried through the male line when setting up 
mating pairs and trios. The F2 generation onwards were used for analysis as 
these mice would share equivalent contribution from the two genetic 
backgrounds (C57BL/6J and SV129).
When breeding the second MAP mouse on the AKR genetic background, the 
C57BL/6J-ApcMm+/~ and SV 129/C51BL/6S-Myh+/' were backcrossed ten times 
on to the AKR genetic background before setting up inter-crosses as described 
above.
The following study groups were set up for both mouse models o f MAP. 
ApcMin+/' /Myh+/+, ApcMin+/~ IMyh+/~ and ApcMin+/' I Myh'A; the three comparison 
groups were Apc+/+ /Myh+/+, Apc+/+ /Myh+/' and Apc+/+ IMyH1' .
5.2.2 Genotyping
DNA was extracted from tail snips as described in Methods 2.1.1.6. All mice 
were genotyped for Ape, Myh and Moml (AKR resistant allele).
The original Myh knockout mouse was developed by Jeffrey Millers group 
using a targeted vector pMC-neoR (neomycin cassette) in exon 6 o f Myh as 
described by Xie et al (Xie, Yang et al. 2004). Myh was genotyped with a
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three primer allele specific PCR assay across exon 6 where neomycin cassette 
insertion occurs. Primers PI and P2 amplify wt Myh (262 bp product) and 
primers PI and P3 amplify mutant Myh (376 bp product).
Ape and Moml(Pla2g2a) were genotyped by sequencing directly across the 
Min mutation at codon 850 of Ape and the resistant allele of Moml located on 
chromosome 4. AKR mice are homozygous for the resistant allele Momlm  
and C57/BL6 mice are homozygous for the sensitive allele Momls/s.
All primer sequences and conditions can be found in Appendix 1.
5.2.3 Adenoma, cystic crypt and aberrant crypt focus 
counts
Mice in the first MAP mouse study were sacrificed between 110 and 130 days 
by CO2 asphyxiation for adenoma, cystic crypt and aberrant crypt focus 
counts.
Four of the second MAP mice bred on the AKR background were sacrificed 
between 110 and 130 days, but as they had no intestinal phenotype the 
remainder were left, initially with the intention of analysing them at 18 
months. However, the majority o f the mice developed lymphoma and 
necessarily had to be sacrificed prior to this.
The intestinal tract was removed and dissected into four segments -  3 small 
intestine (proximal, middle and distal) and 1 colonic. Each segment was 
flushed with PBS and opened longitudinally. Bowel preparations were fixed 
with Camoy’s medium for 3 hours and stored in 70% ethanol. Tissue was 
stained with 0.2% methylene blue for 3 minutes and washied in PBS for 20 
minutes. Adenomas and cystic crypts were counted on a dissecting microscope 
at x3 magnification. Cystic crypts in the small intestine and aberrant crypt foci 
in the colon were counted at x3 and x5 magnification. In the first MAP mouse 
the preparations were counted by both O.Seiber and myself to confirm 
accuracy of results.
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5.2.4 Histology
Following adenoma, cystic crypt and aberrant crypt foci counts, five of 
animals from each study group had their small intestine and colon rolled, 
embedded in paraffin, sectioned at 4pm intervals and stained with 
haematoxylin and eosin. These sections were examined by a pathologist 
blinded to the genotype o f the mice (G. Stamp) to determine the number of 
aberrant crypt foci in the colon. Any abnormal tissue identified at post-mortem 
was also taken for histological analysis (eg mammary tumours and thymic 
masses).
5.2.5 Molecular analysis of adenomas
Adenomas were dissected from whole-mount preparations using a dissection 
microscope at x3 magnification. Each adenoma was sized as either <lmm, 1- 
2mm or >2mm. All samples were placed directly in to coming tubes on dry 
ice. A separate scalpel was used for each individual adenoma to prevent 
contamination and care was taken to avoid sampling of the normal 
surrounding epithelium. Tail tissue and normal bowel epithelium were also 
sampled. DNA was extracted as described in Methods 2.1.1.6.
LOH analysis at Ape and Myh
Adenomas were analysed for LOH at Ape was using fluorescent SSCP 
analysis distinguishing the wt and Min alleles. LOH at Myh was analysed with 
the same allele specific assay as used for genotyping with the common PI 
primer fluorescently labelled. See Methods 2.1.6.4 for LOH analysis and 
Appendix 1 for primer details and conditions.
Mutation analysis
Exons 5-14 o f Ape, Myh exons 2-15 and K-ras exon 1 were screened to 
determine the mutation frequency and mutational signature in the adenomas 
dissected. Exon 15 o f Ape (codons 652 -  1648) was covered by 10 
overlapping primer pairs. Ape and Myh were screened with fluorescent SSCP 
analysis followed by direct sequencing o f samples with aberrant SSCP bands. 
K-ras exon 1 was sequenced directly. See Methods 2.1.6.1 for details o f SSCP
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analysis, Methods 2.1.7 for details o f fluorescent cycling sequencing and 
Appendix 1 for primer details and conditions.
When somatic mutations were identified, these were confirmed by cloning the 
PCR product from the tumour sample. See Methods 2.1.8.
5.3 Results
5.3.1 ApcP,n*/mIMyhm/m mice bred on C57BL6/SV129 
background
In total, 134 small intestine and 6 colonic adenomas were dissected from 12 
ApcMm+/' /Myh*/+mice , 147 small intestine and 21 colonic adenomas from 16 
ApcMm+/' /Myh*f~ mice and 167 small intestine and 16 colonic adenomas from 
13 ApcMin+/~ / Myh'A mice. Adenoma, cystic crypt and aberrant crypt foci counts 
were performed in 15 ApcMin+/ /Myh*/+, 25 ApcMin+/' /Myh r/~ and 15 ApcMin+/~ 
/Myh'1' mice and 15 animals from each o f the three control groups Apc+/+ 
/Myh*/+, Apc+/* /Myh+/~ and Apc+/* !Myh'/'. The three study groups had similar 
male:female ratios 8:7 for ApcMin+/~ /Myh*/+, 11:14 for ApcMin+/~ /Myh+/~ and 
6:9 for ApcMin*A/My h A.
5.3.1.1 Enhanced adenoma and cystic crypt formation
observed in the small intestine of ApcP^IM yh* mice
In the small intestine tumour multiplicity was increased by 53% in the 
ApcMin+/' /M yhA mice when compared to ApcMm+/~ /Myh*/+ mice (p=0.016, 
Mann Whitney U test). A higher number of adenomas developed in the 
proximal and middle segments o f small intestine examined than the distal 
segment (p=0.01, ANOVA for interaction).
No significant increase in tumour multiplicity was seen in the ApcMm+/~ / Myh+/~ 
mice when compared to ApcMm+/' /Myh*/+ mice (p=0.83 Mann Whitney U 
test). See Table 5-1.
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ApcMln/+ M y h + /+  
( n = 1 5 )
ApcMln/+ M y h -/+  
(n = 2 5 )
ApcMln/+ M y h -/-  
(n = 1 5 )
Adenom as 161 ±  58 164 ±  92 228 ±  84(p = 0 .0 1 6 )
Proximal 21 ±  8 25 ±  16 4 4  ±  21
Middle 62 ±  23 60  ±  34 85 ±  35
Distal 7 8  ±  33 79  ± 47 99  ±  36
Cystic crypts 20  ±  24 24  ±  32 46  ±  50
Table 5-1 Summary o f adenoma and cystic crypt formation in the small 
intestine mean and SD shown (p=0.016 for no. adenomas ApcMm+/~ /Myh+/+ 
versus ApcMln+/~ IMyhv' Mann Whitney U  test)
When considering adenoma size, no significant difference was seen between 
the ApcMin+/' /Myh+/~ and ApcMin+/~ I Myh'1' mice when compared with ApcM,n+/~ 
/Myh+/+ mice (p=0.10 for ApcMm+/~ /Myh+/+ versus ApcMin+/~ !Myh+/~ mice; 
p=1.0 for ApcM,n+/~ IMyh+/+ versus ApcMm+/' /Myh'A mice, %2 test)- 
An increased number of cystic crypts was observed in the ApcMm+/~ /Myh'A 
mice (mean = 46 in ApcMm+/~ I Myh''\  24 in ApcMin+/' /Myh+/' and 20 in ApcM,n+/' 
/Myh+/+ mice) however, this was not statistically significant (p=0.17 Mann 
Whitney U test). A sub-population o f cystic crypts demonstrated dysplastic 
features (see Figure 5-1 ). Animals with a higher adenoma burden also had a 
higher cystic crypt count (R2=0.57, p=<0.001, linear regression analysis).
No adenomas or cystic crypts were found in the small intestine of any o f the 
animals in the three control groups (Apc+/+ /Myh+/+, Apc+/+ /Myh+A and Apc+/+ 
/Myh'A).
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Figure 5-1 Adenomas and cystic crypts in the small intestine of Myh deficient 
mice
The above figure demonstrates adenomas and cystic crypts in the small 
intestine of ApcMin+/' /Myh'A mice. Methylene blue stained adenomas and 
cystic crypts are shown in (A) and (B), cystic crypts are arrowed. H&E stained 
transverse sections of small intestine demonstrate cystic crypts with normal 
pathology (C) and dysplasia (D).
5.3.1.2 Increased number of aberrant crypt foci observed in
the colon of ApcM/n+/7My/fA mice
ApcMinW' /Myh+/+, ApcMin+/' !Myh+/' and ApcMinW' /Myh'A mice all developed a 
mean of 2 adenomas in the colon (p=0.18 for ApeMn+A /Myhw* versus 
ApcMn*f' /Myh+/' mice and p=0.16 for ApcMin+/' / Myh+/+ versus ApcMinW~ /Myh~~ 
mice, Mann Whitney U test). No significant difference in size of adenoma was 
observed between study groups with 82% (19/23) ApcMm+/' /Myh+/+, 60%
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(28/47) ApcMm+/~ /Myh+/' and 88% (21/24) ApcMw+/ !MyH/' o f adenomas 
measuring >2mm (p=0.06 for ApcMm+/' /Myh+/+ versus ApcMm+/~ /Myh+/~ and 
p=0.7 for ApcM,n+/~ /Myh+/+ versus ApcMm+/~ /Myh'A, Fishers Exact test).
Myh deficient mice developed an approximately 2-fold increase in number of 
aberrant crypt foci (ACF) predominantly in the distal colon. ApcMm+/~ /Myh+/+, 
ApcMin+/~ /Myh+/' and ApcMln+/~ /Myh'1L mice developing a mean number of 23, 
17 and 48 ACFs respectively (p=0.001 for ApcMm+/~ IMyh+/+ versus ApcMm+/' 
I Myh'1' and p=0.10 for ApcMin+A /Myh+/+ versus ApcMin+/' /Myh+/' Mann 
Whitney U test). The number o f ACFs did not correlate with the number of 
adenomas in any one animal (R2=0.0054, p=0.61, linear regression analysis). 
No adenomas of ACFs were present in any of the control groups.
A pcM,n/+ 
M y h + /+  ( n = 1 5 )
Apc*'n/+ M yh -/+  
(n = 2 5 )
A pcM,n/+ Myh- / -  
(n = 1 5 )
Adenom as 2 ± 3 2 ± 2 2 ± 1
ACFs 23 ± 13 17 ± 12 48 ± 22(p = 0 .0 0 1 )
Table 5-2 Summary of adenoma and aberrant crypt focus counts in Myh 
deficient mice (mean +/- SD, p=0.001 for ApcMtn+/~ IMyh+/+ versus ApcMm+/~ 
Mann Whitney U test)
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Figure 5-2 Adenomas and aberrant crypt foci in the colon of Myh deficient 
mice, bar size = 500pm
The above figure demonstrates adenomas and ACFs in the colons of ApcMin+/' 
/Myh'A mice. Methylene blue-stained adenomatous polys are shown in (A), 
with ACFs demonstrated (with arrow heads) in (B). H&E transverse sections 
demonstrate a monocryptal ACF (C) and polycryptal ACF (D), scale bars = 
500pm.
5.3.1.3 No evidence of progression from adenoma -
carcinoma in A pc^^ 'IM yh^ ' mice
Analysis of 8 small intestine and 8 colonic adenomas from ApcM,n+/' /Myh+/+, 
21 small intestine and 17 colonic adenomas from ApcMm+/' /Myh+/' and 30 
small intestine and 17 colonic adenomas from ApcMin+/1 Myh'1' mice found no 
evidence of progression from adenoma to carcinoma by 120 - 130 days of age.
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5.3.1.4 An increased frequency of mammary gland tumours
was observed in ApcfUn*/‘INIyh'/' mice
Mammary gland tumours were found in 0% (0/16) ApcMin+/' /Myh+/+, 7% 
(3/43) ApcMin+/- /Myh+/- and 27% (4/15) ApcMin+/' /Myh'A mice (p=0.028 when 
comparing Myh'1' with both Myh+/' and Myh +/+ mice, Fishers exact test). See 
Figure 5-3.
Figure 5-3 H&E stain of mammary gland tumour in ApcMin+/VMyh'A mouse 
(x20) with squamous cell differentiation arrowed
5.3.1.5 Molecular analysis of adenomas from A pcMm*/' IMyh'
A mice
LOH analysis at Ape
As all mice in the study groups were ApcMin+/\  initial analysis of all adenomas 
for LOH at Ape was undertaken to determine the mechanism of loss of the 
second Ape allele, either through LOH or through G:C>T:A transversions 
through Myh deficiency.
Ninety-three percent (118/127) adenomas from ApcMin+/' /Myh+/+, 89% (87/98) 
adenomas from ApcMin+/' IMyh+/' and 81% (121/150) from ApcMin+/' /Myh'A
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mice were found to have lost the wt allele o f Ape (p<0.001 for Myh deficient 
mice versus Myh heterozygous and wt mice, Fishers Exact test).
LOH analysis o f colonic adenomas found no significant difference in the 
frequency of allelic loss at Ape. One hundred percent (6/6) of adenomas from 
Ape**”*'' /Myh*'*, 100% (18/18) ApcMn+/' I Myh*'- and 94% (15/16) adenomas
from Ape""*''I Myh'' mice had loss o f the wt allele (p=0.10 for
deficient versus Myh wt mice, Fishers Exact test).
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Figure 5-4 LOH analysis at Ape (A -  wt normal, B -  Min normal tissue) in 
adenomas from ApcMin+/~ /Myh+/+ (C) and ApcMin+/ I Myh'1' (D) mice. LOH at 
Ape when present, occurred at the wt allele (arrowed)
G :O T:A  transversions occur in adenomas o f  ApcMin+/~ /Myh'f' mice
Twenty-nine adenomas from 4/?cM"+A /Myh'A, eight adenomas from ApcM,n+/' 
/Myh+/' and 9 adenomas from ApcMin /' /Myh+/+ mice which had not 
demonstrated LOH for the wt allele o f Ape underwent somatic mutation 
analysis at Ape.
Somatic mutations were detected in 10% (3) adenomas of ApcMin+/' I Myh'1' 
mice. All were G:OT:A transversions (2x G>T nt 3919 (E1307X), lx  C>A nt
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4754 (S1585X). The sequence motif around the E1307X mutation 
(AAAGAGA) is the same as that identified in human MAP as a sequence 
prone to hyper-mutation as a consequence of defective BER. No somatic 
mutations were identified in adenomas from ApcM,n+/~ /Myh+/' and ApcMin+/' 
/Myhw* mice.
A G A A
B A A A A T  A G A A
Figure 5-5 Somatic G>T transversion at nt 3919 of Ape resulting in E1307X 
termination codon, A -  forward sequence from adenoma DNA and B -  cloned 
mutant allele
Adenomas from ApcM,n +/~ /Myh mice did not harbour K-ras mutations
No mutations in exon 1 of K-ras were found in 40 adenomas analysed from 
ApcMn+/' /Myh~A mice and 20 adenomas from ApcMin+/' /Myh+/+ mice.
No LOH at Myh was observed in ApcMin+/' /Myh+/~ mice
In order to determine whether inactivation of the wt allele is selected in 
tumour development in Myh heterozygotes, 137 adenomas from Apcmn+/' 
/Myh+/' mice were screened for LOH at Myh. One percent (2/137) adenomas 
harboured allelic loss at Myh, and in one of these cases the LOH targeted the 
inherited mutant allele rather than the wt allele. Eighty-two adenomas were 
subsequently screened for somatic mutations in exons 2-15 of Myh, but no 
mutations were identified.
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5.3.2 ApcMm+/'IMyhm/m mice bred on AKR background
Following backcrossing o f ApcMln+/’ and Myh+/~ onto AKR and inter-crossing 
of and Myh+/' as described earlier in this chapter, the same study
groups were set up on the AKR genetic background. Twenty-two ApcMtn+/~ 
I Myh'A , 44 ApcMin+/-1 MyhfA , 20 ApcMin+/- /Myh+/+ and 30 Apc+/+ /Myh+/+ mice 
were studied.
Four mice from the ApcM,n+/~ /Myh'A group were culled between 110 and 130 
days, but on examination, none of these animals had developed adenomas, 
cystic crypts or ACFs. In light of these findings and those of (Sakamoto, 
Tominaga et al. 2007) (published whilst this experiment was in progress), it 
was decided to leave these animals for up to 18 months of age in order to 
determine whether they would in fact develop a gastro-intestinal phenotype.
5.3.2.1 The majority of mice across all study groups
developed high grade lymphoma
Whilst waiting for the mice to mature all o f the animals became sick 
necessitating culling. Full post mortems were carried out and none of the mice 
in any of the study groups had developed adenomas, cyctic crypts or ACFs. 
The majority o f the animals had developed high grade lymphoma and had died 
as a consequence o f metastatic spread to other organs and bone marrow failure 
-see Table 5-3 and Table 5-4.
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Animal
ID Genotype
Age at 
death 
(weeks)
PM  find ings  
Cause of death
weight
(9)
LN
size thymus spleen comments
1
X>-Z Min*'' 8 lym phom a 21.6 5-10x lOx NAD
2 MYH''' Min*'- 24 no obvious cause 39.8 NAD NAD NAD subcutaneous chest wall nodule
3 MYH''' Min*'- 24 no obvious cause 28.9 NAD NAD NAD stom ach distended
4 Z -< X Min*'" 28 lym phom a 29.1 5x lOx NAD
5 MYH7 Min*'" 36 lym phom a 30.9 2x lOx 3x
6 MYH7 Min*'' 24 lym phom a 32.5 2x 5x 3x liver infiltrated
7 3 -< X Min*7' 28 lym phom a 33.4 lOx NAD NAD riqht inquinal LN lOx size
8
I>-z Min*'‘ 36 lym phom a 50.2 NAD NAD NAD 2 subcutaneous ab scesses  non-active
9 MYH7 Min*7' 26 lym phom a 26.2 3-5x lOx 3x
10 MYH7 Min*7' 26 no obvious cause 26.7 3-5x lOx 3x
11 MYH7' Min*'" 21 no obvious cause 31.1 NAD NAD NAD hyperplasia of th e  u terus
12 MYH7' Min*'" 28 lym phom a 35.1 NAD NAD NAD culled as piloerect and rapid breathinq
13 MYH7' Min*7' 16 lym phom a 34.1 2x lOx NAD
14 MYH7' Min*'" 24 lym phom a 36.3 3-5x lOx 3x
15 MYH7' Min*'" 38 no obvious cause 30.1 2x lOx NAD liver infiltrated
16 MYH7' Min*'- 38 lym phom a 33.9 3-5x lOx 5x liver infiltrated
17 MYH7' Min*7' 40 no obvious cause 44.8 NAD lOx NAD
18 MYH7' Min*7' 22 lym phom a 25.9 2x lOx NAD liver infiltrated
19 MYH7' Min*'" 30 no obvious cause 32.5 NAD NAD NAD
20 MYH7' Min*7' 30 no obvious cause 37.1 NAD NAD NAD
21
X>-z Min*'' 32 no obvious cause 46.4 NAD 30x NAD
22 MYH7' Min*'" 32 no obvious cause 51.7 NAD 30x NAD subcutanous cyst under chin
Table 5-3 Summary of cause of death and post mortem findings for the Myh'1' 
/ Min+/~ mice (NAD = no abnormality detected)
Genotype
AKR
background
no.
age a t death 
(w eeks) 
median (range)
weight (g) 
median (range) lymphoma
MYH'1' /  Min +/ 22 28 (8 -4 0 ) 32 .5  (2 1 .6 -5 1 .7 ) 1 2 /2 2  (55% )
MYH+I' /  Min +/~ 44 26 (2 -3 2 ) 3 3 .4  (2 5 .7 -4 1 .2 ) 2 8 /4 4  (63% )
MYH+/+ /  M in +/' 20 28 (8 -4 4 ) 31 .4  (1 7 .9 -4 6 .6 ) 1 0 /2 0  (50% )
MYH+I+ /  A p c +h 30 32 (1 5 -4 5 ) 3 9 .6  (2 1 .7 -3 5 .4 ) 2 1 /3 0  (70% )
Table 5-4  Summary o f age and weight at death and incidence of lymphoma at 
post mortem
No significant difference was observed in either the age or weight at death 
between any o f the study groups (p=0.22 for ApcMin+/' IMyh'A versus ApcMm+/~ 
/Myh+/\  p=0.84 for ApcMin+/' /Afyh^ versus ApcMin+/' IMyh+A , p=0.08 for 
ApcM,n+/~ IMyh'A versus Apc+/+ /Myh+/+ for age at death; p=0.68 for ApcMm+/~ 
IMyh'A versus ApcMm+/~ IMyh+/' , p=0.58 for ApcMn+A IMyh'1' versus ApcMln+/' 
IMyh+/+ and p=0.46 for ApcMm+/' IMyh'1' versus Apc+/+ IMyh+/+ for weight at 
death, t-test).
When considering the incidence of lymphoma, no significant difference was 
observed across the study groups (p=0.16 for ApcM,n+/ IMyh'A versus ApcMm+/'
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IMyhfA, p=0.23 for ApcMw+/' IMyhA versus ApcMin+A IMyh+/+ and p=0.12 for 
ApcMn*/' IMyh1' versus Apc+/+ IMyh+/+ Fishers Exact test).
5.3.2.2 Histological findings at post mortem
Full post mortems were performed and gut preparations examined for 
adenomas, cystic cryps and ACFs. As none were seen in any animals for all 
study groups, a sub-set of 5 ApcMin+/' IMyhA and 5 Apc+/f IMyh+/+ animals had 
full gut rolls prepared and were examined by a Histopathologist (G. Stamp) for 
any evidence of cystic crypts ot ACFs. One ACF was identified in the colon of 
one ApcMn+/' IMyh'1' animal.
The figures below show gross pathological and H&E-stained preparations of 
the thymus, mesenteric lymph nodes, spleen and bowel mucosa from both 
ApcMin+/' IMyh'  ^ and wt C57BL6 animals for comparison.
w t Min+'/Myh-'- w t  M in * /M y h *
Figure 5-6 Thymus from ^/7cMn+A / Myh' ' mouse, H&E sections on the right 
demonstrate loss of abnormal parenchymal architecture (x2) and lymphocytic 
infiltration with high grade lymphomatous cells (x40)
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Wt M in *'/M yh +  w t  Min*'-/Myh-'
Figure 5-7 Mesenteric lymph nodes from ApcMin*/' / Myh'1' mouse, H&E 
sections on the right demonstrate loss of abnormal parenchymal architecture 
(x2) and lymphocytic infiltration with high grade lymphomatous cells (x40)
x2
x40
wt M i n + ' / M y t r ' - wt M i n + ' / M y h '
Figure 5-8 Spleen from ApcMin+/' / Myh'1' mouse, H&E sections on the right 
demonstrate loss of abnormal parenchymal architecture (x2 ) and lymphocytic 
infiltration with high grade lymphomatous cells (x40)
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Min+'/Myhr'-
Figure 5-9 Transverse H&E sections of small intestine from wt and Apcmn+/' I 
M yh ' mice. No adenomas are seen, lymphocytic infiltrate is evident in the 
ApcMin+/~ / A/y/^‘section at x4 power
5.4 Discussion
5.4.1 A p c Min*/'INIyh'/’ mice bred on C57BL6/SV129
background
The first mouse model o f MAP bred on a mixed C57B6/SV129 genetic 
background demonstrated an additive effect of defective Myh when crossed 
with ApcMin+/' mice both in the development of intestinal and extra-intestinal 
tumour development.
A significantly increased number of adenomas developed in the small intestine 
of ApcMin+/' IMyh'A mice and a higher number (not statistically significant) of 
cystic crypts was also observed. Cystic crypts are lesions of unknown 
neoplastic potential which occur in the small intestine of ApcM,n+/' mice and 
increase in number when mice are treated with ethylnitrosourea (ENU) or are
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bred with MMR (M lhl) deficient mice (Shoemaker, Moser et al. 1995; 
Shoemaker, Haigis et al. 2000). It is possible that the addition of defective 
BER alongside the ApcMm+/~ mutation may have caused the observed increased 
number of cystic crypts through similar (as yet undetermined) mechanisms to 
those underlying the ApcMm A7Mlh'A mice. The ApcMln+/7Mlh'A mice also 
developed other extra-intestinal manifestations o f defective Ape such as 
desmoids and epidermoid cysts (Shoemaker, Haigis et al. 2000), none of these 
features were seen in the ApcMm+A /Myh'A mice. ApcMln+/7Mlh'A mice also 
developed ~ 2 fold greater number o f ACFs which are putative pre-malignant 
lesions developing in the colon o f ApcMin+A mice (Paulsen, Steffensen et al. 
2001; Yamada, Hata et al. 2002) and that are following treatment with 
chemical carcinogens (Wargovich, Jimenez et al. 2000). This suggests that 
Myh deficiency in the mouse promotes the development of both of these pre- 
malignant lesions.
The proportion o f adenomas in ApcMm+A !Myh'A mice without LOH of the wt 
allele of Ape was similar to that in previous studies in other BER and MMR 
deficient mice -  Mbd4, Mlhl, Msh2 and Pms2 (Wong, Yang et al. 2002) 
(Shoemaker, Haigis et al. 2000) (Reitmair, Cai et al. 1996) (Baker, Harris et 
al. 1998).
The presence o f G:C>T:A transversions at Ape in adenomas from ApcMin+A 
/MyhA mice was indicative that defective BER was promoting tumorigenesis 
in these animals. As no G:C>T:A transversions at Ape were seen in adenomas 
from the ApcMm+/ /Myh+/' and ApcMm+/' IMyh+/+ mice, it can be concluded that 
the pathogenesis in those adenomas demonstrating G:C>T:A transversions 
similar to that occurring in humans (Al-Tassan, Chmiel et al. 2002) (Jones, 
Emmerson et al. 2002).
The low frequency o f somatic truncating mutations at Ape observed in the 
ApcM,n+A IMyh'1' mice may be due to increasing evidence that adenomas from 
ApcMin+A mice and germline APC  mutation carriers in humans (FAP) are 
polyclonal (Merritt, Gould et al. 1997) (Novelli, Williamson et al. 1996) 
(discussed further in Chapter 9). In this situation the overall contribution to the 
tumour DNA from the mutant allele may be too small to be detected (unless 
samples are micro-dissected). This is supported by the finding that the somatic
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mutation (G>T transversion at nt 3919) cited in this chapter (Figure 5-5) 
could only be confirmed on cloning of the PCR product.
The distribution of adenomas within the small intestine of ApcMm+/' IMyh'1' 
mice with a greater proportion developing in the proximal and middle 
segments of the small intestine in part reflect the distribution of adenomas in 
humans MAP (where duodenal and gastric adenomas can occur). When 
ApcMmW' mice are crossed with MMR deficient {Mlhl) mice a uniform 
distribution of adenomas is observed (Shoemaker, Haigis et al. 2000). This 
observation in both human and murine MAP may reflect varying levels, of 
oxidative stress throughout the GI tract or may relate to the level of activity or 
functional redundancy o f MYH in different anatomical regions of the Gl tract. 
The first MAP mouse model was very useful in determination of the 
significance o f the heterozygous state in MYH. The finding that ApcMm+/' 
/Myh+/~ mice did not develop a significantly higher number of adenomas than 
ApcMm+/' /Myh+/+ mice indicated that being a heterozygous carrier of MYH did 
not confer a higher risk o f developing adenomas and CRC. This study and its 
publication (in 2004) came before subsequent population based studies 
confirming this finding (Webb, Rudd et al. 2006).
The first mouse model o f MAP demonstrated elements of tumorigenesis 
similar to that found in the human form of the disease, however adenomas 
were found to have a much higher incidence o f LOH at Ape as the “second 
hit” and lower incidence o f somatic G:C>T:A transversions at Ape.
It was on the basis o f these findings that the second MAP model was bred in 
order to develop a more “faithful” model of the disease.
5.4.2 Apcmn*/~IMyh'/~ mice bred on AKR background
It is known that AKR mice are prone to developing leukaemia and lymphoma 
(http://iaxmice.iax.org) with a lifetime incidence o f 60-90%. However 
previous studies back-crossing ApcM,n+/' on to AKR and subsequent inter­
crossing with Mlhl led to the development o f a gasto-intestinal phenotype 
(Haigis, Hoff et al. 2004). In the study by Haigis et al, ApcM,n+/' /MlhrA mice 
also developed thymic lymphoma at an average age o f 1 0 0  days.
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As four AKR ApcMin +/VMyh~/~ mice in my study had not developed a gastro­
intestinal phenotype or lymphoma by 1 1 0  to 130 days and following the 
findings of Sakamoto et al (Sakamoto, Tominaga et al. 2007), the study and 
control groups in this experiment were left for longer (ideally > 1 year) prior 
to culling.
Sakamoto et al developed a Myh~ mouse bred on the C57BL6 background 
whilst this study was in progress. This mouse develops both spontaneous 
adenomas at > 18 months o f age and a significantly higher number of 
adenomas when fed KBrCh in drinking water. At 18 months of age 109 wt and 
1 2 1  Myh'f' mice were sacrificed and examined for development of adenomas 
and extra-intestinal tumour development, at this time no increased mortality 
was observed in the Myh A mice. Four adenomas and seven carcinomas were 
found in the intestines (small intestine / colon not specified) o f 10 Myh"/‘ mice 
and none were found in the wt controls. When oxidative stress was induced 
with KB1O 3 in drinking water, a higher number o f adenomas was observed in 
16 Myh f' and 15 wt mice (mean no. adenomas = 61.88 in Myh~A and 0.85 in 
wt) when animals were culled at 12 months. The adenomas in the Myh A mice 
were found predominantly in the proximal small intestine (as found in the first 
MAP mouse above). None o f the wt or Myh~A animals which were not fed 
KB1O 3 developed adenomas by 12 months o f age. No mutational analysis was 
undertaken in these studies to determine whether the adenomas which 
developed in the Myh f' mice had an excess of G:C>T:A transversions.
The main obstacle in development o f the second MAP mouse model was the 
discrepancy between the length o f time required for a “simple” Myh'A 
knockout mouse (on C57BL6) to develop a phenotype (18 months of age) 
(Sakamoto, Tominaga et al. 2007), and even then this is found in only 8 % 
(10/121) of animals and the incidence of lymphoma inherent in the AKR 
genetic background. In excess o f 90% of AKR mice develop lymphoma by 18 
months of age.
Interestingly, no difference was observed in either the age of death or 
incidence of lymphoma in any o f the study groups or controls in the second 
MAP mouse .There was a suggestion in the data that the ApcMin+/~ mice died at 
a younger age and weight, but this was not significant. The presence of
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ApcMm+/~ allele either with or without Myh deficiency did not significantly 
affect the age or cause o f death when all o f the study and control groups were 
compared. Mouse models o f lymphoma (with associated microsatellite 
instability) include MMR deficient (Msh2 and M lhl) mice which are thought 
to lead to a higher number o f errors in T-cell and B-cell gene rearrangements 
of the immunoglobulin gene superfamily, but little is known of the target 
genes for defective MMR in this situation. Msh2 deficent murine lymphomas 
develop insertion/deletion muations in TgfjS type 2 gene (Lowsky, Magliocco 
et al. 2000). Up to 75% of Mlhl deficient mice develop lymphomas which 
harbour somatic mutations in the transcription factor ikaros (Kakinuma, 
Kodama et al. 2007).
In the AKR Apc^^'lM yh'1' model, defective BER should not cause the same 
mutation spectra in either T and B cell gene rearrangement (as BER is not 
directly involved in T and B cell gene rearrangement) or Tgffi -  and would not 
lead to the development o f lymphoma at a faster rate than wt animals. This is 
reflected in the observed results presented in this Chapter.
It seems that some other mechanism is required alongside Myh'A deficiency to 
drive tumorigenesis in mouse models of MAP -  either through environmental 
oxidative stress or a predisposition to adenoma development through the 
ApcMin+/~ allele.
5.5 Conclusions
The first mouse model o f MAP (ApcMm+/'/Myh'/ mice bred on C57BL6/SV129 
genetic background) developed several features in keeping with the human 
MAP syndrome -  those o f intestinal adenoma development, with a proximal 
distribution in the GI tract and evidence of somatic G:C>T:A transversions at 
Ape.
Further studies have provided evidence that mouse models of MAP (on both 
the C57B6 and AKR genetic background) appear to require a second promoter 
of tumorigenesis either through external oxidative stress or inherited mutations 
in Ape.
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6 Identification of potential pathogenic 
mechanisms underlying the multiple colorectal 
adenoma phenotype.
6.1 Introduction
The multiple colorectal adenoma (MCRA) phenotype is can be defined as any 
individual who develops between 5-100 adenomas in their lifetime.
These individuals carry an increased risk o f developing CRC. Up to 35% of 
MCRA individuals are homozygous carriers of MYH germline mutations 
(Sieber, Lipton et al. 2003) (Sampson, Dolwani et al. 2003), and a further 15% 
harbour a germline mutation in APC  (“attenuated” FAP, (AFAP)) (Spirio, 
Green et al. 1999). The remaining -50% of MCRA cases are likely to have 
some genetic component which is as yet unidentified.
The concept o f utilising molecular profiling alongside histopathological 
features in adenoma classification has continued to develop since the 
introduction o f the “adenoma -  carcinoma sequence” in the late 1980’s. This 
paradigm describes the progression from normal colonic epithelium through 
adenoma to carcinoma initiated by bi-allelic loss of APC  followed by 
activating K-ras mutation and culminating with inactivation of p53 resulting 
in transition to carcinoma (the “classical” pathway)(Vogelstein, Fearon et al. 
1988).
Activating K-ras mutations have historically been associated with advanced 
adenoma and a higher degree o f “aggressiveness” of an adenoma (Maltzman, 
Knoll et al. 2001). However, K-ras mutations are also found in 
microadenomas and small tubular adenomas indicating a limited potential for 
progression (Takayama, Ohi et al. 2001). Taking this alongside the finding 
that only 30% of CRC’s harbour K-ras mutations (Jass, Whitehall et al. 2002)
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indicates that its historical position in the adenoma — carcinoma sequence 
could be questioned.
The concept o f an alternative “serrated” pathway of colorectal tumorigenesis 
was introduced on the finding that serrated adenomas, hyperplastic polyps and 
mixed polyps harbour mutations in BRAF (Chan, Zhao et al. 2003; Kambara, 
Simms et al. 2004) (Yang, Farraye et al. 2004). They are also commonly 
microsatellite unstable and demonstrate extensive DNA methylation (O’Brien, 
Yang et al. 2004) (Jass 2005).
In reality it is likely that there is a molecular spectrum of (epi)genetic 
mutations and histological findings which are observed in sporadic adenomas, 
serrated adenomas and hyperplastic polyps. It has been suggested that 
molecular “crossover” from the serrated to the classical pathway may occur 
conferring enhanced aggressiveness in certain adenomas (Jass, Baker et al. 
2006).
The histopathological features (the majority being tubular adenomas) of 
MCRAs suggest that they would follow the classical pathway. However, prior 
to this study this area not been specifically explored or studied.
In this study I utilised several approaches in tandem to identify potential 
pathogenic mechanisms leading to the development o f MCRAs in a group of 
patients in whom MYH and APC  mutations had been excluded.
I set out to identify potential pathological mechanisms by looking for clues as 
to the development o f MCRAs from their earliest stages by examination of 
histological slides for the presence or absence of microadenomas, searching 
for evidence o f disruption o f Wnt signalling through performing immuno- 
histochemistry for P-catenin and examining adenomas for evidence of a 
somatic mutation spectrum suggestive o f an underlying disruption of DNA 
repair. Somatic mutation spectra in K-ras and BRAF were also determined to 
further molecularly classify the MCRA phenotype .
The significance o f  the presence o f  microadenomas
The primary tumour predisposition in FAP and MAP is through the formation 
of colorectal adenomas via APC  mutation. FAP and MAP patients develop not 
only macroscopic adenomatous polyps, but also microadenomas -  each 
comprising at most a few dysplastic crypts (Lipton, Halford et al. 2003) and
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more recently described in the duodenum (Preston, Leedham et al. 2008). This 
is consistent with an increased rate o f adenoma initiation in FAP and MAP. In 
HNPCC, by contrast, the primary predisposition is probably to carcinoma (or 
progression from adenoma to carcinoma) and microadenomas are generally 
absent. The presence or absence o f microadenomas in the colonic mucosa of 
MCRA patients would therefore provide evidence as to the origins o f the 
disease.
A similar line o f reasoning can be applied to the observation that (A)FAP and 
MAP patients frequently develop extra-colonic adenomas, particularly in the 
duodenum. The similarity of the MAP and (A)FAP phenotypes suggests that 
all individuals predisposed to inactivation o f APC  may develop both colorectal 
and duodenal adenomas. Interestingly, HNPCC patients are at greatly 
increased relative risk - but low absolute risk - of small bowel cancer, but have 
very few adenomas at this site.
Wnt signalling disruption and adenoma formation
The relationship between APC  and Wnt signalling has been previously 
described in Chapter 1 (1.1.3.4). A simple method with which to assess 
disruption o f APC  function and Wnt signalling is through cellular expression 
of fi-catenin -  a downstream product in the Wnt signalling pathway. FAP and 
AFAP adenomas have increased nuclear and cytoplasmic expression of fi- 
catenin indicative o f Wnt disruption (Seidensticker and Behrens 2000). 
HNPCC tumours in contrast, have relatively low frequency o f nuclear fi- 
catenin.
A previous study screening for germline mutations in the TGF-ft (SMAD4, 
BMPR1A) and Wnt signalling (APC2, conductin, GSK3-fi) pathways in 47 
MCRA cases found only one individual to have a putative pathogenic 
mutation in BMPR1A (Lipton, Sieber et al. 2003).
Considering the complexity o f the Wnt signalling pathway (including 
numerous inhibitory factors -  the Wif family) this pathway warrants further 
study in the MCRA setting.
Determination o f  the presence o f  a somatic mutation signature
Following the precedent of the discovery o f MYH, determination of a potential 
mutation signature at APC  may lead to the identification of an underlying
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defect in DNA repair. This is also evident in HNPCC where the effects of 
DNA mismatch repair (MMR) deficiency can be detected somatically through 
the presence o f microsatellite instability (MSI) and frameshift mutations in 
short repeats within genes such as BAX  and TGFBR2 (Woodford-Richens, 
Rowan et al. 2001). It follows that, should some of the remaining MCRA 
cases be caused by a defect in DNA repair or by some other form of 
hypermutation, the somatic mutation spectrum will reflect the underlying 
cause of genomic instability.
6.1.1 Aims of this chapter
In order to determine the underlying pathogenesis of the MCRA phenotype I 
studied a collection o f 25 MCRA cases in the following ways.
1: Examination for the presence o f microadenomas - an indication that “2- 
hits” at APC  have occurred initiating adenoma formation.
2: Identification o f Wnt activation through immunohistochemistry for f3- 
catenin expression to identify any underlying defect in Wnt signalling and 
somatic mutation screening for the two mutational hotspots found in exons 3 
and 5 o f fFcatenin.
3: Examination o f adenomas for somatic mutation at APC, K-ras, and BRAF 
in order to identify a potential somatic mutation signature relating to an 
underlying defect in DNA repair, using the precedent o f the discovery o f MYH 
as proof o f principle.
4: Molecular classification o f the MCRA phenotype through analysis for 
somatic mutations at K-ras and BRAF to determine whether the “classical” or 
“serrated” pathways are followed.
6.2 Methods
Sample collection and preparation
Patients were recruited through St Mark’s Hospital Colorectal Cancer Unit 
and blood was routinely sampled. Informed consent was obtained prior to
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sample collection. Inclusion criteria for the study were that patients should 
have between 10 and 100 synchronous or metachronous colorectal adenomas, 
irrespective o f follow-up or (prophylactic) colectomy.
Individuals had all coding exons o f APC  and MYH screened for germline 
mutations with fluorescent SSCP and subsequent sequencing prior to entry in 
to the study. Primers and conditions for APC  and MYH analysis are listed in 
appendix 1, SSCP analysis and sequencing were performed as outlined in 
Methods (2.6.1 and 2.7).
In addition, multiplex ligation-dependent probe amplification (MLPA) 
analysis was used to screen for germline deletions or duplications o f APC  
using the Salsa MLPA kit P043 APC (MRC Holland), see Methods (2.6.5). 
This was undertaken in collaboration with E. Volikos at St. Marks Hospital.
A total o f 241 formalin-fixed, paraffin-embedded adenomas were collected 
from the 25 patients who were eligible for the study.
Fifty-six formalin-fixed, paraffin-embedded sporadic adenomas (patients with 
1 or 2 adenomas and no reported family history) were collected from 29 
individuals.
Existing sets o f adenomas from AFAP and MAP patients in our laboratory 
were available for comparison (Sieber, Lipton et al. 2003) (Lamlum, Al 
Tassan et al. 2000) (Sieber, Segditsas et al. 2006).
For all patients, germline DNA was extracted from peripheral blood using 
methods as described Methods (2.1.1.1).
Tumour and normal tissues were dissected from sections cut from archival, 
paraffin-embedded specimens. It was estimated that the resulting tumour 
DNAs were derived from at least 70% dysplastic cells. DNA was extracted 
from these by proteinase K digestion at 55°C as described in Methods 
(2.1.1.4).
Mutation detection
F-SSCP analysis was used to screen the formalin-fixed, paraffin-embedded 
tumours for somatic APC  mutations between codons 1220 and 1620, 
corresponding to the mutation cluster region (MCR) and covering the region 
between the first 20-amino acid beta-catenin binding/degradation repeat
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(20AAR) and the first SAMP repeat. The region was sub-divided into 12 
amplicons (see Appendix 1 for details o f primers and conditions). Any sample 
with a bandshift was sequenced directly in both orientations from a new PCR 
product. Exon 1 of K-ras, /3-catenin exon 3, and the mutational hotspot at 
codon 600 of BRAF were screened by direct DNA sequencing in both 
orientations. Novel mutations were identified through comparison with the 
COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic) and the 
European APC  database (Laurent-Puig, Beroud et al. 1998).
LOH analysis
Loss of heterozygosity (LOH) at APC  was analysed using microsatellite 
markers just distal to the locus (D5S346, D5S421 and D5S656) on the ABI 
3100 sequencer as described in Methods (2.1.6.1). Constitutionally 
homozygous markers (and occasional PCR failures) were scored as non- 
informative. In the event o f discordance between microsatellite markers, 
precedence was given to the marker closest to the APC  gene.
Microadenoma detection
H&E slides o f adenomas from the MCRA, sporadic and MAP groups were 
examined for the presence o f absence o f microadenomas (collections of 
dysplastic crypts <lm m  in diameter) under the guidance of a specialist 
gastroenterological histopathologist. (M.Novelli, Department of 
Histopathology, University College London).
Immunohistochemistry
Immunohistochemistry for (3-catenin was performed on the multiple adenoma 
group, sporadic adenomas and, for comparison, a set of patients with FAP as 
described in Methods (2.1.13). Slides were then examined using a 
conventional light microscope and the level o f expression of fi-catenin (1, 2 or 
3) was recorded separately for the nucleus, cytoplasm and cell membrane 
according to the intensity o f staining in five random high-powered fields per 
slide. This was compared directly with staining in normal crypts from each
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sample. For membranous expression, in order to normalise results across 
different runs o f immunohistochemistry, the abnormal staining for each 
tumour was divided by the membrane staining in surrounding normal cells. 
Normal cytoplasmic and nuclear expression was so weak that such a 
correction was not required. Immunohistochemistry was scored by myself and 
a subset re-scored by another laboratory member (K.Howarth) to ensure 
consistence, all under the guidance o f a specialist gastrointestinal 
histopathologist (M.Novelli); any differences were resolved by consensus.
6.3 Results
6.3.1 Germline screening of APC  and MYH prior to inclusion 
into this study
Sixty-six individuals were screened for germline mutations in APC  exons 1- 
15 and MYH exons 1-16 using fluorescent SSCP analysis. This was followed 
by direct sequencing o f a fresh PCR product if aberrant SSCP bands were 
found (see Table 6-1 for summary).
One individual was found to have a 5 bp deletion in exon 150 (nt 6233) of 
APC. She had 33 adenomas and no extracolonic features. Silent mutations 
were found in seven individuals and missense mutations in three.
One individual had homozygous Y165C mutations in MYH, and one 
individual was a compound heterozygote for G382D and 1395delGAA. These 
are the known pathogenic mutations seen in northern European (Y165C, 
G382D) and southern European (1395delGAA) populations. A previously 
described MYH polymorphism, Q324H, was identified in 30% of individuals. 
No individuals were found to have whole exon deletions or duplications at 
APC using MLPA analysis. All individuals with pathogenic or missense 
germline mutations were excluded from further study.
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Gene and Exon Mutation Outcome Pathogenic
No. indivudals 
harbouring 
mutation
No. TA’s range 
(median)
APC
5 intronic C>T no 18 8-32(15)
7 intronic G>C no 1 29
11 nt1458 C>T silent no 7 10-33(18)
13 nt1635 A>G silent no 35 7-53(17)
15E Q1122R nt3368G>A Q->R no 1 9
151 nt 4479 G>A silent no 11 9-34(19)
15J nt 5034 A>G silent no 4 6-18(10)
nt4904 G>A silent no 1 21
15K nt 5268 G>T silent no 3 7-26(11)
15L D1822V no 1 13
150 del 5bp nt6233 stop 2071 ves 1 33
15Q C>T A2254V A->V no 1 15
15S G>A; G2502S G->S no 1 8. 13 HPP
15T silent nt7704 A>G silent no 1 33
MYH
x7 Y165C hom yes 1 >30
x13 G382D het het 1395delGAA yes 1 >10
x12A Q324H hom Q324H polymorphism 3 8-11 (5)
X12A Q324H het Q324H het polymorphism 20 8-76(17)
Table 6-1 Results of germline screening for APC  and MYH mutations in 66 
MCRA cases
From the 66 individuals screened, 25 were included in the following studies.
6.3.2 Features of the MCRA patients
The clinical features o f the 25 MCRA patients included for further study are 
shown in Table 2. All were o f white UK origin. The mean age at presentation 
was 60 years (median=61, range=44-75). Mean adenoma number at 
presentation was 24 (median=21, range= 10-76), and the great majority of 
adenomas were mildly dysplastic tubular or tubulovillous adenomas less than 
5mm in diameter. One patient had CRC at the time o f presentation. No patient 
had upper gastrointestinal adenomas and there were no other notable or 
consistent extra-colonic features. Most MCRA patients were isolated cases, 
although a few patients had a single sibling affected with multiple adenomas. 
In no case was there multi-generational inheritance of CRAs (except case 19). 
In six patients, CRCs were present in other family members, although none of 
these individuals had been reported as having adenomas.
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Pattent no. Ago a t diagnoais Adonoma no. CRC FH MCRAs FH CRC
1 75 20 No No Mother - 83vrs
2 66 25 No No
3 60 25 No No
4 71 14 No No
5 61 10 No No
6 51 26 No No
7 52 27 No No M other - 60vrs
8 65 10 No No
9 61 19 No No
10 73 10 No No Sister - 64 years
11 68 23 Yes 68 years No
12 69 12 No No
13 67 27 No No
14 73 76 No No Father - 80vrs
15 55 10 No No Brother - 60vrs
16 55 17 No No
17 52 50 No No
18 55 18 No No
19 49 15 No Yes - Father 19 adenom as
20 66 10 No 1st cousin "multiple polyps"
21 55 30 No No
22 44 33 No No
23 48 32 No No
24 64 50 No No
25 51 21 No No M other - 85yrs, Mat GM - 70yrs
Table 6-2 Patient demographics for the 25 MCRA cases studied
The MAP patients used for comparison (Sieber, Lipton et al. 2003) presented 
at a median age o f 57 (range=54-69), not significantly different from the 
MCRA patients (p=0.476, Wilcoxon test).
The AFAP patients used for comparison (Lamlum, Al Tassan et al. 2000) 
(Sieber, Segditsas et al. 2006) had a median age o f 43 (range=27-68) and were 
significantly younger than the MCRA group (p=0.027, Wilcoxon test).
The family histories and phenotypes of the MCRA cases therefore resembled 
MAP. However, no evidence o f a predisposition to extra-colonic disease was 
seen in the MCRA group.
6.3.3 Microadenoma detection
Examination o f H&E-stained sections o f large bowel from FAP, AFAP, MAP 
and multiple adenoma patients for the presence o f microadenomas (dysplastic 
lesions <lmm diameter) was undertaken in otherwise normal large bowel 
mucosa. Microadenomas were present in 16 o f 19 FAP sections examined, the 
mean density being 0.22 per mm of mucosa examined (see Table 6-3). In 
AFAP, microadenomas were present in 2 o f 7 sections examined from four 
patients, with mean density 0.03 per mm o f mucosa examined. In MAP, 
microadenomas were present in 3 of 16 sections examined from six patients at 
0.01 per mm o f mucosa examined. No microadenomas were found on 
examination o f 16 sections from seven MCRA patients. There was a
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significantly higher number o f microadenomas on comparison o f FAP with 
MCRA and FAP and MAP (p<0.001 (FAP versus MCRA); p=0.04 (FAP 
versus MAP) Fishers Exact test). No significant difference was observed 
between MCRA and MAP cases (p=0.23 Fishers Exact test). The majority of 
specimens examined were from colectomies subsequently sporadic adenoma 
cases could not be assessed, as it is very unusual for colectomy to be 
undertaken in these patients.
Adenoma type FAP AFAP MAP MCRA
no. microadenomas 
detected per 
number of sections 
examined
16/19(84%) 2/7 (29%) 3/16 (19%) 0/16 (0%)
density of 
microadenomas per 
mm of colonic 
mucosa examined
0.22 per 
mm
0.03 per 
mm
0.01 per 
mm
0.00 per 
mm
Table 6-3  Summary o f microadenoma detection in FAP, AFAP, MAP and 
MCRA cases
6.3.4 Somatic mutation and LOH frequencies
Truncating somatic mutations at APC  were detected in 49 o f 221 (22%) 
adenomas from the MCRA group (see Table 6-5). Of 190 informative 
tumours, 32 (17%) showed allelic loss (LOH) see Figure 1. Two truncating 
somatic APC changes were detected in 2 tumours and 11 tumours had a single 
APC  mutation and LOH. The APC  mutation and LOH frequencies were not 
significantly different from those found in the sporadic adenomas (Table 6-4); 
however, the AFAP and MAP tumours had significantly higher frequencies of 
truncating mutations and lower frequencies o f LOH than the MCRA tumours 
(Table 6-4). No adenoma was found to have a somatic fi-catenin mutation.
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Table S: Mutation spectrum a t APC Including LOH for 25 MCRA cases
MCRA S poradic AFAP MAP
Truncatinq m utation 49/221 (22%) 10/56 (18%) d=0. 59 91/242 (38%) D<0.001 25/34 (74%) p<0.001
LOH 32/190(17%) 5/56 (9%) p=0.20 19/230 (8%) p=0.01 1/34 (3%) p=0.02
Table 6-4 Comparison between APC  mutation frequencies and LOH in 
MCRA, sporadic, AFAP and MAP cases, p values are comparisons with the 
MCRA group using Fishers Exact test
See Figure 6-1 for example of LOH and Figure 6-2 for examples of somatic 
APC mutations.
Normal
D5S346
Adenoma
D5S346
B lu e
t
LOH
Figure 6-1 LOH at microsatellite marker D5S346 in MCRA adenoma
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Figure 6-2 Frameshift mutation in MCRA adenoma APC MCR9 del A 1472 
frameshift, stop @ 1506
1 8 2
Figure 6-3 Somatic mutation in MCRA adenoma APC MCR5 E1379X (G>T 
arrowed)
When analysing the mutation spectrum on an individual patient basis none had 
a specific tendency to frameshift changes, specific nonsense mutations, or to 
LOH dXAPC (Table 6-5).
One patient (case 21) had acquired frameshift mutations in 13 tumours and no 
nonsense changes, and another (case 23) had 5 frameshift changes and no 
nonsense changes. Although apparently unusual, These frequencies were not 
significantly different from those observed in sporadic adenoma (p>0.1, exact 
binomial test).
Owing to the high frequency of frameshifts, these two patients (case 21 and 
case 23) were then screened for germline mutations in the MMR genes MLH1, 
MSH2, MSH6 and PMS2. Normal tissue was included from around the 
adenomas in this screen in case these individuals were mosaics. No pathogenic 
changes were found in any of the genes analysed.
A total of 12 (24%) K-ras mutations were detected in 51 MCRA tumours 
analysed; 10 mutations occurred at codon 12 and two mutations, at codon 13.
All of the changes - G12A, G12D, G12V and G13D - have been previously 
reported to occur frequently in sporadic adenomas and CRCs.
Nine of 85 (11%) MCRA adenomas analysed had a BRAF mutation V600E 
(all T>A); this is higher that would be expected in tubular adenomas without 
serrated morphology. See Figure 6-4  for examples of K-ras and BRAF 
mutations.
TG G T G G C G B T G G T G G C G A C  A G  T G  A A A D AC AG TG AAA
K -ras wt K-ras G12D G>A 
som atic  m utation
BRAF  wt
Figure 6-4 Examples o f K-ras and BRAF somatic mutations in MCRA cases
No tumour harboured both K-ras and BRAF mutations. The K-ras and BRAF 
mutation frequencies in the MCRA tumours were not significantly different 
from those in the sporadic adenomas (5/34 (p=0.58) and 5/40 (p=0.73) 
respectively, Fisher’s exact test).
6.3.5 Beta-catenin expression
The 57 MCRA tumours analysed for ^-c a ten in expression demonstrated 
increased nuclear expression when compared to the 27 sporadic adenomas 
analysed (p=0.0087, Wilcoxon test) (see Figure 6-5). There was, however, no 
significant difference in nuclear p-catenin expression between the MCRA 
group’s tumours and a set of 33 adenomas of similar size from 6 individuals 
with FAP (p=0.09, Wilcoxon test).
BRAF V600E T>C 
som atic  m utation
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Figure 6-5 P-catenin immunohistochemistry, (A) net membrane score (B) 
mean cytoplasmic score (C) mean nuclear score
Expression was also not significantly different between MCRA and sporadic 
adenomas in the cytoplasm (p=0.12, Wilcoxon test) or at the membrane 
(p=0.63, Wilcoxon test). Examples o f p-catenin expression in MCRA and 
sporadic adenomas can be seen in Figure 6-6.
Figure 6-6 p-catenin immunohistochemistry in MCRA (A) and sporadic (B) 
adenoma both xlOO, crypts demonstrating increased nuclear staining circled
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Logistic regression analysis incorporating the three sites of |3—catenin 
expression, adenoma size, degree o f dysplasia and patient age found increased 
nuclear expression to be the only significant variable which distinguished 
MCRA and sporadic tumours (p=0.017, OR=0.22, 95% Cl 0.065-0.76).
6.4 Discussion
6.4.1 No microadenomas were identified in MCRA cases
Historically, microadenomas have been said to be pathognomic of FAP. This 
study demonstrates that they also occur in AFAP and MAP. Given that FAP 
microadenomas have been found to harbour somatic mutations at APC  (see 
Chapter 9), it is likely that they are the earliest detectable lesion which has 
been “initiated” by “two hits” at APC  (germline plus somatic mutation for 
AFAP, or two somatic mutations in MAP).
The finding that the number and density o f microadenomas detected was 
highest in FAP followed by AFAP and finally MAP fits the “two hit” 
hypothesis o f microadenoma formation with the likelihood and speed at which 
“two hits” would occur in the FAP group being highest and lowest in the MAP 
group.
The absence o f microadenomas in the MCRA cases suggests that their cells 
are not acquiring “two hits” at APC  at an appreciably faster rate than the 
general population. The mechanism of tumour predisposition in the MCRA 
cases may therefore involve a stage of tumorigenesis that is post-initiation.
6.4.2 No definitive mutational signature was identified in the 
MCRA patients’ tumours
In the MCRA patients’ tumours, the total o f 51 truncating APC  mutations 
(Table 6-5) comprised 44 frameshifts (small insertions or deletions) and 7 
nonsense mutations (3 C:G>T:A transitions and 4 G:C>TA transversions). 
Although the proportion o f frameshift mutations was higher than in the APC 
mutation database (Laurent-Puig, Beroud et al. 1998) this may have resulted
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from detection bias in small, archival tumours, which were the only samples 
available from the patients studied. Decreased nonsense and missense 
mutation detection sensitivity in such samples has previously been observed 
(Groves, Lamlum et al. 2002). This is in part due to the poor quality of DNA 
extracted from paraffin embedded samples. The DNA is often “sheared” into 
smaller segments through the extraction process, resulting in fragments often 
only ~200bp in length.
In support of this contention, the excess of frameshifts in the MCRA tumours 
was very similar (p=0.44, Fisher’s exact test) to that in the sporadic adenomas, 
which had acquired 8 frameshift changes, plus one A:T>T:A transition and 
one G:C>T:A transversion. The APC  mutation spectrum in the MCRA 
tumours contrasted with the finding that all 25 truncating mutations in the 
MAP tumours were G:C>T:A transversions (p<0.001, Fisher’s exact test).
If the MCRA cases had, like MAP patients, a tendency to hypermutation of 
APC  in the gastrointestinal tract, it might be expected that a similar spectrum 
of disease to MAP or (A)FAP would occur. Therefore, it is likely that MCRA 
results either from hypermutation of APC  in the large bowel only, or from a 
distinct pathogenic mechanism that does not involve a tendency to inactivation 
of APC.
All changes in the tumours o f patients case 21 and case 23 occurred in a 
particular region o f the APC  gene, between the 2nd and 3rd 20-amino acid p- 
catenin binding and degradation repeats. Such a spectrum of mutations might 
be expected in patients with a germline APC  mutation before codon 1280 
(Albuquerque, Breukel et al. 2002) (Crabtree, Sieber et al. 2003) (Lamlum, 
Ilyas et al. 1999) or with a deficiency in MMR that did not manifest as MSI in 
adenomas (Wu, Berends et al. 1999).
In the MCRA patients, the K-ras mutations comprised 6 G:C>A:T, 5 
G:C:>T:A, and 1 G:C>C:G changes. This mutation spectrum overall was 
similar to that of the sporadic adenomas, which had 9 G:C>A:T, 3 G:C>T:A, 
and 2 T:A>A:T mutations (p=0.31, Fisher’s exact test). As in the case of APC, 
these K-ras mutation spectra contrasted with the sole change, G12C 
(G:C>T:A), found in MAP tumours. As might be expected, all of the BRAF 
mutations were T:A>A:T transitions resulting in the V600E change. No
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adenoma had both K-ras and BRAF mutations. There was no association 
between the presence o f APC  and K-ras or BRAF mutations.
Overall, these findings strongly suggested that there is no common mutational 
signature in the MCRA group o f patients, subject to the limitations of 
screening large genes, such as APC, in DNA of relatively low quantity and 
poor quality. Despite these difficulties, the difference from MAP was striking, 
once again suggesting that there is no specific tendency to hypermutation in 
this set of MCRA cases.
6.4.3 Nuclear Beta-catenin expression is increased in MCRA 
tumours
Unlike the other molecular analyses described in this chapter, p-catenin 
immunohistochemistry showed clear differences between MCRA and sporadic 
adenomas, with expression in MCRA tumours being similar to FAP. The 
greater Wnt activation in MCRA patients’ tumours was too consistent to be 
readily explained by the inclusion of one or two individuals with cryptic, as 
yet undetected, germline APC  or MYH mutations in the MCRA group. 
Allowing for the fact that colorectal microadenomas probably vary in their 
progression to macroscopic lesions (Crabtree, Tomlinson et al. 2001), this 
finding raises the possibility that increased Wnt activation in MCRA may lead 
to microadenoma development more rapidly, or with greater probability to 
progress to macroadenomas. Our studies to date (Lipton, Sieber et al. 2003) 
have not identified causal germline mutations in Wnt pathway genes in 
MCRA cases. However many Wnt related genes remain to be studied in 
MCRA cases such as the Wnt inhibitory factors Wif, Dickkopf-1 and Snail 1 
(Larriba, Valle et al. 2007).
Future work might include immunohistochemistry studies of the Wnt 
inhibitory factors W ifi and Dickkopfl in MCRA cases to determine whether 
their level of expression correlates with the increased nuclear expression of |3- 
catenin in MCRA cases.
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6.4.4 MCRA adenomas do not follow the “classical” pathway 
of tumorigenesis
All of the MCRA adenomas studied had tubular or tubulovillous morphology. 
It is therefore not surprising that the prevalence o f K-ras (24%) and BRAF 
(11 %) mutations detected were in keeping previous published data for these 
morphologies (Jass, Baker et al. 2006). In Jass’s study (Jass, Baker et al. 2006) 
comparison of K-ras and BRAF mutation rates alongside MGMT loss in a 
wide variety of polyps found K-ras mutations in 18% and BRAF mutations in 
5% of TAs <10mm (see Table 6-6 for summary modified from (Jass, Baker et 
al. 2006)). What is surprising is the higher incidence of BRAF mutations in the 
MCRA group none o f which demonstrated serrated morphology.
Table 6-6 Summary o f somatic K-ras and BRAF mutations and loss of 
expression of MGMT found in polyps o f differing histology. Modified from 
(Jass, Baker et al. 2006)
The absence of microadenomas in the MCRA group demonstrates that the 
initiation step of bi-allelic APC  mutation associated with the classical pathway 
of tumorigenesis does not occur.
One explanation which fits this dataset would support the “crossover” theory 
that sessile / serrated adenomas with predominantly BRAF mutations would 
later develop K-ras mutations rendering them more aggressive. A very small 
number of adenomas have been reported to harbour both K-ras and BRAF 
mutations (2% of a series o f 189 polyps studied) (Jass, Baker et al. 2006). No 
adenomas in this study harboured both mutations.
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It was not possible to screen for mutations in other known components o f the 
classical pathway of tumorigenesis (such as p53) due to limited amounts of 
DNA extracted from paraffin embedded tissue.
6.4.5 Limitations of this study
One of the main limitations o f this study was the availability and access to 
high quality (and quantity) o f DNA for analysis in all groups undergoing 
analysis. This was because the majority of samples were paraffin embedded 
tumour blocks.
Following the finding of increased nuclear expression o f p-catenin in the 
MCRA group, I would have wanted to proceed to screen the MCRA cases for 
other Wnt related factors such as the Wnt inhibitory factors should DNA have 
been available.
Examination for loss o f MGMT expression would have helped to support / 
disprove the suggestion that “crossover” may occur from the serrated to the 
classical pathways in the MCRA group.
6.5 Conclusions
To date, Mendelian colorectal cancer syndromes can be categorised in two 
ways. First, the primary predisposition may be to polyps or to carcinoma. 
Second, the primary defect may be in either a ‘gatekeeper gene’ (such as APC, 
LKB1, SMAD4/MADH4 and ALK3/BMPR1A) or a caretaker/DNA repair gene 
(such as the MMR loci and MYH/MUTYH). The MCRA cases studied with no 
germline APC  or MYH mutations are likely a priori to have a strong genetic 
predisposition, given the phenotypic similarity to MAP and AFAP.
In the MCRA cases, multi-generational inheritance o f multiple adenomas was 
not found, suggesting recessive — or, perhaps, multi-locus - inheritance.
Several possible explanations for the MCRA phenotype exist, and these 
patients may be a heterogeneous group.
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The similar frequencies o f changes at APC , K-ras and BRAF in MCRA and 
sporadic cases suggest that the genetic pathways o f tumorigenesis overlap, at 
least with regards to these three genes.
The differences in mutation spectra observed between MAP and AFAP 
reinforce the likelihood that hypermutation of APC  and/or K-ras does not 
drive tumorigenesis in this set o f MCRA patients, particularly as the incidence 
of K-ras mutation is lower in MCRA group than both MAP and AFAP 
adenomas.
The most significant finding separating the MCRA and sporadic groups in 
terms of their molecular profiling was the increased nuclear expression of j3- 
catenin.
Somatic mutation frequencies and spectra in MCRA adenomas were found 
that are very similar to comparable sporadic lesions, and distinct from AFAP 
and, especially, MAP. No microadenomas were found in the MCRA patients’ 
colons. These results suggest that hypermutation of APC does not cause the 
MCRA patients’ disease and indeed does not initiate the disease suggesting 
they do not follow the classical pathway of tumorigenesis. This strongly 
suggests that MAP is not a paradigm for the remaining MCRA patients. One 
possibility may be that those few microadenomas which do occur 
spontaneously in MCRA cases have an increased chance o f progressing to a 
macroadenoma. Another possibility is that o f “crossover” between the serrated 
and classical pathways o f tumorigenesis. This model is supported by the 
immunohistochemical analysis o f p-catenin expression in this study. If this is 
the case, it seems unlikely that the predisposition gene is a ‘gatekeeper’ type 
of tumour suppressor (since MCRA disease seems to be isolated or recessive), 
or a ‘caretaker’ (since no evidence o f a specific DNA repair defect was 
found). It could be suggested that these data best fit a modified ‘landscaper’ 
model of tumorigenesis in which the intra-cellular or extra-cellular 
microenvironment o f cells is altered to favour tumour progression from 
microadenoma to macroadenoma.
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7 Lymphoblastoid cell line expression array
analysis of MCRA cases
7.1 Introduction
To date it has proven very difficult to identify novel predisposition genes in 
the MRCA phenotype. This is in part due to the fact that some o f these cases 
are inherited recessively making traditional linkage analysis harder, and also 
due the likelihood that these cases may be due to inheritance o f mutated genes 
which are o f moderate or low penetrance.
When considering “isolated” or possibly recessive cases in the MCRA group 
one approach which could identify homozygous or compound heterozygous 
mutations is comparison o f mRNA transcripts isolated from lymphoblastoid 
cell line DNA in MCRA cases and normal controls. The differences in 
expression profiles would highlight genes and biological pathways affected by 
inherited germline mutations if  these genes had a profound effect on transcript 
levels.
During cellular replication, mutant mRNA transcripts (where an error in 
replication may have occurred or a correct transcript from a mutated germline 
gene has occurred) are destroyed by a process called nonsense-mediated decay 
NMD, therefore maintaining the integrity cellular replication. The nonsense 
RNA transcripts most commonly arise from nonsense or frameshift mutations 
creating premature translation termination codons (PTC).NMD is activated 
when mulit-protein exon junction complexes (EJC) assemble around aberrant 
exon/exon junctions following the first round of DNA synthesis in cellular 
replication (Ishigaki, Li et al. 2001). The EJCs are removed from spliced 
mRNA during the translation step when mRNA passes through the ribosome. 
This mechanism works for any PTC located more than 50 nucleotides 
upstream if the last exon/exon junction. The unremoved EJCs found 
downstream of the PTC recruit the Upf protein complex subsequently 
initiating the degradation of the PTC containing transcript (Holbrook, Neu- 
Yilik et al. 2004). NMD is therefore an mRNA surveillance mechanism which
prevents the production o f truncated proteins. If putative MCRA pre­
disposition genes are inherited recessively, bi-allelic nonsense mutations could 
trigger NMD and subsequent loss o f expression (if the gene of interest is 
expressed in lymphocytes).
Analysis o f gene expression is viewed by some as the determination o f a more 
refined phenotype as it is a measure o f phenotypic variance at a molecular 
level (Monks, Leonardson et al. 2004). Each gene-expression phenotype can 
provide annotation, pathway and genome location data. In isolated or 
recessive diseases such as the MCRA phenotype this approach could 
potentially identify not only quantitative trait loci, but also identify subsequent 
genes, pathways and biological processes under the influence of such loci.
Jansen and Nap first described the use of expression profiling in separating 
populations (Jansen and Nap 2001). Soon after, differences in expression were 
observed between sexes in Drosophila melanogaster (Jin, Riley et al. 2001) 
which has since been observed in the study of human lymphoblastyoid cell 
lines (Zhang, Bleibel et al. 2007). In Zhang’s study, differences in expression 
between the sexes were observed in pathways involving adherens junctions 
and cytokine-cytokine receptor interaction (based on KEGG (Kyoto 
Encyclopaedia of Genes and Genomes) analysis).
Differences in lymphoblastoid cell line mRNA expression between different 
ethnic populations has also been observed. A study of lymphoblastoid cell line 
expression from the full set o f European and African HapMap samples found 
differing expression in biological processes such as ribosome biogenesis and 
antimicrobial humeral response were found in the 383 transcript clusters found 
between the two populations (Zhang, Duan et al. 2008).
Differences in expression can be also observed if  culturing conditions vary -  if 
the cell line is “stressed” (cultured for too long or cells not split / fed at the 
same time intervals).
In light of these findings, differences in expression between different 
populations, sexes and culture conditions were taken in to account on design 
of this study.
193
A previous study of lymphoblastoid cell lines from autistic cases (another 
heterogenous condition) and control samples demonstrated differences in 
expression profiling between cases and controls (Nishimura, Martin et al. 
2007). Nishimura et al used expression microarray analysis to successfully 
identify differences in mRNA expression profile in lymphoblastoid cells from 
males with autism with known underlying germline mutations (fragile X 
mutation (FMR1-FM), or a 15q 11-ql 3 duplication (dup(15q)), and non- 
autistic controls. I used this data as proof of principle for this study.
For this study I chose the “best” MCRA cases from my cohort, ie those 
individuals with the largest number of adenomas present at the youngest age.
7.1.1 Aims of this chapter
The aim of this study was to identify any differences in mRNA expression 
profiling in MCRA “cases” and normal “controls”. These differences could 
help to identify underlying genetic defects or biological pathways (as a 
secondary aim) affected by an underlying mutated predisposition gene.
7.2 Methods
Patient samples
Venous blood was collected from eleven MCRA patients and 5 controls after 
obtaining informed consent.
Expression array analysis
Eleven MCRA and five control lymphoblastoid cell lines were produced from 
peripheral venous blood samples obtained with prior consent -  see Methods 
(2 . 1.2 . 1).
A total o f ~ 9 x 106 lymphoblastoid cells were seeded in a 150ml falcon 
culture flask (Falcon) and then incubated at 37°C in 10% CO2 for 72 hours -
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see Methods (2.1.9.1-3). mRNA was then extracted from healthy cell lines 
cultured in identical conditions -  see Methods (2.1.2.1). RNA quality and 
quantity was then analysed on the Agilent 2100 Bioanalyser (Agilent, Santa 
Clara, CA, USA).
Complementary RNA ((cRNA) - following synthesis o f cDNA) was 
hybridised to Affymetrix GeneChip® Human Genome U133 Plus 2.0 
Expression Micro-arrays -  see Methods (2.1.10). The U133 Plus 2.0 array 
comprises 54,000 probe sets covering 47,000 transcripts from 38,000 
characterised human genes. All the probe sets are duplicated across the array. 
Oligonucleotide probes (25-mer) complimentary to each sequence are 
synthesised in situ on the array. Eleven pairs of probes are used to measure the 
level of transcription o f each sequence represented on the array. Each array 
includes control sequences covering hybridisation quality, poly-A controls, 
normalization (determination o f consistency of expression) and 
housekeeping/control genes (GAPDH, beta-Actin, ISGF-3 (STAT1). See 
Affymetrix website for further details
http:// www. affymetrix. com/products/array s/specifi c/hgu 133. affx.
Statistical analysis
Statistical analysis and identification o f genes with a significant >3-fold 
change in expression was undertaken using the statistical package R with 
individual programs written for data analysis by the bioinformatics department 
at Cancer Research UK, London Research Institute (P. East).
Probe level intensities were quantile normalised and probeset level signal 
intensity estimates calculated using RMA (Irizarry, Bolstad et al. 2003). A 
linear model was fitted to the data and differential genes between the MCRA 
and control groups were selected using a 0.05 FDR (false discovery rate) 
threshold. T-statistics were moderated prior to differential gene identification 
using an empirical Bayes method to converge probeset sample variances to a 
common value (Smyth 2004). Genes were further filtered using a 5-fold 
threshold. These genes are represented in a heatmap in the Results section. 
The analysis was carried out using the limma package from Bioconductor 2.2. 
(Gentleman, Carey et al. 2004). Reported annotation is from the hgul33plus2 
Bioconductor annotation package.
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Scatter and volcano plots were produced to confirm the quality o f the 
experiment and robustness o f the data. Heirarchical clustering using 
Spearman’s rank correlation with average linkage clustering was then 
performed.
Finally, functional annotation clustering was then performed using DAVID 
KEGG and GO analysis. DAVID (Database for Annotation Visualisation and 
Integrated Discovery) is a clustering algorithm based on the hypothesis that 
similar annotations should have similar gene members from different 
biological pathways (Dennis, Sherman et al. 2003). KEGG is an integrated 
bioinformatics resource which combines information from three databases 
incorporating genomic, chemical and network information (Kaneshisa M 
2004). The GO (Gene Ontology) project provides a systematic description of 
attributes o f genes (and gene products) in three domains shared across all 
organisms, molecular function, biological process and cellular component 
(Ashbumer, Ball et al. 2000).
7.3 Results
7.3.1 Expression micro-array analysis
Patient Demographics
MCRA cases were aged between 28 and 69 years (median 52 years) Adenoma 
burden ranged from 17 to 100 (median 23 adenomas) see Table 7-1. Two 
cases were diagnosed with CRC (case 6 at 67 years and case 9 at 59 years). 
CRC was present in 1st degree relatives o f two cases (case 8 at 85 years and 
case 11 at 60 years). All cases were o f white European origin. Germline APC 
and MYH mutations were excluded prior to inclusion in the study. The control 
set were o f similar age range and ethnic background.
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P t ID A ge D iag n o sis No A ds CRC FH CRC Cell line
1 28 100 N no JUM0287/CORGI/03/MPG
2 69 34 N no EIG0294/CORGI/03/MPG
3 67 27 N no JOH0326/CRMA/03/MPG
4 51 26 N no WIA0324/CRMA/03/MPG
5 52 26 N no FRL0237/CRMA/01/MPG
6 68 23 Y - 67 yrs no LEM0323/CRMA/03/MPG
7 51 21 N M - CRC 85 yrs ANH0207/CRMA/01/MPG
8 61 19 N no TER0297/CORGI/03/MPG
9 50 18 Y - 50 Yrs no STM0315/CRM A/03/M PG
10 50 17 N M - CRC 60 yrs QUB0320/CRMA/03/MPG
11 55 17 N no WIM0313/CRMA/03/MPG
Table 7-1 Patient demographics o f MCRA cases studied
Fold changes o f  mRNA detected in MCRA cases and controls
Overall, 1059 probes representing 881 genes were identified with a FDR 
threshold o f 0.05. The percentage o f “present” calls across all the probesets for 
cases and controls were similar (cases range 36.1 -  47.4, median 43.3; 
controls range32.5 -  46.7, median 43.7).
Transcripts representing 61 genes were expressed with a greater than 3-fold 
difference compared to controls and with a p value of <0.01. See Table 7-2  
for list o f genes with >3 fold change. See Appendix 3 for case-by-case results.
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Gene Symbol Absolute fold Map Gene
RGS13 7.682 1q31.2 regulator of G-protein siqnallinq 13
APP 5.752 21q21 .2;21q2 amyloid beta (A4) precursor protein
IGF2BP3 5.495 7p11 insulin-like growth factor 2 mRNA bindinq protein 3
FAM111B 5.336 11 ql 2.1 family with sequence similarity 111, member B
VSIG9 5.153 3q1 3.31 V-set and immunoqlobulin domain containing 9
SLC39A10 4.775 2q32.3 solute carrier family 39 (zinc transporter), member 10
GRK5 4.435 10q24-qter G protein-coupled receptor kinase 5
DAPP1 4.421 4q25-q27 dual adaptor of phosphotyrosine and 3-phosphoinositides
NC0A6IP 4.296 8q11 nuclear receptor coactivator 6 interacting protein
LM07 4.276 1 3q22.2 LIM domain 7
ZNF83 4.225 19q1 3.3 zinc finger protein 83
ZWILCH 4.148 1 5q22.31 Zwilch, kinetochore associated, homoloq (Drosophila)
RBM25 4.137 14q24.3 RNA binding motif protein 25
TPR 4.13 1 q25 translocated promoter reqion (to activated MET oncogene)
LYAR 4.106 4p16.2 NA
IL6ST 4.094 5q11 interleukin 6 signal transducer (qp130, oncostatin M receptor)
P0LE2 3.938 14q21-q22 polymerase (DNA directed), epsilon 2 (p59 subunit)
FAM111B 3.904 11 ql 2.1 family with sequence similarity 111, member B
CYCS 3.886 7p1 5.2 cytochrome c, somatic
C1orf79 3.722 1 p35.3 chromosome 1 open reading frame 79
NA 3.72 NA NA
SYNE2 3.716 14q23.2 spectrin repeat containing, nuclear envelope 2
CASC5 3.702 1 5q14 cancer susceptibility candidate 5
PITPNC1 3.699 17q24.2 phosphatidylinositol transfer protein, cytoplasmic 1
CD74 3.695 5q32 CD74 molecule, major histocompatibility complex
DUT 3.679 1 5q1 5-q21.1 dUTP pyrophosphatase
PON 2 3.66 7q21.3 paraoxonase 2
CCNE2 3.624 8q22.1 cyclin E2
CDC42BPA 3.624 1q42.11 CDC42 binding protein kinase alpha (DMPK-like)
MLF1IP 3.621 4q35.1 MLF1 interacting protein
HNRPDL 3.599 4q13-q21 heteroqeneous nuclear ribonucleoprotein D-like
CCNE2 3.596 8q22.1 cyclin E2
DDX46 3.58 5q31.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46
POGK 3.534 1q24.1 poqo transposable element with KRAB domain
GDAP1 3.517 8q21.11 qanqlioside-induced differentiation-associated protein 1
HDGFRP3 3.458 15q11.2 NA
UBD 3.432 6p21.3 ubiquitin D
HELLS 3.4 10q24.2 helicase, lymphoid-specific
WBP5 3.371 Xq22.1-q22.2 WW domain binding protein 5
CDC6 3.37 17q21.3 CDC6 cell division cycle 6 homolog (S. cerevisiae)
APP 3.366 21q21.2;21q2 amyloid beta (A4) precursor protein
RGS13 3.359 1 q31.2 requlator of G-protein signalling 13
ANKRD44 3.334 2q33.1 ankyrin repeat domain 44
SCML1 3.315 Xp22.2-p22.1 sex comb on midleq-like 1 (Drosophila)
MCM4 3.289 8q11.2 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
C21orf71 3.281 NA chromosome 21 open reading frame 71
TFAM 3.274 10q21 transcription factor A, mitochondrial
FMNL2 3.258 2q23.3 formin-like 2
UHRF1 3.235 19p1 3.3 ubiquitin-like, containing PHD and RING finger domains, 1
RNF36 3.211 1 5q21.1 rinq finqer protein 36
NASP 3.2 1 p34.1 nuclear autoantiqenic sperm protein (histone-binding)
NA 3.151 NA NA
TNFRSF7 3.123 12p13 tumor necrosis factor receptor superfamily, member 7
MCM10 3.118 10p13 MCM10 minichromosome maintenance deficient 10 (S. cerevisiae)
HLA-E 3.117 6p21.3 major histocompatibility complex, class 1, E
UTP20 3.101 12q23 UTP20, small subunit (SSU) processome component, homolog (yeast)
PAK1IP1 3.086 6p24.2 PAK1 interactinq protein 1
FUS 3.077 16p11.2 fusion (involved in t(12;16) in malignant liposarcoma)
HELLS 3.071 10q24.2 helicase, lymphoid-specific
GPATC4 3.046 1q22 G patch domain containing 4
FUT4 3.039 11 q21 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
MCM4 3.025 8q11.2 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
PCBP2 3.019 I2q13.12-q13 polv(rC) binding protein 2
ZNF718 3.01 4p16.3 zinc finqer protein 718
Table 7-2 Genes with > 3-fold change in expression when compared to 
controls with associated p value <0.01
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No evidence of chromosomal loci o f potential loss or gain were identified 
when fold changes were noted along the whole genome from chromosome lp 
to 22q both with either pooled data for the MCRA cases or on a case-by-case 
basis. This aim of this analysis was to identify any gross chromosomal losses 
or gains leading to altered gene expression, however the likelihood of there 
being this type of change is low.
Individual cases were then reviewed noting genes of interest with markedly 
over or under-expressed genes. See Appendix 3 for individual case results.
The following genes of interest were over-expressed on an individual case 
basis PLAGL1 (pleomorphic adenoma gene like 1, 4.77x over-expressed in 
case 1), PTEN (phosphatase and tensin homologue, 6.09x over-expressed in 
case 6), PERP (TP53 apoptosis effector, 6.8lx  over-expressed in case 9), 
RAB31 (RAS oncogene family member 4.76x over-expressed in case 9) and 
TNFRSF19 (tumour necrosis factor receptor superfamily member 19, 9.03x 
over-expressed in case 11). EphrinBl was under-expressed (5.26x) in case 9.
CXCR4, DUT and POLE2 were under-expressed (> 3 fold) in several cell lines 
and were taken forward for further study as candidate genes in the following 
Chapter. See Table 7-3 for overview of fold changes across the 11 cases 
studied.
Pt ID No Ads Gene
CXCR4 probe 1 CXCR4 probe 2 DUT POLE2
1 100 1.82 2.70 3 .8 4 2.27
2 34 2.94 2.70 5 .8 9 5 .8 8
3 27 0.80 0.53 2.04 1.82
4 26 2.78 5 .0 0 1.58 2.56
5 26 2.00 1.22 2.19 3 .0 0
6 23 4 . 3 5 3 .7 0 1.74 2.43
7 21 0.45 0.45 3 .7 9 2.92
8 19 3 . 2 3 1.37 2.03 2.89
9 18 3 . 1 3 2.32 3 .0 8 3 .33
10 17 3 .0 3 3 .4 5 2.11 3 .0 0
11 17 1.28 1.61 4 .5 8 5 .0 0
Table 7-3 Overview of fold changes across all cell lines in CXCR4, DUT and 
POLE2, dark pink - > 3fold change, light pink — 3 fold change
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Heat maps o f cases and controls
The heatmap below (Figure 7-1) shows the differential genes identified 
between the multiple adenoma and control groups using a 0.1 FDR threshold. 
Genes were further filtered using a >2 fold filter. Each multiple adenoma case 
probeset value has seen scaled to the probeset median across all samples. The 
magnitude o f differential expression is represented on a log2 scale (-4 to 4). 
The cases and controls cluster separately across the heatmap when filtered 
using a >2 fold filter.
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Figure 7-1 Heatmap of MCRA cases and controls demonstrating difference in 
expression in MCRA cases and controls when compared to the median
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Volcano plot
The Volcano plot arranges gene transcriptions studied according to their 
biological and statistical significance. The x-axis (log scale) demonstrates the 
fold change between the two groups The y-axis represents the p-value for each 
t-test of differences between samples (on a negative log scale).
See Figure 7-2 for volcano plot of cases (p) versus controls (c) for the 11 
cases and 5 controls studied. The dots in red represent the transcripts with a 
statistically significant fold change (>3 with a FDR of 0.05 or smaller) when 
comparing the MCRA cases (p) and controls (c).
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Figure 7-2 Volcano plot of MCRA cases (p) versus controls (c), the red dots 
represent the trancripts which are expressed in cases but not controls with > 3 
fold change and FDR <0.05
Comparison PvsC
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Scatter plot
The scatter plot (Figure 7-3) plots gene transcripts of cases against controls 
according to the fold change and the associated statistical significance of the 
observed change. The plot o f the MCRA cases against controls is 
symmetrical- demonstrating a “good” experiment
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Figure 7-3 Scatter plot o f MCRA cases versus controls, transcripts plotted 
according to fold change and associated statistical significance of fold change.
Cluster dendrogram
The cluster dendrogram demonstrates unequivocal hierarchical clustering 
between the MCRA cases and control samples analysed (Figure 7-4). With 
the exception of one MCRA sample and one control sample (clustered 
together on the right of the figure) all o f the remaining MCRA cases and 
control cluster separately indicating similarities of gene expression within the 
groups and differing expression between the groups.
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Figure 7 -4  Cluster dendrogram demonstrating hierarchical clustering between 
MCRA cases and controls
Functional annotation and pathway analysis
No significant biological pathways were disrupted by the loss o f multiple 
genes when using DAVID, KEGG and GO tools of analysis.
7.4 Discussion
Overall, this experimental approach enabled the identification under-expressed 
transcripts in MCRA cases when compared to the expression profile of 
controls. However, one o f the most significant difficulties encountered with
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this approach is the interpretation o f the “missed” or “absent” probe calls. 
Despite the call rate across the cases and controls being equal and of a similar 
standard to other groups (Nishimura, Martin et al. 2007) the fact that a probe 
may have an “absent” call could indicate that the particular gene which it 
represents is not expressed by lymphocytes. In this study, results from every 
probe in the MCRA cases and controls (whether “absent” or not) were 
included in the statistical analysis.
7.4.1 Transcripts chosen for further study
The following transcripts were chosen for further study based on their fold 
change (across all cases) and relevance o f their function in tumorigenesis. All 
were under expressed suggesting a loss o f function.
CXCR4 is the chemokine receptor for stromal cell-derived factor-la (SDF- 
la ). It is a seven-transmembrane receptor G protein coupled receptor and is 
known to be a co-receptor for HIV (Feng, Broder et al. 1996). In haemopoetic 
cells, it has been demonstrated that c-kit and CXCR4 interact to provide 
homing to the bone marrow. CXCR4 has also been shown to have a role in 
migration and metastasis o f solid tumours such as breast, ovarian and small 
cell lung cancer (Muller, Homey et al. 2001) (Scotton, Wilson et al. 2001; 
Kijima, Maulik et al. 2002), reviewed in (Zlotnik 2008). 
dUTP phosphatase (DUT), is a DNA repair gene which prevents mis- 
incorporation o f uracil residues in to DNA during replication. In all known 
organisms uracil is not a native component o f DNA. It can however become 
incorporated in to DNA through spontaneous deamination o f cytosine residues 
or through dUTP utilisation by DNA polymerases during replication (Lindahl 
1993). As cytosine deamination can lead to G:C >A:T transversions, a BER 
repair mechanism has evolved to remove and correct mis-incorporated uracil 
(Lindahl 1982). To prevent dUTP utilisation during DNA replication, DUT 
hydrolyses dUTP to yield dUMP and PPi. This reaction effectively removes 
dUTP from the DNA biosynthetic pathway and provides a substrate (dUMP) 
for de novo synthesis o f thymidylate.
POLE2 (DNA polymerase), pol e B-subunit 2 (p59 subunit) is a replicative 
DNA polymerase which forms a central component in DNA replication,
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repair, recombination and cell cycle control (Hubscher, Nasheuer et al. 2000). 
The DNA polymerase family are multi-subunit enzymes which are up- 
regulated by mitogenic activators. The organisation and induction of the 
POLE2 promoter is similar to the promoter o f cyclin D l (Watanabe, Albanese 
et al. 1998).
To date, no direct link between POLE2 mutations and mammalian 
tumorigenesis have bene observed. However its role in DNA replication and 
repair make it a promising candidate gene to pursue.
7.4.2 Limitations of lymphoblastoid cell line work
Despite working within strict limits to prevent differences in culturing 
conditions, there will always be some differences of the exact conditions that 
each cell line studied was exposed to resulting in observed differences in 
expression. The analysis o f the MCRA cases, both combined and on an 
individual basis, would have highlighted any gross differences in expression 
between cases.
In the cell lines used in this study NMD would theoretically have removed 
many o f the truncated (mutated) transcripts which may have led to the 
identification o f novel germline predisposition genes. In this scenario however 
a fold change (down-regulation) would have been observed. The three 
candidate genes chosen for further study were all down-regulated suggesting 
either an upstream inhibition of transcription or degradation of mutated 
transcripts. It is possible to inhibit mRNA translation and subsequently NMD, 
exploitation o f this could be a useful tool to study lymphoblastoid cell line 
mRNA expression further -  see future work.
When considering changes o f expression, it is difficult in this situation to 
determine where in a biological pathway the initiating mutation has occurred 
to cause the observed effect. It would have been expected that KEGG, DAVID 
and GO analysis would identify any biological or biochemical pathways 
which were grossly affected by an underlying mutation.
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7.4.3 Future work
1: Confirmation o f  fold changes observed
i) Real-time PCR analysis (qRT-PCR) is a useful tool which could be used to 
determine functional levels o f proteins whose expression array levels were 
altered. qRT-PCR of the candidate genes chosen and of those transcripts with 
a more than >3 fold change o f expression would help to identify functional 
changes in expression.
ii) Immunohistochemistry (IHC) o f the protein products o f down-regulated 
transcripts in GI mucosa (if  expressed there and if probes available) would 
confirm any changes at a tissue level.
2: Inhibition o f  NMD to identify mutated transcripts
Several research groups have utilised the inhibition of NMD to identify genes 
carrying nonsense / frameshift mutations. This strategy is termed GINI (gene 
identification by NMD inhibition) and to date has been used successfully in 
colorectal cancer cell lines and prostate cancer cell lines (Ionov, Nowak et al. 
2004) (Huusko, Ponciano-Jackson et al. 2004) (Rossi, Hawthorn et al. 2005). 
A limitation o f earlier studies utilising inhibition o f NMD was that emetine 
(used to inhibit translation) was a strong inducer o f a stress response in the cell 
lines being studied, therefore causing many genes to be up and down 
regulated. This has been overcome in part by the addition of caffeine to 
culturing media (GINI2) (Ivanov, Lo et al. 2007). GINI has not yet been used 
successfully in lymphoblastoid cell lines to identify mutations in constitutional 
DNA.
One approach would be to culture lymphoblastoid cell lines from MCRA 
cases and controls both with and without inhibition of NMD decay. 
Expression array analysis o f these cell lines when compared both with and 
without inhibition o f NMD would identify transcripts which are down- 
regulated due to a constitutional DNA mutation rather than an error in 
replication.
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3: Whole genome sequencing o f  selected MCRA cases
Whole genome sequencing has emerged as a realistic experimental approach 
over the last 2 years (Bentley 2006). This approach which is now available 
through Illumina (Solexa) allows analysis o f the whole genome. It is based on 
parallel sequencing o f millions o f fragments using reversible terminator-based 
sequencing.
See - http://www.illumina.com/sequencing/Technology.ilmn.
Whole genome (or candidate gene region) sequencing of carefully selected 
MCRA cases would enable identification o f constitutional mutations (with the 
caveat that they would be found in the 99% of the human genome re­
sequenced with Solexa).
7.5 Conclusions
Expression array analysis o f 11 MCRA cases and 5 controls identified 3 
candidate genes CXCR4, DUT  and POLE2 which were all under-expressed >3 
fold in the majority o f MCRA cases studied. These candidate genes were then 
taken forward to study further in the following Chapter.
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8 Candidate gene screening in MRCA cases
8.1 Introduction
Candidate gene screens are a useful tool for identification o f novel predisposition 
genes. When considering the MCRA phenotype, genes involved in DNA repair 
and Wnt signalling are the most obvious point at which to start. Cell cycle 
checkpoint genes and regulators o f apoptosis are a priori good candidates for any 
tumour type.
To date, one study has screened candidate genes from the Wnt signalling and 
TGF-fi pathways in the MCRA phenotype (Lipton, Sieber et al. 2003). Lipton et 
al screened 47 MCRA cases (with APC  and MYH mutations excluded) for 
germline mutations in APC2 , conductin and GSK3f5 from the Wnt signalling 
pathway and SMAD4 and BMPR1A from the TGF-p pathway. One patient was 
found to have a putative pathogenic mutation in BMPR1A (3 bp del nt 1079-81, 
resulting in loss o f histidine residue) with no mutations found in the other genes 
screened.
The data presented in Chapter 6 suggests that Wnt signalling is disrupted in 
MCRA cases as a statistically significant increase in nuclear P-catenin was 
observed. Therefore genes (including regulatory genes) in the Wnt signalling 
pathway warrant further study.
A series of candidate genes was selected for further study on the basis of the 
results from Chapters 6 and 7 and from evidence found in current literature.
Table 8-1 provides an overview o f the genes studied and the rationale for their 
selection.
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Candidate Gena Function Reason for selection
OGG1 DNA repair BER M ember of BER family, following discovery of MYH
MTH1 DNA repair BER M ember of BER family, following discovery olM YH
TDG DNA repair BER Evidence of link with BER
MSH6 DNA repair MMR Known interaction with MYH, and evidence of mutations in CRC
PM S2 DNA repair MMR Homozygous germline mutation identified in patient with multiple CRC primaries
MGMT DNA repair Through literature search
MBD4 DNA repair Through literature search
POLE2 DNA repair Expression array work - Chapter 5
DUT DNA repair Expression array work - Chapter 5
CXCR4 DNA repair Expression array work - C hapter 5
WH1 Wnt signalling Evidence of increased nuclear expression of B-cat - Chapter 4
DKK1 Wnt signalling Evidence of increased nuclear expression of B-cat - Chapter 4
Ephrin B2 Wnt signalling Evidence of increased nuclear expression of B-cat - Chapter 4
EphB2 germline mutation idenitifed in HPP case  and selected Finnish CRC cases
CDC4 Cell cycle control Evidence of mutation in CRC
BLM DNA helicase acivity Ashkenazi CRC link, role in genomic instability
Table 8-1 Candidate genes chosen for study in MCRA cases
8.1.1 Selection of candidate genes
DNA repair genes
Base excision repair genes - OGGI, MTH1, TDG
Following the discovery o f MAP (Al-Tassan, Chmiel et al. 2002) (Sieber, Lipton 
et al. 2003), it is possible that disruption o f other BER genes may predispose to 
MCRA development, particularly as there is functional overlap and redundancy 
within the BER system.
Somatic mutations in OGGI have previously been reported in several human 
cancers including gastric, colorectal, lung, renal and leukaemia (Shinmura, Kohno 
et al. 1998) (Park, Choi et al. 2001) (Audebert, Chevillard et al. 2000) (Hyun, 
Choi et al. 2000). More recently the Korean germline OGGI polymorphisms 
R154H and S326C have been identified in sporadic CRC patients (Kim, Ku et al. 
2004) and multiple adenoma cases (Kim, Ka et al. 2007) respectively.
To date, no published polymorphisms or somatic mutations in MTH1 have been 
identified in human cancers, but as a pivotal member o f the BER family it 
warrants further study in MCRA and CRC cases.
Thymidine-DNA glycosylase (TDG) initiates repair o f G>T and G>U mismatches 
(which are commonly associated with CpG islands) by removing thymine and
210
uracil moieties. A recent study found a novel heterozygous germline missense 
mutation (ntA196G, R66G) in 1/94 familial CRC cases and 0/188 controls 
(Broderick, Bagratuni et al. 2006). The variant was identified in a 66 year old 
male with rectal cancer; the patient’s sister died o f CRC at 47. A previously 
identified polymorphism (V367M) was identifed in 1 case and three intronic 
variants were also identified (A166+12G, G167-9A and G167-19C).
Mismatch repair enzymes -  MSH6, PMS2
The MMR and BER DNA repair mechanisms interact through an MSH6 binding 
site present on MYH, therefore preventing deleterious double strand breaks. 
Germline MSH6 mutations account for <5% o f HNPCC cases (Plaschke, Engel et 
al. 2004), these cases have later onset and lower incidence of CRC when 
compared to MLH1 and MSH2 mutation carriers. The MSH6 promoter 
polymorphism 159C>T has also been associated with an increased risk of CRC in 
a study o f 929 CRC cases and 1098 controls (Mrkonjic, Raptis et al. 2007). 
Niessen et al found a higher incidence of heterozygous MYH carriers in 
individuals with missense MMR mutations (4/36 also harbouring MSH6 
mutations) (Niessen, Sijmons et al. 2006). This was further supported by the 
observation o f both MSH6 and MYH mutations in a large branch o f a Dutch 
HNPCC family where 19 family members carried either heterozygous or 
compound heterozygous MYH mutations alongside MSH6 mutations the 
phenotype o f these individuals was more representative o f HNPCC with evidence 
of MSI and an under-representation of G>T transversions (van Puijenbroek, 
Nielsen et al. 2007). In light o f this it was hypothesised that heterozygous MYH 
mutations may act as phenotypical modifiers of HNPCC. The German HNPCC 
consortium investigated this hypothesis further and found no real association 
between MSH6 mutation carriers and MYH inheritance (Steinke, Rahner et al. 
2008). This study found the MYH carrier rate to be similar to the healthy control 
population when 64 MSH6 mutation carriers were screened for MYH 2/64 (3.1%) 
harboured both MSH6 and heterozygous MYH mutations.
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A Danish HNPCC family presenting with CRC and adenomas at 18 years of age 
was found to have mutations in both MSH6 (S612X and R1076C) and APC 
(G2502S). Immunohistochemistry for MSH6 and fi-catenin found lack of 
expression of MSH6 alongside increased nuclear accumulation of fi-catemn 
indicating a phenotypic influence o f both the underlying mutations (Okkels, 
Sunde et al. 2006).
Therefore the role of MSH6 in both MCRA and CRC development (outside 
HNPCC diagnosis) is unclear, germline mutations may play some part in the 
development o f MCRAs.
Homozygous deletion o f PMS2, another MMR gene, in the germline has been 
found to cause a severe CRC phenotype in an individual o f Indian descent with 
parental consanguinity. This individual presented at 23 years with 10 synchronous 
colorectal primaries and 35 adenomas, at 25 years he was found to have duodenal 
adenocarcinoma, he also had dysmorphic features, mental retardation and cafe-au- 
lait spots (Will, Carvajal-Carmona et al. 2007). As this individual harboured 
multiple colorectal adenomas, PMS2 warranted further investigation as a possible 
MCRA predisposition gene.
Other DNA repair enzymes - MGMT, MBD4, POLE2, DUT, CXCR4 
0 6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene which 
removes deleterious 0 6-methylguanine residues from DNA. MGMT loss of 
function results in increased accumulation o f 0 6-methylguanine promoting 
tumorigenesis through G:C > A:T transversions in growth related genes such as 
K-ras and p53 (Esteller, Toyota et al. 2000) (Esteller, Risques et al. 2001). 
Methylation o f MGMT can identify a subset of CRC cases with low-level 
microsatellite instability (Whitehall, Walsh et al. 2001). There is increasing 
evidence to support a role o f increasing levels in MGMT methylation in 
progression from normal colonic epithelia through the adenoma-carcinoma 
sequence (Nagasaka, Goel et al. 2008). Somatic mutations in MGMT have also 
been identified in fresh frozen CRC tissue and CRC cell lines. Six of 113 CRCs 
studied by Halford et al harboured somatic mutations. These tumours
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demonstrated defective MGMT function with G:C>A:T transversions being found 
at other loci such as K-ras and p53 (Halford, Rowan et al. 2005). Furthermore, 
MGMT expression was decreased or lost in over half of the CRCs studied and 
may therefore have a role in MCRA development.
MBD4 is known to bind to methylated CpG and TpG sites, in particular sites 
related to the transcriptional repressor MeCP2. It has a c-terminal domain 
homologous to DNA repair proteins (Hendrich and Bird 1998). MBD4 has the 
ability to remove thymine or uracil from mismatched CpG sites (Hendrich, 
Hardeland et al. 1999). It is thought that mutations causing loss o f MBD4 function 
can lead to a genome wide increase in C>T transitions and therefore have a 
housekeeping role similar to MMR proteins (Liu, Nicolaides et al. 1995) 
(Herman, Umar et al. 1998). A study o f MBD4 in CRC found frameshift 
mutations in over 40% (9 CRC primaries and 1 cell line) of CRC cases studied 
(Bader, Walker et al. 1999). More recently MBD4 has been implicated in DNA 
damage response and chromosomal stability (Abdel-Rahman, Knuutila et al. 
2008).
The functions o f POLE2, DUT  and CXCR4 are discussed in Chapter 5. These 
DNA repair genes were chosen for further study as they were down-regulated >3- 
fold in the majority o f lymphoblastoid cell lines from MCRA cases studied using 
expression array analysis.
Wnt signalling
Wnt signalling related genes -  WIFI, DKK, EPHB2
Wnt signalling inhibitory factors include WIFI and Dickkopfl (DKK) and frizzled 
related proteins. These secreted molecules have been demonstrated to bind Wnt 
proteins and inhibit their activity. The secreted Wnt antagonists can be divided 
based on their function, the soluble frizzled related proteins (sFRPs) includes 
WIFI, sFRPl, 2, 4, 5 and Frisbee. These proteins bind directly to Wnts altering 
their ability to bind the frizzled receptors. The dickkopf class comprises DKK 1-4
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which bind to low density lipoprotein receptor proteins (LRP5 and 6) which are 
contained within the Wnt receptor complex. When bound DKK  proteins inhibit 
Wnt signalling by preventing normal LRP-Fz-Wnt interactions (Kawano and 
Kypta 2003). Byun et al found a difference in expression o f inhibitory Wnt 
factors in the upper and lower GI tract. Increased zonal expression of WIFI was 
observed in colonic crypt bases on in situ RNA analysis suggested a role in 
colonic stem cell maintenance (Byun, Karimi et al. 2005). In this study DKK1 was 
not expressed in normal colonic mucosa.
Epigenetic changes (promoter hypermethylation) of WIFI have been reported in 
gastric and Barretts related oesophageal cancers suggesting a role as a putative 
tumour suppressor gene (Taniguchi, Yamamoto et al. 2005) (Clement, Guilleret et 
al. 2008). Similar epigenetic changes have been observed in DKK1 in CRC cases 
where hypermethylation o f DKK1 was observed in 9/54 CRCs studied (Aguilera, 
Fraga et al. 2006).
Ephrin receptor B2 (EPHB2) is a direct transcriptional target o f /3-catenin. Its 
protein product mediates the bi-directional migration and correct positioning of 
cells along the crypt axis in intestinal epithelium (Batlle, Henderson et al. 2002). 
In murine studies, EPHB2 has been demonstrated to have tumour suppressor 
activity. When the gene is disrupted in Apcmm/+ mice acceleration o f tumour 
growth is observed in both colon and rectum (Batlle, Bacani et al. 2005). 
Germline missense mutations in EPHB2 have been identified in Finnish CRC 
cases (who also had a personal or family history of prostate cancer) and 
individuals from the UK with hyperplastic polyposis (Kokko, Laiho et al. 2006). 
Four missense mutations were identified, two in the CRC cases (1361V, R568W) 
and one (D861N) in a HPP case. The fourth missense mutation (R80H) found in a 
CRC case was also present in 9/281 healthy controls and is likely to be a 
polymorphism. As EPHB2 has an association with serrated adenomas (Laiho, 
Kokko et al. 2007) it is possible that it may also play a role in MCRA 
development based on the findings o f BRAF mutations in the MCRA adenomas 
studied in Chapter 6.
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Cell cycle regulation 
Cell cycle regulation CDC4
CDC4 is a highly conserved E3 ubiquitin ligase which is indirectly involved in 
regulating the G l-S cell cycle checkpoint by targeting proteins for destruction by 
the SCF complex (Winston, Koepp et al. 1999). Mutations in CDC4 have 
previously been identified in breast and ovarian cancer cell lines (Moberg, Bell et 
al. 2001) (Strohmaier, Spruck et al. 2001) and more recently in a subset o f CRCs 
(Rajagopalan, Jallepalli et al. 2004) (Kemp, Rowan et al. 2005). There has been 
some discussion o f a putative role o f CDC4 in chromosomal instability initially 
suggested by Rajopalan et al following the observation that when CDC4 is 
knocked out in CRC lines, changes occur suggestive of CIN (Rajagopalan, 
Jallepalli et al. 2004). Further work by Kemp et al found no association between 
CDC4 mutation and CIN in a study o f 244 colorectal tumours and 40 CRC cell 
lines. Six percent o f tumours (including near-diplod CIN- lesions) harboured 
CDC4 mutations. The mutation spectra included nonsense an missense mutations 
with a bias towards C:G>T:A transversions (Kemp, Rowan et al. 2005).
CDC4 was chosen for further study due to its role in cell cycle regulation and the 
recently identified association between somatic CDC4 mutations and CRC. 
Genomic instability /  other CRC Hereditary syndromes
Other CRC Hereditary Syndromes - BLM
The Ashkenazi Jewish population have a 10-15% lifetime risk of developing 
CRC. There are known founder mutations in both APC  (I1307K) and MSH2 
(1906G>C) in this population which although prevalent do not account for the 
disease burden observed (Zauber, Sabbath-Solitare et al. 2005).
Bloom syndrome is a rare autosomal recessive condition leading to 
immunodeficiency, growth retardation, male sterility, breast cancer and CRC. A 
founder mutation in the Bloom gene BLAfsh (frameshift mutation in exon 10) has 
been identified in one third o f individuals with Bloom syndrome. Two groups 
report an increased risk (2.3 -  2.8 fold) o f CRC in heterozygous carriers of the
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B Lbfsh mutation (Gruber, Ellis et al. 2002) (Cleary, Zhang et al. 2003). Although 
Baris et al reported no increased risk in heterozygous carriers over three 
generations (Baris, Kedar et al. 2007).
The functions o f the BLM gene include roles in genomic stability and meiotic 
recombination. It has helicase activity although its natural substrates have yet to 
be identified (Neff, Ellis et al. 1999). Seven pathogenic missense mutations have 
been identified which have been mapped to seven highly conserved sequence 
motifs (Bernstein, Zittel et al. 2003). The BLM gene warrants further study due to 
its role in genomic stability and association with CRC.
8.1.2 Aims
The aim of this chapter was to screen a selection of MCRA candidate genes 
selected either through my own experimental work in Chapters 6 and 7 or based 
on evidence from current literature.
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8.2 Methods
8.2.1 Mutation detection
Following selection, the genomic sequence of each gene was downloaded from 
the UCSC Genome Browser - http://www.genome.ucsc.edu/
Primers were selected using Primer 3 software - http://frodo.wi.mit.edu/cgi- 
bin/primer3/primer3 www.cgi and annealing conditions determined (as described 
in Methods 2.1.4).
All genes except MSH6, DUT, POLE2 and CXCR4 were screened using 
fluorescent SSCP (Methods 2.1.6.1).
MSH6 was screened using dHPLC WAVE analysis (Methods 2.1.6.2).
DUT, POLE2 and CXCR4 were screened using the Lightscanner melting curve 
analysis (Methods 2.1.6.3).
Following identification of aberrant bands on SSCP, demonstration of 
abnormalities on the dHPLC chromatogram or abnormal melting profile on 
Lightscanner analysis, samples were sequenced in forward and reverse 
orientations using fluorescence cycling sequencing, see Methods 2.1.7 
All non-synonymous SNPs identified were analysed using the Fred Hutchinson 
SIFT analysis software to determine any potential pathogenic downstream 
alterations in protein structure and function 
http://blocks.fhcrc.org/sift/SIFT.html.
The following genes were screened with G. Guerra an Italian collaborator - 
MSH6, Wifi, DKK, MGMT, MBD4, BLM.
POLE2 and DUT were screened with K. Monahan a fellow PhD student.
8.2.2 Immunohistochemistry
Immunohistochemostry for PMS2 was undertaken as described in Methods 2.1.13 
Paraffin embedded tissue from 20 MCRA cases were studied for altered 
expression of PMS2.
217
8.3 Results
In total, 15 candidate genes were screened, 14 (133 exons in total) through 
germline mutation detection using SSCP, dHPLC and Lightscanner mutation 
detection and 1 through immunohistochemistry to determine whether any 
alteration in PMS2 expression occurs in MCRA cases.
8.3.1 Mutation detection
Overall, no obvious pathogenic germline mutations were identified in the MCRA 
cases studied. See Table 8-2 for a summary of the mutations detected.
The majority of mutations detected were in the DNA repair group of candidate 
genes. Of the Wnt signalling genes a single synonymous mutation in EPHB2 
(Q875Q A>G nt 2625) was detected.
Five silent mutations were detected, two in MSH6, one in MBD4 and one in 
EPHB2. Eight heterozygous missense mutations were detected, S326C 
(previously reported in Korean population) in OGGI, V83M in MTH1, L84F, 
I143V and K178R in MGMT, T515S in MBD4, V154G in DUT  and V181I in 
CXCR4. Three homozygous missense mutations were found, S326C in OGGI, 
L84F and L88F in MGMT. Intronic SNPs were identified in OGGI and MSH6. 
Three 3’UTR SNPs were identified two in exon 19 of POLE2 and one in exon 7 
of DUT, all o f which may have some effect on gene expression. Of 47 controls 
examined for these 3 ’UTR SNPs the two SNPs identified in exon 19 o f POLE2 
were found in 15% of controls suggesting that they are not pathogenic. The 
3’UTR SNP associated with exon 7 o f DUT  was not found in any controls 
suggesting that this SNP may alter gene expression. The non-synonymous SNP 
V154G present in exon 7 o f DUT  is thought to be potentially pathogenic as it 
occurs in a highly conserved region of the gene coding for the UTPase region (as 
predicted by the Fred Hutchinson SIFT analysis http://www.fhcrc.org).
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8.3.2 PMS2 immunohistochemistry
A total of 21 paraffin embedded tissue blocks from 20 MCRA cases were studied 
for altered PMS2 expression. Adenoma burden ranged from 5 - 3 4  (median 10) 
and age of individuals studied ranged from 38 -  78 (median 60 years).
No altered expression was observed in any of the cases observed when 
immunhistochemistry staining was compared with normal control slides included 
in the experiment. See Figure 8-1 for example of PMS2 immunohistochemistry.
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normal MCRA
Figure 8-1 PMS2 immunohistochemistry of normal and MCRA colonic 
epithelium both demonstrating normal expression of the PMS2 protein
8.4  Discussion
Despite careful selection o f candidate genes, no obvious pathological germline 
mutations in selected DNA repair, Wnt signalling or cell cycle control genes were 
identified in this study.
mmm
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8.4.1 DNA repair gene non-synonymous SNPs -  potential 
candidates as low risk alleles
Three non-synonymous SNPs were identified in three DNA repair genes which 
warrant further study.
Most interesting is the V154G heterozygous SNP (rsl802838) found in exon 7 of 
DUT  which was identified in 11% o f MCRA cases (Hardy-Weinberg x2 0.34) and 
0% (0/47) o f controls screened. This SNP is predicted to alter the UTPase region 
of the gene and could potentially be deleterious (SIFT analysis prediction). DUT 
V154G may therefore have a role as a disease modifying SNP in the MCRA 
phenotype. DUT  was chosen as a candidate as decreased expression >3 fold 
(range 3.08 -  5.89 fold reduction in expression) was observed in 5/11 
lymphoblastoid cell lines studied (Chapter 7)
The presence o f the 3 ’UTR polymorphism in exon 7 o f DUT  could result in the 
observed altered expression o f the protein in Chapter 5. This could be investigated 
further with quantitative real time PCR (qRT-PCR) analysis.
The MGMT K178R heterozygous SNP (rs2308327) was found in 29% of cases 
(Hardy-Weinberg x2 2.88) and 17% of the control population (HapMap Eur). 
Despite being “tolerated” on SIFT analysis it may still have a role as a low risk 
allele.
The third non-synonymous SNP T515S found in exon 6 o f MBD4 (rs3138359) 
occurred in 26% of cases (Hardy-Weinberg x2 2.23) and 0% of the control 
population (HapMap Eur). There is no SIFT analysis data available for this SNP. 
For all of these SNPs there is a higher frequency in the MCRA cases when 
compared to controls. Unfortunately no germline DNA samples were available 
from other family members o f these cases to use in co-segregation analysis of 
these SNPs.
In order to confirm these findings, these SNPs should be screened in another 
independent cohort o f MCRA cases and control populations.
At this time they could be considered as potential low risk alleles contributing to 
the MCRA phenotype -  in particular the DUT  V154G SNP.
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8.4.2 Potential role of synonymous SNPs and non-synonymous 
SNPs with similar frequencies in MCRA cases and control 
populations
Of the BER genes studied, the OGGI missense mutation S362C was identified in 
27% of individuals screened; 13% were heterozygous and 14% homozygous for 
the mutation. Although not thought to be pathogenic, Goode et al (Goode, Ulrich 
et al. 2002) when reviewing DNA repair gene polymorphisms and cancer risk 
found an increased prevalence o f S326C homozygous mutations in lung, 
oesophageal and prostate cancers. In the control groups, the genotype frequencies 
were 32% for the common allele, 54% for heterozygous carriers and 14% 
homozygous carriers o f the rare allele (326C). There is discrepancy as to the allele 
frequencies as the European HapMap figures for these alleles (rs 1052133) differ, 
citing 31% for S326C heterozygotes and 6.9% for S326C homozygotes. The 
frequency o f the 326C homozygote carriers of the rare allele in my study would 
therefore be double (14%) that o f the HapMap frequency (6.9%) suggesting that it 
may confer increased risk for developing MCRAs.
The MGMT L84F and 1143V SNPs (rsl2917 and rs2308321) were found to have 
very similar frequency as the control population (HapMap Eur) and are unlikely 
to have a role as either a low risk allele or disease modifying allele.
However, the presence o f missense mutations in DNA repair genes may have a 
subtle effect as modifier genes or make an individual more susceptible to 
environmental exposure -  such as free radicals caused by smoking or oxidative 
stress in the intestinal epithelium through poor diet. A candidate gene screen of 
other BER genes in CRC cases by Broderick et al (Broderick, Bagratuni et al. 
2006) detected three missense mutations in NEIL2 (C367A), TDG (A196G) and 
UNG2 (C262T) which were screened alongside NTHLl, NEIL2, MPG and 
SMUG1 in 94 CRC cases and 188 controls. The TDG A196G mutation was not 
detected in the MCRA cases in this study suggesting that if  it is associated with 
CRC it may play a role in tumour progression rather than development.
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There is increasing interest in the potentially pathogenic influence o f “silent” 
mutations on altered protein translation kinetics on transit through the ribosome 
(Komar 2007). Kimchi-Sarfaty et al (Kimchi-Sarfaty, Oh et al. 2007) have 
suggested that silent SNPs can in fact alter in vivo protein folding and ultimately 
function. This finding could have an enormous impact in the interpretation of 
mutation detection studies particularly if these SNPs are occurring at a higher 
frequency in the disease population.
As no pathogenic mutations were found in POLE2 and CXCR4, the observed 
reduced expressionin both o f these genes in Chapter 7 may be due to downstream 
effects or altered expression o f these genes in lymphoblastoid cells. Both o f which 
are limitations o f the experimental approach as discussed in Chapter 7. The two 
3’UTR polymorphisms identified in exon 19 o f POLE2 which were present in 
15% of controls screened suggest that they would not have an effect on 
expression. Again, qRT-PCR would be a useful tool with which this study this 
observation which is not within the scope o f this thesis.
8.4.3 No potential pathogenic mutations identified in Wnt 
signalling genes
No pathogenic mutations were identified in either the Wnt signalling related 
genes or the BLM  gene. Futher Wnt inhibitory factors WIF2, DKK2, DKK3 and 
frizzled related proteins would be appropriate candidate genes to screen in the 
future.
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8.5 Conclusions
Following the identification o f several “good quality” candidate genes either 
based on my own experimental work or from published data from others no 
pathogenic germline mutations were identified which might lead to the 
development o f the MCRA phenotype.
Areas o f interest warranting further study include -
1: Study o f the three non-synonymous SNPs DUT  V154G, MGMT K178R and 
MBD4 T515S identified with higher frequency in the MCRA cases, including 
confirmation studies in an independent cohort o f MCRA cases.
2: Further investigation o f the Wnt signalling pathway following the finding of 
increased nuclear expression o f fi-catenin in the MCRA cases.
3: Real-time PCR to investigate the expression of DUT and POLE2 following 
identification o f 3 ’UTR SNPs in a larger series of MCRA cases.
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9 Investigation of clonal origins in FAP, AFAP 
and sporadic colonic adenomas
9.1 Introduction
9.1.1 The clonal origins of CRC are not fully understood
Clonality studies in colorectal adenomas and CRC have been the source of 
some debate since the early 1960s. The determination of the adenoma- 
carcinoma sequence with its associated genetic changes (Vogelstein, Fearon et 
al. 1988), alongside the ability to study CRC from its earliest stages through 
colonoscopic sampling o f tissue, makes CRC an ideal tumour type in which to 
study clonality theories o f carcinogenesis.
9.1.2 Existing markers of clonality in CRC have limitations
Early studies utilised X-chromosome inactivation in females harbouring 
mosaicism of G6PD isoenzymes. Beutler described a polyclonal CRC 
(Beutler, Collins et al. 1967) and Hsu reported polyclonal adenomas based on 
the findings o f gel electrophoresis of X-inactivation of G6PD isoenzymes 
(Hsu, Luk et al. 1983). Vogelstein and Fearon et al studied X-inactivation 
patterns o f the phosphoglycerate kinase (PGK) gene in DNA (rather than the 
expressed protein) using restriction fragment length polymorphisms. In female 
patients with FAP they demonstrated a monoclonal pattern of X-chromosome 
inactivation (Fearon, Hamilton et al. 1987) (Vogelstein, Fearon et al. 1985). 
The most significant limitation of these studies is the existence of X-linked 
patches in both normal and dysplastic tissue. It is possible that some covert 
polyclonal tumours appeared monoclonal as they arose within an X-linked 
patch of tissue. Since then, Novelli et al have demonstrated through further
analysis of X-linked patch size that X-inactivation studies have a significant 
bias towards demonstrating colorectal tumour monoclonality (Novelli, Cossu 
et al. 2003).
Investigation o f adenomas from an individual with FAP and XO/XY 
mixoploid chromosome (as a consequence o f a dicentric Y chromosome) led 
to further evidence supporting a polyclonal origin of adenoma development in 
FAP (Novelli, Williamson et al. 1996). In this study, clonality was assessed 
through probing for the Y chromosome in adenomas, This approach 
demonstrated that 76% of FAP adenomas were polyclonal.
Mouse studies have supported this finding, Merritt et al (Merritt, Gould et al. 
1997) developed an ApcMin+/~ and ROSA 26 (1 acZ expressing) chimaeric 
mouse. Analysis o f adenomas from these animals found 79% of adenomas to 
be polyclonal (heterotypic for ROSA and non-ROSA lineages), a figure very 
similar to Novelli et al.
Thliveris (Thliveris, Halberg et al. 2005) has suggested three theories of 
colorectal tumour polyclonality (discussed in Introduction). Adenoma 
mosaicism; random or regional collision between independently arising 
neoplasms; and active interaction between adjacent crypts. To date, none of 
these theories fully fits observed experimental findings in either humans or 
animal models.
Since the majority o f adenomas harbour mutations at APC  and as APC  
mutations are the “gatekeeper” mutations in the genesis of colorectal 
tumorigenesis (Kinzler and Vogelstein 1996), identification and utilisation of 
somatic APC  mutations in dysplastic crypts would be a suitable clonal marker 
with which to study adenoma development from its earliest stages.
I set out to analyse the mutation spectrum at APC  on a crypt-by-crypt basis by 
laser micro-dissecting single crypts from adenomas. The identified mutations 
were then utilised as clonal markers in the following adenoma types -  FAP, 
AFAP and sporadic adenomas. I also re-examined tissue from Novelli’s study 
of an XO/XY individual with FAP to compare two different methods of 
assessing tumour clonality.
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9.1.3 Aims of this chapter
The aim of this chapter was to identify and utilise a simple and robust marker 
of clonality in CRC which could be used to study adenoma development from 
its earliest stages and to investigate theories o f clonal development of 
adenomas further.
9.2 Methods
Sample collection and preparation
Patients were recruited through St Mark’s Hospital Colorectal Cancer Unit, 
blood was routinely sampled and paraffin embedded archival tissue was 
collected. Informed consent was obtained prior to sample collection through 
the CORGI study.
A total o f 5 FAP, 5 AFAP and 4 sporadic adenomas plus 3 adenomas from the 
individual with XO/XY chimera and FAP were studied.
The FAP individuals chosen for the study had germline APC  mutations 
between codons 1040 and 1061 as it would be expected that their second hits 
at APC  would occur within the MCR region. In comparison, individuals with 
the del 5bp deletion at codon 1309 o f APC  most commonly lose the second 
allele of APC  through LOH rather than harbouring truncating somatic 
mutations. All o f the AFAP patients had germline mutations in the 
alternatively spliced region of exon 9 (R332X) o f APC.
Laser Capture Micro-dissection
For each adenoma studied, serial dysplastic crypts were laser micro-dissected 
from around the circumference o f the adenoma see Figure 9-1. In order to 
obtain sufficient DNA from each crypt for sequencing analysis, the same crypt 
was micro-dissected from 6 serial slides. Each crypt sample was laser captured 
into a separate collecting tube. To determine whether any contamination may 
have occurred, a “blank” collecting tube was included in every batch analysed. 
DNA was extracted using standard proteinase K digestion overnight at 60°C.
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For each crypt, a total of lOpl starting material was available for subsequent 
analysis.
For SSCP analysis several crypts were dissected into one collecting tube for 
digestion in order to obtain 30pl o f starting material.
See Methods 2.1.12 for overview of technique and extraction of DNA from 
dissected crypts
Figure 9-1 Laser micro-dissection o f FAP adenoma, H&E section (x20) on 
left and serially micro-dissected crypts demonstrated on right
Mutation detection in single micro-dissected crypts
For each adenoma, fluorescent SSCP analysis was performed covering the 
mutation cluster region of APC  (MCR 1-12) to identify somatic APC 
mutations which could be used as clonal markers (see Methods 2.1.6.1.). 
Following identification of aberrant bands on fluorescent SSCP analysis the 
corresponding MCR region was then sequenced using nested PCR. First and 
second round primers were used for each MCR region (see Methods 2.1.7.). 
LOH analysis at codon 1309 of APC  was performed in single crypts dissected 
from adenomas from XO/XY chimeric FAP patient. The germline APC 
mutation for the individual was del 5bp at codon 1309. Subsequently loss of
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the wild type allele could be determined by performing LOH analysis across 
the MCR3 region containing codon 1309.
All primer sequences and conditions can be found in Appendix 1.
Immunohistochemistry
Immunohistochemistry for B-catenin, and Ki-67 was undertaken as described 
in Methods 2.1.13.
Fluorescent in-situ hybridisation (FISH) analysis for X  and Y chromosomes 
FISH for the Y chromosome in the XO/XY patient studied was performed by 
R. Jeffrey in the Histopathology Laboratory, Cancer Research UK, London 
Research Institute.
The work undertaken in this Chapter was in collaboration with SJ. Leedham a 
fellow PhD student in the Histopathology Laboratory, Cancer Research UK, 
London Research Institute.
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9.3 Results
With the limited amount o f DNA available for analysis from each crypt it was 
not always possible to identify the “second hit” at APC. If a neighbouring 
crypt to one harbouring a somatic APC  mutation was found to be wild type, it 
was taken that this crypt had arisen from a different clone. All crypts dissected 
in the study were histologically dysplastic.
9.3.1 FAP adenomas are polyclonal
In total, 36 crypts were dissected from 5 FAP adenomas. Adenomas 1-3 were 
from an individual with a germline mutation at codon 1040 of APC  and 
adenomas 4 and 5 were from an individual with a germline mutation at codon 
1061 o f APC. The mean adenoma size was 9.5 mm2 (median 2.25 mm2, range 
1 . 0 - 4 0  mm ). All o f FAP adenomas were found to be polyclonal, see Table 
9-1.
FAP Polyp ID Size (mm)
Total no.
crypts
(analysed)
Somatic A P C  Mutations Clonality
1 1.5 x 2.0 15(11)
8 crypts - del 2bp nt 4219 
and 2 crypts ins A nt 
3925
Entrapped wild type crypt
Polyclonal
2 1 .5x  1.5 13(5)
3 crypts - del A nt 4364 
1 crypt - ins C nt 4373
1 crypt - wild type for 
above
Polyclonal
3 1 .0x  1.0 9 (6 )
4 crypts - del A nt 4243 
2 crypts - wild type for 
above
Polyclonal
4 1.0 x 1.0 5(4)
2 crypts - del A nt 4195
2 crypts - wild type for 
above
Polyclonal
5 5.0 x 8.0 100(10)
9 crypts - del C nt 4476
1 crypt - wild type for 
above
Polyclonal
Table 9-1 Summary o f somatic APC  mutations identified in single crypts 
from five FAP adenomas
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Figure 9-2 shows SSCP tracings demonstrating aberrant bands in both MCR6 
and MCR9 of FAP adenoma 1. Subsequent crypt-by-crypt sequencing analysis 
identified mutations in both of these regions, see Figure 9-3. Figure 9—4 
demonstrates polyclonality in FAP adenoma 2.
©
MCR 6 wt
-400
-200
©
MCR 6 polyp
-200
-too
MCR 9 wt
-600
-400
-200
-400
-300
-200
-1 0 0
©
MCR 9 polyp
Figure 9-2 Fluorescent SSCP analysis o f FAP adenoma demonstrating 
aberrant bands in MCR6 and MCR9, these were sequenced and are presented 
in Figure 9-3
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MCR 6 -wild type
C C M C ■
MCR 9R -wild type
T T T»C TC C* 6 C T TO C T T • G C C C C I C  : C  TC TC T T_TT£,
del 1bp nt 4395. stop @ 1490 del 2bp nt 4219. stop @ 1408
MCR 9 R MCR 6
Figure 9-3 Polyclonal FAP adenoma (1), crypt in orange box wt for MCR6 
and MCR9, crypt in red box truncating mutation in MCR9 and crypt in blue 
box truncating mutation in MCR6
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MCR 8
del A nt 4364. stop @ 1467
MCR 8
ins C nt 4373. stop @1461 
Figure 9—4 Polyclonal FAP adenoma (2) demonstrating two different 
mutations in MCR8, 3 crypts dissected within the red box harbour del A at nt 
4364 and 1 crypt dissected from within the blue box harbours ins C at nt 4373 
of APC
Two microadenomas (both 1mm2) in FAP colonic epithelia were examined 
and both found to be polyclonal from their earliest stages, see Figure 9-5.
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AB
MCR 6F
wild type
MCR 6F
t
del A nt 4243. stop @ 1418
Figure 9-5 Polyclonal FAP microadenoma (3) patient, A -  H&E stain x40, B 
-  micro-dissected crypts . 3 crypts in blue box have truncating mutation in 
MCR6 and 3 crypts in red box are wt for MCR6
9.3.2 AFAP adenomas are clonal
In total, 36 crypts were analysed from 5 AFAP adenomas collected from 3 
AFAP patients. All patients had germline mutations in the alternatively spliced 
region of exon 9 APC  (R332X). The mean adenoma size was 11.6 mm2 
(median 9 mm2, range 4 - 2 5  mm2). All AFAP adenomas were found to be 
clonal see Table 9-2.
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AFAP Polyp 
ID Size (mm)
Total no.
crypts
(analysed)
Somatic APC 
Mutations Clonality
1 3.0 x 3.0 35 (8)
All crypts
2nd hit - del C nt 
4117 
3rd hit - ins A nt 
4662
Clonal
2 4.0 x 4.0 33 (8)
All crypts
Nonsense 
mutation G1552X
Clonal
3 5.0 x 5.0 60 (6)
All crypts 
Ins A nt 4662
Clonal
4 2.0 x 2.0 25 (8)
All crypts 
Del 4bp nt 4386
Clonal
5 2.0 x 2.0 27 (6)
All crypts
SNP G to A nt 
4478
Clonal
Table 9-2  Summary of somatic APC mutations identified in single crypts 
from five AFAP adenomas
See Figure 9-6  and Figure 9-7  for results o f adenomas 1 - 3 .  AFAP adenoma 
1 is of particular interest in that it demonstrated both second and third hits at 
APC  in every crypt dissected.
234
2nd Hit
3rd Hit
MCR 5
c 14 c< |V | b o i  r e  cq o m *  »
del C nt4117; stop @ 1394
Figure 9-6 Adenoma from AFAP patient (1), A  -  H&E x40, B -  PALM laser 
capture slide. Each crypt dissected was found to have second and third hits at 
APC in MCR5 and MCR11
'5 3 5 5 *
MCR 11
ins A n t4662; s to p  @  1558
MCR 11
Nonsense mutation G1552X
MCR 11
t
Ins A nt 4662; stop @ 1558
Figure 9-7 AFAP adenomas 2 (upper panel) and 3 (lower panel). Adenoma 2 
harboured G1552X nonsense mutation in all crypts studied and adenoma 3 
harboured ins A at nt 4662 of APC in each crypt
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9.3.3 Sporadic adenomas
In total, 44 crypts were analysed from 4 sporadic adenomas. Each adenoma 
studied was collected from a different individual (< 3 adenomas in total), none 
of whom harboured germline APC  or MYH mutations. The mean adenoma 
size was 18.75 mm2 (median 9 mm2, range 8 - 2 5  mm2). Three “mixed” crypts 
were identified in the sporadic adenomas studied whereby the top half of the 
crypt demonstrated evidence o f dysplasia on H&E staining with normal crypt 
appearances in the lower half o f the crypt. These crypts were studied in more 
detail in the following section.
Three sporadic adenomas were found to be clonal and one polyclonal (8mm2 
adenoma 1). There was no correlation between adenoma size and clonality 
observed as adenoma 2 (smaller than adenoma 1) and adenoms 3, 4 (larger 
than adenoma 1) are all found to be clonal. See Table 9-3 for overview.
Sporadic 
Polyp ID Size (mm)
Total no.
crypts
(analysed)
Somatic APC 
Mutations Clonality
1 8.0 x 1.0 70(11)
9 crypts - del 4bp 
nt 4388 
2 crypts - wild 
type for above
2 mixed crypts
Polyclonal
2 3.0 x 3.0 30(10)
All crypts 
Del T nt 4473
Clonal
3 5.0 x 5.0 100 (12)
All crypts 
1st hit - del A nt 
3700 
2nd hit - del 4bp 
nt 4463
Clonal
4 5.0 x 5.0 50(11)
All crypts
Nonsense 
mutation G1312X
1 mixed crypt
Clonal
Table 9-3 Summary o f somatic APC  mutations identified in single crypts 
from four sporadic adenomas
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9.3.4 Evidence for “top down” growth in sporadic adenoma 
development
Figure 9-8 Mixed crypt identified in sporadic adenoma 1, A -  H&E stain x40, 
B -B-catenin immunohistochemostry demonstrating increased nuclear staining 
in upper half o f crypt, C -  Ki-67 immunohistochemistry demonstrating higher 
rate of cellular proliferation in upper half of crypt
Three crypts (from 2 adenomas) were identified in the sporadic adenomas 
which demonstrated mixed morphology. These were studied further by micro- 
dissecting the dysplastic region of the crypt separately to the region 
demonstrating normal morphology. In order to confirm progression from 
normal crypt architecture to histological dysplasia B-catenin and Ki-67 
immunohistochemistry was performed prior to micro-dissection see Figure 9 -  
8 .
On clonal analysis o f this crypt the dyplastic top half harboured a mutation in 
MCR9 and the bottom half with normal histological appearances was found to 
be wt, see Figure 9-9.
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MCR 9R
I
del 4bp nt 4388. stop @ 1472
MCR 9R
wild type
Figure 9-9 Evidence o f “top down” growth in mixed crypt from sporadic 
adenoma, the top (dyplastic) half of the crypt when micro-dissected harboured 
a 4bp deletion at nt 4388 APC, the bottom half was wt
9.3.5 Stroma did not harbour APC  mutations in FAP, AFAP 
or sporadic adenomas
When histologically normal stroma was micro-dissected from 3 FAP, 3 AFAP 
and 2 sporadic adenomas, none of the tissue was found to harbour the same 
APC mutations as identified through SSCP analysis and direct sequencing of 
the dysplastic crypts within the adenoma.
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9.3.6 Polyclonal adenomas demonstrated in XO/XY FAP 
individual using two different clonal markers
Three informative adenomas from the XO/XY individual with FAP (del 5bp 
1309 germline APC  mutation) decribed by Novelli et al (Novelli, Williamson 
et al. 1996) were re-examined using FISH and laser-microdissection of single 
crypts for LOH analysis at codon 1309 of APC. All o f the adenomas were 
found to be polyclonal using both of these techniques. Figure 9-10 
demonstrates FISH analysis and Figure 9-11 demonstrates LOH analysis in 
single crypts dissected from adenoma 1. LOH is considered present if the 
LOH ratio of the two alleles studied is >2.0 or <0.5 (see Methods 2.1.6.4 for 
summary o f LOH). Table 9 -4  summarises the LOH findings in the three 
adenomas studied.
Figure 9-10 Fluorescent in-situ hybridisation for X and Y chromosomes on 
adenoma of XO/XY patient with FAP, A -  H&E stain x20, B -  crypts 
demonstrated with FISH, C -  FISH demonstrating XY and XO crypts adjacent 
to each other, X chromosome = green and Y chromosome = red, DAPI = blue. 
D -  XO crypt, E = XY crypt
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JL- J_^  JL
LOH analysis at 
codon 1309 APC
A B
Figure 9-11 LOH analysis at codon 1309 APC in adenoma (1) from XO/XY 
patient with FAP. A -  H&E stain x20, B -  crypt 1 has no LOH and crypts 2-4 
have LOH of the somatic (wt) allele o f APC demonstrating different clonal 
origin
Adenoma ID Crypt no LOH ratio Clonality
1 1 0.55 polyclonal
2 4.26
3 4.23
4 5.27
2 1 4.49 polyclonal
2 2.19
3 1.38
4 1.33
3 1 5.32 polyclonal
2 9.19
3 5.42
4 3.65
5 1.24
Table 9-4 Summary o f LOH analysis at codon 1309 APC from single crypts 
dissected from XO/XY individual with FAP. Blue shading = LOH present 
(ratio >2.0)
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9.4 Discussion
9.4.1 Theories of differing clonal origins of FAP, AFAP and 
sporadic adenomas
This is the first study to investigate colorectal adenoma clonality in 
individually dissected dysplastic crypts utilising a clonal marker specific to the 
underlying pathogenesis o f the disease.
The finding that 100% of FAP adenomas were polyclonal including re­
examination o f XO/XY FAP tissue supports the findings of Novelli and 
Merritt in both human and mouse tissue (Novelli, Williamson et al. 1996) 
(Merritt, Gould et al. 1997). There are no published studies o f clonality to date 
in AFAP, the finding that 100% of adenomas studied were o f single clonal 
origin is intriguing and lends weight to the theories o f random collision and 
field cancerisation (as a result o f the first germline APC  “hit”). The finding 
that 75% of sporadic adenomas are clonal and 25% polyclonal is of great 
interest. Evidence o f “top down” growth as demonstrated in sporadic adenoma 
“mixed” crypts suggests active interaction between crypts and raises the 
possibility that an adjacent dysplastic crypt may induce proliferation in its 
neighbouring crypts.
Therefore, when considering existing theories of clonal origins in adenoma 
development the data presented in this chapter supports some elements of the 
random / regional collision, active interaction and field cancerisation theories.
Random or regional collision between independently arising neoplasms
Previously Novelli and Merritt have suggested random / regional collision as a 
mechanism underlying polyclonality in FAP as a consequence o f high tumour 
burden in FAP patients (Novelli, Williamson et al. 1996) and chimeric 
ApcMin+/' mice (Merritt, Gould et al. 1997).
To test this hypothesis Thliveris et al reduced tumour multiplicity in the 
chimeric ApcMin+/' mouse model used by Merritt et al by introducing 
homozygosity for the tumour resistance allele of Moml. Overall tumour 
multiplicity was reduced 8-fold but the percentage of mixed tumours ranged
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from 8-63%, with a mean of 22% (Thliveris, Halberg et al. 2005). This figure 
is higher than would be expected if  heterotypic tumours are formed by random 
collision when consideration o f tumour burden is taken into account. 
Therefore it was suggested that random collision is an unlikely mechanism 
leading to polyclonality in the chimaeric mouse model.
The finding o f a polyclonal sporadic adenoma in this study suggests a separate 
pathological process to that o f FAP adenoma development and lends more 
weight to the concept o f active interaction between dysplastic crypts and 
environmental impact on gastro-intestinal epithelia in different regions of the 
colon.
Active interaction between adjacent crypts
Thliveris and Novelli both believe active interaction between crypts to be the 
most likely cause o f polyclonality observed in human and mouse models of 
FAP. The possible mechanisms underlying this include microheterogeneity of 
tumour susceptibility where local stroma promotes somatic mutation in 
adjacent crypts - the so-called landscaper effect, or stem cell interaction 
between neighbouring initiated crypts.
These concepts are supported by the observation of polyclonality in FAP 
microadenomas o f 4 crypts diameter in this study. This may be a consequence 
of paracrine secretion o f mitogens or stimulatory proliferogens from 
neighbouring dysplastic crypts. A different explanation could be the direct 
effects of epithelial-epithelial interactions between crypts initiating loss of 
control of cellular proliferation (for example through epidermal growth factor 
receptor signalling).
Support of epithelial-epithelial interaction causing increased cellular 
proliferation can be found in mouse studies where hyperplastic (“colossal”) 
crypts found adjacent to adenomas are found to have a higher rate of 
proliferation (Bjerknes and Cheng 1999). The finding of increased Ki-67 
expression in the upper half o f the “mixed” crypts studied in sporadic 
adenomas supports this observation.
Field cancerisation
The theory o f “field cancerisation” was first suggested in the 1950s when it 
was demonstrated that multiple oral tumours could arise from a field of
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mutated cells following exposure to a known carcinogen (Slaughter, 
Southwick et al. 1953). This (albeit old) theory is easily applicable to 
colorectal epithelia when considering both FAP and AFAP germline first hits 
and the impact o f environmental dietary / oxidative stress in the gastro­
intestinal tract.
Histologically normal crypts in individuals with FAP (harbouring the germline 
A PC  mutation only) have a significantly different proliferation pattern to that 
of wild-type crypts -  with an upwards shift (towards the top o f the crypt) of 
DNA synthesising (S-phase) cells (Potten, Kellett et al. 1992). Mathematical 
modelling o f stem cell kinetics in FAP crypts led to similar results where 
tumor initiation in the colon was thought to be due to crypt stem cell 
overproduction and increased proliferation (Boman, Fields et al. 2001). 
Methylation patterns in histologically normal FAP crypts differ to wild-type 
crypts, these findings were consistent with slower clonal evolution and 
subsequent stem cell survival advantage (Kim and Shibata 2004).
Studies o f mitochondrial DNA have identified patches o f clonally related 
crypts occuring in normal human colon (Greaves, Preston et al. 2006). 
Therefore if the first “hit” at APC  alters cellular proliferation and stem cell 
survival as discussed above it could theoretically give rise to a 
morphologically normal “patch” o f colonic epithelia harbouring an identical 
first hit mutation at APC. This could result in a field of stem cells harbouring a 
first hit at APC  which would be more susceptible to a second hit and 
subsequent initiation o f the adenoma -  carcinoma sequence. This could 
explain the development o f clonal adenomas observed in AFAP. Therefore in 
FAP and AFAP the entire colon could represent a fertile “field” for 
development o f somatic mutations. If this theory is applied to my data it could 
be suggested that in FAP active interaction occurs alongside the field effect of 
the germline first hit resulting in polyclonal adenomas. In AFAP the germline 
first hit at APC  may result in a less mutation prone “field” therefore second -  
and as demonstrated in this study and Sieber et al (Sieber, Segditsas et al. 
2006) - third hits are required for initiation of the adenoma-carcinoma 
sequence. As this would take a longer period of time chronologically it is 
more likely that the resulting adenomas would be clonal.
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9.4.2 Further work
These results although intriguing require further confirmation through analysis 
of a greater number o f FAP, AFAP and sporadic adenomas. In particular 
AFAP adenomas from individuals with 5’ and 3’ germline APC  mutations 
should be studied to determine whether they too are clonal in origin or 
whether my observations relate to AFAP cases with alternatively spliced exon 
9 germline mutations only.
In order to further understand pathogenic mechanisms in MYH tumorigenesis 
and explore the effects o f environmental stresses on adenoma clonality a 
collection o f MAP adenomas should also be studied.
9.5 Conclusions
Somatic APC  mutations can be successfully utilised as clonal markers in 
crypt-by-crypt analysis o f adenomas from their earliest stages (including 
microadenomas from just 4 crypts in diameter).
The finding that FAP adenomas are polyclonal and AFAP adenomas are 
clonal is intriguing -  this lends support to the theories of active interaction and 
random collision. Evidence o f “top down” growth again supports active 
interaction and suggests that the “second hit” at APC  would not always have 
to occur in the bottom o f the intestinal crypt where stem cells reside.
A landscaper effect was excluded by the analysis o f histologically normal 
tissue within adenomas which did not harbour APC mutations.
This is the first study to investigate colorectal adenoma clonality in individual 
dysplastic crypts utilising a clonal marker specific to the underlying 
pathogenesis.
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10 Discussion and Conclusions
MYH related studies
MYH associated polyposis (MAP) is a recessively inherited colorectal cancer 
syndrome accounting for -1% of all CRC. MAP is caused by inheritance of 
bi-allelic mutations at MYH, a base excision repair (BER) glycosylase. MAP 
leads to the development of multiple colorectal adenomas and CRC. To date, 
there have been reports o f extra-colonic features associated with MAP, all in 
small case series. There are known common pathogenic variants which occur 
in MYH amongst different ethnic groups. Northern European populations have 
a predominance o f Y165C and G382D mutations (Jones, Emmerson et al. 
2002). Other variants include Y90X in patients of Pakistani origin and E466X 
which has been found solely in patients o f Indian origin. An in frame deletion 
ntl395delGGA has been identified in patients of Mediterranean origin 
(Gismondi, Meta et al. 2004).
I studied a cohort o f 34 bi-allelic carriers o f MYH mutations, 18 E466X 
homozygotes, with the remainder, either Y165C, G382D homozygotes or 
compound heterozygotes (Y165C/G382D) in search of any genotype- 
phenotype correlation (Chapter 3). Although a similar incidence of CRC was 
observed between the Y165C, G382D and E466X homozygotes (62% and 
61% respectively), a significantly higher number of the E466X homozygotes 
developed Dukes stage (B-D) CRC (Table 3-3) than the Northern European 
mutation carriers suggesting that E466X mutation carriers develop more 
aggressive disease. This finding is borne out when comparing adenoma 
burden, a total o f 8 E466X homozygote carriers developed >100 and <1000 
adenomas with one exceptional individual developing 6250 adenomas. This 
dataset includes the largest cohort of E466X homozygotes to be studied to 
date. Future studies to investigate the effectiveness of E466X mutation carriers 
to repair oxidative DNA damage should include site directed mutagenesis 
studies in E.coli (previously undertaken in Y165C and G382D mutations). If it 
were found that the E466X mutation were less able to repair oxidative DNA 
damage this would support the finding that harbouring this mutation would 
lead to the development o f a more aggressive phenotype. Further clinical
246
research should include collaborative studies to investigate this finding in 
larger patient cohorts.
On commencing my thesis, screening and clinical surveillance guidelines for 
MAP were under development, and the significance of being a heterozygous 
MYH mutation carrier was the source of some debate. Through my study of bi- 
allelic MYH mutation carriers it was determined that duodenal polyps occurred 
in 28% and fundal polyps in 17% of homozygote patients necessitating upper 
GI endoscopy as screening in all bi-allelic mutation carriers. This is now 
accepted as best practice.
The development o f a mouse model o f MAP (Chapter 5) was particularly 
useful in determination o f the significance of being a heterozygous MYH 
mutation carrier. In my study heterozygous Myh+/~ mice had no increased risk 
of tumour development than Myh+/+ mice. This data was published in 2004 
before large population based studies in humans were available (Farrington, 
Tenesa et al. 2005) (Webb, Rudd et al. 2006).
Further study o f MAP adenomas and colectomy specimens from MAP 
patients found the presence o f microadenomas in colonic epithelium 
demonstrating that “2 hits” at APC  are necessary to initiate tumourigenesis 
(Chapter 3). However, it is still not understood as to why APC  (and the gastro­
intestinal tract) appear to be targeted in MYH deficient individuals It could be 
postulated that the GI tract is more vulnerable to defective BER through 
environmental exposure to oxidative damage.
Array CGH analysis o f MAP tumours (Chapter 4) demonstrated evidence of 
CIN in 78% (11/14) adenomas studied, with small-scale and large-scale 
chromosomal changes observed. This included copy number neutral LOH (in 
one o f 3 MAP adenomas examined by SNP-LOH). The observed small-scale 
changes may be as a consequence of defective BER, whereas the large-scale 
changes may represent abnormal function of APC  as APC  is targeted in MAP. 
No correlation was identified between the size or grade of dysplasia in 
adenomas studied and the number of losses and gains observed on aCGH. 
Previous data had suggested that MAP tumours are diploid on flow-cytometry 
(Lipton, Halford et al. 2003). At the same time as my study, Cardoso et al 
(Cardoso, Molenaar et al. 2006) were also undertaking aCGH analysis on 
MAP tumours. The results o f Cardoso’s and mine are similar (in terms of site
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and nature o f chromosomal changes cross the genome). However, Cardoso et 
al used whole-genome amplification o f extracted DNA prior to aCGH 
hybridisation. This step is likely to introduce atrefactual errors making 
interpretation o f their data more difficult. Both aCGH and flow-cytometry are 
limited by their lack o f sensitivity in identifying copy number neutral LOH, 
the finding o f copy-number neutral LOH through SNP-LOH analysis is 
particularly interesting as it may represent small-scale genome wide changes 
associated with the underlying defect in BER. This data suggests that the 
previous analysis o f MAP adenomas by flow cytometry should not be 
dismissed as those tumours studied may have harboured copy number neutral 
LOH.
The development o f the first mouse model of MAP (Apc^^'/M yh^  mice bred 
on C57BL6/SV129 genetic background) (Chapter 5) was successful in that 
this mouse developed several features in keeping with the human MAP 
syndrome, those o f intestinal adenoma development and evidence of somatic 
G:C>T:A transversions at Ape. However, due to the influence of the Min allele 
on adenoma development the majority o f adenomas developed in this model 
lost the second allele o f Ape through LOH rather than through truncating 
mutations (as observed in human MAP). Furthermore, somatic Ape mutation 
screening in these animals suggested a polyclonal origin from the ApcMin+/' /  
Myh'1' mice studied. This finding was explored further in the clonal analysis of 
adenoma development in Chapter 9.
It is still not understood why when Myh is knocked out alone in mice no 
gastrointestinal phenotype develops. The influence of the genetic background 
on which the mouse is bred appears to have a profound effect. This was borne 
out in the development o f the second mouse model of MAP whereby none of 
the animals developed a gastro-intestinal phenotype when bred on the AKR 
genetic background. The basis of the second mouse model of MAP was to 
produce a mouse model was to reduce the incidence of LOH at Ape as the 
second hit in adenoma development by breeding ApcMin+/' /  Myh'1' mice on 
the AKR genetic background. My study, alongside the findings of Sakamoto 
et al (Sakamoto, Tominaga et al. 2007), who developed a mouse model of 
MAP during the course o f my thesis, have provided evidence that mouse 
models o f MAP (on both the C57B6 and AKR genetic background) appear to
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require a second promoter o f tumorigenesis either through external oxidative 
stress (Sakamoto, Tominaga et al. 2007), or inherited mutations through the 
ApcMin+/' allele.
Pathogenesis and identification o f  potential candidate genes in the MCRA 
phenotype
To date, the understanding o f the underlying pathogenesis of the multiple 
colorectal adenoma phenotype (individuals who develop between 5-100 
adenomas) includes the identification of a subset cases with underlying 
germline APC  mutations (AFAP) and bi-alleleic MYH mutation carriers, 
together these account for up to 50% of cases. Previously, candidate gene 
screens have included those involved in Wnt signalling (APC2, conductin and 
GSK3/3) the TGF-/3 pathway {SMAD4 and BMPR1A) and DNA repair (NEIL2, 
TDG, UNG2, NTHL1, NEJL2, MPG and SMUG1) (Lipton, Sieber et al. 2003) 
(Broderick, Bagratuni et al. 2006). No pathogenic germline predisposition 
genes were identified.
I set out to determine potential pathogenic mechanisms and candidate genes in 
the MCRA phenotype utilising several approaches in tandem.
In my study o f 25 MCRA cases (with no underlying APC  or MYH mutations), 
I demonstrated disruption o f Wnt signalling in MCRA cases through increased 
nuclear B-catenin expression on immunohistochemistry when compared to 
sporadic adenomas (Chapter 6). Somatic mutation screening at APC was 
undertaken in MCRA cases in order to identify any mutational signature 
indicative o f an underlying defect in DNA repair. No such mutational 
signature was identified. However, on lymphoblastoid cell line expression 
array analysis on 11 MCRA cases and controls (Chapter 7), 3 candidate genes 
(all related to DNA repair) were identified. Expression of DUT, CXCR4 and 
POLE2 were all reduced >3 fold in MCRA cases when compared to controls. 
These were taken forward for screening as potential candidate genes with 12 
other candidates in Chapter 8. Further work of interest in utilising expression 
analysis in lymphoblastoid cell lines would include the inhibition of nonsense 
mediated decay (NMD) in order to identify transcripts harbouring mutations, 
this would be within the remit that lymphocytes express the genes of interest.
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On guidance o f the results from Chapters 6 and 7, and from evidence in 
current literature, 15 candidate genes were screened in 95 MCRA cases in 
Chapter 8. These included Wnt related genes following the discovery of 
significantly increased nuclear B-catenin expression in MCRA cases in 
Chapter 6 and the DNA repair genes DUT, CXCR4 and POLE2 as identified in 
Chapter 7.
The most interesting and significant finding was the V154G heterozygous 
SNP (rs 1802838) found in exon 7 of DUT which was identified in 11% of 
MCRA cases (Hardy-Weinberg x2 0.34) and 0% (0/47) of controls screened. 
This SNP is predicted to alter the UTPase region of the gene and could 
potentially be deleterious. Further studies o f this SNP are warranted in an 
independent MCRA cohort and a larger control population. At this time 
population based data is not available for this SNP through the HapMap 
consortium.
My data suggest that the remaining MCRA genes as yet to be identified would 
include further candidates from the Wnt signalling pathway (including Wnt 
inhibitory factors) and DNA repair genes. It is likely that the remaining genes 
are o f low to moderate penetrance and multiple loci may be involved. 
Therefore future strategies should incorporate a genome wide association 
studies in selected cases and controls, and whole genome sequencing in 
carefully selected MCRA cases.
Investigation o f  clonality in adenoma development
In Chapter 9, I demonstrated that somatic APC  mutations can be successfully 
utilised as clonal markers in adenoma development. This is the first clonal 
marker in CRC which utilises a marker relevant to the pathogenesis of the 
underlying disease.
Clonality in FAP, AFAP and sporadic adenomas were studied through laser- 
capture micro-dissection o f individual crypts and subsequent analysis of DNA 
for somatic mutations at APC  which were used as clonal markers.
The findings were intriguing, 100% of FAP adenomas were found to be 
polyclonal which support previous studies in both human and mouse models 
of FAP (Novelli, Williamson et al. 1996) (Merritt, Gould et al. 1997). One 
hundred percent o f AFAP adenomas were clonal (with one adenoma
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demonstrating 2nd and 3rd hits at APC in every crypt dissected). This is the first 
study of clonality in AFAP and supports Sieber et a l’s findings that up to three 
hits at APC  are required to initiate tumorigenesis (Sieber, Segditsas et al. 
2006). All AFAP adenomas studied were from individuals with a germline 
mutation in the altemitvely spliced region of exon 9 (R332X) therefore further 
studies should include individuals with both 5’ and 3’ germline mutations at 
APC.
Interestingly, examination o f sporadic adenomas found evidence to support 
“top down” growth in crypts leading weight to the theory of “active 
interaction” between crypts in the colorectal epithelium suggested by 
(Thliveris, Halberg et al. 2005). This finding also questions the role of stem 
cells the transition from normal to dyplastic crypt architecture as stem cells 
reside in the bottom o f the intestinal crypt. Therefore, my data (albeit in 
limited numbers o f sporadic adenomas) supports “top down” growth as 
suggested by Shih et al (Shih, Wang et al. 2001).
Future work should include the study of a greater number of adenomas from 
each group including AFAP tumours from individuals with 5’ and 3’ germline 
mutations.
In terms o f furthering the understanding MAP tumours particularly in light of 
findings o f evidence o f polyclonality in the MAP mouse model (although it is 
likely that this was driven by the Min allele), it is planned that this 
experimental technique be applied to MAP adenomas. This work is planned 
for the future.
In conclusion, the work in this thesis has helped to further define the clinico- 
pathological features o f MAP, and through the development of a mouse 
model, demonstrate that there is no increased risk o f tumour development in 
heterozygous carriers. I have furthered the understanding of the pathogenesis 
of MAP adenomas by demonstrating chromosomal instability (both small and 
large-scale) in 78% of adenomas from MAP patients through aCGH analysis. 
On studying MCRA cases, I identified and screened potential candidate genes 
from the Wnt signalling signalling pathway and DNA repair. I subsequently 
identified a non-synonymous SNP in exon 7 of DUT  in 11% of MCRA cases 
which has pathogeneic potential. Future approaches in MCRA gene
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identification would include genome-wide association studies and whole 
genome sequencing in selected MCRA cases.
Investigation of clonality in FAP, AFAP and sporadic adenomas has furthered 
the understanding o f pathogenesis o f adenoma development, in particular 
AFAP, and questioned some long-held beliefs in CRC pathogenesis.
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Gene name Primer name Primer sequence 5’ to 3’ Label Amplicon Size, bp Mg mM Q soln. (Qiagen) .A nnealing Temp °C No. CyclesAPC
Exon 1 IF ATT AAC AC A ATT CTT CTT AA ACGT C FAM 300 1.5 57 35
1R T GGATAAACTACAATTAAAAGTCACAG FAM
Exon 2 2F A AAT ACAG AAT CAT GT CTT G AAGT TET 200 1.5 57 35
2R ACACCTAAAGATGACAATTTGAG TET
Exon 3 3F T AACTTAGAT AGCAGT AATTT CCC HEX 212 2 57 35
3R ACCTCT CTTT CT CAAGTT CTT CTA A A HEX
Exon 4 4F AT AGGT CATTGCTTCTTGCTGAT FAM 185 1 57 35
4R T GAATTTT AATGGATTACCTAGGT FAM
Exon 5 5F Cl 1 1TTTTGCI TTT ACT GATT AACG TET 248 2 57 35
5R TGIAAI ICAI ITTATTCCTAATAGCTC TET
Exon 6 6F GGT AGCCATA GTATGATTATTT CT HEX 200 1.5 55 35
6R CT ACCT ATTTTT AT ACCC ACAAAC HEX
Exon 7 7F A AG A AAGCCT AC ACCATTTTT GC FAM 250 2 57 35
7R GAT C ATT CTT AG A ACC AT CTT GC FAM
Exon 8 8F ACCTAT AGTCT AAATTATACCATC TET 190 2 57 35
8R GTCATGGCATTAGTGACCAG TET
Exon 9A 9(I)F AGTCGT A ATTTT GTTT CTA A ACTC HEX 495 1.5 55 35
9(I)R AT GT A AA AGCT GG ATGAGGA HEX
Exon 9B 9(H)F GCTATGTCT AGCTCCCAAGA FAM 225 1.5 55 35
9(II)R CT CT CTT GT CAT C AGGCT GT FAM
Exon 9C 9(III)F CAACATCATTCACTCACAGC TET 185 1.5 55 35
9(III)R CTTT G AA AC ATGCACT ACGA TET
Exon 10 10F AAACAT CATT GCT CTT CAAAT AAC HEX 220 2 57 35
1 OR T ACCAT GATTT A AAAAT CCACCAG HEX
Exon 10A 10AF AAT CAT AACAGGAAGGGGAT FAM 290 2 55 35
10AR CAGTCACACCCCCAGAGG FAM
Exon 11 11F GAT GATT GT CTTTTT CCT CTTGC TET 220 1.5 55 35
HR CT GAGCT ATCTT AAGA A AT ACAT G TET
Exon 12 12F TTTT A A AT GAT CCT CT ATT CT GT AT HEX 180 2 60 35
12R AC AG AGT CAG ACCCTGCCTCA A A G HEX
Exon 13 13F TTT CT ATTCTT ACTGCT AGCATT FAM 300 1.5 55 35
13R AT ACACAGGT AAGAAATTAGGA FAM
Exon 14 14F TAGAT G ACCC AT ATT CT GTTT C HEX 325 1.5 55 35
14R CAATT AGGT CTTTTT GAGAGT A HEX
Exon 15A 15AF GTT ACT GCAT ACACATTGTGAC FAM 417 1.5 55 35
15AR GCTTTTTGT'ITCCiAACA 1GAAG FAM
Exon 1 5B 15BF AGTACAAGGATGCCAATATT ATG TET 346 1.5 55 35
15BR ACTTCTATCTTT I ICAGAACGAG TET
A ppendix  1: P rim ers an d  co n d itio n s
Exon 15C 15CF ATTT GAAT ACT ACAGT GTT ACCC HEX 399 2 59 35
15CR CTT GT ATT CT A ATTT GGC ATAAGG HEX
Exon 15D 15DF CT GCCCAT ACACATT CAAACAC FAM 382 1.5 55 35
15DR T GTTT GGGT CTT GCCCAT CTT FAM
Exon 15E 15EF AGTCTT AAAT ATT CAGATGAGCAG TET 420 1.5 55 35
15ER G1 1 TCTCTTCATIA1A1 1 1 1ATGCTA TET
Exon 15F 15FF AAGCCT ACCAATT AT AGT GAACG HEX 428 1.5 55 35
15FR AGCT GAT GACAAAGATGATAATG HEX
Exon 15G 15GF AAGAAACAAT ACAGACTT ATT GT G FAM 382 1.5 55 35
15GR AT GAGT GGGGTCTCCTGAAC FAM
Exon 15H 15HF AT CT CCCT CCA AAAGT GGTGC TET 420 1.5 55 35
15HR T CCAT CT GGAGT ACTTT CT GT G TET
Exon 151 15IF AGT AA ATGCTGCAGTT CAGAGG HEX 508 1 yes 60 35
15IR CCGTGGCAT AT CAT CCCCC HEX
Exon 15J 15JF CCCAGACT GCTTC AAAATT ACC FAM 317 1.5 55 35
15JR GAGCCT CAT CT GT ACTT CTGC FAM
Exon 15K 15KF CCCT CCA AAT GAGTTAGCTGC FAM 352 1.5 55 35
15KR 1IGIGGIAIAGGI111ACTGGTG FAM
Exon 15L 15LF ACCCAAC AAA AAT CAGTT AG AT G TET 417 1.5 55 35
15LR GTGGCTGGTAACTTTAGCCTC TET
Exon 15M 15MF AT GAT GTT GACCTTTCCAGGG FAM 250 1.5 55 35
15MR Al IGIGI'AACI 1 1 ICATCAGTTGC FAM
Exon 15N 15NF AAAGACAT ACCAGACAGAGGG TET 338 1.5 55 35
15NR Cl 1 1 11IGGCAI1GCGGAGCT TET
Exon 150 150F A AG AT GACCT GTT GCAGG AAT G FAM 291 1.5 55 35
1 5 OR GAAT CAG ACG AAGCTT GT CT AG AT FAM
Exon 15P 15PF CCAT AGT A AGT AGTTT AC AT CA AG TET 400 1.5 55 35
15PR AAACAGG ACTT GTACTGT AGG A TET
Exon 15Q 15QF CAGCCCCTT CA AGC A AACAT G FAM 373 1.5 55 35
150R GAGGACTT ATT CCATTTCT ACC FAM
Exon 15R 15RF CAGTCT CCT GGCCG AAACT C TET 361 1.5 55 35
15RR GTT G ACT GGCGT ACT AATAC AG TET
Exon 15S 15SF T GGT AAT GG AGCC AAT AAAAAGG FAM 306 1.5 55 35
15SR TGGGAGI11rCGCCATCCAC FAM
Exon 15T 15TF TGTCTCT ATCCACACATTCGTC TET 301 2 58 35
15TR A 1G1TTTTCA1CCTCACTTTTTGC TET
Exon 15U 15UF GGAGAAGA ACTGG A AGTT CAT C FAM 401 1.5 57 35
15UR TT GAAT CTTT AAT GTTTGGATTT GC FAM
Exon 15V 15VF T CT CCCACAGGT AAT ACT CCC TET 275 1.5 55 35
15VR GCTAGAACTGAATGGGGTACG TET
A ppend ix  1: P rim e rs  a n d  c o n d itio n s
Exon 15W 15WF C AGG ACA AA ATAAT CCT GT CCC FAM 341 1.5 58 35
15WR ATTTT CTT AGTTT CATT CTT CCT C FAM
APC MCR region___________  Paraffin samples
exon 15 F MCR IF CAAGCAGT GAGAATACGTCCA FAM 134 1 55 35
MCR 1R TTT CTT GGTT AAT AGAAGAAACTTTGC FAM
exon 15 F-G MCR 2F GCCACTTGC AAAG1 H CTTCT FAM 144 2 yes 55 35
MCR2R TGCTTCCTGTGTCGTCTGA FAM
exon 15 G MCR 3-2F CAGACGACACAGGAAGCAGA FAM 182 1 60 35
MCR 3-2F T GGA ACTT CGCT CACAGGAT FAM
exon 15 G MCR 4F GAT CCTGT G AGCG AAGTT CC HEX 149 1 58 35
MCR 4R CIGAGCACCAC1 1ITGGAGG HEX
exon 15 G-H MCR 5F AGAATCAGCCAGGCACAAAG FAM 173 1 55 35
MCR 5R GCAATCGAACGACTCTCAAA FAM
exon 15 H MCR 6F CACTAT GTTCAGGAGACCCCA FAM 149 1 58 35
MCR 6R TGGAAGATCACTGGGGCTT A FAM
exon 15 H MCR 7F GT GAACCAT GCAGTGGAATG HEX 135 1 60 35
MCR 7R ACTT CT CGCTT GGTTT GAGC HEX
exon 15 H MCR 8F AA ACACCT CCACCACCTCCT HEX 145 1 58 35
MCR 8R AGCATCT GGA AGAACCTGGA HEX
exon 15 l-H MCR 9F CCT AA AA AT A AAGC ACCT ACTGCTG FAM 165 3 60 35
MCR 9R CACTCAGGCTGGATGAACAA FAM
exon 15 1 MCR 10F ACATTTT GCCACGG A AAGT A HEX 158 2 55 35
MCR 1 OR GGCTGCTCTGATTCTGTTTC HEX
exon 15 1 MCR 11F CAGGAAAATGACAATGGGAAT FAM 168 2 55 35
MCR HR T GGCAT GGCAGAAATAATACA FAM
exon 15 1 MCR 12F GGACCT ATTAGATGATTCAGATGATG HEX 148 2 55 35
MCR 12R ACTTGGTTTCCTTGCCACAG HEX
APC MCR region____________ 1st round PCR
exon 15 F MCR IF GGACAAAGCAGT AAAACCGAAC 220 1 60 35
MCR 1R AACT ACAT CTT GAA AA ACAT ATT GGA
exon 15 F-G MCR 2F AAGT GGT CAGCCT CA AA AGG 198 3 yes 60 35
MCR 2R GCT ATTT GCAGGGT ATT AGCA
exon 15 G MCR 3F GATACTCCAATAT GTI ITTCAAGA1G 250 1 55 35
MCR 3R GCCT GGCT GATT CT G AAG AT
exon 15 G-H MCR 5F CAG ACT GCAGGGTT CT AGTTT AT C 235 2 60 35
MCR 5R CATT CCACTGCAT GGTT CAC
exon 15 H MCR 6F CC AA AAGT GGT GCT CAG ACA 209 2 60 35
MCR 6R CAT GGTTT GT CCAGGGCT AT
exon 15 H MCR 7F TTT GAGAGTCGTTCGATTGC 204 1 60 35
MCR 7R T CT CTTTT CAGCAGT AGGT GCTT
A ppend ix  1: P rim e rs  a n d  co n d itio n s
Exon 1 5W 15WF C AGG ACA AA AT AAT CCT GTCCC FAM 341 1.5 58 35
15WR ATTTT CTT AGTTT CATT CTT CCT C FAM
APC MCR region___________  Paraffin samples
exon 15 F MCR 1F CAAGCAGT GAGAATACGTCCA FAM 134 1 55 35
MCR 1R TTT CTT GGTT AATAG AAGAA ACTTT GC FAM
exon 15 F-G MCR 2F GCCACTTGCAAAG1TTCTTCT FAM 144 2 yes 55 35
MCR 2R TGCTTCCTGTGTCGTCTGA FAM
exon 15 G MCR 3-2F CAGACGACACAGGAAGCAGA FAM 182 1 60 35
MCR 3-2F T GGAACTT CGCT CACAGGAT FAM
exon 15 G MCR 4F GATCCTGTGAGCGAAGTTCC HEX 149 1 58 35
MCR 4R CTGAGCACCACTTTTGGAGG HEX
exon 15 G-H MCR 5F AGAATCAGCCAGGCACAAAG FAM 173 1 55 35
MCR 5R GCAAT CGAACGACTCT CAAA FAM
exon 15 H MCR 6F CACTAT GTT CAGGAGACCCCA FAM 149 1 58 35
MCR 6R T GGAAGAT CACTGGGGCTT A FAM
exon 15 H MCR 7F GT GAACCATGCAGTGGAATG HEX 135 1 60 35
MCR 7R ACTT CT CGCTT GGTTT GAGC HEX
exon 15 H MCR 8F AAACACCTCCACCACCTCCT HEX 145 1 58 35
MCR 8R AGCAT CT GGA AGA ACCT GGA HEX
exon 15 l-H MCR 9F CCT AA AA AT A AAGC ACCT ACT GCT G FAM 165 3 60 35
MCR 9R CACT CAGGCTGGATGAACAA FAM
exon 15 1 MCR 10F ACATTTT GCCACGGAAAGT A HEX 158 2 55 35
MCR 10R GGCTGCTCTGATTCTGTTTC HEX
exon 15 1 MCR 11F CAGGAAAATGACAATGGGAAT FAM 168 2 55 35
MCR HR T GGCAT GGCAGAAATAATACA FAM
exon 15 1 MCR 12F GGACCT ATTAGATGATTCAGATGATG HEX 148 2 55 35
MCR 12R ACTTGGTTTCCTTGCCACAG HEX
/4PCMCR region____________ 1st round PCR
exon 15 F MCR IF GGACAAAGCAGTAAAACCGAAC 220 1 60 35
MCR 1R AACT ACAT CTT G A A A A ACAT ATT GGA
exon 15 F-G MCR2F AAGTGGT CAGCCT CAAA AGG 198 3 yes 60 35
P Y n n  1 C
MCR 2R
u p n  o r
GCT ATTT GCAGGGT ATT A GCA
r*  a  t  a  r ' T r ' r '  a  a  nr a  i  i i i i /-» a a  r  a t oC a U i I 1 j  Vj MCR oF 
MCR 3R
GATACT CCAAT AT GTTTTT C AAG AT G 
GCCT GGCT GATT CTGAAG AT
250 1 55 35
exon 15 G-H MCR 5F CAGACTGCAGGGTTCTAGTTTATC 235 2 60 35
MCR 5R CATTCCACTGCATGGTTCAC
exon 15 H MCR 6F CC AA AAGT GGT GCT CAG AC A 209 2 60 35
P Y n n  I S M
MCR 6R
i  i p n  7 c
CAT GGTTT GT CCAGGGCT AT
c a u i  i i o n MCR 7 F 
MCR 7R
I I rGAGAGTCGTTCGATTGC 
TCTCTTTTCAGCAGTAGGTGCTT
204 1 60 35
A ppendix  1: P rim ers an d  co n d itio n s
exon 15 H MCR 8F CAT GCAGT GGAATGGTAAGT 199 2 55 35
MCR 8R GCAGCATTTACTGCAGCTT
exon 15 l-H MCR 9F CAAGCGAGAAGTACCTAAAAA 210 2 55 35
MCR 9R TTCTGT AT A A AT GGCT CAT CG
exon 15 I MCR 1 OF GGTT CTT CCAG AT GCT GAT A 209 2 55 35
MCR 1 OR CTT GGTTTT CATTTGATT CTTT
exon 15 1 MCR 1 IF A ATT A AG A AT AAT GCCT CC AGT 209 2 55 35
MCR HR TTT ACGT GAT G ACTTT GTT GG
exon 15 1 MCR 12F CCAAGAGAAAGAGGCAGAAAAA 217 1 yes 55 35
MCR12R T GAT GGT AGAAGTTT GT ACACAGG
APC microsatdlite markers
D5S346 346F ACT CACT CT AGTG AT A A ATCGGG FAM 125 1 55 35
346R AGC AG AT A AG AC AGT ATT ACT AGTT
D5S421 42 IF T GG AA AT AG AAT CCAGGCTT FAM 170 1 55 35
421R TCT AT CGTT AACTTTATTGATTCAG
D5S656 656F GCT AAGAAAATACGACAACT AA AT G FAM 187 1 55 35
656R CAT AAT AA ACT GAT GTT G ACAC AC
hMYH region
exon 1 IF T GAAGGCT ACCT CT GGG A AG FAM 141 1 55 35
1R AGGAGACGGACCGCAAGT FAM
exon 2 2F GGCTGGGTCTTTTTGTTTCA HEX 164 1 60 35
2R GGGCCACAACCT AGTT CCTT HEX
exon 3 3AF CT GT GT CCCA AGACCCT GAT HEX 187 yes 55 35
3AR TTGGTCGTACCAGCTTAGCA HEX
exon 3 3BF AGCTGAAGTCACAGCCTTCC FAM 110 1 60 35
3BR CACCCACT GT CCCT GCT C FAM
exon 4 4F CCT CCACCCT AACTCCTCATC FAM 110 1 55 35
4R A AAGT GGCCCT GCT CTCAG FAM
exon 5 5F CAGGT CAGCAGT GT CCT CAT FAM 152 2 60 35
5R GT CT GACCCATGACCCTTCC FAM
exon 6 6F GTCTCTTTCTGCCTGCCTGT FAM 125 2 60 35
6R T CACCCGT CAGT CCCT CT AT FAM
exon 7 7F CGGGT GAT CT CTTT GACCTC FAM 134 2 60 35
7R GTT CCT ACCCTCCTGCCAT C FAM
exon 8 8F T CTT GAGT CTTGCACTCCAATC HEX 164 1 55 35
8R AAAGTGGGGGTGGGCTGT HEX
exon 9 9F GCT AACT CTTT GGCCCCT CT FAM 150 3 yes 60 35
9R CACCCTT GTT ACCCCAACAT FAM
exon 10 10F CT GCTT C ACAGCAGT GTT CC HEX 208 2 yes 60 35
10R GACTTCTCACTGCCCCTT CC HEX
A ppendix  1: P rim ers a n d  co n d itio n s
exon 11 11F ACACTCAACCCT GTGCCT CT FAM 147 1 60 35
11R GGA AT GGGGCTT CTG ACTG FAM
exon 12A 12AF CTT GGCTT GAGT AGGGTTCG HEX 179 1 yes 60 35
12AR GGCT GTT CCAGAAC ACAGGT HEX
exon 12B 12BF GAGT GGTCAACTTCCCCAGA FAM 146 1 60 35
12BR CACGCCCAGT AT CCAGGT A FAM
exon 13 13F AGGGAAT CGGCAGCTGAG HEX 209 1 60 35
13R GCT ATT CCGCT GCT CACTTA HEX
exon 14 14F AGGCCT ATTTGAACCCCTT G HEX 210 T 60 35
14R CAACAAAGACAACAAAGGT AGTGC HEX
exon 15 15F CCCTCACCTCCCTGTCTTCT HEX 159 3 yes 55 35
15R T GTT CACCCAGACATTCGTT HEX
exon 16A 16AF CT ACAAGGCCTCCCTCCTTC HEX 158 1 yes 55 35
16AR GCT GCACTGTTGAGGCT GT HEX
exon 16B 16BF GCCAGCAAGT CCT GGAT AAT HEX 181 2 60 35
16BR ACATAGCGAGACCCCCATCT HEX
hMTHl region
exon 2 2F GCCTT ATCGCAAGGACAGAG HEX 241 3 yes 60 35
2R T GATGGAACCAT GAGTTTGG HEX
exon 3 3F TGACTCTGCCCTCTCACCTT FAM 224 1 60 35
3R CGGTT CT AT GGCCAGACCT FAM
exon 4 4F TCCCTGGGCTGTGTGTAGAT HEX 270 1 60 35
4R GAGCAGGCCCTGTGAGACT HEX
exon 5 5F CT CTT CCCCCATT GGT ACAG FAM 240 1 60 35
5R CT GTT CAGCAGCCACGT CT FAM
hOGGI region
exon 1 IF GGGTAGGCGGGGCT ACTAC HEX 266 1 55 35
1R CCCCA AATT CCTTT GT ACCC HEX
exon 2 2F AATTGAGT GCCAGGGTTGTC FAM 313 1 55 35
2R CT AACCCCAGCCCAGGT C FAM
exon 3 3F CAGCAGGT ACCT CTCCT ACCC FAM 269 yes 55 35
3R T CTT GAAAGCTGATGGAAGG FAM
exon 4 4F TT GA AG AT GCCT GAT GCTT G HEX 258 1 55 35
4R T AGAGAGGGCAGCT CCTACC HEX
exon 5 5F T CTT CCACAAGGGCT CATT C HEX 232 1 55 35
5R T CT ACCAT CCCAGCCCACT HEX
exon 6 6F T CACAGAAGGGGT CAGAT AACTT HEX 197 3 60 35
exon 7
6R
7P
GGCTGGAGAGTCCTTTAGGG HEX
( r
7R
GACCCCAGT GT ACCCT CCT C 
AT AT CCCCCACCCCAT CTT
FAM
FAM
311 1 55 35
A ppendix  1: P rim ers an d  co n d itio n s
exon 8 8F ATT CT CCAT GCT GCCTT CCT FAM 346 1 55 35
8R GTAAGCT GGCTT GCAT CACA FAM
hMSH6 region
exon 1 IF AG AT GCGGT GCTTTT AGG AG 473 1.5 yes 60 35
1R T GCACT CATT CA AGCC AACT
exon 2 2F TGCCAGAAGACTTGGAATTG 448 1.5 yes 60 35
2R CAT GCCAGAAGCTTT CACA A
exon 3 3F CT CCCAAAAT GCT GGG ATT A 486 2.5 yes 60 35
3R GGGAACTACAGAAGTATGCATGT
exon 4 4AF TGAACTGTCTTACATTATGGTTTTCC 468 2.5 yes 60 35
4AR GGGC AGAG AAAGCT CT CAAA
exon 4 4BF AA AGGAAAAGCT CT AGGAAGG AA 494 1.5 yes 55 35
4BR T GCACCAGGGAAT CTGAAT
exon 4 4CF CAGT GAACTGGGGCTGGTAT 488 1.5 . yes 55 35
4CR 1 1 1 1 AG 1 TTCCTTTGAGAGAITTCC
exon 4 4DF GGACTCTAGTGGCACACTATCC 500 2.5 yes 55 35
4DR T CC ATT CAGA A AA AT CTCC A AG
exon 4 4EF CAAAGCCTATCAACGAATGG 497 1.5 yes 60 35
4ER GAGAGATGACCTGCTTAAGGATT
exon 4 4FF AAAATCCTTAAGCAGGTCATCTC 578 2.5 yes 60 35
4FR CAGCTGGCAAACAGCACTAC
exon 5 5F AAAGAAGACCTATAAAACACTTAGGC 428 2.5 yes 60 35
5R CT GT GTTT GGA A AAT G ATCACC
exon 6 6F T GGATTT CAGAACAG AACCAA 391 1.5 yes 55 35
6R TGATGI 1 1 1 1AAAGTAACACCAGAAAA
exon 7 7F CT CCCAA AGT GCT GGG ATT A 356 1.5 yes 55 35
7R TTTT'I AGAGCACGCAC1 CA
exon 8 8F CCGATGTTGCTTTTCTGTCC 454 1.5 yes 55 35
8R CCTT GCT GCATT AA AGCCAT A
exon 9 9F T GAGAGGGC ACTT CT CTT GC 396 2.5 yes 60 35
9R CC AGGC A A ACTT CCCTT AAA
exon 10 10F ACCCCAGCCAGGAGACT ATT 425 2.5 yes 60 35
10R CC ACCTTT GT CAGA AGT C AACKras region
exon 1 IF TT AACCTT AT GT GT G ACAT GTT CTA A 220 1 55 35
1R GGT CCT GCACCAGT AAT AT GCBraf region
exon 15 15F TCATAATGCTTGCTCTGATAGGA 224 1.5 55 35
15R GGCCA A A A ATTT AAT CAGT GGAB-catenin region
A ppendix  1: P rim ers an d  co n d itio n s
exon 3 3F
3R
ATT GAT GGAGTT GGACATGGC 
CCAGCTACTTGTTCTTGACTGAAGG
236 1.5 55 35
exon 5 5F GGT GGTT AAT AAGGCT GCAGTT 231 1.5 55 35
5R ATTTT CACC AGGGC AGGAAT
BUM
exon 1 IF TT CAAGT GT CACTAGTTGT AAAT GT CA 
CAGGAACCAT GCAAAGAT GA 
CTTT GCT CAGTT GGGAT ACAA
500 1.5 yes 60 35
1R
exon 2A 2AF 500 2.5 yes 60 35
2AR T CAT CCAT AT CAT CCCAAT CAT
exon 2B 2BF GCAGACT CCGA AGGAAGTT G 542 1.5 yes 60 35
2BR T CAT GACT ATT CCCAAT GGCT A
exon 3 3F AAAGGGAGAGGATCCATACAAA 486 2.5 yes 60 35
3R T GGG ACTT CAT CTTT AG AAT GC
exon 4 4F T GA AA AGGGCT CTTT CTGG A 494 2.5 yes 60 35
4R T CAGGCAAAT GCT GGCT AAC
exon 5 5F TGACAGGGTCTCACTGTGTTG 478 1.5 yes 55 35
5R CG AAT GTT AA AGG AGT GGTTT G
exon 6A 6AF TTTT GCT ACA ATTT CT ATTT GGT AT G A 472 2.5 yes 60 35
6AR CAGCAGT GCTT GT GAG A ACA
exon 6B 6BF AGT AGCAACTGGGCT GA AACA 499 2.5 yes 60 35
6BR AG AA ATTT GCAT AGCAAC AAT G
exon 7 7F GCAAGTTTTTGG1 GGCT 1 IG 493 1.5 yes 60 35
7R T GGT ACAGGAGGTTTAAGAGGTC
exon 8 8F CCTGGGCAACAGAATGAGAC 497 1.5 yes 55 35
8R T GCAAATTT AACTGCT GTGCTT
exon 9 9F GCCCTGCCTGAGTTATGCT 476 2.5 yes 60 35
9R T GCAGAGAGAGAATACAAAGCAA
exon 10 10F TGTTGGTTAGGCTGGTCACA 485 2.5 yes 60 35
10R T CAGACT ACTT GGAGCTT CCTT C
exon 11 11F T CCGGAAATACCGATAAATACA 478 2.5 yes 55 35
11R CT GCCATCGGGTT ACAACTT
exon 12 12F AT AT GCGGGT GGGGAGAG 488 2.5 yes 60 35
12R TTT CCAGAATTGAGAGAGTTGC
exon 13 13F GCACACAT GA ATT CCTT GCTT 491 2.5 yes 60 35
13R GCA ACTTT AGA AGT CT CA A AGAA AA
exon 14 14F AAT GGCATTGCAAGTTATCAG 530 2.5 yes 60 35
14R TTGCCAATCTGTATAAACTCCTC
exon 15 15F AT GCCAT GTT GACAATGCTG 452 1.5 yes 60 35
15R GGAAGCTGT CTTT CCCCTGT
exon 16 16F T GA A ATTT CCGT AGGTTTT GG 497 2.5 yes 55 35
A ppendix  1: P rim ers an d  cond itio n s
16R TTCTTTGTATGTGAAACCATCTCAA
exon 17 17F CGGGGTTT GT GAT CT ATT CC 491 2.5 yes 55 35
17R GGTT G AATTTT A AGAT CT CTTT CCA
exon 18 18F AGAATGCACAGCCCCTGTT 491 1.5 yes 55 35
18R GGGT GACACAGCGAGACC
exon 19 19F GTCTGCTGCCTCTGAGGTG 476 1.5 yes 60 35
19R CACAGGGGGCATAAGCACTA
exon 20 20F GAATCCATATGGCAGGGAA G 472 1.5 yes 60 35
20R CT CCATT AACAACT GTCATT CCA
exon 21 21F GGGTT GGT CAC AAGT CAGA A A 498 1.5 yes 60 35
21R T GGTCAG AT GCT GAC AAACA
CDC4
exon 1 1F CAGGAGCAGGAGCTTTCACT 144 2.5 yes 55 35
1R TTTT CACT AAAAGAGGCCA AGG
exon 2 2F CCAT GCT GACTC AA GATTT GAT A 164 2.5 yes 55 35
2R TT CCGGT AAT CT CAA AAT GT GTT
exon 3 3F T GCCAGAT CAT CATT CTTT G 142 2.5 yes 55 35
3R GCAGCAATT AAGT GAGGCATT
exon 4 4F GCCTGT AATTT GGGACATCTG 135 2.5 yes 55 35
4R C ACCC AAT G AAG AAT GT A ATT GA
exon 5 5F T CAAGTAT CTCATCCTGTGGAGAA 124 2.5 yes 55 35
5R TTT CAG A AT CACT CT GCTTTT C A
exon 6 6F T GGT G A AGGC A ATTT ACT CTT G 137 2.5 yes 55 35
6R AACGGTTT CT GTT ACATT GTGC
exon 7 7F AT CT GCACAT CTTTCTTATAGGTGCT 114 2.5 yes 55 35
7R G A AG AGT A A ACTT ACTTT GCCT GT G A
exon 8 8F ICACI rTTCCTTTCTACCCAAAA 182 2.5 yes 55 35
8R GGAAGAAGTCCCAACCATGA
exon 9 9F I 1111CTGTTTCTCCCTCTGC 226 2.5 yes 55 35
9R TT CAT CAGGAGAGCATTTAAGG
exon 10 10F T CCT CTT CCCCCTTT CCT AC 211 2.5 yes 55 35
10R TTT GT GAT GCT AAGGCTCCAMBD4
exon 1 IF ATCTTACTCCGCCCCACAC 206 1.5 60 35
1R GTGAAACTGAGGCCCAAAAG
exon 2 2F AAT CACTT AGACTTT G I I I  TTCCAG 295 2.5 yes 55 35
2R T CATTTGGCTGTACTATCTTTACCA
exon 3A 3AF ACCT AT GGC A AC ATTT GGA A 680 2.5 yes 55 35
3AR T CACACT GAGGGTCTCACCA
exon 3B 3BF T GAT AGC A AA AGAG AAT CTGTGTG 496 2.5 yes 55 35
A ppendix  1: P rim ers an d  co n d itio n s
exon 4 -5
3BR
4-5F
GGCACGAAT ACAAGAT GCAG 
GCCT GGCAT GCTTT GT AAT A 496 2.5 yes 55 35
4-5R TCCCAGGTGACACACT CAAA
exon 6 6F GCCCACCTGGAGTCTTGTAA 225 2.5 yes 55 35
6R iGirmccn igggtgtatagg
exon 7 7F CACATTTTGGGAGGGTGTCT 212 1.5 yes 55 35
7R GCCT CAGAGACCAAATGTGC
exon 8 8F AT GT ACT GT CCCCCAGC A AA 202 T 55 35
8R T GAGCTTGAAAGCTGCAGAG
MGMT
exon 2 2F CGACCAGCCT CTT ACCT AT ACA 211 2 60 35
2R AGGAT CACGT GGGCT CAT AC
exon 3 3F GGTGTTTGCTTTTCCGATGT 195 2 _ ves 55 35
3R ACACCGCAGATGGCTTAGTT
exon 4 4F TCCTGCATTCTTCCTTTCAG 243 1 55 35
4R GAGGAAACACGTGGGATCAG
exon 5 5F CGTT GT CCAGATCCCT GACT 299 t 60 35
5R T ACACGT GT GT GT CGCTCAA
TDG
exonl IF TCTCTGGGGTTGTCTTACC 225 1.5 yes 55 35
1R GGCCGGGATTT A A A AG AC
exon 2 2F AGA 1 1 1 r 1G1ACAGCTGA I'CATT 299 1.5 ves 55 35
2R A ATT C ACC AT G AA ACCCTTT
exon 3 3F TTCTG C ATTT CT GGA A ATT AT 299 2.5 ves 55 35
3R AAT CCAACGAGGACAAAGAT
exon 4 4F T CCT CCAT AGAAACGCT AAG 222 1.5 yes 55 35
4R AACACAA1 1 GG 1 1 ITT C1 GA
exon 5 5F T ACACTCT AGCCTGGGTGAC 246 1.5 yes 55 35
5R AAGGTTCCAACCCATAAAAG
exon 6 6F AAGCTGTCTGAATTTAGCATATTA 208 2.5 yes 55 35
6R ACATT GCCCAT AAT GTT AGC
exon 7 7F AAAT AT CAGCCACGAATAGC 250 1.5 yes 55 35
7R TTCACATTT AGCT GATTT ACAA
exon 8 8F CCCAA AT A A AG ACA A AT ATT CTA A 289 1.5 yes 55 35
8R T GAAT AAAAGGAAT GAGGACA
exon 9 9F TT CAT GATTT CT G A AT A AAGCT A 249 1.5 yes 55 35
9R GACCAAACCGTCTTTGAA
exon 10 10F T GGGCGAT AGAGTAAGACC 288 2.5 yes 55 35
1 OR TT GTT G AC A ACT GCATT A AAA
A ppendix  1: P rim ers an d  cond itions
CXCR4
exon 1 1F GTAGCAAAGT GACGCCGAG 149 1 60 35
exon 2-1
1R 
2-1F
A b A b b b b L 1 b b b b 1 L 1A A b  
T GCTT GCT G A ATT GGA AGT G 170 1 60 35
2-1R GAGTAGATGGTGGGCAGGAA
exon 2-2 2-2F GGATT GGT CAT CCT GGT CAT 174 2 60 35
2-2R GACATGGACT GCCTTGCATA
exon 2-3 2-3F T AT GCAAGGCAGTCCATGTC 215 1 60 35
2-3R CT CACTGACGTT GGCAAAGA
exon 2-4 2-4F T GACTT GT GGGT GGTT GT GT 165 1 60 35
2-4R GCCAGGATGAGGATGACTGT
exon 2-5 2-5F ATT GGGATCAGCATCGACTC 154 2 60 35
2-5R T GGCT CCAAGGA AAGCAT AG
exon 2-6 2-6F AAGCGAGGTGGACATTCATC 176 1 55 35
2-6R AAAT CCA ACAAGCAAT AAAAACT G
exon 2-7 2-7F TGCTTG'l IGGAI 1 1 1 IGTCTTG 180 1 55 35
2-7R CACGCT CT GGAAT GTT CAGT
exon 2-8 2-8F CATT CCAGAGCGT GTAGTGAA 295 1 60 35
2-8R GCCAAA AGA AT GT CAACAGA AA
DUT
exon la 1aF GCAAGACTCAAGACGCCAAC 270 1 60 35
1aR T GAGCGAAGCAGAGACGTAA
exon 1b 1bF GGGG AA AT G ACT CCCCT CT 362 1 60 35
1 bR CACCCTACTTCCCCCACAG
exon 2 2F CTCATCGTGCGCTCTC 278 2 55 35
2R GTTTCTAGCTGTGGCAGCG
exon 3 3F CACT G A A AGT AATTTT GT AT GCTT GG 272 2 60 35
3R GCCT GCTT ATTACCCC A AAT G
exon 4 4F T GACATGCTTAAATTGCATCAG 279 1 60 35
4R AAAAT AACCACAAAGCTTTTCCT C
exon 5 5F C A ATT GT A AG A AT ACAA AT CT C AGAGC 244 1 55 35
5R CACATACATGACTCTGAAAATTCACTA
exon 6 6F AA r TTTAG 1GAAT TTTCAGAG1CA1G1 290 2 55 35
6R TTACAAACAGCATATTAAATTCTCAAG
exon 7 7F AA1I I 1 AG 1GAATTTT CAGAG1CA1G1 254 1 60 35
7R T GCAAAACACCAAAACACTTGP0LE2
exon 1 IF TAACAGGGTTTAGCGCC 289 2 55 35
1R AATTTAAGGTCAAGCCCC
A ppendix  1: P rim ers an d  co n d itio n s
exon 2 2F CCTTTCAGTGCCAGATTG 308 1 55 35
2R GGG ACAT CTT AAT AGT G AAGC
exon 3 3F T GGG AAA AG AGCT GT CTG 242 1 55 35
3R TT GAT CACT AAT AATTTT CCA AG
exon 4 4F CTT AT AAT GCAAGTT AT CAT GTT C 247 1 55 35
4R GT GAGCCAAAAGTGAAGC
exon 5 5F TCTCTTGCTTCACTTTTGG 246 2 55 35
5R CCCT GAG ATTT CCCT AA AC
exon 6 6F ACAGTGTTTCATCAGGGC 291 2 55 35
6R GCAGCCCATCCAGTT AG
exon 7 7F TTGT AGGACAAAATTAAACATCC 358 1 55 35
7R CATTCCTGTGCCCACTAC
exon 8 8F TTTT A A AAT CCACTTT CTCCC 302 1 55 35
8R ACATTCCTACACCAGCAAC
exon 9 9F TT AGAAGCCTT GTT GGACT C 206 1 55 35
9R AACAT ATTTT ACCCAAAGCAG
exon 10 10F GTTCACAGGGCATGAGAC 290 2 55 35
1 OR GACACAAAGCCT GACACC
exon 11 11F CT CAA AA AGAT AAAT AG AAT ACT CAAA 381 1 55 35
11R C A A AG AGT ACCTTTTT ACACTGG
exon 12 12F AATTT GCAT AT AATGCCATAAA 385 2 55 35
12R AAT GAAT GGCT ACT GTT ATT AGT ATT
exon 13 13F AAGCTTTGAAAGGTATTAACG 331 1 55 35
13R T CCTTAGTTTT GT AAT A ATT GCTG
exon 14-15 14-15F AACTT GCTTTT A AGCT ATT GG 417 1 55 35
14-15R AACTCCAAGCAACCTGC
exon 16 16F GGAATGGGGTTGTATTGTAAG 285 2 55 35
16R CCCAAGGACAAATT ATT AAGT G
exon 17 17F GCAIAI I I I I AC I ICGACAAT AAT C 407 1 55 35
17R TTCCT AGTTT CT CAAATTTT CT G
exon 18 18F AGCCTGGGTGATGAGAG 358 2 55 35
18R CCGT GAT AAGCTCAGCC
exon 19 19F TTT GGG AGCA GAA A AGG 327 1 55 35
19R ACAAATTT AAGCAGAACAT CCDKK1
exon1A 1AF GCAAGACTCAAGACGCCAAC 277 2 60 35
1AR TGAGCGAAGCAGAGACGTAA
exon IB 1BF GGGG AA AT GACT CCCCT CT 362 1 60 35
1BR CACCCT ACTT CCCCCACAG
exon 2 2F CT CAT CGTGCGCTCTCC 278 1 60 35
A ppendix  1: P rim ers a n d  c o n d itio n s
2R GTTTCT AGCTGT GGCAGCG
exon 3 3F CACTGAAAGT AATTTT GT AT GCTTGG 272 2 60 35
3R GCCT GCTT ATT ACCCCA AAT G
exon 4 4F T GACAT GCTT AAATT GCATCAG 279 1 60 35
4R AAAATAACCACAAAGCTTTTCCTC
exon 5 5F CAATT GT AAG AAT ACAAATCT CAGAGC 244 2 55 35
5R CACATACATGACTCTGAAAATTCACTA
exon 6 6F AATTTT AGT G AATTTT CAG AGT CAT GT 290 1 55 35
6R TTACAAACAGCAT ATT A AATTCTCAAG
exon 7 7F GGAGCTGGAGAGGAAAACTG 218 \ 60 35
7R T GCAAAACACCAAAACACTT G
EPHB2
exon 1 IF CT GGAT GGCT CATT CT GCT G FAM 433 1 55 35
1R CTCCTCCT GGC ACAGT CAAT
exon 2 2F AGATT GACAGCGCCTGGTAG HEX 220 1 55 35
2R AGGGGGAA AGGGGTTAGAAT
exon 3A 3AF CCTT ACCT CCCCACCTGAC HEX 195 1 55 35
3AR CGCACCGAAAACTTCAT CT
exon 3B 3BF CCACGTGGAGATGAAGTTTTC HEX 250 2 55 35
3BR CGGT GTT GATTTTCATGACG
exon 3C 3CF CCGCGT CAT G A A A AT C A AC FAM 412 2 55 35
3CR AGT CT GC AGCCA AGACC AGT
exon 4 4F T CCAGTTTCCT GGT GACT CT HEX 250 1 60 35
4R GCAGGTAGACCT GGGACT C
exon 5 5F GGG A AT AGT ACCCCCT G AGC FAM 464 1 55 35
5R CTTTT GT GAGGACTGCAGGA
exon 6 6F CTCCCTGATCCCTGACCTCT HEX 237 1 55 35
6R CAGAACT CCCAGGCCT CA
exon 7 7F CCCACT AT GAGCCACAACCT HEX 250 2 55 35
7R AGTCTGTGCCCTCCTCTTGC
exon 8 8F CT GAGA AT GCCCT ACC AT GC HEX 194 2 60 35
8R GAGAGAAGCCATCTGGGACA
exon 9 9F GCT CCAGCCCTTTGCTCT FAM 161 2 55 35
9R T AAGAGGT CACTGGGGAACC
exon 10 10F CTCCCGCI111CCTTTTTG1 HEX 236 1 55 35
10R GCCAT GGCT AAGGT CAT AGT ACA
exon 11 11F GGC A AGTG AC ATCCTGTCTG FAM 336 1 60 35
11R Cl 111CC1GCCCCA1ICAI
exon 12 12F 111 AC 1CTGTGTT11CCCCAC11 FAM 296 2 55 35
12R CCCTCTTCTCTGGCTCTGTG
A ppendix  1: P rim ers an d  co n d itio n s
exon 13 13F ACCCACAAACCCTCCTCTTT HEX 206 2 55 35
13R CTT GCCT AT CCCCTT GGAG
exon 14 14F AACCCCACTGCACTCCTG FAM 281 2 60 35
14R AT GGGAGACGGGAAGAGG
exon 15 15F GT GCCCTGACCATCTCTGTC HEX 238 2 60 35
15R AGAGGGGGTGCTAAGGTGAC
exon 16 16F CCCGCATATTT CCCT AACAC FAM 500 1 60 35
16R AACTGLI1 ITCTCTCCGATTC
Wifi
exon 1 IF CTCTCGCAGGCTCCTTGG FAM 356 1 55 35
1R GAGGACATAGGCAGGGGAAG
exon 2 2F T CAAGTCTACCTGGTTT GATCG HEX 231 1 55 35
2R T GCCAT AAGGCAGTGGAAAT
exon 3 3F GCCTT CT CCCT CT CT GGTTT FAM 189 1 60 35
3R CCTTT CTT C AGGC A A AG ACC
exon 4 4F CTT GGTT CCC AAGATTT CT G FAM 248 2 55 35
4R T CTT CT CTT G AAT CACC AT CG
exon 5 5F GGCT GT GATT CACCCAACAT FAM 236 1 55 35
5R AC A AT AC AC AT GGGGCT CCT
exon 6 6F T GGCCTT AAT CAGGGTT CT C HEX 243 2 60 35
6R CCCT AAGCCATACATTCTCAGAGC
exon 7 7F GAAATGGGCAAGTAGCAAGC HEX 247 2 55 35
7R CT CCCCAAGT CAAA AGAACG
exon 8 8F T GAAT GAAGCACCAGGTT CC FAM 242 1 55 35
8R CAGGCAACATGCACTAAGCA
exon 9 9F CCAACTT ATGACTGGAGACTGA C HEX 350 1 55 35
9R AGCCAAGAAACCGAAGT GAA
exon 10A 1 OAF GAA1C1GAAGAGCC1 GG I I T I'G HEX 195 1 55 35
10AR TCAGATGTCGGAGTTCACCA
exon 1 OB 10BF GCCTTT GTT AACCTTT CAT GT G FAM 276 2 55 35
10BR GCCCCCAGACACC AT AAAT
exon IOC 10CF CAAT GCATTTATGGTGTCTGG FAM 224 2 60 35
10CR CT GAAT CT CT GGAAT AAT GGTA AGG
exon 10D 10DF ACACTGTGGTAGTGGCATTT HEX 218 1 55 35
10DR GCAT GT GCAAAGATCACCTCMicrosatellite markers
chromosome 1 D1S201F GGT AT GGAAGT CACCCAACA FAM 186 1.5 yes 55 35
D1S201R CT CAAA AT G ACT GAT GGGGT
D1S2729F T ACTT GCCT AAT GCT GT GT G FAM 208 1.5 yes 55 35
D1S2729R T AT C AAT CCTT GGGAG ACC
A ppendix  1: P rim ers an d  co n d itio n s
D1S2749F GAT CCT GCCTTT ACT GCTT G FAM 195 1.5 ves 55 35
D1S2749R GGCCAT GT GT AGCCTTT C
D1S470F AAAT GGGGCT AAT AAAT CT CCT GG FAM 155 1.5 yes 55 35
D1S470R CT ACACCAT AGGCAT AGGT GCAA
chromosome 9 D9S1818F GGAT CT ATGCT GGCT ACTT CATAAC FAM 133 1.5 yes 55 35
D9S1818R T ATTT GGACTCTGTAGTGCTGAAC
D9S1826F ATGTTGATTGCCGCAGTG FAM 133 1.5 yes 55 35
D9S1826R T GCAG AACCAGGT CTT ATT CG
D9S1829F AGCT ACTCAGGAGGCTAAGG FAM 198 1.5 yes 55 35
D9S1829R GCGA ACTT CAG A AAA AC AT C
D9S1830F CAGAGT GGT GGGACTCAA FAM 107 1.5 yes 55 35
D9S1830R AGCTGCAGACTGCCTTC
chromosome 17 D17S786F T ACAGGGAT AGGT AGCCGAG FAM 135 1.5 yes 55 35
D17S786R GGATTTGGGCTCTTTTGTAA
D17S1832F ACGCCTT GACATAGTTGC FAM 151 1.5 yes 55 35
D17S1832R T GT GT GACTGTTCAGCCTC
D17S1353F CT GAGGCACGAGAATTGCAC FAM 184 1.5 yes 55 35
D17S1353R T ACT ATT CAGCCCGAGGTGC
D17S1844F CATT CCAGCCT GGGT GA FAM 227 1.5 yes 55 35
D17S1844R GGAACCAT AGGAGGCGTTTT
chromosome 19 D19S886F T GGAT CT ACACTCCGGC FAM 134 1.5 yes 55 35
D19S886R A 1 1TTACTGGCTGGCACTTG
D19S878F GCCT GGGCGACAGAG AAT FAM 208 1.5 yes 55 35
D19S878R GGTT GCCCGCAGAGTG
D19S215F CAT GC ATT A A A A AT GACAACT GT FAM 252 1.5 yes 55 35
D19S215R GCT CT GCANTCCATT ACT CA
D19S656F GTGATTGCACCACGGG FAM 168 1.5 yes 55 35
D19S656R T CAAGT CATT GGGTT GGC
D19S591F TTCCAGCCTAGGT AGCAGTG FAM 96 1.5 yes 55 35
D19S591R GCAACT GAGGAAAT GCATCT
M ou se  P r im e r  s e q u e n c e s
G ene nam e Prim er nam e Prim er se q u e n c e  5’ to  3’ Label Am plicon Size, bp Mg mM Q so ln . (Q iagen) A nnealina Temn °C No. C yclesAPC
mAPC xl 5AF CTT GTT GTCACTAATCA C ATTTT C 550 2 55 35
mAPC x15AR T CCAGT ATT GAAATT GT CT GACC
mApc x15BF GACGCCAATCGACATGAT 547 2 55 35
mApc xl 5BF CAACTGAGGGTTTCATTTGG
mApc x15CF TGATGGATATGGTAAAAGAGG 544 2 55 35
mApc xl 5CR TTCTTCCTCAGAATAACGTTCAC
A ppendix  1: P rim ers a n d  co n d itio n s
mApc x15DF T GAAGATGATAAACCTACCA AC 545 2 55 35
mApc xl 5DF CAGCTGACCGAGTTACATCA
mApc x1 5EF T GCAGACAGCAGAAGTAAAAGA 504 2 60 35
mApc xl 5EF GCTT AGGCCCACT CT CT CT C
mApc xl 5FF AGT AA AGT CCCT GCT GCT G A 453 2 55 35
mApc xl 5FR T GCCACAGGT GGAGGT AAT
mApc LOH 1F T ACGGT ATT GCCCAGCTCTT FAM 153 2 55 35
mApc LOH 1R T GC AG ACCT CGTTTT GAT G A
mAPC xl 5 (-1 )F T GCCCCTTTACTT GTT GT CA FAM 308 1 55 35
mAPC xl 5 (-1 )R T CT GTTT GCCAT GAGATT CCT FAM
mAPC x1 5 (0)F CCT CATT CATT CC A AGCAC A FAM 376 1 55 35
mAPC xl 5 (0)F AGAGCTGGGCAATACCGTAG FAM
mAPC xl 5 (LOH5&6)F IT 11GACGCCAATCGACAT FAM 310 2 60 35
mAPC xl 5 (LOH5&6)R GTCGT CCT GGGAGGTATGAA FAM
mAPC xl 5 (1 )F GCCAAAGTTATGGAAGAAGTATCA FAM 411 1 60 35
mAPCx15 (1)R TGGTGTAT CCAGTT CTCCATCA FAM
mAPC xl 5 (2)F CAGT GCAAATCATATGGATGATAA HEX 372 2 55 35
mAPC xl 5 (2)R TCTTCCTGACACAGAGACTGG HEX
mAPC xl 5 (3)F T CGAATGGGTTCTAGTCAT GC FAM 418 1 60 35
mAPC xl 5 (3)R GGGGACTTTGCAAGTAGTGC FAM
mAPC xl 5 (4)F GCACAAAGAA AT GGCC AGAC HEX 391 2 55 35
mAPC xl 5 (4)R CACCACTTTT GGAGGGAG AC HEX
mApc x6F CCCAT GT CAAGACACTCCAG FAM 204 1 55 35
mApc x6R T GT ACCAGAAGGGGGCTTT A FAM
mApc x7F TT CAT CGAGAGTTTT G AAGCA A HEX 228 2 55 35
mApc x7R CAGACAGG ACTT GT C AGTTT GAA HEX
mApc x8F AATTGGGAGCTTCAGAGTGG FAM 196 2 yes 55 35
mApc x8R GCAAG AGGGTTT GT AAT CTGC FAM
mAPC x9F TA AACT CATTT GGCCCAC AG FAM 555 1 60 35
mAPC x9R CAGGGAAATGCAGATTT AAGC FAM
mApc xlOF T GAGGG AT GT GT CAATAACGTC FAM 223 3 60 35
mApc xlOR ATTT GTGGCGTT AGGAAAGC FAM
mApc xl IF T GTTT CCTTTT GCCCTT GTT HEX 272 2 yes 55 35
mApc xl 1R GTT CAACTGGGCTGCTGTG HEX
mAPC xl 2F T C AGGC AGATT CCTT GAT G A FAM 208 1 55 35
mAPC xl2R GCCAT ACTTT AACACAAGCCACT FAM
mAPC xl 3F CCT CT AGC ATT AG A A AC A A A A AG ACA HEX 226 1 55 35
mAPC x!3R CCT ATT CCAGCACCCAACAT HEX
mAPC xl 4F CAGCACT GACCCAAATTTCA HEX 475 1 55 35
mAPC x14F GGCCT CTTT GCTT AG AGCTT HEX
A ppend ix  1: P rim e rs  a n d  co n d itio n s
Mom 1
MomlF GT CCAAGGGAACATTGCG 465 1 55 35
MomIR AG AACAGGT GATTT GGCCC
Kras
mKras x1F n i l  1 ATT G1AAGGCCTGC VGA 161 2 55 35
mKras xIR GCACGCAGACT GT AGAGCAG
BRAF
mBRAFxl 5F AGGCCT GGGACAGCTTAA AA 529 3 yes 65 35
mBRAFxl 5R CAGCTTTCTAAGTGCTGGGATT
MYH
mMYH xl F CTTTGCCCTTTTGTTTCGAG FAM 199 2 60 35
mMYH xIR GAAACT GGT GAGGGACAAGC FAM
mMYH x2F CT GAGTTCCCCT GGCTGTC FAM 199 2 55 35
mMYH x2R CACT GTCTCTGT CCCAT CCA FAM
mMYH X3&4F ITCACCC11GGTTTTATTGACA FAM 278 2 60 35
mMYH x3&4R CT CCCT CCCCAAC AT CAC FAM
mMYH X5&6F 1111TGCCTGTCTTGGGTTT FAM 254 1 60 35
mMYH X5&6R CACCGGGC1ATTT 1TCAGTG FAM
mMYH x7&8F CT GT G AGCTT CCTGCT CCAT FAM 337 2 60 35
mMYH x7&8R CCCGT CACCTCATTACCCTA FAM
mMYH X9&10F AAGGGCCTTTGCTTACAGAA FAM 357 2 60 35
mMYH X9&10R CT CT GAAAGGGACAGGGATG FAM
mMYH xl 1&12F GCT GGG AAT CTTT GTTT CCA FAM 466 2 yes 60 35
mMYH xl 1&12R CCCT GT CACCTTTGCT AACC FAM
mMYH xl 3&14F CAGACCTGGTTCGGTCT CTT FAM 460 2 60 35
mMYH xl 3&14R GAAGAGGGCGGAATGCAC FAM
mMYH xl 5F GGGT AGAAGAGT CCCTGGT G FAM 201 2 60 35
mMYH xl 5R TTTGGGT AGGGAAT CCCAGT FAMMYH genotyping
PI (21-mer) CAAGT GCT GGGAT CAAAGGT G 1 55 35
P2 (20-mer) GCT CCTT CTT GT AGCCG ACG P1/P2 262
P3 (neo, 21-mer) TCCT CGT GCTTTACGGT ATCG P1/P3 376
A ppend ix  1: P rim ers  an d  c o n d itio n s
Mom 7
MomlF GT CCAAGGGAACATTGCG 465 1 55 35
Kras
MomlR AGAACAGGTGAT11GGCCC
mKras xlF 1111IA I1G1AAGGCCTGCTGA 161 2 55 35
mKras xIR GCACGCAGACTGTAGAGCAG
BRAF
mBRAFxl 5F AGGCCT GGGACAGCTT AAAA 529 3 yes 65 35
mBRAFxl 5R CAGCTTT CT A AGT GCTGGGATT
MYH
mMYH x1F CTTTGCCCTTTTGTTTCGAG FAM 199 2 60 35
mMYH x1R GAAACT GGT GAGGGAC AAGC FAM
mMYH x2F CTGAGTTCCCCTGGCTGTC FAM 199 2 55 35
mMYH x2R CACTGTCTCTGTCCCATCCA FAM
mMYH x3&4F TT CACCCTT GGTTTT ATT G ACA FAM 278 2 60 35
mMYH X3&4R CT CCCT CCCCA AC AT C AC FAM
mMYH X5&6F 11111GCCTGTCTTGGGTTT FAM 254 1 60 35
mMYH X5&6R CACCGGGC1A 11T1TCAGTG FAM
mMYH X7&8F CT GT GAGCTT CCTGCTCCAT FAM 337 2 60 35
mMYH X7&8R CCCGTCACCTCATTACCCTA FAM
mMYH X9&10F AAGGGCCTTTGCTTACAGAA FAM 357 2 60 35
mMYH X9&10R CT CT GAAAGGGACAGGGATG FAM
mMYH xl 1&12F GCTGGGAATCTTTGTTTCCA FAM 466 2 yes 60 35
mMYH xl 1&12R CCCT GT CACCTTT GCT A ACC FAM
mMYH xl 3&14F CAGACCT GGTTCGGTCT CTT FAM 460 2 60 35
mMYH X13&14R GAAGAGGGCGGAATGCAC FAM
mMYH x15F GGGT AGA AGAGTCCCT GGT G FAM 201 2 60 35
mMYH xl 5R TTT GGGT AGGGAATCCCAGT FAMMYH qenotypinq
PI (21-mer) CAAGTGCTGGGATCAAAGGTG 1 55 35
P2 (20-mer) GCT CCTT CTT GT AGCCGACG P1/P2 262
P3 (neo, 21-mer) T CCT CGT GCTTT ACGGTATCG P1/P3 376
A ppendix  1: P rim ers a n d  co n d itio n s
ID
hitological morphology 
size adenom a (cm) 
histological grade
chrom osom al lo sses  and gains
No. aCGH changes
ID
hitological morphology 
size adenom a 
histological grade
chrom osom al lo sses and gains
No. aCGH changes
FAP 1
TA
2.1
mild dysplasia 
none
FAP 2
TA
3
mild dysplasia
17.0-8,del
19.0-18,del 
19,51-ter,del
FAP 3
TA
2.6
mod dysplasia
none
FAP 4
TA
1.5
mild dysplasia
1,76-112,del 
1,188-218,del 
13,53-96,del
16,all gain
17,all gain 
18,24-39,del
19,all gain 
21,33-ter,gain 
22,all gain
FAP 5
TA
1
mild dysplasia
1,183-196,del 
13,54-104,del 
21,all gain
Sporadic 1
TA
1
mild dysplasia
1.0-54,del 
6,33-47,del
8,all gain 
9,122-ter,del 
13,all gain
16.0-31,del 
16,67-ter,del
17.0-50,del
19,all del
20,all gain
21,all gain
22,all del
Sporadic 2
TVA
1.3
mod dysplasia
1,0-51,del 
2 ,123-152,del 
17,all del 
19,all del
Sporadic 3
TA
1.6
mild dysplasia
1.0-57,del 
9 ,104-111,del
17.0-50,del
Sporadic 4
TA
3
mild dysplasia
1.0-47,del
17.0-50,del 
22,all del
Sporadic 5
TA
1
mild dysplasia 
none
12
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FAP 6
TA
2.6
mild dysplasia
21,41-ter,gain
1
Sporadic 6
TA
1.5
mild dysplasia
1,0-46,del 
17,44-50,del
FAP 7 FAP 8 FAP 9
TA TA TA
1.8 3.5 2.3
mod dysplasia mod dysplasia mild dysplasia
1,0-118,del 
1,143-244,gain 
5,55-165,del 
6 ,all gain 
13,all gain 
18,all del 
20,all gain
19,0-18,del none
7 1 0
Sporadic 7 Sporadic 8 Sporadic 9 Sporadic 10 Sporadic 11
TVA VA TVA TVA TVA
1 6 7 3.8 2.4
mild dysplasia mod dysplasia mod dysplasia mod dysplasia mod dysplasia
1,0-46,del 1,0-46,del none 1,0-51 del 13,all gain
10,91-103,del 7,62-74,del
18,51-64,del 9,123-ter,del
19,?all del 1 2 ,lll- te r ,d e l 
13,53-96,gain
16.0-31,del 
16,66-ter,del
17.0-50,del 
17,72-ter,del
19.0-18,del 
19,38-ter,del 
20,31-36,del
22,all del
4 13 0 1 1
ID
hitological morphology 
size adenom a (cm) 
histological grade
chrom osom al lo sses and gains
No. aCGH changes
ID
hitological morphology 
size adenom a 
histological grade
Sporadic 12
TVA
1.5
mild dysplasia
Sporadic 13
TVA
3.5
mod dysplasia
Sporadic 14
TA
1
mild dysplasia
chrom osom al lo sses and gains 17,0-14,del none
No. aCGH changes
Appendix 2: FAP and Sporadic aCGH changes
In d  1 JUM-MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
204517 at 6.97 PPIC 5q23.2 peptidylprolyl isomerase C (cvclophilin C)
206366 x at 6.95 XCL1 1023 chemokine (C motif) liqand 1
204983 s at 6.07 GPC4 Xo26.1 glypican 4
203325 s at 6.01 COL5A1 9o34.2-034.3 collaqen, type V, alpha 1
1559401 a at 5.80 ZNF609 15022.31 zinc finger protein 609
1569237 at 5.26 RAPGEF2 4032.1 Rap quanine nucleotide exchanqe factor (GEF) 2
226665 at 5.21 AHSA2 2pl5 AHA1, activator of heat shock 90kDa protein ATPase homoloq 2 (yeast)
207836 s at 5.18 RBPMS 8p l2 -p l1 RNA bindinq protein with multiple splicinq
236404 at 5.10 ATXN1 6P23 ataxin 1
239808 at 4.91 PITPNC1 17024.2 phosphatidylinositol transfer protein, cytoplasmic 1
229026 at 4.89 CDC42SE2 5031.1 CDC42 small effector 2
207002 s at 4.77 PLAGL1 6024-025 pleiomorphic adenoma qene-like 1
221042 s at 4.73 CLMN 14032.13 calmin (calponin-like, transmembrane)
546 s at 4.63 APOL1 22013.1 apolipoprotein L, 1
s at 5.03 PSME3 17021 proteasome (prosome, macropain) activator subunit 3 (PA28 qamma; Ki)
215001 s at 4.84 GLUL 1031 qlutamate-ammonia liqase (qlutamine synthetase)
200762 at 4.51 DPYSL2 8p22-p21 dihydropyrimidinase-like 2
215073 s at 4.45 NR2F2 15o26 nuclear receptor subfamily 2, qroup F, member 2
44783 s  at 4.27 HEY1 8021 hairy/enhancer-of-split related with YRPW motif 1
202613 at 4.14 CTPS 1P34.1 CTP synthase
201360 at 4.09 CST3 20pl 1.21 cystatin C (amyloid anqiopathy and cerebral hemorrhaqe)
20305 4 PTPRK 6022.2-23.1 protein tyrosine phosphatase, receptor type, K
In d  2 EIG - MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
213524 s at 20.91 G0S2 1032.2-Q41 GO/Glswitch 2
205220 at 13.24 GPR109B 12q24.31 G protein-coupled receptor 109B
219622 at 10.31 RAB20 13034 RAB20, member RAS oncoqene family
202581 at 8.99 HSPA1B 6P21.3 heat shock 70kDa protein IB
225803 at 8.57 FBX032 8o24.13 F-box protein 32
210448 s at 8.34 P2RX5 17pl3.3 purinerqic receptor P2X, liqand-qated ion channel, 5
227850 x at 7.81 CDC42EP5 19013.42 CDC42 effector protein (Rho GTPase bindinq) 5
211214 s at 6.38 DAPK1 9034.1 death-associated protein kinase 1
202770 s at 5.52 CCNG2 4021.1 cyclin G2
17.29 IGF2BP3 7p ll insulin-like qrowth factor 2 mRNA bindinq protein 3
203820 s at 14.21 IGF2BP3 7p ll insulin-like qrowth factor 2 mRNA bindinq protein 3
210138 at 10.92 RGS20 8012.1 requlator of G-protein siqnallinq 20
A ppendix  3: E xp ressio n  a r ra y  re su lts  fo r individual p a tie n ts
| P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
206618 at 10.34 IL18R1 2al2 interleukin 18 receptor 1
201387 s at 10.36 UCHL1 4pl4 ubiquitin carboxyl-terminal esterase LI (ubiquitin thiolesterase)
204410 at 9.27 EIF1AY Yall.222 eukaryotic translation initiation factor 1A, Y-linked
218589 at 8.21 P2RY5 13ql4 purinerqic receptor P2Y, G-Drotein coupled, 5
205034 at 7.43 CCNE2 8q22.1 cyclin E2
210279 at 6.29 GPR18 13q32 G protein-coupled receptor 18
.1552680 a at 6.13 CASC5 15ql4 cancer susceptibility candidate 5
In d  3 JOH-MA
P ro b e  ID  
207095 at
fo ld  c h a n g e
13.91
g e n e .sy m b o l
SLC10A2
m ap
13q33
d e s c r ip t io n
solute carrier family 10 (sodium/bile acid cotransporter family), member 2
205518 s at 10.22 CMAH 6P21.32 cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate monooxyqenase)
201125 s at 7.53 ITGB5 3q21.2 integrin, beta 5
205991 s at 6.58 PRRX1 lq24 paired related homeobox 1
235349 at 6.43 FAM82A 2P22.2 family with sequence similarity 82, member A
211535 s at 6.42 FGFR1 8 p ll .2 -p ll. l fibroblast qrowth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
1556096 s at 6.23 UNC13C 15q21.3 unc-13 homoloq C (C. elegans)
225168 at 5.66 FRMD4A 10pl3 FERM domain containinq 4A
210571 s  at 5.64 CMAH 6p21.32 cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-acetylneuraminate monooxyqenase)
227620 at 5.55 SLC44A1 9q31.2 solute carrier family 44, member 1
204633 s at 5.40 RPS6KA5 14q31-q32.1 ribosomal protein S6 kinase, 90kDa, polypeptide 5
208475 at 5.29 FRMD4A 10pl3 FERM domain containinq 4A
222314 x at 4.95 ITPR1 3p26-p25 inositol 1,4,5-triphosphate receptor, type 1
225167 at 4.69 FRMD4A 10pl3 FERM domain containinq 4A
8.45 AK3L1 1P31.3 adenylate kinase 3-like 1
210643 at 8.44 TNFSF11 13ql4 tumor necrosis factor (liqand) superfamily, member 11
242517 at 8.42 KISS1R 19P13.3 KISS1 receptor
218094 s at 6.87 DBNDD2 20ql3.12 dysbindin (dystrobrevin bindinq protein 1) domain containinq 2
225342 at 6.67 AK3L1 1P31.3 adenylate kinase 3-like 1
209822 s at 5.42 VLDLR 9p24 very low density lipoprotein receptor
221491 x at 4.36 HLA-DRB1 6p21.3 major histocompatibility complex, class II, DR beta 1
230102 at 4.23 ETV5 3q28 ets variant qene 5 (ets-related molecule)
4.21 CYP1B1 2p21 cytochrome P450, family 1, subfamily B, polypeptide 1
230967 s at 4.12 USP7 16pl3.3 ubiquitin specific peptidase 7 (herpes virus-associated)
In d  4 WA-MA
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
8.30 MOXD1 6q23.1-23.3 monooxyqenase, DBH-like 1
2206b 8.05 TBX21 17q21.32 T-box 21
A ppendix  3: E x p ressio n  a r ra y  re su lts  fo r individual p a tie n ts
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m a p d e s c r ip t io n
225728 at 5.80 SORBS2 4a35.1 sorbin and SH3 domain containinq 2
203828 s at 5.02 IL32 16P13.3 interleukin 32
229764 at 4.86 FAM79B 3q28 family with sequence similarity 79, member B
8 at 4.37 MOXD1 6q23.1-23.3 monooxyqenase, DBH-like 1
59644 at 5.4 BMP2K 4q21.21 BMP2 inducible kinase
242903 at 4.98 IFNGR1 6q23-q24 interferon qamma receptor 1
217028 at 4.9 CXCR4 2q21 chemokine (C-X-C motif) receptor 4
230413 s  at 4.77 AP1S2 Xp22.2 adaptor-related protein complex 1, siqma 2 subunit
209604 s at 4.77 GATA3 10pl5 GATA bindinq protein 3
209948 at 4.69 KCNMB1 5q34 potassium larqe conductance calcium-activated channel, subfamily M, beta member 1
230921 s at 4.49 PCBP2 12ql3.12-ql3.13 poly(rC) bindinq protein 2
Z J 1 4 o 4  a t  
209725 at
4 . 4 /
4.37 UTP20 12q23 UTP20, small subunit (SSU) processome component, homoloq (yeast)
243916  x at 4.18 UBLCP1 5q33.3 ubiquitin-like domain containinq CTD phosphatase 1
229500 at 4.09 SLC30A9 4pl3-pl2 solute carrier family 30 (zinc transporter), member 9
223210 at 4.08 CHURC1 14q23.3 Churchill domain containinq 1
204863 s  at 4.08 IL6ST 5q ll interleukin 6 siqnal transducer (qpl30, oncostatin M receptor)
227740 at 4.05 UHMK1 lq23.3 U2AF homoloqy motif (UHM) kinase 1
22541 4.04 GPAM 10q25.2 qlycerol-3-phosphate acyltransferase, mitochondrial
In d  5 FRL-MA
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
12.84 SNORA68 19pl3 small nucleolar RNA, H/ACA box 68
211993 at 10.49 WNK1 12pl3.3 WNK lysine deficient protein kinase 1
208151 x at 8.38 DDX17 22ql3.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
208719 s at 7.60 DDX17 22ql3.1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
222450  at 6.76 TMEPAI 20ql3.31-ql3.33 transmembrane, prostate androqen induced RNA
211082  x at 5.37 MARK2 11012-013 MAP/microtubule affinity-requlatinq kinase 2
201008 , s at 5.26 TXNIP lq21.1 thioredoxin interacting protein
224828 at 5.12 CPEB4 5q21 cytoplasmic polyadenylation element bindinq protein 4
202205 at 4.97 VASP 19ol3.2-ol3.3 vasodilator-stimulated phosphoprotein
208583  x at 4.97 HIST1H2AJ 6 d 2 2 - p 21.3 histone 1, H2aj
208547  at 4.96 HIST1H2BB 6D21.3 histone 1, H2bb
221092  at 4.92 ZNFN1A3 17q21 zinc finqer protein, subfamily 1A, 3 (Aiolos)
2 08496  x at 4.89 HIST1H3G 6p21.3 histone 1, H3g
1552263 at 4.76 MAPK1 22qll.2;22qll.21 mitoqen-activated protein kinase 1
228181 at 4.73 SLC30A1 Iq32-q41 solute carrier family 30 (zinc transporter), member 1
222439 s at 4.73 THRAP3 lp34.3 thyroid hormone receptor associated protein 3
202082 s at 4.70 SEC14L1 17q25.1-17025.2 SEC14-like 1 (S. cerevisiae)
A ppend ix  3: E x p ressio n  a r ra y  re su lts  fo r indiv idual p a tie n ts
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
229371 ar 4.69 GPR114 I6a l3 G protein-coupled receptor 114
205124 at 4.69 MEF2B 19pl2 MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 2B)
221881 s at 4.68 CLIC4 lp 3 6 .ll chloride intracellular channel 4
223062 s  at 4.65 PS ATI 9a21.2 phosphoserine aminotransferase 1
200835 s at 4.63 MAP4 3p21 microtubule-associated protein 4
22884 15.41 HINT1 5q31.2 histidine triad nucleotide binding protein 1
2 4 1 1 63_at 14.93 NAALADL2 3q26.31 N-acetvlated alpha-linked acidic dipeptidase-like 2
2 2 5 0 9 2 _ a t 11.38 NUP88 17pl3.2 nucleoporin 88kDa
2 1 2 1 9 5  at 11.15 IL6ST 5q ll interleukin 6 siqnal transducer (qpl30, oncostatin M receptor)
24 2 5 8 6 _ a t 11.05 FSD1L 9q31 fibronectin type III and SPRY domain containinq 1-like
23 0 3 8 7 _ a t 10.51 ATP2C1 3q22.1 ATPase, Ca++ transporting, type 2C, member 1
22 2 8 0 5 _ a t 9.98 MANEA 6ql6.1 mannosidase, endo-alpha
1556121 _at 9.2 NAP1L1 12q21.2 nucleosome assembly protein 1-like 1
2 1 29 8 0 _ a t 8.79 USP34 2pl5 ubiquitin specific peptidase 34
2 1 2 0 3 7 _ a t 8.3 PNN 14q21.1 pinin, desmosome associated protein
2 1 3 0 7 0 _ a t 7.96 PIK3C2A Ilp l5 .5 -p l4 phosphoinositide-3-kinase, class 2, alpha polypeptide
2 2 2 6 8 5 _ a t 7.66 FAM29A 9p22.1 family with sequence similarity 29, member A
2 296 9 2 _ a t 7.62 API5 Ilp l2 -q l2 apoptosis inhibitor 5
2 301 7 4 _ a t 7.27 LYPLAL1 lq41 lysophospholipase-like 1
209902^ at 7.17 ATR 3q22-q24 ataxia telanqiectasia and Rad3 related
2 2 6 9 9 8 _ a t 7.16 NARG1 4q31.1 NMDA receptor requlated 1
2 1 2 5 4 2 _ s_ a t 6.95 PHIP 6ql4 pleckstrin homoloqy domain interacting protein
2 1 2 6 5 3 _ s_ a t 6.94 EHBP1 2pl5 EH domain binding protein 1
2 1 2 0 3 6 _ s_ a t 6.92 PNN 14q21.1 pinin, desmosome associated protein
2 4 1 734_at 6.75 SRFBP1 5q23.1 serum response factor bindinq protein 1
155 8 9 5 6 _ s_ a t 6.62 IFT80 3q26.1 intraflaqellar transport 80 homoloq (Chlamydomonas)
2 3 5 3 9 0 _ a t 6.44 P18SRP 5ql2.3 NA
206059_  at 6.39 ZNF91 19pl3.1-pl2 zinc finqer protein 91
In d  6  LEM-MA
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
213913 s at 25.39 KIAA0984 12ql4.3 NA
228335 at 16.69 CLDN11 3q26.2-q26.3 claudin 11 (oliqodendrocyte transmembrane protein)
213912 at 16.25 KIAA0984 12ql4.3 NA
209839 at 6.79 DNM3 lq24.3 dynamin 3
201427 s  at 6.70 SEPP1 5q31 selenoprotein P, plasma, 1
215392 at 6.27 USP3 15q22.3 ubiquitin specific peptidase 3
214056 at 6.22 MCL1 lq21 myeloid cell leukemia sequence 1 (BCL2-related)
233314 a t 6.09 PTEN 10q23.3 phosphatase and tensin homoloq (m utated  in multiple advanced cancers 1)
A ppendix  3: E xpressio n  a r ra y  re su lts  fo r  individual p a tie n ts
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
3 at 5.92 KCNMB2 3a26.2-q27.1 potassium larqe conductance calcium-activated channel, subfamily M, beta member 2
210473 s at 5.76 GPR125 4P15.31 G protein-coupled receptor 125
232528 at 5.75 UBE2E3 2q32.1 ubiquitin-coniuqatinq enzyme E2E 3 (UBC4/5 homoloo. veast)
209459 s at 5.55 ABAT 16P13.2 4-aminobutyrate aminotransferase
205498 at 5.45 GHR 5pl3-pl2 qrowth hormone receptor
1556361 s at 5.31 ANKRD13C 1P32.3-P31.3 ankyrin repeat domain 13C
240594_at 5.30 CDYL 6p25.1 chromodomain protein, Y-like
206032 at 5.21 DSC3 18ql2.1 desmocollin 3
223424 at 5.51 GBP3 lp22.2 quanylate bindinq protein 3
1558217 at 5.45 SLFN13 17ql2 schlafen family member 13
201692 at 5.42 OPRS1 9P13.3 opioid receptor, sigma 1
1553423 a at 5.35 SLFN13 17ql2 schlafen family member 13
237215  s at 5.22 TFRC 3q29 transferrin receptor (p90, CD71)
201850 at 5.07 CAPG 2pll.2 cappinq protein (actin filament), qelsolin-like
230543 at 4.99 USP9X Xpll.4 ubiquitin specific peptidase 9, X-linked
217728. at 4.87 S100A6 lq21 S100 calcium bindinq protein A6 (calcydin)
227354_at 4.57 PAG1 8q21.13 phosphoprotein associated with qlycosphinqolipid microdomains 1
212999 x at 4.44 HLA-DOB1 6p21.3 major histocompatibility complex, class II, DQ beta 1
211919 s at 4.41 CXCR4 2q21 chemokine (C-X-C motif) receptor 4
2 1 1 0 1 6 . x . at 4.02 HSPA4 5q31.1-q31.2 heat shock 70kDa protein 4
In d  7 AH-MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m a p d e s c r ip t io n
226811 at 9.64 FAM46C lp l2 family with sequence similarity 46, member C
232112 at 8.75 RALGPS2 lq25.2 Ral GEF with PH domain and SH3 bindinq motif 2
202620  s at 8.54 PLOD2 3q23-q24 procollaqen-lysine, 2-oxoqlutarate 5-dioxygenase 2
234792  x at 8.53 IGHA1 14q32.33 immunoqlobulin heavy constant alpha 1
207734  at 7.16 LAX1 lq32.1 lymphocyte transmembrane adaptor 1
202843 at 7.00 DNAJB9 7q31; 14q24.2-q24.3 DnaJ (Hsp40) homoloq, subfamily B, member 9
^203574 at 6.91 NFIL3 9q22 nuclear factor, interleukin 3 requlated
239258_at 6.54 RHOQ 2p21 ras homoloq qene family, member Q
204992  s  at 6.50 PFN2 3q25.1-q25.2 profilin 2
203543 s at 6.41 KLF9 9ql3 Kruppel-like factor 9
210426  x at 6.38 RORA 15q21-q22 RAR-related orphan receptor A
217732  s  at 6.16 ITM2B 13ql4.3 inteqral membrane protein 2B
213856  at 6.09 CD47 3ql3.1-ql3.2 CD47 molecule
209845 at 6.06 MKRN1 7q34 makorin, rinq finqer protein, 1
225464  at 6.06 FRMD6 14q22.1 FERM domain containing 6
24484 6.04 SEC24A 5q31.1 SEC24 related qene family, member A (S. cerevisiae)
A ppendix  3: E x p ression  a rra y  re su lts  fo r individual p a tie n ts
P ro b e  ID fo ld  c h a n q e g e n e .sy m b o l m ap d e s c r ip t io n
231202 at 6.01 ALDH1L2 12023.3 aldehyde dehydrogenase 1 familv. member L7
239246 at 5.96 FARP1 13032.2 FERM, RhoGEF (ARHGEF) and Dleckstrin domain Drotein 1 (chondrocyte-derived)
1561195 at 5.61 GPR137B 1q 4 2 - q4 3 G protein-coupled receptor 137B
220377 at 5.59 FAM30A 14032.33 family with sequence similarity 30, member A
233463 _at
9 9  c q q q
5.56
5 55
RASSF6
GAR1
4ql3.3 
4 n 3 1  ?1
Ras association (RalGDS/AF-6) domain family 6
241844 x at 5.46 TMEM156 4pl4 transmembrane protein 156
210875 S at 5.42 TCF8 lO pll.2 transcription factor 8 (represses interleukin 2 expression)
2 0 7 9 0 l_ a t 5.39 IL12B 5q31.1-033.1 interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)
1554462 a_at 5.37 DNAJB9 7q31; 14024.2-024.3 DnaJ (Hsp40) homoloq, subfamily B, member 9
210479_s_at 5.37 RORA 15q21-q22 RAR-related orphan receptor A
1557257_at 5.32 BCL10 lp22 B-cell CLL/lymphoma 10
215641 at 5.31 SEC24D 4q26 SEC24 related qene family, member D (S. cerevisiae)
at 7.83 UBD 6p21.3 ubiquitin D
208814 at 4.66 HSPA4 5q31.1-031.2 heat shock 70kDa protein 4
208712 at 4.65 CCND1 11013 cyclin D1
241403 at 4.50 CLK4 5o35 CDC-like kinase 4
1569025 s  at 4.43 FAM13A1 4o22.1 family with sequence similarity 13, member A1
241937_s_at 4.26 WDR4 21022.3 WD repeat domain 4
209278 s at 4.20 TFPI2 7q22 tissue factor pathway inhibitor 2
208711 s at 4.14 CCND1 11013 cyclin D1
2 3 1 5 7 7 s  at 4.10 GBP1 1P22.2 quanylate bindinq protein 1, interferon-inducible, 67kDa
222912 at 4.06 ARRB1 11013 arrestin, beta 1
208920 at 4.03 SRI 7021.1 sorcin
at 4.02 PTPLAD1 15q22.2 protein tyrosine phosphatase-like A domain containinq 1
In d  8  TER-MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e sc r ip t io n
205659 at 6.80 HDAC9 7p21.1 histone deacetylase 9
213793 s at 
2 1 3 5 7 ?  5 a t
5.54
4  Q 8
HOMER1
C C D  DTMD 1
5014.2 homer homoloq 1 (Drosophila)
-L J - /  /  2. j  Q t
224800 at
*t.yo
4.39
O uKrllM Dl
WDFYl
op Z d  
2036.1
serpin peptidase inhibitor, clade B (ovalbumin), member 1 
WD repeat and FYVE domain containinq 1
229695 at 4.39 FAM107B 10pl3 family with sequence similarity 107, member B
213075 at 4.18 OLFML2A 9o33.3 olfactomedin-like 2A
223503 at 4.16 TMEM163 2o21.3 transmembrane protein 163
227803 at 4.16 ENPP5 6p21.1-pll.2 ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function)
240413 at 4.15 PYHIN1 1023.1 pyrin and HIN domain family, member 1
236235 at 4.09 ITCH 2 0 q ll.2 2 -a ll.23 itchy homoloq E3 ubiquitin protein liqase (mouse)
23800; 4.08 GOLPH4 3026.2 qolqi phosphoprotein 4
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P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
213446 5 at 
213122 at
11.2
10.94
IOGAP1
TSPYL5
15q26.1
8a22.1
IO motif containinq GTPase activatinq protein 1 
TSPY-like 5
212257 s at 9.34 SMARCA2 9p22.3 SWI/SNF related, matrix associated, actin dependent requlator of chromatin, subfamily a, member 2
242774 at 8.73 SYNE2 14023.2 spectrin repeat containina. nuclear envelope 2
230058 at 8.62 SDCCAG3 9034.3 serologically defined colon cancer antiqen 3
209088 s at 7.5 UBN1 16P13.3 ubinuclein 1
223161 at 7.02 MULK 7034 multiple substrate lipid kinase
211672 s a t 6.53 ARPC4 3p25.3 actin related protein 2/3 complex, subunit 4, 20kDa
227884 at 6.49 TAF15 1 7 o ll.l-a ll .2 TAF15 RNA polymerase II, TATA box bindinq protein (TBP)-associated factor, 68kDa
213286 at 6.48 ZFR 5P13.3 zinc finqer RNA binding protein
206983_at 6.47 CCR6 6q27 chemokine (C-C motif) receptor 6
242352 at 6.43 NIPBL 5 p 13.2 Nipped-B homoloq (Drosophila)
1557100 s at 6.31 HECTD1 14012 HECT domain containinq 1
1563321 s at 5.86 MLL 11023 myeloid/lymphoid or mixed-lineaqe leukemia (trithorax homoloq, Drosophila)
236462 at 5.77 YEATS2 3027.1 YEATS domain containing 2
202855 s at 5.68 SLC16A3 17q25 solute carrier family 16, member 3 (monocarboxylic acid transporter 4)
at 5.67 BCLAF1 6022-023 BCL2-associated transcription factor 1
In d  9 STM-MA
KrOD6 ID 
209189 at
fo ld  c h a n g e
14.61
g e n e .s y m b o l
FOS
m ap
14024.3
d e s c r ip t io n
v-fos FBJ murine osteosarcoma viral oncoqene homoloq
205931 s at 12.30 CREB5 7pl5.1 cAMP responsive element bindinq protein 5
210942 s at 9.22 ST3GAL6 3012.1 ST3 beta-qalactoside alpha-2,3-sialyltransferase 6
205476 at 7.76 CCL20 2033-037 chemokine (C-C motif) liqand 20
237485 at 7.66 SFRS3 6p21 splicinq factor, arqinine/serine-rich 3
203397 s at 7.19 GALNT3 2024-031 UDP-N-acetyl-alpha-D-qalactosamine: polypeptide N-acetylqalactosaminyltransferase 3 (GalNAc-T3)
220051 at 6.82 PRSS21 16P13.3 protease, serine, 21 (testisin)
222392 x at 6.81 PERP 6024 PERP, TP53 apoptosis effector
218764 at 6.73 PRKCH 14q22-o23 protein kinase C, eta
213355 at 5.71 ST3GAL6 3012.1 ST3 beta-qalactoside alpha-2,3-sialyltransferase 6
204995 at 5.56 CDK5R1 17011.2 cyclin-dependent kinase 5, requlatory subunit 1 (p35)
212715 s at 5.46 MICAL3 22011.21 microtubule associated monoxyqenase, calponin and LIM domain containinq 3
235142 at 5.38 ZBTB8 1P35.1 zinc finqer and BTB domain containinq 8
241843 at 5.32 EIF5 14q32.32 eukaryotic translation initiation factor 5
1553105 s at 5.19 DSG2 18012.1 desmoglein 2
235458 at 5.17 HAVCR2 5q33.3 hepatitis A virus cellular receptor 2
205270 s at 4.96 LCP2 5q33.1-oter lymphocyte cytosolic protein 2 (SH2 domain containinq leukocyte protein of 76kDa)
241745 at 4.88 FBXO30 6q24 F-box protein 30
217764 s at 4.76 RAB31 18pl 1.3 RAB31, member RAS oncoqene family
A ppendix  3: E xpression  a rra y  re su lts  fo r individual p a tie n ts
P ro b e  ID fo ld  c h a n q e g e n e .sy m b o l m ap d e s c r ip t io n
205798 at 4.72 IL7R 5pl3 interleukin 7 receptor
209682 at 4.45 CBLB 3 d l3 .ll Cas-Br-M ( murine) ecotropic retroviral transforminq sequence b
204614 at 4.45 SERPINB2 18q21.3 serpin peptidase inhibitor, clade B (ovalbumin), member 2
225147 at 4.33 PSCD3 7P22.1 pleckstrin homoloqy, Sec7 and coiled-coil domains 3
204472 at 4.30 GEM 8ql3-q21 GTP bindinq protein overexpressed in skeletal muscle
218805. at 4.28 GIMAP5 7q36.1 GTPase, IMAP family member 5
217763 s at 4.14 RAB31 18pl 1.3 RAB31, member RAS oncoqene family
204174 at 5.04 ALOX5AP 13ql2 arachidonate 5-lipoxyqenase-activatinq protein
230425 at 5.02 EPHB1 3q21-q23 EPH recep tor B1
230292 at 4.95 RCBTB2 13ql4.3 requlator of chromosome condensation (RCC1) and BTB (POZ) domain containinq protein 2
230896 at 4.82 CCDC4 4pl3 coiled-coil domain containing 4
238332 at 4.71 ANKRD29 18qll.2 ankyrin repeat domain 29
203132 at 4.21 RBI 13ql4.2 retinoblastoma 1 (includinq osteosarcoma)
242890 at 4.19 HELLS 10q24.2 helicase, lymphoid-specific
227176 at 4.02 SLC2A13 12ql2 solute carrier family 2 (facilitated qlucose transporter), member 13
204103 at 4.01 CCL4 17ql2 chemokine (C-C motif) liqand 4
In d  10  QUB-MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
205749 at 8.88 CYP1A1 15q22-q24 cytochrome P450, family 1, subfamily A, polypeptide 1
217867 x at 8.81 BACE2 21q22.3 beta-site APP-cleavinq enzyme 2
202967 at 7.97 GSTA4 6pl2.1 qlutathione S-transferase A4
209793 at 6.40 GRIA1 5q33;5q31.1 qlutamate receptor, ionotropic, AMPA 1
58916 _at 6.21 KCTD14 llq l4 .1 potassium channel tetramerisation domain containinq 14
229893 at 5.99 FRMD3 9q21.32 FERM domain containinq 3
209496 at 5.61 RARRES2 7q36.1 retinoic acid receptor responder (tazarotene induced) 2
204395  s at 5.58 GRK5 10q24-qter G protein-coupled receptor kinase 5
219545 at 5.51 KCTD14 l la  14.1 potassium channel tetramerisation domain containinq 14
221690 s at 5.48 NALP2 19ql3.42 NACHT, leucine rich repeat and PYD containinq 2
206951 at 4.51 HIST1H4E 6p21.3 histone 1, H4e
205660 at 4.50 OASL 12q24.2 2'-5'-oliqoadenylate synthetase-like
219637 at 4.24 ARMC9 2q37.1 armadillo repeat containinq 9
219667 s at 4.24 BANK1 4q24 B-cell scaffold protein with ankyrin repeats 1
242600 at 4.22 FRMD3 9q21.32 FERM domain containing 3
208523 x at 4.13 HIST1H2BI 6p21.3 histone 1, H2bi
< at 11.01 PDCD6 5pter-pl5.2 proqrammed cell death 6
236244 at 5.20 HNRPU lq44 heteroqeneous nuclear ribonucleoprotein U (scaffold attachment factor A)
4.67 ATF5 19ql3.3 activatinq transcription factor 5
A ppendix  3: E xpression  a rra y  re su lts  fo r individual p a tie n ts
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
at
1556054 at
4.ZO
4.28
D c K A
RPL31
lzpiz.j
2a ll.2
2-deoxyribose-5-phosphate aldolase homoloq (C. elegans) 
ribosomal protein L31
213907 at 4.22 EEF1E1 6P24.3-D25.1 eukaryotic translation elonqation factor 1 epsilon 1
1558102 at 4.13 TM6SF1 15q24-q26 transmembrane 6 superfamily member 1
4.09 BMP2K 4q21.21 BMP2 inducible kinase
In d  11 WM-MA
P ro b e  ID fo ld  c h a n g e g e n e .sy m b o l m ap d e s c r ip t io n
217179 x at 33.28 IGLV1-44 22qll.2 immunoqlobulin lambda variable 1-44
213245 at 11.42 ADCY1 7pl3-pl2 adenylate cyclase 1 (brain)
228434 at 10.58 BTNL9 5q35.3 butyrophilin-like 9
219947 at 9.53 CLEC4A 12d13 C-type lectin domain family 4, member A
223827 at 9.03 TNFRSF19 13ql2.11-ql2.3 tumor necrosis factor receptor superfamily, member 19
228974 at 9.01 ZNF677 19ql3.41 zinc finqer protein 677
206110 at 8.82 HIST1H3H 6p22-p21.3 histone 1, H3h
229985_at 8.48 BTNL9 5q35.3 butyrophilin-like 9
210299 s at 8.45 FHL1 Xq26 four and a half LIM domains 1
207156 at 8.24 HIST1H2AG 6p22.1 histone 1, H2aq
230992 at 8.12 BTNL9 5q35.3 butyrophilin-like 9
215071 s at 8.08 HIST1H2AC 6p21.3 histone 1, H2ac
235953 at 7.39 ZNF610 19ql3.33 zinc finqer protein 610
207120 at 6.67 ZNF667 19ql3.43 zinc finqer protein 667
1560562 a at 6.67 ZNF677 19ql3.41 zinc finqer protein 677
1554679 a at 6.62 LAPTM4B 8q22.1 lysosomal associated protein transmembrane 4 beta
214505 s at 6.45 FHL1 Xq26 four and a half LIM domains 1
206030 at 6.41 ASPA 17pter-pl3 aspartoacylase (Canavan disease)
221724 s at 6.25 CLEC4A 12pl3 C-type lectin domain family 4, member A
1552610 a at 6.20 JAK1 1P32.3-D31.3 Janus kinase 1 (a protein tyrosine kinase)
243514 at 6.18 WDFY2 13ql4.3 WD repeat and FYVE domain containinq 2
235315 at 6.15 TSC22D1 13ql4 TSC22 domain family, member 1
214455 at 6.09 HIST1H2BC 6p21.3 histone 1, H2bc
2012 12.2 ATP1B1 lq24 ATPase, Na+/K+ transporting, beta 1 polypeptide
204014 at 8.4 DUSP4 8p l2 -p ll dual specificity phosphatase 4
213350 at 7.1 RPS11 19ql3.3 ribosomal protein S ll
212097 at 7.08 CAVl 7q31.1 caveolin 1, caveolae protein, 22kDa
226022 at 6.68 SASH1 6q24.3 SAM and SH3 domain containing 1
2Q9444 at 6.6 RAP1GDS1 4q23-q25 RAP1, GTP-GDP dissociation stimulator 1
201243 s at 6.24 ATP1B1 lq24 ATPase, Na+/K+ transporting, beta 1 polypeptide
6.16 RBPMS2 15q22.31 RNA binding protein with multiple splicing 2
A ppendix  3: E xpression  a r ra y  re su lts  fo r individual p a tie n ts
P ro b e  ID fo ld  c h a n g e g e n e .s y m b o l m ap d e s c r ip t io n
; 204015 s at 6.15 DUSP4 8D12-P11 dual specificity phosphatase 4
224209 s  at 5.34 GDA 9021.13 quanine deaminase
206102 at 5.11 GINS1 20011.21 GINS complex subunit 1 (Psfl homoloq)
218910_.at 5.1 TMEM16K 3p22.l-p21.33 transmembrane protein 16K
201890 at 5.07 RRM2 2p25-p24 ribonucleotide reductase M2 polypeptide
217996 at 5.05 PHLDA1 12ql5 pleckstrin homoloqy-like domain, family A, member 1
229420 at 4.85 RPL23A 17qll ribosomal protein L23a
1201426 s  at 4.76 VIM 10pl3 vimentin
[225660 at 4.6 SEMA6A 5q23.1 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A
212044 s at 4.52 RPL27A llp l5 ribosomal protein L27a
205203 at 4.48 PLD1 3q26 phospholipase D l, phosphatidylcholine-specific
4.47 BIRC5 17q25 baculoviral IAP repeat-containing 5 (surviving
Appendix 3: Expression array results for individual patients
